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Abstract 
 TNFα plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA), however 
the mechanisms underlying its dysregulation are not completely understood. TNFα 
production by macrophages is dependent on their contact with synovial T cells. In an 
in vitro model of RA, peripheral blood lymphocytes stimulated with a cocktail of 
cytokines mimic this RA T cell effector function. This thesis defines and 
characterises the effector population of cytokine-activated human T cells through two 
different approaches.  
  Studies presented here show that within a population of cytokine-activated T cells, 
CD4+CD45RO+CCR7- cells induce the highest levels of TNFα when co-cultured 
with monocytes. Cytokine-activated CD4+ memory T cells phenotypically and 
functionally resemble lymphocytes isolated from RA synovial tissue. The cytokine 
cocktail induces proliferation and differentiation of peripheral blood T cells into highly 
potent effectors. These cells upregulate specific activation markers, adhesion 
molecules and chemokine receptors; such as CD25, CD69, CD62L, VLA-4, LFA-1 
and CXCR4 which directly or indirectly, contribute to the induction of TNFα. By 
defining the phenotype of the lymphocytes most capable of inducing TNFα in our 
model, I isolated a population of T cells on which to focus my studies. 
 The molecular nature of contact-dependent monocyte activation by cytokine-
activated T cells was further investigated through proteomic profiling of the T cell 
surface. Plasma membrane protein-enriched samples were resolved in one- and 
two-dimensions. Subsequent mass spectrometry identified two molecules of interest. 
CD97 was found to be highly expressed by cytokine-activated CD4+ memory T cells, 
and contributed to both the induction of monocyte TNFα and spontaneous TNFα 
release from rheumatoid synovial tissue. Expression of CD81 and other tetraspanin 
family members increased on cytokine activation and was observed in synovial 
tissue. The results presented in this thesis provide further insight into the contribution 
of T cells in RA. 
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1.0 The Immune System 
 The immune system has evolved to protect the host from infectious agents 
encountered in the environment including viruses, bacteria, protozoa and 
multicellular parasites. To do this efficiently different strategies have been 
developed.  When a pathogen enters the body; it elicits an immediate and non-
specific immune response (innate immunity) which provides no long-term protection 
in the event of recurrent infection. A slower, but specific immune response by cells of 
the adaptive immune system confers long-term protection and memory of invading 
organism. The innate and adaptive immune systems are integrated and work 
together through the actions of, amongst others, white blood cells (leukocytes) and 
small soluble proteins known as cytokines which allow fast communication between 
cell types. 
  
 Hematopoietic stem cells (HSCs) give rise to progenitors from which two classes of 
leukocytes, red blood cells and platelets are derived. Monocytes, dendritic cells, 
granulocytes and mast cells are all derived from the myeloid progenitor. Monocytes 
circulate in the blood and mature to macrophages in the tissues. Granulocytes are a 
family of polymorphonuclear leukocytes which include neutrophils, basophils and 
eosinophils. Immature dendritic cells migrate from the blood to reside in the tissues 
until an encounter with antigen leads to maturation and migration to lymphoid 
tissues. The common lymphoid progenitor gives rise to the lymphocytes – T cells, B 
cells and natural killer cells. Another important group of cells in the immune system 
are the stromal fibroblastic cells (fibroblasts) which are generated from the 
mesochymal stem cells. Leukocytes express a large number of cell surface proteins, 
some of which have unique expression patterns and are used to distinguish cellular 
subsets and activation status. Many of these molecules act as receptors and ligands 
allowing communication between individual cells by direct contact or via cytokines.  
 
1.0.1 The Inflammatory response 
 When an invading microorganism breaches an epithelial surface of the body (e.g. 
the skin) local infection occurs and the inflammatory response is initiated. The roles 
of the inflammatory response are to restrict tissue damage by neutralising and/or 
destroying the foreign body, to alert the cells of the adaptive system and induce 
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healing of injured tissue. Micro-organisms are initially recognised by tissue resident 
macrophages via pattern recognition receptors (PRR) which are specific for 
components of pathogen surfaces. Some PRRs are also able to recognise self-
proteins, danger associated molecular patterns (DAMPs) that result as a 
consequence of tissue injury, such as components of the extracellular matrix (ECM) 
and contents of necrotic cells. The binding of these components activates 
macrophages and triggers phagocytosis and elimination of the pathogen. Activated 
macrophages also produce soluble mediators such as cytokines and chemotactic 
molecules which activate and alert other cell types to the invasion. The activation of 
the vascular endothelium results in the upregulation of adhesion molecules and 
secretion of additional chemotactic factors facilitating the adherence and migration of 
circulating effector cells from the peripheral blood (PB). The release of cytokines and 
migration of cells to sites of infection is the process known is inflammation and is 
characterised by heat, pain, redness and swelling (calor, dolor, rubor and tumor) of 
the host tissues. Inflammation is also triggered by the activation of complement on 
the surface of microorganisms. Complement is a system of plasma proteins that are 
activated in defined cascades of proteolytic reactions and result in the coating of cell 
surfaces with complement protein fragments for recognition by phagocytes or the 
direct lysis of cells plus the release of small chemotactic peptides known as 
anaphylatoxins. 
 
 Recruitment of phagocytic neutrophils, is followed by monocytes, which 
subsequently differentiate into macrophages at the site of inflammation. Natural killer 
(NK) cells are the cytotoxic lymphocytes of the innate immune system which migrate 
in response to chemotactic signals from inflamed tissues, and are adapted to 
recognise and kill virus-infected cells. Phagocytosis and release of inflammatory 
mediators by cells contains infection and sets up chemotactic gradients for the arrival 
of the lymphocytes of the adaptive immune system. These are T and B cells, which 
are activated at regional lymph nodes through antigen presentation by dendritic cells 
(DCs) that have migrated from the site of inflammation where they internalised 
microbial components or by antigen that has drained from the inflamed tissue via the 
lymphatic system. In infected tissues they mediate specific clearance of pathogens 
through direct lysis by cytotoxic T cells, T cell activation of macrophages or antibody-
mediated phagocytosis.    
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1.0.2 Adaptive Immunity 
 The specificity of the adaptive immune system is conferred by the generation of 
unique T cell and B cell receptors (TCR and BCR) by complex somatic gene 
rearrangements and selection processes in the thymus and bone marrow 
respectively. This generates a vast repertoire of antigen receptors in the lymphocyte 
pool. Each receptor generated is unique to a single naϊve T or B cell, which upon 
encountering their respective antigens undergo rapid proliferation known as clonal 
expansion in order to massively increase the number of specific cells and launch an 
efficient immune response. As a result of the TCR repertoire and clonal expansion of 
some naϊve T cells, the average adult human has 300 billion T cells with 300 million 
different TCR specificities (Naylor et al., 2005). The B cell receptor is an 
immunoglobulin (Ig) molecule that is expressed on the cell surface and is uniquely 
specific for antigen. Antigen recognition results in the production of a soluble 
immunoglobulin (antibody) of the same specificity. Antibodies are the effector 
molecules of B cells and bind soluble antigen forming immune complexes or surface 
antigen resulting in opsonisation with downstream effects such as phagocytosis, 
complement activation and antibody-dependent cellular cytotoxicity. B cells can also 
function as antigen presenting cells (APC), binding of soluble antigen at the BCR 
and subsequent antibody production enables cross-linking of the BCR, 
internalisation and presentation of antigen peptide by MHC for T cell activation.  
1.0.3 T cells 
 T cells develop from a subset of HSCs that move from the bone marrow to the 
thymus, where TCR gene rearrangement and selection occurs. For valid selection, a 
TCR must bind but only weakly to a specific self-peptide bound to a specific allelic 
form of a protein complex encoded by HLA genes of the major histocompatibility 
complexes (MHC). Insufficient or too high avidity results in the elimination of the 
thymocyte and TCR in question. Approximately 5% of thymocytes complete selection 
and complete T cell development. Selection against self-peptides in the thymus 
prevents self reactivity in the periphery ensuring recognition of non-self antigens 
only. This is the concept of immune tolerance. When tolerance is broken 
autoimmunity occurs. The selection of BCR is guided by the same principles. TCR 
selection also determines the expression of co-receptors on mature T cells. A T cell 
with a TCR recognising a Class I MHC will retain expression of CD8 co-receptor and 
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a cell with a TCR recognising a Class II MHC retains CD4. Mature T cells migrate 
from the thymus to secondary or regional lymphoid nodes ready to encounter 
antigen. 
1.0.3.1 Antigen-presentation and T cell activation 
 Dendritic cells are known as professional antigen presenting cells (APC) and act as 
a key bridge between the innate and adaptive immune systems. DCs in the 
peripheral tissues respond to microbial products via PRRs and to inflammatory 
cytokines resulting in the capture of pathogen by phagocytosis. DCs mature and 
leave the tissues, migrating to the secondary lymphoid tissues via the lymphatic 
system. These tissues are highly organised structures containing fibroblast stromal 
cells that form networks of collagen fibres, which act as a filter allowing small 
molecules such as antigen and chemokines through, and also organises T and B 
cells into discrete domains. Secondary lymphoid tissues are densely packed with T 
and B cells undergoing rapid and random locomotion in search of antigen, and with 
sessile DCs presenting antigen. It is estimated that each DC makes contact with up 
to 5000 T cells per hour (Miller et al., 2004). The mode of antigen presentation 
depends on the nature of the antigen itself. Endogenous antigens such as viral 
peptides in infected cells are presented on MHC Class I molecules to CD8+ T cells. 
Whereas exogenous antigens, in endosomes following phagocytosis, for example, 
are presented as peptides on MHC Class II molecules to CD4+ or helper T cells 
(Th).  
  Recognition of an MHC-peptide complex on an APC by a TCR provides the first 
activation signal to naϊve T cells but is not sufficient for full activation. An additional 
secondary amplification signal is necessary, and is provided by the ligation of B7 co-
stimulatory ligands CD80 and CD86 on the APC with CD28 on the T cell surface. 
Ligation of the TCR alone results in T cell anergy or deletion. T cells upregulate the 
surface CD40 ligand (CD40L) soon after activation, which functions as a secondary 
co-stimulatory molecule through the binding of CD40 on the APC. CD40L-CD40 
interaction delivers activation signals to both the T cell and APC (Xu and Song, 
2004). Following these interactions, a number of other proteins such as CD2/LFA-3 
and LFA-1/ICAM-1 are recruited to the point of contact between T cell and APC 
forming the immunological synapse and enabling successful T cell activation. 
Activated T cells then undergo clonal expansion supported by autocrine production 
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of the cytokine interleukin-2 (IL-2), and differentiate into effector cells before 
migrating to sites of infection in the periphery. DCs are specialised to deliver the two 
signals capable of activating naϊve cells. Once activated T cells perform their effector 
functions in the periphery after recognition of the specific peptide-MHC complex on 
other APCs. At these immunological synapses the interactions of many other co-
stimulatory molecules in addition to CD28 e.g. CD40L, ICOS (CD278), OX40 
(CD134), CTLA-4 (CD152) and LFA-1 (CD11a/CD18) which are only expressed on 
activated T cells regulate T cell function in the periphery. CTLA4 is particularly 
important in regulating T cell responses in lymphoid tissue and in the periphery. It 
also binds CD80 and CD86, and delivers a negative signal to the T cell, resulting in 
inactivation and cell death. This is important for the resolution of the immune 
response, which is necessary to prevent aberrant tissue destruction and restore 
homeostasis. 
1.0.3.2 CD8+ T cells 
 The role of CD8+ T cells or cytotoxic T lymphocytes (CTL) in the periphery is to 
recognise virally infected cells presenting peptide-MHC Class I, and mediate 
cytotoxic lysis and apoptosis of the target cell.  Perforin channelling of the pro-
apoptotic protein granzyme induces programmed cell death as does the binding of 
Fas (CD95) by Fas ligand (FasL) on the CTL.   
1.0.3.3 CD4+ T cells 
 Activated CD4+ T cells are polarised into subsets depending on the stimuli they 
receive from the APC and other inflammatory cells (Figure 1.1). Each subset is 
characterised by its cytokine profile and the signalling pathways utilised. Th1 cells 
differentiate in the presence of APC-derived IL-12 and IL-18, and secrete the pro-
inflammatory cytokines lymphotoxin (LT) and Interferon γ (IFNγ). IFNγ activates NK 
cells, CD8+ T cells and macrophages. Together this enables the efficient clearance 
of intracellular pathogens. Th2 cells require IL-4 for their differentiation and in 
contrast with Th1 cells produce anti-inflammatory cytokines such as IL-4, IL-5, IL-10 
and IL-13 that mediate allergic immune responses by promoting B cell activation, 
antibody production and immunoglobulin (Ig) class switching. Th1/2 subsets cross-
regulate the polarisation of the opposite subset, i.e. IFNγ inhibits the differentiation of 
T cells into Th2 cells and IL-4 inhibits differentiation of Th1 cells. 
Chapter 1  Introduction 
26 
 
 
Th2 Th17 iTregTh1 
Th0 
IFNγ
LTβ
IL-4
IL-5
IL-10
IL-13
IL-17
IL-17A
IL-22
IL-10
TGFβ
nTreg
Thymus 
 
 
  
  
 A third helper T subset has recently been discovered, based on the secretion of the  
 
pro-inflammatory cytokine IL-17; these cells are termed Th17 cells (Harrington et al., 
2005; Langrish et al., 2005). Th17 cells secrete IL-17, related IL-17F and IL-22. Their 
main role is in immunity against extracellular bacterial and fungal infection. However, 
recent evidence from mice and human experiments also indicates a central role for 
Th17 cells in a wide range of autoimmune diseases. The conditions which promote 
differentiation to Th17 cells are still under investigation and differences between 
mice and human differentiation conditions have emerged. In mice the general 
consensus is that the presence of IL-6 and TGFβ are sufficient to drive differentiation 
of naϊve T cells (Bettelli et al., 2006; Mangan et al., 2006). IL-6 induces the 
upregulation of IL-23 receptor (IL-23R) and APC derived IL-23 acts to maintain Th17 
cells (Veldhoen et al., 2006). Unlike other T cells Th17 cells do not require IL-2 for 
differentiation; IL-21 shares the common γ chain receptor with IL-2, and is thought to 
act as a substitute. In mice IL-21 has been observed to act in an autocrine manner 
promoting the generation of Th17 (Nurieva et al., 2007). As yet it is unclear whether 
Figure 1.1 CD4+ T cell subsets in humans. A summary of the cytokines required for the 
differentiation of human CD4+ T cells and the cytokines secreted by each subset. See text for 
details. Abbreviations – LT= Lymphotoxin, IL = interleukin, iTreg = induced regulatory T cell, 
TGFβ = transforming growth factor, Th0 = activated by undifferentiated CD4+ T cell, Th1 = type 1 
helper T cell, Th2 = type 2 helper T cell, Th17 = IL-17 secreting helper T cell, nTreg = naturally 
occurring regulatory T cell. 
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the TGFβ required for Th17 generation is derived from regulatory T cells (section 
1.0.3.5) and/or APCs.  However it is clear that the addition of Th1 or 2-related 
cytokines such as IL-12, IFNγ or IL-4 is able to inhibit IL-23 or TGFβ plus IL-6 
induced differentiation of Th17 in mice and humans (McGeachy and Cua, 2008). In 
humans several groups have reported that IL-6 plus TGFβ is not capable of driving 
Th17 cells in vitro. Instead suggesting roles for IL-1, IL-23 and IL-6, although the 
hierarchy of each cytokine in the differentiation process is still a matter of debate 
(Acosta-Rodriguez et al., 2007; Chen et al., 2007; van Beelen et al., 2007; Wilson et 
al., 2007). Controversy over the role of TGFβ also remains. Differing experimental 
setup may offer an explanation, human serum is a potent source of this cytokine and 
culture conditions used have not necessarily eliminated this source of TGFβ.  
1.0.3.4 Memory T cells 
 Immunologic memory is unique to the adaptive immune system and to T and B cells 
in particular. It is based upon the capacity of cells to “remember” an encounter with 
antigen, even after clonal expansion and resolution of the initial response, through 
the persistence of long lived memory populations that respond more quickly on re-
exposure to antigen. Immunologic T cell memory is in fact an effective division of 
labour between two subsets of memory T cells. Long-lived central memory T cells 
(TCM) have limited effector function, but home to the secondary lymphoid from where 
they can respond upon re-encountering antigen, resulting in proliferation and 
expansion of specific effector T cells. In contrast, effector memory T cells (TEM) home 
to the peripheral tissue and provide an immediate response on exposure to antigen, 
through the production of effector cytokines such as IFNγ, but have limited 
proliferative capacity. Differences in the homing of TCM and TEM cells are reflected in 
their expression of the cell surface proteins CCR7 and CD62L. Both are required for 
entry into secondary lymphoid tissues, and thus act as markers for naïve and central 
memory T cells. In contrast activated effector T cells and effector memory T cells 
have lost CCR7 and CD62L, marking transition to the periphery (Sallusto et al., 
1999).  Both TCM and TEM behave as differentiation intermediates arrested at different 
stages. For instance, TCM can differentiate into Th1 or Th2 effector cells in the 
absence of polarising cytokines, and both Th1- and Th2-differentiated TEM cells when 
re-stimulated under the opposing polarising conditions adopt the expression of the 
alternative’s effector cytokine, as well as maintaining expression of its own (Messi et 
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al., 2003; Rivino et al., 2004). Lanzavecchia and Sallusto proposed that the strength 
of the TCR signal delivered by an APC directs the differentiation of memory and 
effector cells. A weak signal delivered by immature DCs with low expression of co-
stimulatory molecules results in T cell anergy and deletion, and is tolerogenic. 
Mature DCs provide signals for efficient expansion of effector T cells, polarising cells 
leading to antigen clearance. Effector T cells become exhausted and undergo 
programmed cell death. However mature DCs also become exhausted in their ability 
to produce cytokines and can only engage T cells in transient immune synapses 
delivering enough stimulus to prime cells but not enough for a full effector response. 
These T cells become differentiation intermediates and are memory precursors, 
depending on the amount of stimulus received they will express differing levels of 
receptors for homeostatic cytokines, anti-apoptotic molecules and lymphoid and 
tissue homing receptors, thus determining a TCM or a TEM cell (Lanzavecchia and 
Sallusto, 2002).  
1.0.3.5 Regulatory T cells 
 CD4+ helper T cells are regulated by populations of regulatory T cells (Treg). These 
cells are able to suppress proliferation and cytokine production by activated CD4+ T 
cells, and to modulate immune responses by APCs. In humans Tregs are defined by 
high levels of the IL-2α chain (CD25high) expression and express other activation 
markers including TNFα receptor 2 (TNFRII), CD62L, CTLA-4 and glucocorticoid-
induced TNF receptor (GITR) and low expression of IL-7 receptor (CD127) (Liu et 
al., 2006; Yi et al., 2006). Expression of the transcription factor foxp3 is believed to 
be the master regulator of Treg function. Mutations in the foxp3 gene of mice (scurfy 
mouse) and humans (IPEX syndrome) confer a high incidence of autoimmune and 
allergic diseases (Brunkow et al., 2001; Hori et al., 2003).  However contradictory 
data exists from both species, where transfection of foxp3 has been assessed in 
foxp3 null cells, as to the necessity of this transcription factor alone in conferring an 
immunosuppressive phenotype (Allan et al., 2005; Gavin et al., 2006; Kim and 
Rudensky, 2006; Lin et al., 2007; Yagi et al., 2004).  
 Tregs can be divided into two groups: naturally occurring CD4+CD25high Tregs 
(nTreg) which originate in the thymus and inducible Tregs (iTreg) which are 
generated from naϊve CD4+ populations in the periphery upon activation (Figure 1.1). 
The latter depend on interleukin-10 (IL-10) or transforming growth factor β (TGFβ) 
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for differentiation and either remain foxp3- or become foxp3+ respectively. They also 
secrete the anti-inflammatory cytokine themselves which promoted their original 
differentiation (Barrat et al., 2002; Zheng et al., 2002). Recent human data has 
shown the induction of suppressive population of cells upon activation of 
CD4+CD25- T cells in the presence of IL-2, which are foxp3+ CTLA-4+ but it is the 
expression of CTLA-4 that confers suppressive function and not foxp3 (Zheng et al., 
2008). The suppressive activity of Treg is measured in vitro by co-culture assays of 
Treg and CD25- responder cells. The suppression of anti-CD3 activated responder 
cells in the presence of anti-CD28 or APCs is assessed in terms of proliferation and 
cytokine production e.g. IFNγ. Experiments in transgenic mice demonstrated that 
Treg cells were able to suppress responses to the same, but not to unrelated 
antigens (Thornton and Shevach, 2000). However, once activated they are generally 
suppressive in an antigen-independent manner. The exact mechanism of 
suppression remains unclear but is contact-dependent, as Treg which are chemically 
fixed remain capable of suppression. A number of candidates have been implicated 
as key Treg ‘effector molecules’ including membrane bound TGFβ (mTGFβ), GITR 
and CTLA-4.  
 Tregs play a vital role in restraining T cell responses and preventing excessive 
deleterious immune responses, but also in the maintenance of tolerance to self-
antigens in the periphery and the prevention of autoimmune diseases such as 
rheumatoid arthritis (RA).  
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1.1 Rheumatoid arthritis 
 Rheumatoid arthritis (RA) is an autoimmune disease manifesting as chronic 
inflammatory arthritis. Patients primarily suffer from severely inflamed synovial joints 
(synovitis) leading to joint destruction, pain and functional disability. An associated 
systemic inflammation leads to co-morbidities including vasculitis, percarditis, 
pleuritis and anemia in some patients. Clinical diagnosis is made when an individual 
satisfies at least four of the seven 1988 American College of Rheumatology criteria 
for a minimum of 6 weeks:  
 
1) Morning stiffness of joints that persists for longer than 1 hour.  
2) Arthritis of three or more joints areas, defined as swollen and tender soft tissue at 
the proximal interphalangeal (PIP), metacarpophalangeal (MCP), wrist, elbow, knee 
ankle or metatarsophalangeal (MTP) joints.  
3) Arthritis of at least one hand joint (PIP, MCP or wrist).  
4) Symmetrical arthritis on the same joint areas on both sides of the body.  
5) Presence of firm, non-tender, subcutaneous regions known rheumatoid nodules. 
6) Seropositive for anti-IgG antibodies known as Rheumatoid Factor (RF). 
7) Erosive changes on arthritic joint radiographs.  
    
 RA affects approximately 1% of the population worldwide. The incidence of disease 
is approximately 3 fold higher in females than males and can occur between 25 - 60 
years but risk increases with age (Linos et al., 1980). RA is a chronic and 
progressive illness, but patients typically experience periods of symptomatic 
remission followed by relapse and disease flare. Length and frequency of remission 
and flares differs between individuals. RA patients are treated with disease-
modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) and a 
growing range of biologicals such as anti-TNFα therapies. These drugs act to 
temporarily disrupt inflammatory processes and slow disease progression, but do not 
provide a cure. Recent evidence suggests an early and aggressive approach to 
treatment with DMARDs provides the best prognosis. 
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1.1.1 Pathology of RA 
 In a normal joint the synovial membrane surrounds the joint cavity, enclosing 
synovial fluid and protecting the bone and cartilage. The membrane consists of an 
intimal layer a few cells thick of predominately fibroblasts with scattered 
macrophages, and a sublining layer of mainly fatty and fibrous tissue, plus some 
blood vessels. These synoviocytes secrete cytokines, enzymes, TIMPs, hyaluronan 
and proteoglycans into the synovial fluid where they help to maintain bone and 
cartilage homeostatis (Smith et al., 2003). In contrast, in RA the synovial membrane 
becomes hyperplastic with infiltrating lymphocytes, plasma cells, macrophages and 
dendritic cells, plus proliferation of the resident synovial fibroblasts. An increase in 
the number of cells results in a greater oxygen and nutrient demand such that the 
tissue becomes hypoxic. Neovascularisation also occurs to support the formation of 
a aggressive front or pannus which invades adjacent bone and cartilage, causing 
progressive destruction through excessive production of matrix metalloproteinases 
(MMPs) including collagenase, and other destructive enzymes (Feldmann, 2002).  
The synovial fluid (SF) of a rheumatoid joint also becomes more cellular with a large 
number of neutrophils, lymphocytes and high levels of immune complexes, in 
comparison to the clear acellular fluid of a normal joint. A healthy and inflamed joint 
are illustrated in Figure 1.2. 
 
 
  
 
 
Figure 1.2 Comparison of normal versus rheumatoid joint.    
Taken from (Feldmann, 2002) 
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 Infiltrating lymphocytes form different patterns of organisation within the synovium. T 
and B cells are either described as diffusely distributed, loosely aggregrated, or in 
20% of individuals ordered in ectopic germinal centre-like structures (Manzo et al., 
2005). These structures act to organise and maintain T cell contacts with other cells 
that further sustain immune and inflammatory responses. Intensive studies have 
revealed the rheumatoid synovium to be a cytokine rich microenvironment, biased 
towards the pro-inflammatory arm of the immunological response (Feldmann et al., 
1996). Complex interactions of different cell types and cytokines perpetuate chronic 
disease. 
1.1.2 Aetiopathogenesis 
  A unifying causal factor in the development of RA remains elusive, despite a 
number of autoantigens having been implicated. The emergence of autoantibodies in 
the serum of patients often precedes the clinical onset of joint inflammation and 
destruction (Rantapaa-Dahlqvist et al., 2003).  RF describes autoantibodies against 
the Fc regions of IgG that are found in around 80% of RA patients (Franklin et al., 
1957). Levels of RF positively correlate with severity of disease observed (van 
Zeben et al., 1992). However RF is not specific for RA as it is found in systemic 
infections and other autoimmune diseases (Sutton et al., 2000). Recently, focus has 
turned to anti-citrullinated peptides antibodies as more specific diagnostic and 
predicative marker of RA than RF (Avouac et al., 2006). These antibodies are 
generated against peptides in which post-translational deimination of arginine to 
citrulline by peptidyl arginine deiminase has occurred. Autoantibodies could lead to 
joint disease following the ligation of Fc receptors and activation of inflammatory 
cells. Also, the formation of immune complexes and subsequent activation of the 
complement cascade releases anaphylatoxin C5a which acts as a chemoattractant 
for immune cells to the joint. Both pathways have been demonstrated in the glucose-
6-phosphate isomerase autoantigen K/BxN mouse model where FcγRII-deficiency 
accelerates disease but neutralisation of the C5a receptor ameliorated it (Corr and 
Crain, 2002; Grant et al., 2002). In addition, local production of complement proteins 
is observed the synovial tissue; the presence of the immune complexes on cartilage 
surface and active neutrophils in the synovial fluid supports these models. The 
pathogenic potential of autoantibodies was demonstrated by the treatment of severe 
combined immunodeficiency (SCID) mice lacking T and B cells with serum from mice 
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with collagen-induced arthritis (section 1.1.3.2.2) (Nandakumar et al., 2004; Taylor et 
al., 1995). These mice develop arthritis although, it is transient and less severe than 
if serum is co-transferred with collagen sensitised T cells or conventional CIA. 
Therefore, although autoantibodies may be able to initiate disease, lymphocytes are 
required to maintain an inflammatory response. This, along with the fact that 10% of 
healthy individuals are seropositive for RF and that immune complex formation is not 
unique to RA, suggests that a break in tolerance leading to self-antibody production 
does not of itself explain the articular localisation and unique features of 
inflammation observed in RA. 
  A number of genetic susceptibility loci have been associated with RA, but the 
strongest predisposing alleles observed map to the MHC Class II, in particular the 
third hypervariable region of DRβ chains.  Over 80% of Caucasian RA patients have 
a shared epitope of either Glu-Lys-Arg-Ala-Ala or Glu-Arg-Arg-Ala-Ala at amino acids 
70 – 74, close to the peptide binding groove. This is conserved in many haplotypes 
including DRB*0101, DRB*0401, DRB*0404 and DRB*1402) (Nepom et al., 1989; 
Stastny, 1976). Such a strong genetic predisposition implies that RA is a disease 
resulting, at least in part, from the recognition of antigen and subsequent T cell 
activation. Recent data suggest that the predisposition observed with shared epitope 
alleles (SA) is linked to the development of anti-citrulline antibodies rather than being 
an independent risk factor for disease (van der Helm-van Mil et al., 2006).  In 
addition smoking has been shown to be an important environmental factor promoting 
the development of RA in SA  and RF positive individuals and this may be linked to 
anti-citrulline responses, as smoking is known to promote citrullination of proteins 
(Klareskog et al., 2007; Padyukov et al., 2004). The pathogenic potential of anti-
citrulline antibodies has been hinted at in CIA studies, transferral of anti-citrullinated 
fibrinogen antibodies to recipient mice failed to induce disease but did reduce the 
concentration of anti-collagen antibodies required for induction of arthritis upon co-
transfer (Kuhn et al., 2006). The targets of anti-citrulline antibodies in the context of 
RA tissue remain unknown. Thus a number of factors appear to predispose an 
individual to break T and B cell tolerance, but although many antigens have been 
implicated, none have been substantiated as singularly causal in pathogenesis. 
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1.1.3 T cells in RA 
 T cells are estimated to account for approximately 40% of the synovium’s cellular 
infiltrate in RA. First identified as the predominant infiltrating lymphocyte in synovial 
tissue back in 1975, they have since been extensively phenotyped (Bankhurst et al., 
1976; Van Boxel and Paget, 1975). Predominantly CD4+ with a mature activated 
phenotype, they express the memory marker CD45RO and activation markers HLA-
DP, -DQ, -DR and CD69, but low level CD25. This led to CD4+ T cells being 
described as ‘frustrated’ as they appear active but dysfunctional (Koch et al., 1990; 
Laffon et al., 1991; Pitzalis et al., 1987a; Pitzalis et al., 1987b). Increased expression 
of integrins and adhesion molecules corroborates their migration from the blood to 
the joint (Hemler et al., 1986; Potocnik et al., 1990). Once in the joint T cells do not 
proliferate and are resistant to apoptosis, further contributing to hyperplasia of the 
synovial membrane (Salmon et al., 1997). The presence of active effector CD4+ T 
cells is indicative of an essential role in the perpetuation of an inflammatory immune 
response of the joint. However, a classical T-cell response to one unifying antigen in 
the joint is unlikely to propagate disease, as autoantigens and TCR idiotypes are 
heterogeneous between RA patients. Furthermore synovial T cells have impaired T 
cells responses, they are hyporesponsive to TCR cross-linking ex vivo. This is 
suggested to be due to dysregulated TCR signalling and uncoupling of the ZAP70 – 
zeta ζ chain brought about by chronic stimulation of cells by high levels of tumour 
necrosis factor α (TNFα) in the joint (Berg et al., 2000; Cope et al., 1994; Isomaki et 
al., 2001). 
1.1.3.1 Defects observed in RA peripheral blood T cells 
 Abnormalities in the proliferation, repertoire and maturation of peripheral blood T 
cells have been observed in RA patients. The peripheral CD4+ T cell compartment in 
patients is altered and gives rise to lymphopenia in these individuals. Patients have 
reduced levels of TCR rearrangement excision circles, reflecting fewer thymic 
emigrants and compromised thymic output.  In addition, fewer naϊve CD4+ T cells 
are seen in RA patients compared to healthy individuals, but both naϊve and memory 
CD4+ T cells in patients have prematurely shortened telomeres compared to aged 
matched controls, indicative of increased proliferation (Koetz et al., 2000). Atypical 
CD4+ T cells with immature memory phenotypes that include unusual patterns of 
CD45 isoform expression and premature loss of CD62L are thought to be the 
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progeny of aberrantly proliferating naϊve cells (Ponchel et al., 2002). RA CD4+ T 
cells also show a contracted TCR repertoire, the frequency of arbitrarily chosen TCR 
β chains were found to be 10-fold higher in RA patients compared to controls 
(Wagner et al., 1998). This was observed in naϊve and memory populations, 
suggesting restriction is not a consequence of peripheral antigen recognition but 
abnormal peripheral T cell homeostasis, potentially due to insufficient thymic output 
and lymphopenia. Expanded clonotypes are often autoreactive in the peripheral 
blood, some of these but not all are also observed in the synovial membrane. They 
have unusual phenotypes with loss of CD28, CD7 and gain of NK cell receptors 
KIR2DS2 and NKG2D (Groh et al., 2003; Namekawa et al., 2000; Pawlik et al., 
2003; Schmidt et al., 1996). Emergence of these expanded clones has been 
observed in recent onset patients and specific clones have been identified in both 
RA patients and their healthy siblings, suggesting that oligoclonality is an inherited 
risk factor and not the result of chronic disease (Waase et al., 1996). In contrast 
levels of C reactive protein (CRP), indicative of systemic inflammation, correlate with 
the numbers of atypical immature CD4+ T cells (Ponchel et al., 2002). It is therefore 
as yet unclear whether dysregulation of homeostatic proliferation is a consequence 
of chronic disease or a primary defect contributing to pathogenesis, but it does 
promote inappropriate expansion and differentiation of T cells underlying 
autoimmunity.  
1.1.3.2 Evidence for the role of T cells 
1.1.3.2.1 Genetics 
 As previously mentioned, the best established genetic loci associated with RA are 
the shared epitope alleles. A number of other loci have been found that are 
associated with altered T cell function.  The protein tyrosine phosphatase non-
receptor type 22 (PTPN22) locus encodes the tyrosine phosphatase Lyp which 
regulates TCR signalling and within which single nucleotide polymorphism (SNP) 
have been associated with increased susceptibility. The resultant substitution of 
tryptophan for arginine induces a “gain-of-function”, leading to decreased TCR 
signalling via dephosphorylation of associated tyrosine kinases (Lck, Fyn and 
ZAP70), and subsequent reduction in IL-2 production (Pierer et al., 2006; van Oene 
et al., 2005; Vang et al., 2005). Furthermore the combination of the SA and PPTN22 
allele has been associated with T cell autoreactivity in early disease (Burkhardt et al., 
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2006). It is thought that decreased TCR signalling imparts a failure to delete 
autoreactive T cells in the thymus and/or defective Treg development.  
 SNPs in two genes encoding negative co-stimulatory molecules are associated with 
autoimmune diseases including RA. CT60 is an allelic variant of CTLA-4 with a SNP 
in the 3’ UTR which has been shown to alter the TCR signalling phosphorylation 
patterns of CD4+ T cells (Maier et al., 2007). The hypothesis suggests that such a 
genotype results in a phenotype where T cell activation threshold is altered and 
autoreactive T cells are more likely to be activated. A set of SNPs with the gene 
encoding PD-1 (programme death-1) have also been identified in RA patients. Like 
CTLA-4, PD-1 delivers a negative signal in normal T cell activation, inhibiting 
proliferation and promoting apoptosis. It is thought that the SNPs lead to a defective 
protein that influences the deletion of autoreactive T cells. The association of both of 
these genes implicates defects in the suppression of T cell responses to be 
important in RA. 
 Genome-wide screening for RA susceptibility genes revealed a linkage peak on 
chromosome 2q that mapped to four SNPs within the third intron of signal transducer 
and activator of transcription 4 (STAT4). SNP rs7574865 has shown significant 
association with disease and is common susceptibility marker in European and Asian 
populations, plus it appears to be independent of RF or anti-cyclic citrulline peptide 
seropositivity (Lee et al., 2007b; Orozco et al., 2008; Remmers et al., 2007). The 
mechanism by which the variant form of STAT4 modulates the immune response 
and leads to disease is currently unclear. However, STAT4 is involved in signalling 
downstream of IL-12 and IL-23, cytokines which are key to the Th1 and Th17 
lineages respectively. In turn these lineages are linked to joint inflammation and thus 
aberrant signalling in this pathway could lead to altered polarisation and downstream 
T cell function.  
1.1.3.2.2 T cells in animal models of RA 
 Experimental animal models in which an inflammatory polyarthritis with similar 
histopathological features as RA can be induced, have contributed extensively to our 
understanding of RA pathogenesis and in particular the role of T cells. In the 
Collagen-induced arthritis (CIA) model of autoimmune arthritis susceptible rodents 
(I-Aq) are immunised with type II collagen emulsified in complete Freund’s adjuvant 
(CFA) (Wooley et al., 1981). CD4+ T cells play a critical role in development CIA, 
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CD4 deficient mice are less suspectible to disease and treatment in the early stages, 
with monoclonal antibodies against CD4, TCR, CD25 and MHC Class II, suppresses 
arthritis (Banerjee et al., 1988; Chiocchia et al., 1991; Ehinger et al., 2001; Ranges 
et al., 1985; Wooley et al., 1985; Yoshino et al., 1991). In addition, T cell activation is 
necessary for pathogenesis as CD28 null mice are resistant to CIA (Tada et al., 
1999). Antigen-induced arthritis is another T-cell driven model. Here antigen (such 
as ovalbumin or methylated BSA) is directly injected into the knee joint of a rat that 
has been pre-immunised with antigen in CFA.  As with CIA, inhibition of T cell 
function through anti-TCR, anti-CD4 or cyclosporin treatment prevents or 
ameliorates disease depending on the time of administration (Blackham and 
Griffiths, 1991; Pohlers et al., 2004; Yoshino and Yoshino, 1992) and adoptive 
transfer of CD4+ T cells from immunised mice, before or after the induction of 
arthritis, induces autoantibodies and joint pathology in SCID mice (Petrow et al., 
1996). Thirdly Adjuvant-induced arthritis uses a single intradermal injection of CFA 
to induce a rapid and transient (approximately 10 days) polyarthritis. This model has 
been shown to be neutrophils- and T cell-dependent with Th1 and Th17 involvement 
implicated (Van Eden and Waksman, 2003). 
 Recently attention has turned to a number of spontaneous arthritis models that are 
dependent on T cells and occur as a result of defective TCR signalling or cytokine 
regulation. The SKG mutant mouse has a point mutation in the TCR signalling 
molecule ZAP70 (Sakaguchi et al., 2003). These animals not only develop joint 
pathology similar to RA, but also exhibit extra-articular inflammation including 
vasculitis and pleuritis also seen in human disease. SKG mice express normal levels 
of ZAP70, but the protein no longer associates with the TCR complex resulting in 
abnormal signalling and increased positive selection of self-reactive T cells in the 
thymus. The joints are predominantly infiltrated with the same Vβ restricted clones of 
CD4+ T cells, implying uniform clonal expansion of T cells in response to antigen at 
each joint (Zhao et al., 2004). Adoptive transfer of T cells or lymph nodes from SKG 
mice to wild type (WT) or SCID mice leads to arthritis, demonstrating the 
fundamental role of T cells in this model. However spontaneous arthritis is 
dependent on pro-inflammatory cytokines TNFα, IL-6 and IL-1β and only develops in 
‘dirty’ mouse facilities, or after administration of Toll-like receptor (TLR) agonists 
such as zymosan or lipopolysacchride (LPS), indicating a requirement for innate 
immunity as well (Hata et al., 2004; Kobayashi et al., 2006).  
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 IL-1 receptor antagonist (IL-1ra) deficient mice also develop a spontaneous 
arthritis that is not observed in the absence of CD4+ T cells (Horai et al., 2004; Horai 
et al., 2000). Like the SKG model, IL-1Ra deficient T cells transfer disease 
susceptibility to immune-compromised recipients, which is also dependent of TNFα 
and on IL-17 (Nakae et al., 2003b).  
  Mice with a mutation in the gp130 subunit of IL-6 receptor develop a 
spontaneous arthritis. Mutant gp130 subunit have lost a tyrosine residue that causes 
increased signalling through STAT3, increased proliferation and decreased 
apoptosis (Sawa et al., 2006). Interestingly arthritis is dependent on CD4+ T cells 
even though a gp130 mutation in non-hematopoietic cells is sufficient for disease. 
This suggests the development of pathogenic T cells is usually regulated by non-
hematopoietic cells, but can be overridden by increased IL-6R signalling.  
 The K/BxN transgenic mouse is the F1 offspring of a non-obese diabetic mouse 
and a KRN TCR transgenic, which specifically recognises glucose-6-phosphate 
isomerase peptide presented by I-Ag7 class II molecules and spontaneously 
develops arthritis at around 4-5 weeks old. CD4+ T cells carrying the KRN TCR 
transgene infiltrate the joint and are important for the induction of arthritis but not for 
the chronic phase of disease as anti-CD4 treatment is effective only before onset of 
arthritis and not during (Kouskoff et al., 1996). Further evidence comes from 
experiments investigating the homeostatic proliferation of autoreactive T cells in 
these mice. Like RA patients, K/BxN mice are lymphopenic, with reduced numbers of 
thymic emigrants as a result of skewed T cell selection and restriction of the 
peripheral repertoire caused by the TCR transgene. In elegant experiments, 
homeostatic proliferation of autoreactive T cells in K/BxN mice was found to be 
required for the induction of arthritis, but disease was prevented by removing the 
space available for expansion of transgenic T cells through the infusion of naϊve 
CD4+ T cells from non-transgenic BxN donor mice. These experiments not only 
demonstrate the central role of the TCR transgenic T cell, but also that its dominance 
in the repertoire, due intrinsic homeostatic mechanisms is necessary for induction of 
autoimmunity with relevance to RA (Jang et al., 2006). However successful transfer 
of disease from a K/BxN mouse to a non-arthritic RAG-/-BxN mouse requires 
reconstitution of both donor T and B cells into the recipient. T cell help is required for 
autoantibody production and initiation of disease, before innate immune responses 
take over and drive chronic disease (Maccioni et al., 2002).  
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1.1.3.2.3 T cell directed therapies in RA 
 Early therapeutic approaches targeting T cells in RA were largely ineffective due to 
a lack of understanding of T cell biology in terms of specific functions of subsets and 
homeostatic proliferation. Total immunoablation of T cells from RA patients via 
lymphoid irradiation or thoracic duct drainage, followed by autologous stem cell 
transplantation led to long term clinical immunosuppression and selective survival 
advantage of autoreactive T cells. A retrospective study in the late 1990s reported a 
higher incidence of deaths in RA patients that underwent total lymphoid irradiation 
compared to those treated by other means (Westhovens et al., 1997). Treatment 
with T cell-depleting drugs such as antibodies against CD4 or CD52 (Campeth-1H), 
or directed toxins like anti-CD5 ricin or diphtheria toxin-IL-2 fusion protein had only 
modest and transient efficacy, and caused lymphopenia. Non-depleting anti-CD4 
antibody treatment initially showed promise, but trials were halted due to the 
unacceptable side effects of long-term administration (Choy et al., 2002). 
Unsuccessful efforts were also made to inhibit T cell activation by disrupting the 
formation of TCR-peptide-MHC Class II complexes using a vaccination with peptides 
matching epitopes of specific TCR Vβ chains, collagen or cartilage gp36 (Keystone, 
2003).  
 Inhibition of TCR signalling and thus T cell activation has shown clinical efficacy in 
RA. Cyclosporin A (CsA) blocks the phosphatase activity of calcineurin and thus the 
dephosphorylation, translocation and activation of NFAT. Low dose CsA in 
combination with MTX is more effective at slowing joint damage and improving 
disease activity compared to CsA alone; however neither regime induces disease 
remission (Gerards et al., 2003).  Specific small inhibitor molecules of T cell 
signalling pathways are hoped to provide improved clinical benefit in the future.  The 
most successful T cell based therapy currently on the market arises from successful 
blockade of T cell – APC co-stimulation via the competitive binding of CD28 with a 
CTLA-fusion protein over ligands CD80 and CD86. Abatacept is discussed in more 
detail in section 1.1.3.3.4. The exact mechanism action of MTX remains unclear but 
it is thought that one mode of action is its ability to disrupt T cell-fibroblast 
interactions, reduce osteoclastogenesis and progressive joint damage (Chan and 
Cronstein, 2002; Miranda-Carus et al., 2004).  
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1.1.3.3 Function of T cells in RA 
 Precise combinations of specific cytokines and direct interactions with other cell 
types in the rheumatoid synovium lead to the activation of T cells, and enable them 
to exert their own destructive effector functions. These are described in detail below 
and summarised in Figure 1.3.   
Th0
Th1 
or 
Th17
Treg
Cell-contact-mediated 
activation 
Macrophages, fibroblasts 
and endothelial cells
Cytokine release 
TNFα, IL-1, IL-6, IL-15, 
IL-12, IL-18 and TGFβ
Peptide-MHC and 
co-stimulation
Activation
Impaired?
Cytotoxicity
CD8 T cells
B-cell help  
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Cytokine release
Cytokine release 
IL-17, IFNγ, IL-22, 
LT, GM-CSF and 
RANKL
Activation of leukocytes and 
fibroblasts, reciprocal inhibition 
of T helper subsets and 
osteoclastogenesis
 
 
 
 
 
1.1.3.3.1 RA – a Th1 or Th17 mediated disease? 
 Th1 cytokines LT and GM-CSF are readily detectable in the rheumatoid synovium 
as well as mRNA for IL-2 and IFNγ although levels of these proteins are low in 
comparison to macrophage- and fibroblast-derived pro-inflammatory cytokines 
(Buchan et al., 1988a). IL-4, produced by Th2 cells is not found within the synovium 
in established disease, and IL-13 levels are low, although both cytokines may be 
detected synovial lavages of very early RA patients (Raza et al., 2005). Pro-
inflammatory cytokines present in the synovium are powerful inducers of IFNγ from 
Figure 1.3 Key pathways of synovial T cell activation and effector function. Adapted from 
(McInnes and Schett, 2007). See text for details. Th0 = resident synovial T cell predominately of 
a memory phenotype. Treg = regulatory T cell. Th1 = type 1 T helper cell. Th17 = IL-17 secreting 
T helper cell 
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CD4+ T cells, these include; IL-7, IL-12 and IL-18 (Tanaka et al., 2001). Levels of IL-
12 in the serum and synovial fluid of patients were observed to correlate with 
disease activity (Kim et al., 2000). In addition, T cell clones from RA patients 
challenged in vitro with the relevant antigen produced high levels of IFNγ but no IL-4, 
and the number of IFNγ producing CD4+ T cells was significantly higher in synovial 
fluid than in peripheral blood of RA patients (Davis et al., 2001; Miltenburg et al., 
1992). Taken together this provides strong evidence for Th1 driven inflammation in 
RA.  
 With the discovery of IL-17 T cells as a separate lineage there is increasing 
evidence that Th1 cells may have been falsely implicated in RA pathogenesis and 
the functions of Th17 cells may explain some of the experimental data which 
contradicts the Th1 hypothesis. In contrast to the paucity of Th1 cytokines in the 
synovium, IL-17A mRNA and protein is highly expressed in RA SF and synovial 
tissue, particularly in T cell rich areas of the sublining layer (Chabaud et al., 1999). 
Abundant IL-17 could in itself suppress Th1 cells, providing a possible explanation 
for the lack of IFNγ in the synovium. In 1997 Vermeire et al found that IFNγ receptor 
null mice showed exacerbated disease in the CIA model, at odds with the hypothesis 
of a Th1 driven disease (Vermeire et al., 1997). Early studies on the role of IL-12 in 
CIA demonstrated that it could replace CFA, and when administered with collagen 
induce severe arthritis with enhanced IFNγ production (Germann et al., 1995). 
Similarly inhibition of IL-12 with mAb during induction of CIA ameliorated disease, 
but prolonged blockade exacerbated arthritis, indicating a dual role for IL-12 in CIA: 
initially pro-inflammatory followed by an anti-inflammatory effect (Joosten et al., 
1997; Malfait et al., 1998). This may be reflective of a switch in the relative influences 
of Th1 and Th17 cells and the protective role of Th1 cytokines in inhibiting the 
development of pathogenic Th17 cells in the later stages of disease. In support of 
this, a similar biphasic role was observed with anti-IFNγ mAb treatment in CIA and 
IFNγ mRNA levels have been shown to be predictive of protection from disease 
whereas, IL-17 was indicative of progressive joint damage (Boissier et al., 1995; 
Kirkham et al., 2006). However IL-17 appears to be required at early and late stages 
for a full CIA disease profile, as treatment with soluble IL-17R or IL-17 mAb in 
induction and effector phases diminishes arthritis (Lubberts et al., 2005). Both IL-17 
and IL-17 receptor knockout mice have decreased incidence and severity of disease, 
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and spontaneous disease in IL-1Ra deficient mice is dependent on IL-17 (Nakae et 
al., 2003a) further supporting a role for the Th17 lineage. 
1.1.3.3.2 T cell polarising cytokines 
  The nature, site and timing of T cell differentiation into pathogenic effector cells 
remain unclear in RA. The synovium is rich in cytokines produced by myeloid and 
fibroblastic cells such as IL-6, IL-7, IL-12, IL-15, IL-18, IL-23 and TGFβ which have 
been proposed to support polarisation to either the Th1 and/or Th17 lineages.  
 The inhibition of disease by IL-12 mAb treatment in early phase CIA may have an 
alternative explanation, as the antibodies used were against the p40 subunit of IL-12 
which it shares with the cytokine IL-23. Both IL-12 and IL-23 are heterodimers with 
the shared p40 subunit and unique p35 and p19 subunits respectively, which bind to 
heterodimeric receptors which again have a common IL-12Rβ1 chain and unique IL-
12Rβ2 and IL-23R chains. Thus the inflammatory role of IL-12 in early CIA may in 
fact be attributable to IL-23. A series of knockout experiments in CIA support a role 
for IL-23 over IL-12 in this animal model of RA. Mice deficient in p35 (no IL-12) 
developed more severe arthritis compared to wild type (WT) whereas those deficient 
in p19 (no IL-23) and deficient in p40 (no IL-23 or IL-12) were protected (Murphy et 
al., 2003). The key to IL-23 in CIA is thought to be its role in maintaining, and/or 
inducing, pro-inflammatory Th17 cells. Similarly, high levels of IL-6 within the 
synovium may also contribute to polarising infiltrating T cells to Th17, and so 
perpetuate inflammation. Experiments in SKG mice have demonstrated that T cells 
activated in the periphery by self-peptide MHC Class II complexes induce IL-6 
production from both APC and T cells, which promote the differentiation of naϊve T 
cells towards a Th17 phenotype. IL-17 and IL-6 knockout SKG mice do not develop 
spontaneous arthritis, but IFNγ knockouts develop a more aggressive disease. Thus 
conditions which favour the differentiation and expansion of autoimmune Th17 cells 
promote arthritis in this model (Hirota et al., 2007). Data in human arthritis is less 
clear cut than murine studies, IL-6 is abundant in the synovium (section 1.1.5.3) but 
only low levels of bioactive IL-23 have been observed (predominantly cell-
associated) despite high levels of p19 mRNA and protein (Brentano et al., 2008); 
(Hillyer et al, submitted). As clear differences in requirements for the generation of 
Th17 cells exist in mice and humans, it is perhaps not surprising to observe 
discrepancies between animals models and human disease. However, human 
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synovial tissue does contain a cytokine milieu whose components are apparently 
favourable to the expansion and maintenance of a Th17 population - low IFNγ, 
(TGFβ), IL-6, and IL-23. 
 IL-18 is expressed in RA synovial tissue by macrophages and dendritic cells. Levels 
of IL-18 in patient sera and synovial fluid correlate to disease activity (Petrovic-
Rackov and Pejnovic, 2006), and treatment with a DMARD decreased expression of 
IL-18 in tissue biopsies (Rooney et al., 2004).  In synovial tissue cultures, IL-18 
synergises with IL-12 to induce IFNγ and IL-17 production, potentially influencing T 
cell polarisation. IL-18 also promotes GM-CSF, nitric oxide and TNFα synthesis by 
synovial macrophages, and vascular endothelial growth factor (VEGF) by synovial 
fibroblasts. TNFα feeds back, and along with IL-1β, inducing further IL-18 production 
from synovial fibroblasts (Cho et al., 2006; Gracie et al., 1999). Consistent with a 
pathogenic role for IL-18 in RA, recombinant IL-18 (rIL-18) can substitute for 
complete CFA in CIA induction. Mice develop more severe disease with increased 
circulating TNFα, IL-6 and IFNγ (indicative of a Th1 response) compared to controls. 
IL-18 knockout mice show reduced incidence and severity of CIA, which is reversed 
by administration of rIL-18. The naturally occurring soluble IL-18 receptor IL-18 
binding protein (IL-18BP) has shown therapeutic efficacy and is well-tolerated by 
patients with RA and Psoriasis; further clinical trials are ongoing (Banda et al., 2003; 
Tak et al., 2006). 
 IL-21, a member of the common γ chain receptor family, has been detected in RA 
synovial membrane cultures at the mRNA level despite little protein being present. 
Blockade with IL-21R-fusion protein suppresses the spontaneous release of TNFα, 
IL-6 and IL-1β (Andersson et al., 2008). In agreement with this human data, 
administration of IL-21R fusion protein also improves arthritis in the CIA model 
(Young et al., 2007). IL-21 receptor is expressed by synovial fibroblasts, 
macrophages and lymphocytes (Jungel et al., 2004). Indeed the addition of 
exogenous cytokine to synovial T cell cultures induces proliferation and release of 
TNFα and IFNγ, which appears to conflict with emerging data suggesting IL-21 in 
combination with TGFβ, is involved Th17 polarisation (Li et al., 2006). Thus the role 
of IL-21 in RA remains unclear and warrants further investigation. 
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1.1.3.3.3 T cell effector cytokines  
 Production of cytokines is one mechanism whereby synovial T cells contribute to 
synovitis. Th17 cells are known to secrete IL-17 and IL-22, plus in mice they also 
produce IL-6 and TNFα. The latter two cytokines are not unique to T cells, and their 
influence and predominance within RA synovium is discussed in section 1.1.5. 
Human IL-17, when added to cultures of human RA synovial fibroblasts increases 
levels of IL-6, IL-8, G-CSF and prostaglandin E2, and acts in synergy with TNFα in 
the induction of IL-6 and GM-CSF (Fossiez et al., 1996). It is now known that the 
pro-inflammatory effects of IL-17 often overlap with, but are independent of, TNFα 
and IL-1β (Koenders et al., 2006). Addition of anti-TNFα mAb and anti-IL-1β mAb or 
anti-IL-17 mAb to synovial tissue cultures was more effective at inhibiting IL-6 levels 
and collagen degradation than anti-TNFα alone (Chabaud and Miossec, 2001). IL-17 
receptor is widely expressed which accounts for its wide ranging effects on multiple 
cell types, and their subsequent contribution to inflammatory disease. Table 1.1 
summarises IL-17 inducible molecules from RA synovial cells and their downstream 
activities, which contribute to, amongst other functions, a positive feedback on IL-17 
production thus driving inflammation in the joint.  
Bone homeostasis in normal physiology involves a balance between bone resorption 
mediated by osteoclasts, and bone formation by osteoblasts. In RA this balance is 
skewed in favour of bone resorption by inflammatory processes. Osteoclast 
precursors, such as monocytes, infiltrate the synovium from the periphery, where 
they differentiate into osteoclasts under the influence of cytokine receptor activator 
of nuclear factor-κB ligand (RANKL) and monocyte-colony inducing factor (M-
CSF) (Lacey et al., 1998; Yoshida et al., 1990). Both are expressed by activated 
synovial T cells (Th1 and Th17) and fibroblasts, and are augmented by IL-17, TNFα, 
IL-6 and IL-1 (Horwood et al., 1998; Kotake et al., 1999). Osteoclasts mediate 
rheumatoid joint destruction. Th1 activation by IL-18 or IL-12 induces IFNγ and GM-
CSF which suppress osteoclastogenesis, as does the macrophage-derived anti-
inflammatory cytokine IL-10 present in RA (Takayanagi et al., 2000). 
Osteoprotegerin (OPG) is a natural occurring regulatory soluble RANK decoy 
receptor which, although expressed in the synovium, when in imbalance with RANKL 
results in cartilage and bone destruction. OPG treatment at the onset of adjuvant-
induced arthritis inhibits bone destruction, but not inflammation, and reverses bone 
resorption induced by activated T cells in CTLA4 null mice (Kong et al., 1999). 
Chapter 1  Introduction 
45 
 
Similarly, treatment of RA patients with denosumab, a neutralising antibody against 
RANKL, reduced bone erosion in RA patients as measured by MRI and radiography 
but did not ameliorate inflammation or disease (Cohen et al., 2008).  
Table 1.1 IL-17 inducible molecules 
Molecule Cell Source Major Function Section of 
thesisIL-1β F, Mye, Oc Inflammation, synergy with IL-17 1.1.5.2 
IL-6 F, Mye, Oc Inflammation, B cell stimulation, 
Th17 differentiation 
1.1.5.3 
IL-23 F Inflammation, Th17 growth 
factor 
1.1.3.3.2 
TNFα Mye Inflammation, synergy with IL-17  1.1.5.1 
IL-8 F Leukocyte recruitment 1.1.6.2.1 
CXCL1 F, Oc Leukocyte recruitment “ 
CXCL5 Oc Leukocyte recruitment “ 
CCL2 F, Oc Leukocyte recruitment “ 
CCL20 F Leukocyte recruitment  “ 
G-CSF F Granulopoiesis 1.1.5.1 
GM-CSF F Granulopoiesis “ 
VEGF F, Oc Angiogenesis “ 
Cyclooxgenase-2 F, Mye, Oc Inflammation - 
Prostaglandin E2 F, Mye, Oc Inflammation - 
RANK/RANKL  Oc Osteoclastogenesis 1.1.3.3.3 
Nitric oxide  Oc Tissue destruction - 
MMPs Mye, Oc Tissue and cartilage destruction 1.1.1 
 
   Cells:  F – synovial fibroblasts; Mye – monocytes, macrophages and dendritic cells; Oc – osteoclasts.  
Adapted from (Lundy et al., 2007) 
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 IL-22, a member of the IL-10 cytokine family, is produced by Th17 cells in response 
to IL-6 or IL-23 stimulation. In RA synovial membranes however IL-22 and its 
receptor seem to be associated with macrophages or fibroblasts rather than T cells 
(Ikeuchi et al., 2005). Other novel family members IL-19 and IL-20 show a similar 
expression pattern in RA (Hsu et al., 2006; Sakurai et al., 2008). It has been 
suggested that the lack of T cell-associated IL-22 maybe due to inhibition of its 
secretion from Th17 cells by TGFβ in the joint.  
 TGFβ is an anti-inflammatory cytokine produced by activated T cells, fibroblasts and 
monocytes, inhibiting cell proliferation and activation. Murine data suggests TGFβ 
may have both pro- and anti- inflammatory roles, since in combination with IL-6 it is 
required for Th17 cell generation but in the absence of IL-6 (e.g. in therapeutic IL-6 
blockade) it promotes Treg functions. As discussed earlier, in humans the role of 
TGFβ in Th17 differentiation remains unclear, and discrepancies in data may be due 
to subtle differences in TGFβ levels in serum and as a supplemented cytokine for the 
generation of these cells.  
 Expressed by activated T and B cells, LT exhibits similar biological effects to TNFα 
as a mediator of the inflammatory response on a local but not a systemic level. LTβ 
expression in the synovium on B cells has been implicated in the formation of 
germinal centres and lymphoid neogenesis found within a subset of RA patients, 
thus contributing to the autoimmune pathology (Takemura et al., 2001).  LTα1β2 from 
synovial T cells induces the production by synovial fibroblasts of other pro-
inflammatory cytokines (IL-6), inflammatory chemokines (CCL5, CCL2 and CXCL8) 
and matrix proteases (MMP1 and MMP3) via ligation of LTβR (Braun et al., 2004). A 
phase IIa trial of a LTβR:Fc fusion protein (baminercept) reported significant clinical 
improvement by ACR criteria through inhibition of the LTβR pathway (Abstract at 
ACR Annual meeting 2007).  
1.1.3.3.4 T cells function through cell-cell contact in RA 
 Direct interaction of T cells with APCs, such as macrophages, DCs and B cells, and 
with synovial fibroblasts contributes to synovial inflammation. As discussed earlier a 
number of potential self-antigens, including heat shock proteins, collagen-type II, 
glucose-6-phosphate isomerase and citrullinated proteins, have been implicated in 
RA from the presence of autoantibodies and from murine models, yet no consensus 
has been reached as to the exact nature of their individual involvements in the 
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pathogenesis of human disease. (Kinloch et al., 2005; Londei et al., 1989; 
Matsumoto et al., 1999; Res et al., 1988; Schellekens et al., 1998; Tsoulfa et al., 
1989). One way to implicate potential antigens is to map TCR usage in synovial T 
cells. Analysis of Vβ5 and Vβ8 TCR molecules in 10 RA patients found 
heterogeneity and no restricted usage (Brennan et al., 1988).  
 However the importance of antigen dependent activation of T cells in RA has been 
recently highlighted by the success of the CTLA4:Ig fusion protein Abatacept in 
treating patients. Co-stimulation of naϊve T cells by CD28 ligation of CD80/86 on 
APCs provides the crucial secondary signal required for subsequent T cell 
proliferation, cytokine production and differentiation. Following activation, the T cell 
expresses CTLA4 on its surface, which also binds CD80/CD86 providing a negative 
signal thus regulating T cell activation. Abatacept exploits the higher affinity of 
CTLA4 for CD80/CD86, and its soluble nature, to compete with CD28 and prevent T 
cell activation. Treatment with CTLA4:Ig fusion protein or even gene transfer via 
adenoviruses in CIA prevented disease if given alongside collagen immunisation or 
significantly ameliorated disease if administered after onset (Quattrocchi et al., 2000; 
Webb et al., 1996). Clinical trials showed efficacy of Abatacept in RA patients such 
that the drug is currently licensed in Europe and the US for treatment of non-
responders to MTX or anti-TNFα biologics (section 1.1.5.1.1.) (Genovese et al., 
2005). A recent Phase III trial of patients who have failed MTX has shown equivalent 
efficacy of anti-TNFα mAb therapy Infliximab and of Abatacept (Schiff et al., 2008). 
 Other proteins from the CD28-B7 family form co-stimulatory pairs which have been 
shown to be important in RA. Inducible co-stimulator (ICOS/CD278) is expressed 
at higher levels on activated T cells in RA patients compared to in healthy controls 
and its ligand CD275 is found on APCs in the synovial membrane (Okamoto et al., 
2003). In CIA, neutralisation of CD275, did not reduce the incidence of disease, but 
ameliorated inflammation and reduced autoantibody production, even in established 
disease (Iwai et al., 2002). This is consistent with a role for ICOS-CD275 in co-
stimulation of activated and antigen-experienced T cells contributing to ongoing 
pathogenic processes in the joint.   
 OX40 is highly expressed by CD4+ T cells in RA synovial fluid of compared to the 
blood, and these cells are thought to define a subset of highly aggressive 
autoreactive T cells. OX40+ cells can be specifically targeted by liposomes coated 
with mAb against OX40 and loaded with the drug 5’fluorodeoxyuridine. In adjuvant-
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induced arthritis such treatment successfully inhibited OX40+ T cell proliferation and 
ameliorated disease (Boot et al., 2005). OX40 delivers a co-stimulatory signal to 
polarised effector CD4+ T cells, and to memory CD4+ T cells, but in contrast has 
been shown to deliver inhibitory signals that suppress the development of Foxp3+ 
Tregs by TGFβ (Demirci and Li, 2008). OX40L transgenic mice show unusually 
aggressive expansion and secretion of IFNγ by memory T cells, which completely 
suppresses development of Tregs from naϊve cells. This has implications for the 
induction of Treg mediated peripheral tolerance as a therapeutic strategy in 
autoimmunity and transplantation (Xiao et al., 2008). It is interesting to speculate 
whether increased Treg induction after selective inhibition of OX40+ T cells in 
adjuvant-induced arthritis contributes to the observed improvement in disease. 
Blockade of OX40-OX40L also suppresses arthritis in IL-1ra deficient mice (Horai et 
al., 2004).  
 Integrin LFA-1 (CD18/CD11a) is expressed by activated T cells and binds to ICAM-
1(CD54). As well as a role in T cell migration this interacting pair is important in T cell 
and APC contact mediated processes, as translocation of these proteins to areas of 
contact on the cell surface could help stabilise the interaction of the two cells during 
antigen presentation (Dustin, 2008). Disruption of LFA-1/ICAM-1 interactions in 
animal models of arthritis causes a reduction in inflammation (Agarwal and Brenner, 
2006). Similarly CD2/LFA-3 interactions have been implicated in T cell – APC 
interactions in RA pathogenesis (Dayer and Burger, 2004).   
  The inflamed synovium of RA patients is known to contain CD40L positive T cells, 
CD40 positive macrophages, fibroblasts and B cells. Neutralising mAbs against 
CD40L inhibits inflammation, joint damage and autoantibody production in CIA and 
spontaneous arthritis in IL-1ra deficient mice is also inhibited (Durie et al., 1993; 
Horai et al., 2004). Conversely agonist anti-CD40 treatment resulted in enhanced 
disease, with increased levels of IFNγ and IgG2a antibody production, indicating a 
key role in driving Th1 responses in this model. In agreement with this data, T cells 
isolated from RA synovial fluid and peripheral blood are able to induce CD40L-CD40 
dependent antibody production from peripheral blood B cells, and IL-12 production 
from peripheral blood DCs whereas, T cells from control individuals were not 
(MacDonald et al., 1997). CD40-CD40L ligation events do not only occur between T 
and B cells in synovitis. Ligation of CD40 by T cells in synovial cultures enhances 
TNFα, IL-1β and IL-6 production from macrophages and monocytes perpetuating 
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inflammation (Harigai et al., 2004; Sekine et al., 1998). CD40 ligation of synovial 
fibroblasts by T cells has multiple reported effects, including increased expression of 
ICAM-1, VCAM-1, vascular endothelial growth factor (VEGF) and IL-6 which promote 
fibroblast proliferation, adhesion and angiogenesis within the joint. In addition, 
activated T cells indirectly promote osteoclastogenesis via CD40L-CD40 by inducing 
the expression of cell surface RANKL on synovial fibroblasts (Lee et al., 2006). The 
multiple functions of CD40L - CD40 make it an attractive therapeutic target in RA, 
however results of clinical trials in lupus with the anti-CD40L mAb IDEC-131 have 
not shown significant improvement in disease, despite a reduction in autoantibody 
levels and one trial was stopped prematurely due to adverse effects in 2 individuals 
(Yanaba et al., 2008).  
 Synovial fibroblasts are also thought to be capable of antigen-presentation within 
the joint. IFNγ primed synovial fibroblasts lines generated from tissues of patients 
with RA expressed MHC Class II, and are capable of inducing T cell responses to 
superantigens, as well as IL-2 production from arthritogenic cartilage-peptide specific 
HLA-DR SE–restricted T cell hydridomas (Tran et al., 2007a; Tsai et al., 1996). LFA-
1(CD18/CD11a) and ICAM-1 molecules cluster at contact points between T cells and 
fibroblasts respectively and anti-LFA-1 antibodies inhibit T cell-fibroblast interactions 
(Krzesicki et al., 1991; Nakatsuka et al., 1997). Like professional APCs, fibroblasts 
express other ligands important in T cells interactions including VCAM-1, CD40 and 
LFA-3, but not the classical B7 co-stimulatory molecules CD80 or CD86. Recent 
data has demonstrated the expression of an alternative B7-H3 co-stimulatory 
molecule on synovial fibroblasts, and indicates a role for this protein in the induction 
of IFNγ, TNFα and IL-2 from T cells (Tran et al., 2008).  
 Macrophages are the dominant producers of TNFα, IL-6, IL-1β, GM-CSF, and 
chemokines including IL-8, in the rheumatoid synovium, at least in part, this is due to 
their contact with T cells. These cells are in close proximity in synovial tissue, and 
removal of T cells from synovial tissue cultures significantly inhibits spontaneous 
TNFα production. When these T cells are co-cultured with peripheral blood 
monocytes they induce monocytic TNFα (Brennan et al., 2002). Thus activated 
synovial T cells are a key driving force behind the pro-inflammatory environment in 
RA synovium. The expression of co-stimulatory molecules such as CD40L on T cells 
after antigen activation leads to pro-inflammatory cytokine production, which acts 
reciprocally on T cells influencing their differentiation, but also generates effector T 
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cells in the joint which have not been locally activated by antigen. The latter forms 
the basis for the generation of an in vitro model which is investigated in this thesis 
and is discussed in detail in section 1.1.7. 
 The expression of cytokines on the cell surface is important in a number of cell-cell 
interactions. IL-15 and IL-7 amplify T cell interactions with macrophages and 
fibroblasts, as does membrane bound TNFα (McInnes et al., 1997; Parry et al., 1997; 
Tran et al., 2007b; van Roon et al., 2005). IL-15 and IL-7 belong to the common γ 
chain receptor family of cytokines, and in general act as non-polarising growth 
factors for T cells. They are both required for T cell homeostasis and have pro-
inflammatory properties in RA, but are expressed at different levels in synovial 
membranes. IL-7 is synthesised at low levels by synovial fibroblasts and also has a 
role in the formation of cell-cell interactions during lymphoid neogenesis within the 
synovium (Harada et al., 1999). IL-15 is produced in abundance by macrophages, 
DCs and synovial fibroblasts, but is rapidly turned over and is often observed on the 
cell surface bound to IL-15Rα from where it is able to act in trans with other cells 
expressing IL-15R (Dubois et al., 2002; Miranda-Carus et al., 2004). IL-15 induces 
the release of both IFNγ and IL-17 from CD4+ T cells and promotes B cell maturation 
(McInnes et al., 1996). It amplifies TNFα and chemokine release from myeloid cells 
thus enhancing T cell migration. Neutralising IL-15 with a soluble IL-15 receptor (sIL-
15R) and human anti-IL-15 mAb (AMG714) ameliorated CIA, and showed modest 
clinical efficacy in Phase I trials. The efficacy of targeting IL-15 comes from inhibiting 
its ability to influence the functions of multiple cell types in RA; however a central role 
or necessity for this cytokine is unlikely. 
 The direct interaction of T cell surface RANKL with monocyte precursor RANK 
promotes osteoclastogenesis (Kotake et al., 2005). It has been shown that peripheral 
blood T cells isolated from patients with early RA who have not yet received 
treatment and SF T cells from patients with established disease are  both capable of 
osteoclastogenesis from autologous peripheral blood monocytes. This is dependent 
on surface expression of RANKL on T cells, and also requires the presence of IL-15 
on the surface of both cells. Consistent with previous data, osteoclastogenesis via 
cell surface RANKL-RANK is potentiated by IL-17, TNFα, IL-6 and IL-1β (Miranda-
Carus et al., 2006).  
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1.1.3.4 Regulatory T cells in RA 
 The aberrant autoimmune response observed in RA has lead to intensive 
investigation into the function of Treg cells in this disease. In mice CD4+CD25+ Treg 
cells play an important role in controlling the pathogenesis of arthritis in experimental 
models. Depletion of Treg cells with anti-CD25 mAb in CIA, aggravated disease 
which was reversed by adoptive transfer of CD4+CD25+ (Morgan et al., 2003). 
Adoptive transfer of CD4+CD25+ Treg cells prior to onset of arthritis reduced the 
severity of arthritis and transfer of cells into mice with established arthritis also had a 
therapeutic effect (Morgan et al., 2005). No significant changes in collagen specific T 
or B cell responses were observed as a result of Treg therapy, but these adoptively 
transferred cells were capable of suppression within in vitro assays and were found 
to have migrated to the inflamed synovial tissue, suggesting localised suppressive 
action in this environment. Treg cells shed TNFRII from their surface after TCR 
triggering, and are capable of reducing systemic inflammation, indicating that the 
success of Treg therapy may be due to an increase in endogenous TNFα inhibitory 
mechanisms in the mouse joint (van Mierlo et al., 2008).  In the KxB/N model, Tregs 
against the self-antigen glucose-6-phosphate isomerase attempt to control the 
immune response. Massive thymic deletion delays disease due to the elimination of 
pathogenic T cells but mice eventually succumb to systemic autoimmunity with multi-
organ involvement because of concomitant elimination of self reactive Treg cells 
(Shih et al., 2004). In addition, CIA mice have been successfully treated with a 
recombinant form of the novel cytokine IL-35 (IL-12 family) which attenuated disease 
through the expansion of CD4+CD25+foxp3+ Treg and the suppression of IL-17 
production from Th17 cells (Niedbala et al., 2007).  
 In humans initial comparisons of Treg cell numbers in the PB of RA patients and 
healthy individuals have shown conflicting results: separate studies have shown 
relative increases, decreases or no differences between RA and normal PB (Cao et 
al., 2004; Lawson et al., 2006; van Amelsfort et al., 2004). However there is a 
consensus from all these studies that Treg cells are increased in the SF of RA 
patients, compared to the PB. Using more defined markers for the identification of 
Treg populations such as foxp3+, CD27+ and/or CD127low expression has confirmed 
the presence of these cells within inflamed synovium (Ruprecht et al., 2005; Seddiki 
et al., 2006). Synovial Treg cells express activation markers CD69 and MHC Class 
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II, co-stimulatory molecules OX40 and CTLA4, and have high levels of TNFRII and 
glucocorticoid-induced TNF receptor family-related protein (GITR).  
  Controversy also exists about the suppressive capacity of synovial Treg cells. A 
number of reports have suggested an increase in the ability to suppress in vitro T cell 
proliferation compared to those isolated from the periphery (Cao et al., 2004; van 
Amelsfort et al., 2004). CD4+CD25- responder cells isolated from the synovial fluid 
of patients have also been shown to be less responsive to Treg suppression, which 
may explain defective regulation of synovitis despite an apparent increase in 
suppressive activity (van Amelsfort et al., 2004). In contrast, others studies have 
shown impaired Treg function, not only in their ability to suppress T cell proliferation 
but also T cell and macrophage cytokine production (Ehrenstein et al., 2004; 
Valencia et al., 2006). It is possible that discrepancies in these data may be due to 
differences in Treg definition as CD4+CD25+ or CD4+CD25high, since there is strong 
evidence that defects in Treg function are a result of the highly pro-inflammatory 
nature of the RA synovium. Incubation of Treg cells with high levels of TNFα impairs 
their suppression of responder T cell proliferation and cytokine production in 
subsequent in vitro assays which is associated with a decrease in foxp3 expression 
and an increase in TNFRII expression (Valencia et al., 2006). Furthermore pre-
incubation of RA T cells with TNFα or IL-7, but not IL-6 was found to inhibit 
suppressive capacity of SF Treg cells. Thus it appears that both Treg and 
CD4+CD25- responder cell functions are modified by pro-inflammatory cytokines 
(van Amelsfort et al., 2007). Anti-TNFα treatment restores suppressive activity in 
vitro and in vivo. Treg cells isolated from RA patients treated with anti-TNFα antibody 
(Infliximab) are able to suppress T cell cytokine production to a greater extent than 
those isolated from other treatment groups or controls (Ehrenstein et al., 2004). It is 
believed that this occurs not through the direct restoration of original synovial Treg 
cells, but via the emergence of a novel subset of TGFβ secreting CD62L- Treg cells 
(Nadkarni et al., 2007). TGFβ can inhibit T cell proliferation and function, and it 
promotes the de novo generation and maintenance of CD4+CD25+foxp3+ Treg cells 
from CD4+CD25-foxp3- effector cells which themselves produce TGFβ and IL-10. 
TGFβ in the synovial joint is mainly produced by fibroblasts, but its 
immunosuppressive properties are outweighed by the actions of pro-inflammatory 
cytokines. In fact TGFβ may have pro-inflammatory properties, since in combination 
Chapter 1  Introduction 
53 
 
with IL-6 it has been reported to promote Th17 differentiation, although this has yet 
to be confirmed in the context of human immunology 
1.1.3.5 CD8+ T cells in RA 
 Synovial CD8+ T cells produce large quantities of IFNγ and a CD40L+ subset has 
been closely associated with the formation with germinal centres in synovial tissue 
and LTβ production (Kang et al., 2002; Morita et al., 1998). Auto-reactive CD8+ T 
cells are present in inflamed synovium and have been implicated in RA pathology. A 
sub-group of CD8+ cells that co-express the NK cell marker CD57 are of particular 
interest. Increased numbers are observed in the peripheral blood, synovial fluid, 
synovial membrane and bone marrow of RA patients compared to normal controls; 
this oligoclonality is particularly with the Vβ3 T cell receptor (TCR) (Arai et al., 1998; 
Hingorani et al., 1996). The significance of clonally expanded CD8+ T cells in RA 
joints is unclear; populations with TCRs specific for viral epitopes may suggest 
merely the enrichment of CD8+ memory cells to foreign antigens by chemokines 
such as CCL5 (RANTES) or CCL3 rather than expansion of auto-reactive cells to 
self-antigen (Fazou et al., 2001; Patel et al., 2001). Like CD4+ T cells, CD8+ 
memory T cells can be divided into subpopulations depending of their expression of 
chemokine receptors and adhesion molecules. RA patients have significantly fewer 
effector memory CD45RA-CCR7-CD62L- and terminally differentiated 
CD45RA+CCR7-CD62L- T cells in the peripheral blood than controls, reflecting 
migration of these highly cytotoxic cells to the joint (Maldonado et al., 2003). 
Immunoregulatory properties of CD8+ T cells have also been observed in the RA 
synovium. A novel subset of CD8+CD56+CD28- NKT cells can be isolated and 
expanded from synovial tissues and are capable of inhibiting CD4+ T cell 
proliferation in vitro. On adoptive transfer into NOD/SCID mice engrafted with human 
synovial explants, these cells migrate to the tissue reducing cytokine and chemokine 
production, plus fibroblast CD80 and CD86 expression (Davila et al., 2005). 
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1.1.4 B cells in RA 
The role of B cells in RA pathogenesis is highlighted by the efficacy of Rituximab 
therapy in patients. Rituximab is an anti-CD20 mAb that mediates antibody 
dependent cell-mediated cytotoxicity, depleting all B-cell subsets except plasma 
cells. Clinical benefits are associated with a dramatic reduction of circulating B cells 
that typically lasts 7-8 months. During this time systemic and joint inflammation is 
reduced and autoantibody levels fall (Edwards and Cambridge, 2006). In addition to 
autoantibody production and pathogenesis via immune complex mediated pathways, 
B cells contribute to inflammation by the production of IL-6 and LTβ. The 
accumulation of B cells within the synovium, and the formation of germinal centres 
are aided by chemokines such as CXCL13, CXCL12 and LTβ as well as B cell 
survival cytokines. B-cell-activating factor (BAFF) and a proliferation-inducing ligand 
(APRIL) are members of the TNF-superfamily. BAFF is produced by macrophages 
and by synovial fibroblasts in response to TNFα and IFNγ. Dendritic cells (DC) 
secrete APRIL particularly within germinal centre-containing tissues. BAFF and 
APRIL share a receptor known as transmembrane activator and calcium-modulating 
cyclophilin-ligand interactor (TACI) which is expressed on mature B cells and 
activated T cells. TACI:Fc fusion protein, Atacicept, was well tolerated with no 
adverse effects in a Phase Ib trial. Disruption of B cell function was demonstrated by 
decreases in autoantibody levels. B cells may also function as antigen presenting 
cells in RA autoimmunity. For instance, RF-producing B cells have been found to be 
very effective at presenting immune complexes to T cells, irrespective of the antigen 
(Roosnek and Lanzavecchia, 1991).  
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1.1.5 Cytokines in RA 
 So far I have discussed cytokines in the context of synovial lymphocyte function; 
however the most abundant cytokines found in the RA joint are produced by 
macrophages and fibroblasts in the synovial membrane and at the cartilage-pannus 
junction (Chu et al., 1991; Husby and Williams, 1988). Figure 1.4 summarises the 
complex interplay and functions of cytokines within the RA synovium. Cytokines can 
be induced from macrophages and fibroblasts by cellular contact with T and B cells 
(section 1.1.3.3.4), by other cytokines, by immune-complexes or by exogenous and 
endogenous Toll-like Receptor (TLR) ligands. The role of TLRs in RA is beyond the 
scope of this thesis but is reviewed in (Sacre et al., 2007). 
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1.1.5.1 Tumour Necrosis Factor α 
Figure 1.5 The RA synovium is a complex network of cytokines. See text for details. Key - Green 
denotes potential activation processes. Blue denotes cytokines and processes which are impaired. Red 
denotes inhibition. Curved arrows represent cytokine production. Straight arrows represent processes 
downstream of cytokines. Dashed arrows represent differentiation. Abbreviations – CCL = chemokine of CC 
family, GM-CSF = granulocyte monocyte colony stimulatory factor, IFN = interferon, IL = interleukin, LT = 
lymphotoxin, RANKL = Receptor activator of NFκB ligand, TGFβ = transforming growth factor, Th0 = resident 
synovial T cell predominately of a memory phenotype. Treg = regulatory T cell. Th1 = type 1 T helper cell. 
Th17 = IL-17 secreting T helper cell, TLR = Toll-like receptor, VEGF = vascular endothelial growth factor. 
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 TNFα is a pleiotropic cytokine named after the role for which originally described, 
the ability to cause necrosis in tumour cell lines (Carswell et al., 1975). Its principal 
function in immunity is to mediate the acute inflammatory response to microbial 
infection. Produced predominately by macrophages, TNFα stimulates the vascular 
endothelium to express adhesion molecules and chemokines, recruiting neutrophils, 
monocytes and lymphocytes to sites of infection, thus enabling their activation. It is 
also able to induce apoptosis in many cell types. In sepsis the response to infection 
results in large scale TNFα production, such that it enters the bloodstream and acts 
systemically, inducing fever, cachexia, an increased in acute-phase serum protein 
production by the liver, reduced blood glucose levels and thrombosis.  It is 
synthesised as a membrane bound trimer (26kD) which is cleaved by TNFα-
Converting Enzyme (TACE) to a 17kD protein. The biologically active homotrimer 
binds to trimeric receptors. There are two types of TNFα receptor, TNFRI (p55) and 
TNFRII (p75); both are widely expressed on all major cell types. The receptors signal 
via different pathways and elicit different responses due to the presence of a death 
domain in TNFRI but not in TNFRII (Gravestein and Borst, 1998).  
 Early studies of RA detected elevated levels of TNF in synovial fluid, tissue and 
even peripheral blood in RA patients compared to controls, at both the protein and 
mRNA level (Buchan et al., 1988b; Hopkins and Meager, 1988; Husby and Williams, 
1988). The rheumatoid synovium also expresses elevated levels of the TNF 
receptor, and functionally active soluble forms, which act as natural TNF inhibitors, 
are also present (Brennan et al., 1992; Cope et al., 1992).    The importance of this 
cytokine in controlling inflammation in RA became apparent with the development of 
a method of dissociating and culturing cells in vitro from RA synovium without 
purification or extrinsic stimulation enabling spontaneous cytokine release into the 
culture medium, which allowed dissection cytokine of regulation within the 
rheumatoid joint (Brennan et al., 1989b). The regulation of the pro-inflammatory 
cytokine interleukin-1 (IL-1) was initially studied as it had been implicated in joint 
damage in osteoarthritis (OA), and was abundant in RA synovial cultures (Saklatvala 
et al., 1985). Addition of anti-TNFα mAb to RA, but not OA synovial cultures, was 
found to inhibit the production of IL-1. Inhibition was not observed with the addition of 
anti-interleukin-6 (IL-6) mAb to either culture type placing TNFα above IL-1 and IL-1 
above IL-6 in a regulatory cytokine-cascade (Brennan et al., 1989a). A central role 
for TNFα in RA was further strengthened by studies showing that other pro-
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inflammatory cytokines are also regulated by TNFα. Anti-TNFα neutralising 
antibodies inhibited spontaneous granulocyte monocyte-colony inducing factor (GM-
CSF) production by RA synovial cells (Haworth et al., 1991). Furthermore, GM-CSF 
mRNA and protein synthesis was elevated on addition of TNFα or IL-1β to RA 
synovial fibroblasts, but not by addition of M-CSF, IFNγ or interleukin-6 (Alvaro-
Gracia et al., 1991). A comparative study on the effects of anti-TNFα antibodies and 
IL-1 receptor antagonist (IL-1ra), a naturally occurring IL-1 inhibitor, on cytokine 
production from synovial cultures determined the hierarchy of control between the 
two cytokines. Neutralising TNFα substantially downregulated IL-1β, IL-6 and IL-8 
production in synovial membrane cultures. The addition of IL-1ra also reduced IL-6 
and IL-8 levels but importantly not TNF levels (Butler et al., 1995). Thus the 
relationship between TNFα and IL-1 is non-reciprocal, and cytokine regulation in 
chronically inflamed synovial joints can be described as a cascade of pro-
inflammatory cytokines with TNFα at its apex. However TNFα also induces the 
synthesis of anti-inflammatory cytokines such as IL-10, IL-1ra and sTNFR, but these 
seem incapable of counteracting the pro-inflammatory processes at work within the 
synovium (Feldmann et al., 1996).  
 1.1.5.1.1 Anti-TNFα therapy 
 As the apex of a cytokine cascade in rheumatoid synovium, TNFα was an obvious 
therapeutic target. Proof of principle was obtained in vivo using the CIA murine 
model. Mice treated with anti-TNFα/β mAb either prior to induction of disease or after 
the disease was established showed reduction in paw swelling and histological 
severity of disease compared to controls (Williams et al., 1992). In 1992 a PhaseI/II 
clinical trial of a humanised anti-mouse monoclonal anti-TNFα antibody (Infliximab) 
was carried out in 20 patients with active RA. Treatment was well tolerated and 
significant clinical improvements were observed, however relapse after termination 
of treatment occurred indicating the effects were transient and not a cure (Elliott et 
al., 1993). A Phase II randomised, double-blind placebo–controlled trial followed, 
involving patients and rheumatologists across Europe, formally establishing TNF 
blockade treatment as clinically effective (Elliott et al., 1994a). A trial to assess the 
effects of long-term treatment indicated the best dose required to optimise efficacy 
and reduce immunogenicity to the chimeric antibody, but also demonstrated a key 
synergy between anti-TNFα treatment and the standard methotrexate (MTX) 
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treatment when given in combination (Elliott et al., 1994b; Maini et al., 1998). 
Following Phase III trials, treatment with Infliximab was deemed effective and safe, 
and in 1999 was approved  for use in combination with MTX, in the US and Europe 
(Maini et al., 1999). In 2004 the results of the ASPIRE (Active Controlled Study of 
Patients Receiving Infliximab for Treatment of Rheumatoid Arthritis of Early Onset) 
study demonstrated clinical, radiographic and functional benefits of combination 
therapy over MTX alone in treatment-naϊve patients with less than 3 years active 
disease (St Clair et al., 2004). Subsequently the use of Infliximab in combination with 
MTX has been approved, by the Federal Drugs Administration (FDA) in the US, for 
the initial treatment of moderate-to-severe RA patients removing a previous 
requirement to fail MTX first. There are currently three anti-TNF biological therapies 
licensed in the UK: Infliximab (Remicade™, Centocor) and adalimumab (Humira™, 
Abbott Laboratories) are both anti-TNFα antibodies whereas Etanercept (Enbrel™, 
Immunex) is a soluble form of the p75 TNF receptor II. Licences have been 
expanded beyond the treatment of RA to include other inflammatory diseases such 
as Crohn’s disease, ankylosing spondylitis and psoriatic arthritis.  
  A new generation anti-TNF therapies, that bind both soluble and membrane bound 
TNFα, are in the pipeline and include a third anti-TNFα mAb known as 
golimumab/CNTO148 which has shown efficacy in combination with MTX in a Phase 
II trial and is undergoing Phase III trials in RA, ankylosing spondylitis and psoriatic 
arthritis (Kay et al., 2008). In addition UCB/Celltech developed 
certolizumab/CDP870, a humanised pegylated anti-TNFα Fab fragment which 
showed efficacy in Crohn’s disease.  
 Throughout their development questions have been raised about the safety of these 
drugs due to the protracted reduction of systemic TNFα and its implications on the 
immune system of the patient. A small but significant increase in latent or 
opportunistic infections have been observed, such as Tuberculosis (TB), 
Pneumocystis carinii and development of Salmonella septicaemia (Netea et al., 
2003). Screening for latent TB infection by physicians is now advised prior to 
prescribing anti-TNFα therapy. Despite this more than 1.5 million RA patients have 
been given anti-TNFα biologicals worldwide as a safe and efficacious treatment. 
However, approximately 30% of RA patients do not respond to anti-TNFα treatment; 
therefore continuing research into the mechanisms underlying TNFα production and 
other pathogenic components in RA is required in order to provide a cure. 
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1.1.5.2 Interleukin-1 and its superfamily 
 The IL-1 superfamily of proteins includes IL-1α, IL-1β, IL-1ra, IL-18 and IL-33 all of 
which are detectable in rheumatoid synovium, but their role in the pathogenesis of 
the disease has not yet been substantiated. IL-1α and IL-1β are less than 30% 
homologous but bind the same receptors, as does their antagonist IL-1ra. IL-1 has 
similar biological functions as TNFα on a local and systemic level. A role in RA was 
originally proposed due to its destructive activities on bone and cartilage (Saklatvala, 
1986; Saklatvala et al., 1985). IL-1 is secreted by activated macrophages, 
monocytes and fibroblasts. In turn it promotes pro-inflammatory cytokine production 
from these cells, as well as upregulating adhesion molecule expression on 
endothelial cells and promoting osteoclastogenesis. A comparison of anti-IL-1β or IL-
1ra treatment with anti-TNFα revealed IL-1 blockade to be more successful in 
established disease compared to TNFα blockade which ameliorated disease only 
when administered early in CIA (Joosten et al., 2008).  In humans treatment of RA 
with recombinant human IL-1ra (Anakinra) showed clinical benefit and thus was 
licensed (Benito et al., 2004; Bresnihan, 2002; Campion et al., 1996). However it has 
failed to make any dramatic impact in the treatment of the disease, indeed only 17% 
of patients reach ACR50 responses, in comparison to 50-70% patients on anti-TNF 
therapy. It was hypothesised that perhaps in patients who fail to respond to anti-
TNFα treatment, IL-1 plays the greater pathogenic role. However when these 
patients were treated with Anakinra no further clinical response was observed (Buch 
et al., 2004). A combination of anti-TNFα and IL-1ra showed promise as a 
therapeutic strategy in both CIA and in synovial cultures in vitro. Despite this, 
patients who had failed MTX and were given a combination of Etanercept and 
Anakinra showed no additional benefit, and the incidence of serious adverse effects 
was increased compared to Etanercept treatment alone (Genovese et al., 2004).   
 IL-33 (IL-1F11) was identified by its binding to the IL-1 receptor super family 
member ST2 (Schmitz et al., 2005). Like other IL-1 super family members it is 
produced as a pro-protein that is cleaved to an active form by caspase-1. Ligation of 
ST2 by IL-33 leads to activation of the mitogen-activated protein (MAP) kinase 
pathways and of the transcription factor NFκB, characteristic of IL-1 superfamily 
signalling.  IL-33 stimulation increases IL-5 and IL-13 production by Th2 and inhibits 
IFNγ production by Th1 cells. In addition it acts as a Th2 chemoattractant (Komai-
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Koma et al., 2007). IL-33 (mRNA and protein) has recently been reported to be 
present in RA synovial membranes. Synovial fibroblasts express IL-33 in the 
presence of TNFα and IL-6. In CIA, administration of IL-33 exacerbates disease and 
increased levels of TNFα, IL-17 and IL-5 are observed, whereas in the IL-33 
knockout mouse disease is reduced. Data from adoptive transfer experiments 
suggest that mast cells (which express high levels of ST2) are the key mediators of 
IL-33 effects in CIA (Xu et al., 2008).  
1.1.5.3 Interleukin-6 
 Human IL-6 is a 26kDa homodimeric cytokine secreted by monocytes, 
macrophages, endothelial cells and fibroblasts in response to microbial components 
such as LPS and other cytokines such as TNFα and IL-1β, leading to the acute-
phase response to inflammation. In conjunction with colony-stimulating factors, it 
also promotes hematopoiesis of myeloid progenitor cells. Secretion of IL-6 by Th2 
cells promotes the differentiation of proliferating B cells into plasma cells and thus 
antibody production. It has also been shown to increase proliferation of activated T 
cells. Binding of IL-6 to its receptor, induces the dimerisation of the associated 
signal-transducing protein gp130, and activation of the JAK/STAT3 signalling 
pathway.  
   A role of IL-6 in the pathogenesis of RA has been suggested by its abundance in 
the inflamed joint, by the resistance of IL-6 knockout mice to CIA and from the 
results of clinical trials with an anti-IL-6R antibody. Elevated levels of IL-6 are found 
in the synovial fluid of RA patients compared to OA patients and levels of serum IL-6 
correlate with levels of C-reactive protein and disease severity (Houssiau et al., 
1988).   Spontaneous release of IL-6 by synoviocytes in vitro is downstream of TNFα 
and IL-1β, since addition of recombinant TNFα or IL-1β enhances IL-6 release and 
anti-TNFα or IL-1 receptor antagonist inhibits it (Butler et al., 1995; Guerne et al., 
1989). However IL-6 is required for the development of arthritis, as in its absence 
mice do not develop CIA, display no cellular infiltrate or tissue damage in the joints 
and a exhibit reduced antibody response to collagen (Alonzi et al., 1998). Thus IL-6 
contributes to disease by promoting plasma cell development and autoantibody 
production as well as activating endothelium and recruiting leukocytes to the joint 
(Romano et al., 1997). Synovial fibroblasts are a major source of IL-6 and autocrine 
amplification of IL-6 production and fibroblast activity leads to prolific fibrosis and 
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joint damage (Mihara et al., 1995). Blockade of IL-6 could yield beneficial effects in 
the treatment of RA. To this end, a humanised anti-IL-6 receptor (IL-6R) antibody 
known as MRA or tocilizumab was developed and has been shown to be safe and 
capable of significantly improving disease symptoms in clinical trials. Tocilizumab 
competes with IL-6 for both the membrane-bound and soluble forms of IL-6R, 
preventing the formation of the ligand/receptor complex and subsequent signal 
transduction via gp130. In a multicentre, double-blind, placebo-controlled Phase II, 
trial 164 patients with refractory RA received either 4mg/kg or 8mg/kg of tocilizimab 
every 4 weeks for 3months. Compared to placebo, treatment significantly improved 
disease in a dose-dependent manner with 78% patients in the 8mg/kg group 
achieving a 20% improvement in ACR clinical criteria (ACR 20 response). A second 
phase II trial conducted in Europe with patients who had failed MTX treatment 
showed significant ACR 50 and ACR 70 responses in patients treated with a 
combination of tocilizumab and MTX, compared to either therapy alone. A variety of 
adverse effects were observed over each of the trials; however none were directly 
attributable to tocilizumab treatment. A phase III trial of tocilizumab versus placebo 
alongside MTX treatment in 364 patients showed significantly higher ACR20 
responses when compared to placebo plus MTX.  The role of IL-6 in the 
pathogenesis of disease is clear as the efficacy of IL-6 blockade was comparable to 
that delivered by TNFα inhibition, and treatment by tocilizumab could soon be an 
viable treatment option (Smolen et al., 2008).  
1.1.5.4. Interleukin-10 
 IL-10 is a potent anti-inflammatory cytokine expressed in RA synovial tissue. In 
immune response it is able to inhibit TNFα production from activated myeloid cells 
(Williams et al., 2004). However in RA these anti-inflammatory properties are not 
sufficient to overcome chronic inflammation (Katsikis et al., 1994). 
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1.1.6 Leukocyte migration in RA 
 The migration of leukocytes from the blood to sites of inflammation occurs by a 
multi-step process (Figure 1.4) involving leukocyte capture and rolling via selectins; 
activation of integrins and endothelial adhesion, transendothelial migration, and 
chemotaxis through tissues (Springer, 1994). Differential upregulation of selectin 
and/or integrin adhesion molecule expression allows regulation of organ-specific 
trafficking by leukocytes; however if these regulatory mechanisms become altered 
chronic inflammation can occur. Leukocytes adhere to endothelial cells and 
transmigrate into the synovial sublining layer. Increased leukocyte recruitment to the 
joint is important in the inflammatory processes and in the pathogenesis of RA. 
Evidence from both animal models of arthritis and RA patients suggests that 
trafficking to the synovium is adhesion molecule dependent.  
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Figure 1.5 Schematic of leukocyte transendothelial migration. See text for details. 
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1.1.6.1 Adhesion molecule expression in RA  
 Selectins are a group of glycoproteins expressed on the cell surface in response to 
inflammatory signals which mediate the initial attachment, tethering and rolling of 
leukocytes along the endothelium. They bind carbohydrate moieties on target 
proteins via a common lectin-like domain and are cleaved from the cell surface after 
cellular activation. P-selectin (CD62P) and E-selectin (CD62E) are expressed by 
endothelial cells whereas L-selectin (CD62L) is found on the surface of leukocytes. 
During rolling, leukocytes are triggered by chemokines bound to the endothelial 
surface, leading to activation of integrins and firm adhesion to the endothelial 
surface. Integrins are glycoproteins consisting of α and β subunits which form a 
variety of heterodimers. Both subunits consist of an extended extracellular (EC) 
domain, a transmembrane domain (TM) and an intracellular domain (IC) which is 
capable of signal transduction and binding to the cytoskeleton. Integrins are 
classified according to their β chain. Those commonly involved in leukocyte 
migration include the β2 integrins - αLβ2 or LFA-1 (CD11a/CD18); αMβ2 Mac-
1(CD11b/CD18) and αXβ2(CD11c/CD18) plus the β1 integrin α4β1 or VLA-4 
(CD49d/CD29). The ligands for integrins are the cell adhesion molecules (CAMs) of 
the Ig superfamily such as the ICAMs, VCAM-1, PECAM-1 and MadCAM-1 on 
endothelium. Adhesion molecule expression throughout the synovium is summarised 
in Table 1.2. Their expression is not just required for cellular infiltration but is also 
important in the organisation of cells within the sublining and the hyperplastic lining 
layer. 
1.1.6.1.1 Role in cellular migration  
Studies in rodent arthritis models have given mixed and apparently contradictory 
results. The roles of CD62P and CD62E (E-selectin) were investigated in mice using 
blocking antibodies before onset of arthritis.  Anti-CD62E treatment, but not anti-
CD62P, ameliorated disease. In contrast CD62P, CD62E deficient mice and the 
double knockout develop a more severe arthritis in the CIA model (Bullard et al., 
1999; Ruth et al., 2005). Indeed studies with radiolabelled neutrophils and 
monocytes in adjuvant-induced arthritis have shown that in established disease P-
selectin migration predominates, whereas CD62E is not essential (Walter and 
Issekutz, 1997). Thus the relative roles of selectins in murine arthritis appear to 
change with disease progression.  
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Studies following the course of CIA suggested a link between the expression of pro-
inflammatory cytokines and the increased expression and activation of adhesion 
molecules (Hersmann et al., 1998). This was elegantly demonstrated in the in vivo 
murine SCID model with human RA synovium implanted subcutaneously; TNFα in 
the synovium enhanced not only the expression of ICAM-1 and VCAM-1 but also 
increased the migration of injected human PBLs to the synovium (Wahid et al., 
2000). Similar experiments showed a role for IL-15 produced by synovial endothelial 
cells in T cell trafficking via upregulation of LFA-1 (Oppenheimer-Marks et al., 1998). 
Furthermore, the expression of VCAM-1, ICAM-1 and CD62E is lower in RA patients 
on anti-TNFα therapy, providing strong evidence that one way in which TNFα exerts 
its pro-inflammatory effect is by enhancing mechanisms involved in cellular adhesion 
and migration (Klimiuk et al., 2004; Paleolog et al., 1996; Tak et al., 1996). 
 
Table 1.2 Expression of adhesion molecules in the RA synovium 
Location Selectins Integrins Ig Cadherins 
CD62E β1 β3 VCAM-1  
CD62P α1 α3 α5 α6 αv ICAM-1 -2 -3  
  PECAM-1  
Endothelium 
  LFA-3  
CD62E β1 β2 β7 VCAM-1  
CD62L α1 α4 α6 αv αL αM αX ICAM-1 -3  
  PECAM-1  
Sublining 
  LFA-3  
CD62L β1 β3 β4 β5 VCAM-1 Cadherin-11 
 α1 α2 α3 α4 α5 α6 αV  αX ICAM-1  
  PECAM-1  
Lining 
  LFA-3  
 β1 β2 β3 β7 ICAM-1  Synovial fluid 
 α1 α2 α3 α4 α5 α6 αL LFA-3  
 
 
 
Adapted from (Agarwal and Brenner, 2006). Abbreviations – CD = cluster differentiation, ICAM = 
intercellular adhesion molecule, LFA = lymphocyte function-associated antigen, PECAM = platelet-
endothelial cell adhesion molecule, VCAM = vascular cell adhesion molecule. 
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 RA synovial endothelial cells express CD62E and CD62P while elevated levels of 
soluble CD62P (sCD62P) and CD62L (sCD62L) are present in the serum of RA 
patients (Littler et al., 1997; Tak et al., 1996). The fact that sCD62P levels correlate 
to disease activity indicates a predominance of this selectin on endothelia in active 
human disease too (Veale et al., 1998). ICAM-1 and VCAM-1 are also widely 
expressed in synovial tissue, on endothelial cells of the microvasculature and on 
synovial macrophages (Koch et al., 1991a). In vitro synovial T cells have been 
shown to exhibit strong binding to CD62E and VCAM-1 (Postigo et al., 1992). These 
T cells express LFA-1 and VLA-4, allowing them to bind to ICAM-1 and VCAM-1 
respectively and to migrate into the sublining, in addition to binding at the lining layer 
(Ueki et al., 1994; van Dinther-Janssen et al., 1994). CD44 also mediates leukocyte 
adhesion to the endothelial surface via binding to hyaluronan molecules. It is up 
regulated in the inflamed synovium of RA patients and inhibition of CD44 in mouse 
models reduces leukocyte trafficking (Mikecz et al., 1995). 
1.1.6.1.2 Organisation of the synovium 
 Studies of secondary lymphoid tissues have led to the hypothesis that the lymphoid-
like microarchitecture observed in the sublining layer of the rheumatoid synovium 
can be regulated via the interactions of β1 integrins with CAMs and with components 
of the extracellular matrix (ECM) (Agarwal and Brenner, 2006). For instance 
interactions between VLA-4 /VCAM-1 and LFA-1/ICAM-1  on B cells and DCs (Ogata 
et al., 1996). Interactions also influence the activation status of cells in the sublining. 
The survival of B cells in the joint is in part dependent upon the interactions with 
synovial fibroblasts. The interaction of VLA-4 and VCAM-1 upregulates B cell BclXL, 
leading to a decrease in apoptosis (Hayashida et al., 2000). As previous discussed 
in sections 1.0.3.1 and 1.1.3.3.4, β2 mediated interactions such as LFA-1/ICAM-1 
play a role in T cell activation via the formation of conventional immune synapses 
with APCs and the induction of pro-inflammatory mediators from macrophages and 
fibroblasts by cytokine-activated T cells (Bachmann et al., 1997; Brennan et al., 
2008; Nakatsuka et al., 1997).  
  The synovial lining layer consists of predominantly fibroblast and macrophage-like 
synoviocytes interacting with each other within a meshwork of ECM. In RA the 
number of fibroblasts and macrophages increases, and the cells become active, 
extending into the joint space and attaching to the cartilage forming an invasive and 
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destructive pannus. α5β1 expressed by fibroblasts plays an important role; its 
interaction with fibronectin promotes fibroblast proliferation and decreases apoptosis 
encouraging hyperplasia. IL-1β in the synovium promotes the invasion of the pannus 
into cartilage by fibroblasts through upregulation of β1 integrins and the production of 
collagenase (Wang et al., 1997). Fibroblasts also express VCAM-1, which is 
upregulated by TNFα and IL-18, and is involved in cellular contact with VLA-4-
expressing macrophages (Morales-Ducret et al., 1992; Morel et al., 2002). However 
detailed analysis of inflamed synovial lining layers in mice indicates expression of 
VCAM-1 on the articular facing surface of fibroblasts and ICAM-1 expression on cell 
protrusions that form inwards creating a scaffold occupied by macrophages 
expressing both LFA-1 and Mac-1 (Liang et al., 2004). Recently one member of the 
Cadherin family of adhesion proteins, Cadherin-11, was detected in normal and 
disease synovium. Cadherins form calcium-dependent homophilic intercellular 
interactions and are able to modulate cell proliferation and invasion via associations 
with growth factor receptors, signal transduction and modulation of MMP production. 
Cadherin-11 is expressed by fibroblasts at points of contact between the cells and is 
crucial for the formation of the lining layer. Cadherin-11 knockout mice exhibit 
hypoplasia of the synovial lining layer and their fibroblasts are less invasive than 
wild-type (Lee et al., 2007a).  
1.1.6.2 Chemokines and their receptors in RA  
 In addition to adhesion molecule expression, cellular trafficking to inflammatory sites 
is dependent upon the interaction of chemokines and their appropriate receptors. 
Chemokines are small chemoattractant proteins secreted by many cell types 
including leukocytes and endothelial cells. They are able to recruit leukocytes by 
providing a chemotactic gradient, activating integrins, stimulating cytokine release 
and modulating vascularisation, and thus are integral to the inflammatory process. 
Chemokines are classified according to the position of conserved cysteines and are 
given the suffix L to denote ligand whereas the receptors have the suffix R.  Single 
chemokines bind and signal through number of different chemokine receptors 
resulting in redundancy in the system. The expression of chemokines and their 
receptors has been extensively explored in RA, along with their modulation by the 
pro-inflammatory environment. Synovial monocytes, macrophages and fibroblasts 
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are the main source of a variety of chemokines attracting T cells, B cells, DCs, 
monocytes and neutrophils to the joint. 
1.1.6.2.1 Chemokines 
 IL-8 (CXCL8) is abundant in the synovial tissue, fluid and sera of RA patients and 
plays an important role in mediating synovial inflammation as a potent neutophil 
chemoattractant and angiogenic agent. Spontaneous IL-8 expression from synovial 
cultures is regulated by TNFα and IL-1β (Butler et al., 1995), however further 
analysis found that it is the production of IL-8 by synovial fibroblasts that is regulated, 
whereas synovial macrophages constitutively express IL-8 (Koch et al., 1991b). 
TNFα, IL-1 and IL-18 induce production of CXCL5 (ENA-78), CCL2 (MCP-1) and 
CCL3 (MIP-1α) from synovial macrophage and fibroblasts (Koch, 2005). IL-8 and 
CCL2 levels declined in patients given anti-TNFα treatment and this corresponded to 
a reduction in leukocyte migration (Taylor et al., 2000). CCL3 production by CD44+ 
synovial T cells is augmented by IL-15 (Wang and Liu, 2003). CCL20 (MIP-3α) is a 
potent chemoattractant for monocytes, dendritic cells, T cells and B cells. It is 
expressed by macrophages and fibroblasts in the lining layer, as well as infiltrated 
macrophages in the sublining. Expression is driven by TNFα, IL-1β, IL-17 and IL-18 
(Chabaud et al., 2001; Matsui et al., 2001). Similarly CCL5 (RANTES) expression by 
macrophages and fibroblasts in the synovium is upregulated by TNFα, IL-1β and 
IFNγ (Volin et al., 1998). Chemokines can also promote the secretion of each other, 
for instance CXCL12 (SDF-1), CCL2 and CCL5 upregulate IL-8 from fibroblasts 
(Nanki et al., 2001). Cell-cell contact can also induce chemokine production. Type II 
collagen-reactive T cells from synovial fluid of RA patients increase the production of 
IL-8, CCL2 and CCL3 when co-cultured with synovial fibroblasts via CD40L-CD40 
ligation (Min et al., 2004). In addition, T cells activated via ligation of the TCR or via 
chronic cytokine-stimulation with IL-2, IL-6 and TNFα are able to induce CCL2, 
CCL3, CCL4, CCL5, IL-8, CXCL3 and CXCL10 production from in vitro derived 
macrophages in co-culture (Beech et al., 2006). Chemokine expression in RA is 
summarised in Table 1.3. 
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Table 1.3 Expression of chemokines in the RA synovium 
Expressed by 
Chemokine 
Cell Location 
Cell type 
attracted 
Other 
functions Receptors 
CXCL1 M SF, ST N Angiogenic CXCR2 
CXCL4  serum  Angiostatic CXCR3 
CXCL5 M, F SF, ST N Angiogenic CXCR2 
CXCL6 F* SF, ST N  CXCR1 
CXCL7 M ST N Angiogenic CXCR2 
IL-8 M, F SF, ST, 
serum 
N Angiogenic CXCR1 
CXCR2 
CXCL9 M SF, ST  Angiostatic CXCR3 
CXCL10 M SF, ST T Angiostatic CXCR3 
CXCL12 M, F ST T, B, Mo Angiostatic CXCR4 
CXCL13 F, DC, E ST** T, B  CXCR5 
CXCL16 M ST, SL Mo  CXCR6 
CCL2 M, F SF, serum Mo  CCR2 
CCL3 M, F, T, N SF, ST T, B, Mo  CCR1 
CCR5 
CCL5 M, F SF, ST, 
SL 
T, B, Mo  CCR1 
CCR3 
CCL8 F* SF   CCR3 
CCR5 
CCL19  ST B, DC  CCR7 
CCL20 M, F SF, ST T, B, Mo, 
DC 
 CCR6 
CX3CL1 M, F, DC, 
E, Mo 
SF T, Mo Induces MMPs 
from fibroblasts 
CX3CR1 
XCL1 T PB, ST T Inhibits MMPs 
from fibroblasts 
XCR1 
 
  
 
 
Table summarises expression of individual CXC, CC and other chemokines in RA. The cells they are 
expressed by, the location of expression, the cells attracted by the chemokine, other properties such as 
vascular regulation and their appropriate receptors. See text for further details. Table collated from data 
presented in (Koch, 2005; Szekanecz and Koch, 2007). Abbreviations – B = B cell, DC = dendritic cell, 
E = endothelial cells, F = fibroblast, M = macrophage, MMP = matrix metalloproteinase, Mo = 
monocyte, N = neutrophil, PB = peripheral blood, SF = synovial fluid, SL = synovial lining layer, ST = 
synovial sublining tissue, T = T cell. * = toll-like receptor activated fibroblasts, ** = within germinal 
centres.  
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1.1.6.2.2 Chemokine receptors 
 CCR5 and CCR2 are observed on infiltrating monocytes and on T cells in synovial 
tissue (Katschke et al., 2001). The importance of both these receptors has been 
investigated in animal models. Deletion of CCR5 in the CIA model did not affect the 
course or severity disease due to the redundancy of the chemokine system, as 
CCR1 and CCR3 also able to bind CCR5’s ligands CCL3 and CCL5. However, a 
polymorphism in the CCR5 gene has been reported to confer a milder disease 
although this has not been confirmed (Garred et al., 1998; John et al., 2003).  CCR2 
knockout mice develop severe CIA, yet blockade in wild type with anti-CCR2 
antibody ameliorates disease if administered early in disease, but exacerbates it if 
administered at late-stage. This is thought to be due to a population of CCR2+ 
regulatory T cells whose numbers increase 5-fold as CIA progresses and only in the 
latter stages are they impaired by the mAb, probably as a result of their incorrect 
location within the joint manifesting in exacerbated disease (Bruhl et al., 2004). The 
expression of CCR1 and CCR5 on monocytes has been compared in paired 
peripheral blood and synovial tissue samples from individual RA patients and healthy 
controls. In the peripheral blood the number of cells expressing these receptors is 
low, but within the synovial tissue expression is high indicating pronounced migration 
of these cells to the inflamed joint (Haringman et al., 2006). 
 CXCR4 is highly expressed by synovial T cells and ligation of CXCL12 on the 
endothelial surface is required for T cell adhesion to ICAM-1 leading to their 
infiltration and accumulation in the joint. Expression of CXCR4 on CD4+ synovial T 
cells is promoted by TGFβ in the joint and may be a factor in the persistence of cells 
in the joint (Buckley et al., 2000). The idea that modulation of chemokine receptor 
expression within synovial tissue leads to aberrant retention of pathogenic cells has 
been proposed by Salmon and Buckley. Chemokines CCL5 and CXCL11, ligands to 
CCR5 and CXCR3 respectively, are expressed by synovial stromal tissue and not 
endothelium, implying a role for these receptors in accumulation of leukocytes over 
recruitment.  CCL19 and CXCL12 expression is localised to vascular and lymphatic 
vessels. Both chemokines are known to be required for germinal centre formation in 
lymphoid tissue and are thus thought to be involved in the lymphoid-like 
microarchitecture often seen in the RA. This localised expression may also prevent 
of lymphatic re-entry of CD4+ T cells out of the synovium, as the majority are CCR7-, 
leading to further accumulation in the synovium (Bradfield et al., 2003; Burman et al., 
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2005). In addition the accumulation of Th17 cells in the joint maybe due to CCL20 
expression by synovial tissue and their preferential chemotaxis via CCR6 (Hirota et 
al., 2007; Singh et al., 2008).  
 The regulation of cellular trafficking is complex and finely balanced and thus 
intervention at the chemokine receptor interface seems an unlikely therapeutic 
strategy in inflammatory disease. However, some success has been reported using 
a small molecular weight antagonist to CCR1 (Amat et al., 2006; Haringman et al., 
2003). 
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1.1.7 Bystander model of T cell activation in the rheumatoid joint 
 Antigen-dependent activation of T cells is thought to be an initiating factor early in 
the disease process. Lymphopenia and expanded clonotypes in the PB of RA 
patients indicate a break in peripheral tolerance to a number of autoantigens. 
Evidence for expanded clonotype in the joint itself is less convincing. In the synovium 
activated synovial T cells exhibit impaired TCR signalling and are resident in a highly 
complex and pro-inflammatory cytokine environment. Therefore we propose that an 
antigen-independent activation mechanism predominate in the chronic stages of 
disease. T cells activated by cytokines in the joint acquire effector functions that 
enable them to induce further pro-inflammatory cytokine production from monocytes, 
macrophages and fibroblasts as well as chemokines. This in turn promotes migration 
and subsequently induces the activation of infiltrating T cells. This is termed 
bystander-activation and is independent of the TCR.   
 Bystander cytokine-activation of CD4+ T cells may be mimicked in vitro and was 
reported in 1994 using a cocktail of IL-2, IL-6 and TNFα (Unutmaz et al., 1994). 
Cytokine-activated T cells were able to proliferate, produce IFNγ and induce 
immunoglobulin production from B cells. Professor Brennan’s group at the Kennedy 
Institute has shown that lymphocytes isolated from peripheral blood and stimulated 
with TNFα, IL-2 and IL-6 also induce the production of TNFα from monocytes in a 
contact-dependent manner. This is in contrast to lymphocytes stimulated via their 
TCR with anti-CD3 antibodies, which cause induction of both TNFα and IL-10 in 
monocytes (Parry et al., 1997; Sebbag et al., 1997). RA T cells isolated from 
synovium act similarly to bystander or cytokine-activated T cells, inducing only TNFα 
in co-culture with monocytes. Differences in the induced cytokine profile by 
bystander lymphocytes and anti-CD3 activated T cells can be explained by 
differences in the signalling pathways activated within the monocyte. Figure 1.6 
summarises the bystander model for activation of T cells in RA and the downstream 
consequences in co-culture with PB monocytes. RA T cells and PBLs stimulated with 
IL-15 also show similar effector responses in co-culture with the macrophage cell line 
U397 and with adherent RA synovial cells (McInnes et al., 1997). In addition IL-15 
stimulated T cells can induce IL-1β and IL-12 from monocytes (Avice et al., 1998; 
Ribbens et al., 2000).  
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1.1.7.1 T cell-monocyte interactions 
  Activation of monocytes by cytokine-activated PBLs in vitro is a valuable model in 
which to investigate the molecular mechanisms involved in pro-inflammatory 
cytokine production from myeloid cells upon direct contact with synovial T cells in the 
joint. Many molecular interactions have been implicated in cognate signalling 
between T cells and monocytes resulting in the synthesis of pro-inflammatory 
cytokines. Dayer’s group has investigated the contact-dependent production of 
TNFα, IL-1β, IL-6, IL-8, MMPs and tissue inhibitors of metalloproteinases (TIMP) 
from THP-1 monocytic cell lines and fibroblasts by mitogen-activated PBL, T cell 
clones or HUT-78 T cell lines (Burger et al., 1998; Chizzolini et al., 1997; Lacraz et 
al., 1994; Li et al., 1995; Vey et al., 1996; Vey et al., 1997). Membrane-bound 
cytokines have been implicated in this signalling; however blocking antibodies to 
TNFα, IL-1, IL-2, IFNγ and GM-CSF did not inhibit monocyte activation by 
membranes from stimulated T cells. Neutralising antibodies to mTNFα decreased 
monocyte IL-10 and TNFα in co-culture with anti-CD3 stimulated PB T cells (Isler et 
Figure 1.6 Cytokine-activated PBLs mimic RA T cells in effector function but differ 
from PBLs activated via the TCR. See text for details. Abbreviations – Anti-CD3 = 
activation via immobilised antibodies against CD3, IL = interleukin, NFκB = nuclear factor-
kappa B, PBL = peripheral blood lymphocyte, PI3-K = Phosphatidylinositide 3-kinase. 
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al., 1993; Parry et al., 1997; Rossol et al., 2007). Synthesis of macrophage TNFα in 
contact with IL-15 stimulated bystander T cells was significantly inhibited, but not 
abolished by neutralising antibodies against CD69, ICAM-1 and LFA-1. Furthermore 
treatment with the cAMP-specific phosphodiesterase inhibitor Rolipram, inhibited 
expression of LFA-1, ICAM-1 and CD69. A reduction in TNFα production from 
monocytes was also observed when IL-15 bystander T cells were pre-treated with 
Rolipram suggesting these molecules may be important in this cell-cell signalling. A 
further candidate is the CD40-CD40L interaction. Ligation of CD40 expressed by RA 
synovial monocytes enhances spontaneous TNFα release, which in turn can be 
inhibited by addition of anti-CD40 antibodies (Sekine et al., 1998). It has also been 
shown to be required, but not essential, for IL-1β induction in monocytes by IL-2 or 
IL-15 activated Th1 cells (Ribbens et al., 2000), and studies with CD40L 
transfectants demonstrated induction of TNFα and IL-10 in GM-CSF macrophages 
through distinct signalling pathways post-CD40 ligation (Foey et al., 2001). Despite 
this, other data indicates CD40L is not critical for pro-inflammatory cytokine release 
(Burger et al., 2004). 
 Although many data suggest these molecules contribute to cell-cell contact 
interactions, no molecular interaction has proved essential or unique to cytokine-
activated T cells compared to antigen-activated ones.   
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1.2 Proteomics 
 The proteome was originally defined as “the entire protein complement able to be 
expressed by a genome” (Wilkins et al., 1996) and proteomics is now understood as 
the global study of protein expression in organelles, cells, tissues or even whole 
organisms. Proteomic studies are not dependent on knowing which proteins are 
present (i.e. they do not need specific reagents such as antibodies or primers), and 
thus take an unbiased look at protein expression of a cell under a chosen condition. 
Information provided by genomics has been crucial in the implicating genes involved 
in disease; however an understanding of the role of the products of these genes in 
the mechanism of pathogenesis is essential. For instance, proteomics can reveal 
abnormal regulation of protein expression, post-translational modifications (PTM) 
and protein-protein interactions, information that is not deducible from genomic or 
transcriptomic studies. By studying the proteome in the context of a disease state we 
can examine aberrant protein expression and function at a global level to reveal 
candidate targets for therapeutic intervention or biomarkers for diagnosis.  
1.2.1 Principles of Proteomics 
 Most proteomic studies, while differing in details of experimental strategy,  conform 
to a generic workflow involving extraction of proteins from the biological sample, 
followed by some form of fractionation to simplify the resulting complex mixture, prior 
to proteolytic digestion and protein identification by mass spectrometry (MS). 
  Proteins must be extracted from cells or tissues free from contaminating 
macromolecules such as carbohydrates, lipids and nucleic acids. This involves cell 
lysis followed by solubilization with detergents and/or chaotropes containing buffers 
to separate them from lipid components. Nucleic acid contamination is reduced by 
centrifugation to pellet nuclei. The addition of reducing agents disrupts a protein’s 
secondary and tertiary structure, and protease inhibitors ensure the full-length 
protein sequence remains intact.   
   The mixture of proteins may then be separated by nonelectrophoretic or 
electrophoretic techniques. Nonelectrophoretic methods include high-performance 
liquid chromatography (HPLC) or density gradient centrifugation. SDS-PAGE in one-
dimension (1D) resolves proteins by apparent molecular mass, whereas two-
dimensional (2D) electrophoresis initially separates proteins according to their 
isoelectric point (pI) in a process termed isoelectric focussing (IEF) and then by 
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mass on SDS-PAGE. This orthogonal separation by charge and mass provides 
superior resolution of complex mixtures, and will usually also resolve different post-
translationally modified forms of individual proteins. After visualisation by staining, 
individual protein bands or spots are excised and digested in situ by proteolytic 
enzymes such as trypsin, to generate a set of shorter peptides suitable for 
characterization by mass spectrometry (MS). A reversed phase HPLC column 
coupled to a mass spectrometer separates these peptides according to 
hydrophobicity prior to MS analysis. Such separation techniques are the staple of 
proteomic studies and have enabled analysis of an ever increasing number of 
organisms, tissues and cell types.  
 An alternative ‘shotgun’ approach to proteomic studies bypasses electrophoretic 
separation of proteins by applying direct proteolytic digestion of the sample to 
generate a highly complex peptide mixture that is separated by liquid 
chromatography (strong-cation exchange and reverse-phase) prior to HPLC and 
mass spectrometry. This approach has the advantage that it circumvents some of 
the limitations of 2DE for the analysis of membrane proteins (see section 1.2.3) and 
is generally more sensitive than 2DE based workflows. However, it is 
computationally intensive because the datasets are inevitably large (multiple high 
resolution HPLC MS runs, possibly comprising several hundred thousand individual 
mass spectra). Since the analysis is conducted entirely at the peptide level protein 
molecular masses and pIs are not available, so analysis of post-translational 
modifications is more complex because of this loss of connectivity between parent 
proteins and tryptic peptides. 
1.2.1.1 Mass Spectrometry 
 By accurately measuring the molecular masses of proteolytic peptides and their gas 
phase decomposition products, mass spectrometers can determine their amino acid 
sequences, which in conjunction with protein and DNA sequence databases, 
enables identification of the parent proteins. While many designs of mass 
spectrometer exist, based on differing physical principals, all include a means of 
converting sample molecules to gas phase ions (the ionisation source), a mass 
analyser  to measure their masses, and a detector to record the intensity of signal at 
each mass. 
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  There are two main ionisation methods used in proteomic studies; electrospray 
(ESI) and matrix-assisted laser desorption ionisation (MALDI). Electrospray 
generates peptide ions from acidic aqueous solutions by spraying at atmospheric 
pressure through a capillary orifice maintained at high voltage, creating a mist of 
electrically charged liquid droplets. Evaporation of the solvent (assisted by heat and 
a nitrogen bath gas) results in multiply charged unsolvated peptide ions, which then 
enter the vacuum system of the mass spectrometer. In MALDI the sample is mixed 
with an ultraviolet-absorbing solid matrix such as α-cyano-4-hydroxycinnamic acid, 
which is irradiated by short pulses of laser energy, resulting in desorption of peptide 
ions into the gas phase.  
 The mass analyser determines the mass to charge (m/z) ratios of gas-phase 
peptide ions. Several different types of analyser are in use, varying in geometry, 
mass range, resolution and measurement accuracy, but all rely on the mass specific 
responses of ions in electric and/or magnetic fields. Early mass spectrometers used 
magnetic fields for mass analysis, since  the deflection experienced by a charged 
particle in a field of given strength is proportional to its mass. More recently other 
types of mass analyser have been developed, including quadrupoles and time of 
flight analysers, both of which were used in the present study. 
  A quadrupole analyser consists of four opposed parallel metal rods, to which DC 
and radiofrequency voltages are applied. Ions in this oscillating electric field describe 
a trajectory which depends on their mass. Hence manipulation of these voltages 
enables selective transmission of ions of particular masses. In a time of flight (ToF) 
analysers, an accelerating voltage propels the ions away from the source region into 
a time of flight tube, where they drift towards a detector. Since ions arrive in the drift 
tube with similar kinetic energy (equal to 1/2mv2), ions of different mass must have 
correspondingly different velocities, the heavier ions travelling more slowly. 
Measurement of the time of flight over the constant distance to the detector thus 
enables calculation of velocity and therefore mass. 
 Both electrospray and matrix assisted laser desorption are ‘soft ionization’ 
techniques, in that they do not impart enough excess energy to break covalent 
bonds, so the gas phase ions produced are largely cationized molecules, which 
reveal the molecular mass of the intact peptide, but provide little structural 
information.  Hence to obtain information about peptide sequence it is necessary to 
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increase the internal energy of the gas phase ions to induce additional 
fragmentation. This is usually achieved by collision with molecules of a neutral gas 
such as argon, a process known as collision induced dissociation (CID). Optimum 
use of this technique requires selection of ions of a single mass for fragmentation, so 
that the products can be unambiguously associated with their parent peptides. This 
can be achieved using a tandem mass spectrometer, which has two separate mass 
analysers for measurement of precursor and product ion m/z values. In the Waters 
Q-Tof instrument used for the studies described in this thesis, precursor peptide ions 
are selected with a quadrupole lens placed in front of a collision cell filled with argon, 
where fragmentation occurs, and the resulting fragment ions are ejected into a time 
of flight analyser which measures their masses.  
   When a peptide ion fragments, cleavage occurs predominantly at the peptide 
bonds, resulting in a series of truncated peptide ions. The mass increment between 
successive ions corresponds to the masses of amino acid residues, allowing the 
sequence to be read off.  Cleavage between the carbonyl group and the nitrogen of 
the peptide bond is the most important collisional fragmentation process of tryptic 
peptides under low energy conditions. The fragments produced may retain charge 
on either the original carboxyl end of the peptide, or the original amino end. 
Fragments containing the amino terminus are known as B ions, whereas those 
retaining the original carboxyl terminus are known as Y ions. When tryptic peptides 
are fragmented by CID, Y type cleavages usually predominate, because tryptic 
peptides have either arginine or lysine at the carboxyl terminus.  Both of these 
residues are basic and easily protonated thus favouring fragmentation with charge 
retention on the carboxyl terminus. 
 Proteins can be identified from tandem mass spectra by deducing amino acid 
sequences by manual interpretation of the fragmentation patterns, then using these 
sequences to interrogate a database of known protein sequences. While this 
approach has the advantage that non-identical orthologous sequences can be 
retrieved when the target protein is not present in the database, it is extremely 
laborious, and not really feasible for high-throughput proteomic studies. Most 
proteomic studies therefore achieve protein identification by computerised prediction 
of the fragments expected from a database of known proteins and correlation of 
these to the uninterpreted experimental mass spectra. The database matches are 
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statistically evaluated and ranked according to probability of the hit arising by chance 
alone.  
1.2.2 Membrane proteins 
 Proteins expressed on the surface of cells play vital roles in cell biology including, 
signal transduction, cell adhesion, ion and metabolite transport and endocytosis. The 
identification of plasma membrane proteins on pathogenic cells has the potential to 
increase our understanding of disease processes and to provide new therapeutic 
targets. Indeed over two-thirds of drugs exert their pharmacological action through 
modulation of a membrane protein (Hopkins and Groom, 2002).  Membrane proteins 
are defined as proteins associated with a lipid bilayer of a cell, this includes the 
internal membrane subcellular compartments, as well as the external plasma 
membrane. A typical cell’s plasma membrane is 50% protein by mass.  
 Transmembrane (TM) or integral membrane proteins are defined as proteins which 
extend through the lipid bilayer with regions of their backbone emerging on either 
side. TM proteins are comprised of one or more membrane spanning regions of 
hydrophobic residues, which in eukaryotes tend to form alpha-helices approximately 
15-25 residues in length. TM proteins that span the lipid bilayer only once are sub-
classified as type 1 or type 2 depending on their orientation as shown in Figure 1.7.  
 
N
N
N
C
C
C
Type 1 Type 2
Multi-pass
 
  
 Peripheral membrane proteins do not contain membrane spanning regions and 
associate with the lipid bilayer via hydrophobic anchors or non-covalent interactions 
with the membrane itself or other membrane proteins. Lipid-linkage of soluble 
proteins to the membrane may be provided by amide linkages of mysristic acid to N-
terminal glycine residues, or thioester linkages from cysteines to prenyl groups or 
Figure 1.7 Classes of integral membrane 
proteins. Abbreviations – N = amino terminus 
of protein, C = carboxyl terminus of protein.   
Type 1 proteins have their NH2 terminus 
facing the extracellular space or luminal 
space of an organelle. Type 2 proteins have 
the inverse orientation. The orientation and 
number of transmembrane regions of multi-
pass proteins varies. 
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palmitic acid. Alternatively proteins can be glycosylphosphatidylinositol (GPI)-
anchored.  
1.2.3 Plasma Membrane Proteomics  
 Genomic analysis predicts that 20-30% of open reading frames encode proteins 
embedded in cellular membranes (intracellular organelle and plasma membrane) 
however their representation in proteomic data sets is much lower (Kanapin et al., 
2003; Wallin and von Heijne, 1998; Wilkins et al., 1998). The intrinsic hydrophobicity 
of transmembrane domains results in low aqueous solubility and hinders not only 
their initial extraction from the lipid bilayer but also their separation by IEF. 
Membrane spanning domains are also often resistant to digestion by trypsin as they 
lack hydrophilic arginine and lysine residues resulting in difficult identification by MS 
and reduced sequence coverage and (Santoni et al., 2000). Despite total membrane 
proteins constituting a relatively large fraction of the total cellular proteins those 
located within the plasma membrane are estimated at only 2-3%. Thus the relatively 
low abundance further adds to the challenge of plasma membrane proteomics. 
  
 A variety of methods to create enriched plasma membrane samples have been 
explored with varied success. As with all proteomic studies the number of steps 
taken in sample preparation should be kept to a minimum to avoid protein losses. 
The differing physical properties of sub-cellular compartments can be exploited to 
achieve enrichment of a particular organelle or membrane, for instance by density 
gradients or differential centrifugation (Pasquali et al., 1999). Tagging of cell-surface 
proteins with biotinylating reagents and subsequent avidin affinity purification has 
been used to isolate plasma membrane enriched preparations from rat kidneys (Yu 
et al., 2006) to mouse splenocytes (Peirce et al., 2004). However this method 
requires a large number of cells and relies on the biotin reagent’s accessibility to the 
cell surface protein amines and sulfhydral groups as well as its impermeability to the 
cell membrane. The use of detergents or organic solvents to solubilise membrane 
proteins is essential for the extraction of proteins from the lipid bilayer and 
subsequent 2D gel or liquid chromatography. Indeed the choice of detergent or 
solvent must be compatible with the intended proteomic approaches and MS. A 
number of studies have shown that the use of particular detergents or solvents can 
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affect the success of proteolytic digestion and generation of peptides for MS 
analysis, resulting in differences in the data sets obtained from each condition.  
 
 Conventional 2D - IEF is commonly achieved with immobilised pH gradients (IPG). 
These are gel strips of a defined pH range which are rehydrated prior to use when 
samples are often simultaneously applied. However proteins with a high molecular 
weight, alkaline pH or hydrophobic nature are not readily taken up by the gel strips 
and thus membrane proteins with these properties can often be excluded (Gorg et 
al., 2004). Losses may also occur at the transition between the first dimension and 
the second. As a general phenomenon proteins are least soluble at their pI where 
their net charge is by definition zero, and may come out of solution. The hydrophobic 
nature of integral membrane proteins makes them particularly prone to precipitation. 
Hydrophobic interactions between precipitated proteins and the IEF gel matrix 
reduce mobility and transition of these proteins into SDS-PAGE (Adessi et al., 1997). 
IEF separation in the solution phase can circumvent some of these issues. Invitrogen 
supply the ZOOM® IEF Fractionator developed from a prototype device by Zuo and 
Speicher (Zuo and Speicher, 2000) which focuses proteins into separate sample 
chambers formed by small membranes of specific pH. The use of a gel free solution 
phase IEF system can replace IEF by IPGs and potentially provide better resolution 
of membrane proteins with fewer losses. Studies carried out at the Kennedy Institute 
using solution phase IEF followed by 1D SDS PAGE to effectively separate proteins 
in two dimensions led to the successful identification of plasma membrane proteins 
expressed on a murine T cell hybridoma and on primary murine splenocytes (Peirce 
et al., 2004).  
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1.3 Aims of this thesis 
  It is hypothesised that it is the T cells within a PBL population which on cytokine-
activation most closely resemble RA synovial cells. These cells mimic RA T cells 
both in terms of phenotype and their ability to induce TNFα when in contact with 
monocytes. T cells themselves are a heterogeneous set of lymphocytes with distinct 
functions in normal immune responses and in RA. This thesis aims to investigate the 
phenotypic changes that occur during cytokine-activation and how these are 
reflected in terms of the effector function acquired. To do this two parallel 
approaches have been employed. First, is a conventional approach based on known 
markers and the biology of T cells. Second, is the use of proteomic techniques to 
obtain a profile of the plasma membrane proteins expressed on the surface of 
cytokine-activated T cells which could provide clues for identification of the novel 
ligand(s) important in driving TNFα production in RA. 
 
More specifically my aims are as follows: 
1) To investigate the response of primary human peripheral blood T cells after 
activation with IL-2, IL-6 and TNFα in vitro in terms of the surface phenotype 
of known T cell markers, proliferation and cytokine production. To investigate 
the relative roles of T cell subsets in co-culture with peripheral blood 
monocytes and to relate my findings to T cells isolated from the synovial 
tissue cultures. 
2) To investigate the feasibility of isolating plasma membrane proteins from 
resting and cytokine-activated PBLs and their separation by electrophoretic 
techniques in order to identify novel effector protein candidates by mass 
spectrometry 
3) To validate any novel findings within our in vitro model of bystander T cells 
and RA synovial tissue.  
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2.1 Reagents 
 Unless otherwise stated, all laboratory reagents were purchased from Sigma-
Aldrich, Dorset, UK or BDH chemicals, Dorset, UK. All ZOOM™ reagents were 
purchased from Invitrogen, Paisley, UK. 
2.1.1 Cytokines 
 Human recombinant cytokines used for tissue culture or as standards for enzyme-
linked immuno-sorbent sandwich assay (ELISA) are summarised in Table 2.1 
 
Table 2.1: Human recombinant cytokines 
Cytokine Concentration Use Source 
GM-CSF 4000-62pg/ml ELISA R&D Systems, Minneapolis, USA 
IFNγ 5000-6.8pg/ml ELISA BD Biosciences, Oxford, UK 
IL-2 25ng/ml Tissue culture Hoffman-LaRoche, Nutley, NJ, USA 
IL-6 100ng/ml Tissue culture Novartis Pharma, Basel, Switzerland 
IL-8 10000-13pg/ml ELISA R&D Systems, Minneapolis, USA 
IL-10 10000-13pg/ml ELISA R&D Systems, Minneapolis, USA 
IL-17 10000-15.6pg/ml ELISA R&D Systems, Minneapolis, USA 
IFNγ 5000-6.8pg/ml ELISA BD Biosciences, Oxford, UK 
LTα 5000-6.8pg/ml ELISA BD Biosciences, Oxford, UK 
sCD62L 60-1.9ng/ml ELISA (kit) Diaclone Research, Besancon, France 
TGFβ  ELISA (kit) R&D Systems, Minneapolis, USA 
TNFα 25ng/ml Tissue culture Abbot Research Center, Massachusetts, USA
 5000-6.6pg/ml ELISA Peprotech, Rock Hilly, NJ, USA 
 
2.1.2 Antibodies 
 Capture and detect antibodies used for enzyme linked immunosorbent sandwich 
assay (ELISA) are listed in Table 2.2. Concentrations shown are working 
concentrations diluted from a 0.5mg/ml stock solution. Western blotting antibodies 
and their dilutions from the manufacturer’s supplied stock are listed in Table 2.3. 
Antibodies used to isolate CD4+CD45RO+ T cells in tissue culture (Section 2.2.4) 
were all purchased from BD Biosciences, Oxford, UK.  
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Table 2.2 ELISA antibodies 
Specificity Antibody Concentration  Source 
TNFα Coat 4μg/ml BD Biosciences, UK 
 Detect 0.5μg/ml BD Biosciences, UK 
IFNγ Coat 4μg/ml BD Biosciences, UK 
 Detect 1μg/ml BD Biosciences, UK 
LTα Coat 4μg/ml BD Biosciences, UK 
 Detect 1μg/ml BD Biosciences, UK 
GM-CSF Coat 2μg/ml R&D Systems, MN, USA 
 Detect 1μg/ml R&D Systems, MN, USA 
IL-8 Coat 2μg/ml BD Biosciences, UK 
 Detect 0.5μg/ml BD Biosciences, UK 
IL-10 Coat 1 μg/ml BD Biosciences, UK 
 Detect 1 μg/ml BD Biosciences, UK 
IL-17 Coat 4µg/ml R&D Systems, MN, USA 
 Detect 200ng/ml R&D Systems, MN, USA 
 
 
Table 2.3 Western blotting antibodies 
Specificity Species Dilution Source 
ATP synthase β Mouse 1:1000 AbCam, Cambridge, UK 
CD45 Mouse 1:2000 Alexis, Lausen, CH 
CD81 Mouse 1:1000 Santa Cruz, CA, USA 
CD97 Mouse 1:500 R&D Systems, MN, USA 
GRP75 Mouse 1:5000 AbCam, Cambridge, UK 
Tubulin Mouse 1:5000 Sigma Aldrich, UK 
Anti-mouse IgG F(ab)2 
HRP conjugate  
Sheep 1:2000 GE Healthcare, Bucks, UK 
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 Antibodies used for flow cytometry are summarised in Table 2.4 and are mouse 
anti-human except for CCR7 (rat anti-human). The majority of antibodies for flow 
cytometry were purchased from BD Biosciences, Oxford, UK. Exceptions are anti-
CD9 PE, anti-CD97 and anti-CXCR4 PE which were purchased from R&D Systems, 
MN, USA; and anti-CD82 which was purchased from AbCam, Cambridge, UK. All 
antibodies, except anti-CD82 and anti-CD97, were supplied in PBS plus 0.05% 
sodium azide at an unknown concentration. Working stock solutions at 25µg/ml for 
anti-CD97 was used for flow cytometry. Anti-CD82 antibody was supplied in PBS at 
an unknown concentration by Abcam, UK. All antibodies were titrated on human 
PBMCs to obtain the test volumes shown. Goat anti-mouse Ig PE was used as a 
second layer for unconjugated antibodies (CD82 and CD97) and was purchased 
from BD Biosciences, UK. 
 
 Neutralising antibodies used in tissue culture blockade experiments are listed in 
Table 2.5. Isotype IgG1 (MOPC-21) and IgG2a (UPC-10) control antibodies in sterile 
PBS (Sigma Aldrich, UK) were used as controls in neutralisation experiments and in 
flow cytometry studies for anti-CD82 and anti-CD97 respectively. A range of directly 
conjugated isotype antibodies to matching fluorochromes were purchased from BD 
Biosciences and R&D Systems. 
 
 
 
 
 
 
 
 
 
 
 
 
+ 
 
 
Chapter 2  Materials and methods 
86 
 
Table 2.4 Flow cytometry antibodies 
Specificity Label Clone Isotype 
Volume per 
105 cells (µl) 
CCR5 PE 2D7 IgG2a 5 
CCR7 PE 3D12 IgG2a 5 
CD4 PE RPA-T4 IgG1 5 
CD4 PE-Cy5 RPA-T4 IgG1 5 
CD8 PerCP SK1 IgG1 5 
CD9 PE 209306 IgG2b 20 
CD14 PE M5E2 IgG2a 5 
CD18 PE 6.7 IgG1 5 
CD19 FITC HIB19 IgG1 5 
CD25 PE M-A251 IgG1 5 
CD29 PE HUTS-21 IgG2a 5 
CD37 PE M-B371 IgG1 5 
CD45RA PE-Cy5 HI100 IgG2b 5 
CD45RO FITC UCHL1 IgG2a 5 
CD45RO PE UCHL1 IgG2a 5 
CD45RO PE-Cy5 UCHL1 IgG2a 5 
CD49d PE 9F10 IgG1 5 
CD53 PE HI29 IgG1 5 
CD55 PE IA10 IgG2a 5 
CD56 PE B159 IgG1 5 
CD62L PE-Cy5 Dreg-56 IgG1 5 
CD63 PE H5C6 IgG1 5 
CD69 PE FN50 IgG1 5 
CD81 PE JS-81 IgG1 5 
CD82 Un B-L2 IgG1 2 
CD97 Un 380903 IgG2a 10 
CD151 PE 14A2.H1 IgG1 5 
CXCR3 PE IC6 IgG1 5 
CXCR4 PE 12G5 IgG2a 4 
HLA-DR PE G46-6 IgG2a 5 
 
 
 
Abbreviations – FITC = Fluorescein isothiocyanate; PE = R-phycoerythrin; PerCP = 
Peridinin chlorophyll protein; PE-Cy5 = Tandem conjugate of R-phycoerythrin and cyanine 
dye; Un = unconjugated 
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Table 2.5 Neutralising antibodies 
Specificity Clone Isotype Source 
CD18 TS1/18 IgG1 BioLegend, Cambridge, UK 
CD49d TA-2 IgG1 Endogen, Illinois, USA 
CD69 TP1.55.3 IgG1 Beckman Coulter, Bucks, UK 
CD97 380903 IgG2a R&D Systems, Minneapolis, USA 
 
  
2.1.3 Inhibitors 
 Phosphoinositide 3-kinase (PI 3-Kinase) inhibitor, LY294002 was obtained from 
Calbiochem, Darmstadt, DE. LY294002 was stored at -20°C in aliquots of a working 
20mM stock solution in DMSO.  
 Protease inhibitors used in lysis buffers were purchased as a cocktail containing 
AEBSF (104mM), Aprotinin (80μM), Leupeptin (2.1mM), Bestatin (3.6mM), Pepstatin 
A (1.5mM) and E-64 (1.4mM) from Sigma-Aldrich, UK (Product no. P8340). Cocktail 
solution, reconstituted according to the manufacturer’s instructions in DMSO, was 
stored at -20°C and used at 1:100. 
 
2.1.4 Tissue culture reagents  
 Roswell Park Memorial Institute (RPMI 1640) media containing 25mM L-glutamine; 
Hanks Balanced Salt Solution (HBSS); serum; sterile 10 x Phosphate Buffered 
Saline (PBS) and distilled water were obtained as sterile solutions from Lonza, 
Basel, CH.  
  
 Foetal Calf Serum (FCS) was supplied heat-inactivated from Biosera, East Sussex, 
UK.  Normal human male AB serum (NHS) was purchased from PAA Laboratories, 
Somerset, UK and required heat-inactivation for 60 minutes at 57oC prior to use.  
 
 All reagents used in tissue were tested for the presence of endotoxin using the 
Limulus amebocyte assay (Lonza, Basel, CH). Endotoxin levels were measured in a 
flat-bottomed 96-well Maxisorb plate (Nunc) alongside an endotoxin standard 
(0.1EU/ml equivalent to 100pg/ml), which was serially diluted in LPS-free H2O. 
Samples, standards and blanks were added to the plate (equilibrated to 37°C) in 
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duplicate at a volume of 50μl each. A further 50μl of Limulus amebocyte was then 
added to each well and the plate was placed at 37°C for 10 minutes. Subsequently, 
100μl of substrate solution (37°C) was added to each well and incubated for an 
additional 6 min at 37°C. The reaction was stopped with 100μl per well of the 
provided stop reagent. Absorbance was read at 410nm on a Multiskan® 
BiochromicaticTM plate reader using Ascent™ 2.4.2 software (Labsystems, Helsinki, 
FI). Assay sensitivity is <10pg/ml endotoxin. All assays were kindly performed by Ms 
Patricia Green.  
 
2.1.5 Biochemical materials 
 All other reagents used for SDS-PAGE, western blots and ELISA are listed in Table 
2.6 
 
Table 2.6 Biochemical reagents 
Reagent Source 
BCA™ Protein assay kit Pierce, Illinois, USA 
BupH™ Tris-HEPES-SDS Running buffer Pierce, Illinois, USA 
ECL™ Western blotting detection reagent Amersham Biosciences, Bucks, UK 
Maxisorb™ ELISA plates Nunc A/S Roskilde, DK 
PDVF transfer membrane Perkin Elmer Life Sciences, 
Massachusetts, USA 
Peroxidase substrate solution B KPL, Maryland, USA 
Protein desalting spin columns Pierce, Illinois, USA 
Rainbow molecular weight marker RNP800 Amersham Biosciences, Bucks, UK 
Re-Blot Western Blot recycling kit (acid strip 
buffer) 
Chemicon International, California, 
USA 
SDS-PAGE Clean-Up kit Amersham Biosciences, Bucks, UK 
Super RX medical X-ray film Fujifilm UK, Bedford, UK 
TMB peroxidase substrate KPL, Maryland, USA 
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2.1.6 Solutions 
General Buffers 
Phosphate Buffered Saline (PBS)  4.3mM Na2HPO4 
1.4mM KH2CO3 
1.4mM KCl 
37mM NaCl, adjusted to pH 7.2 
 
Tris Buffered Saline (TBS)   20mM Tris/Base 
137mM NaCl, adjusted to pH 8.0 
ELISA Buffers 
ELISA buffer     PBS 
0.5% (w/v) bovine serum albumin (BSA) 
 
ELISA blocking buffer   PBS 
2% (w/v) BSA 
 
ELISA wash buffer (PBS/T)  PBS  
      0.1% (v/v) Tween-20 
 
ELISA substrate solution   TMB peroxidase  
ELISA stop solution    6% (v/v) H2SO4 
 
Cell lysis and protein extraction buffers 
Hypotonic lysis buffer   20mM Tris/HCl pH7.5 
      5mM EDTA     
      Supplement: 150mM NaCl 
      1% (v/v) Triton-X100 
 
Sodium Carbonate wash buffer  100mM Na2CO3 pH 11.3 
      1mM EDTA  
 
SDS-PAGE and Western Blotting buffers 
Resolving gel buffer    3M Tris/Base pH 8.8 
      0.6% (w/v) SDS 
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Stacking gel buffer    140mM Tris/HCl pH 6.8 
      0.11% (w/v) SDS 
 
Running buffer     25mM Tris/Base 
      192mM Glycine 
      0.1% (w/v) SDS 
    (Purchased as 10x solution  
from National Diagnostics,  
Georgia, USA.) 
 
5x Gel sample buffer (GSB)  250mM Tris/HCl pH 6.8 
10% (w/v) SDS 
50% (v/v) glycerol 
2.5% (v/v) β-mercaptoethanol* 
(Combine Tris/HCl, SDS and H2O, heat to 
50°C, add glycerol, β-mercaptoethanol and 
trace bromophenol blue) 
* - excluded for SDS-PAGE under non-
reducing conditions 
 
Transfer buffer    25mN Tris/Base 
      192mM glycine 
      20% (v/v) methanol 
 
Wash buffer (TBS/T)   TBS 
      0.1% (v/v) Tween-20 
 
Blocking buffer    TBS/T 
5% (w/v) skimmed milk powder 
 
Solution-phase Isoelectric Focussing (IEF) buffers 
IEF sample denaturant   7.7M ZOOM® Urea 
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      2.2M ZOOM® Thiourea 
      4.4% (w/v) ZOOM® CHAPS 
 
IEF Anode buffer   50x Novex® IEF Anode buffer  
      7M ZOOM® Urea 
2M ZOOM® Thiourea 
pH 3.0 
 
IEF Cathode buffer    10x Novex® IEF Cathode buffer  
      7M ZOOM® Urea 
      2M ZOOM® Thiourea 
      pH 10.4 
 
Silver staining solutions 
Gel fixative     50% (v/v) methanol  
      5% (v/v) glacial acetic acid 
 
 Gel wash buffer    50% (v/v) methanol 
 
Sensitiser solution    0.02% (w/v) sodium thiosulphate 
 
Silver stain solution    0.1% (w/v) silver nitrate 
 
Developing solution    2% (w/v) sodium carbonate 
      0.0368%(v/v) formaldehyde  
 
Silver stain stop solution   5% glacial acetic acid 
 
Cell separation and flow cytometry buffers 
Miltenyi separation buffer   PBS 
      2mM EDTA 
      0.5% (v/v) FCS 
Dynal separation buffer   PBS 
      2mM EDTA 
Chapter 2  Materials and methods 
92 
 
      1% (v/v) FCS 
 
FACS wash buffer (FWB)   PBS 
      2% (v/v) FCS 
      0.02% (v/v) sodium azide 
 
Cell Freezing Mixture   FCS 
      10% (v/v) DMSO 
       
 
2.2 Cell isolation and purification 
2.2.1 Isolation of peripheral blood mononuclear cells 
 Peripheral blood mononuclear cells (PBMCs) were isolated from single donor 
heparinised leucophoresis residues (known as buffy coats) purchased from the North 
London Transfusion Service (Colindale, UK).  Buffy coats were made up to 100ml 
with Hank’s Balanced Salt Solution (HBSS) (Lonza, CH), layered onto 4 x 20ml 
Lympholyte®-H solution (Cedarline Laboratories Limited, CA) in 50ml Falcon® tubes 
and separated through centrifugation at 2200 revolutions per minute (rpm) for 25 
minutes. PBMCs lying at the interface between the two layers were carefully 
removed and resuspended in 50ml HBSS. The separation process was then 
repeated over 2x 20ml Lympholyte®-H solution to reduce the number of red blood 
cells. PBMCs were washed once in HBSS prior to suspension in 50ml 1% FCS 
RPMI.   
 
2.2.2 Isolation of peripheral blood lymphocytes and monocytes 
 Lymphocytes and monocytes were separated by counter-current centrifugal 
elutriation, a process which allows for the separation of a heterogeneous population 
of cells, such as PBMCs, into their individual populations. Separation is achieved by 
combining two separate and opposing processes of centrifugal force and fluid flow 
velocity. A suspension of PBMCs isolated by Lympholyte® centrifugation are loaded 
into a funnel-shaped elutriation chamber in a specifically designed centrifuge rotor 
under the influence of centrifugal force and at a constant flow rate (Figure 2.1). As 
media flows through the chamber, its velocity decreases as the chamber widens and 
Chapter 2  Materials and methods 
93 
 
a velocity gradient is created from the narrowest to widest part. Cells entering the 
chamber migrate to a position where the effects of centrifugal force and fluid velocity 
are in equilibrium, which is determined by the size of each individual cell. Smaller 
cells are at equilibrium at the widest part of the chamber (the elutriation boundary) 
where the centrifugal force field and the velocity are low. In contrast larger cells will 
remain near the inlet to the chamber where the centrifugal force and velocity are 
high. By gradually increasing the flow rate through the system, successive fractions 
of increasingly large or dense cells are washed out of the chamber and collected 
(Figure 2.1). Elutriation was carried out in 1% FCS RPMI at 2500 rpm in a Beckman 
JE6 Elutriator. PBMCs were loaded into the chamber at 11ml/min and 3 x 50ml of 
cells/media were collected at this velocity and at each subsequent 1ml/min increase 
until no cells remain within the chamber. Generally platelets and red blood cells are 
washed out of the chamber between 11-13ml/min, lymphocytes between 13-
17ml/min, monocytes emerge 19-22ml/min and finally granulocytes above 22ml/min.  
Lymphocyte and monocyte purity was assessed every 50ml fraction by flow 
cytometry based on cell size (forward side scatter (FSC)) and granularity (side 
scatter (SSC)), only fractions of ≥85% purity were retained for each population.  
PBMCs 
loaded
Cell populations 
out
Elutriation 
boundary Fluid flow
Centrifugal force
Velocity gradient
Red blood cell
Lymphocyte
Monocyte
Granulocyte  
 
 
 
 
Figure 2.1 Centrifugal elutriation 
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2.2.3 Separation of CD4+/CD8+ lymphocytes 
 Freshly elutriated lymphocytes were separated on the basis of CD4 or CD8 
expression using the respective Dynal® positive isolation kits (Invitrogen, UK) 
according to the manufacturer’s instructions. Briefly, cells were washed once in 1% 
FCS RPMI and resuspended at 107cells/ml. 25μl of CD4 or CD8 Dynabeads™ were 
added per 107 cells and incubated for 30 min at 4°C whilst rotating. The cell/bead 
mixture tube was placed in the Dynal MPC-L® magnet for two minutes and the 
supernatant containing CD4- or CD8- cells was removed.  The cell/bead mixture was 
removed from the magnetic field and washed twice in Dynal separation buffer 
(section 2.1.6) at a volume of 107cells/ml. The cell/bead mixture was resuspended in 
1% FCS RPMI at 107cells/ml. The addition of the provided DETACHaBEAD™ 
solution, at 10μl per 100μl cell suspension, allows for the removal of antibody and 
bead from the surface of the positively selected cells. Subsequently cells were 
incubated for 1 hour at room temperature whilst rotating, before being replaced in the 
magnet. The supernatant containing the released CD4+ or CD8+ cells  was removed 
and the beads were washed twice with 500μl 1% FCS RPMI to ensure full recovery  
of all positively selected cells. Cells were washed twice in RPMI supplemented with 
1% FCS to remove DETACHaBEAD™ prior to use. Population purity was assessed 
by flow cytometry and was routinely found to be >90% 
 
2.2.4 Isolation of CD4+CD45RO+ lymphocytes 
 CD4+CD45RO+ lymphocytes were isolated by negative selection on a Miltenyi 
Biotec based system by the selective removal of contaminating lymphocytes - NK 
cells (CD56+), B cells (CD19+), naїve lymphocytes (CD45RA+) and cytotoxic T cells 
(CD8+) as summarised in Figure 2.2. Freshly elutriated lymphocytes were analysed 
by flow cytometry to determine the exact number of CD4, CD45RO, CD45RA, CD56, 
CD8 and CD19 positive cells within the PBL population. Based on the number of 
cells in each population and a titrated optimum amount of antibody for each marker 
(Table 2.6), an appropriate volume of antibody to be added to the cells was 
calculated.  
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Table 2.7 Amount of antibodies required for isolating CD4+CD45RO+ T cells 
Antibody μg/106 cells μg/ml 
Anti – CD8 0.03 500 
Anti – CD56 0.05 500 
Anti – CD19 0.025 500 
Anti – CD45RA 0.03 500 
 
  Cells were resuspended in MACS buffer (section 2.1.6) at 50μl per 107 cells and 
incubated with antibodies for 10 min at 4°C. Cells were washed with 1ml MACS 
buffer per 107 cells and resuspended in 80μl MACS buffer plus 20μl goat anti-mouse 
IgG Microbeads (Miltenyi Biotec, Surrey, UK) per 107 cells for 15 min at 4°C. Cells 
were washed as before and finally resuspended at 50μl per 107 cells in MACS. The 
labelled cells were passed through equilibrated LS columns with thorough washing 
(2 x 3ml) in a VarioMACS™ separator (Miltenyi Biotec, UK). The unlabelled 
CD4+CD45RO+ cells passed through the column and were collected. Purity was 
assessed by flow cytometry and found to be ≥ 95%. 
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2.2.5 Depletion of CD56+ lymphocytes 
 CD56+ NK cells were depleted from freshly elutriated PBLs by positive selection 
using directly conjugated human CD56-microbeads (Miltenyi Biotec, UK). Depletion 
was carried out according to the manufacturer’s instructions. Briefly, cells were 
resuspended in 80μl MACS buffer plus 20μl CD56-microbeads per 107 cells for 15 
min at 4°C. Cells were washed with 1ml MACS buffer per 107 cells and resuspended 
at 50μl per 107 cells in MACS. The labelled cells were passed through equilibrated 
LD columns (Miltenyi Biotec, UK) with thorough washing (2 x 2ml) in a VarioMACS™ 
separator. Labelled NK cells were retained on the LD column and the depleted PBL 
population was collected as the unbound cells. Cell population purity was assessed 
by flow cytometry and found to be ≥ 98%. 
Figure 2.2 The negative selection of CD4+CD45RO+ T cells 
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2.3 Cell culture and stimulation 
2.3.1 Anti-CD3 monoclonal antibody stimulation of lymphocytes 
 Six well tissue culture plates (Falcon, UK) were coated with anti-CD3 mAb (OKT3 
from ATCC, USA) at 10μg/ml in PBS overnight at 4°C. Wells were washed 3 times 
with PBS to remove unbound antibody prior to addition of lymphocytes. Elutriated 
lymphocytes were resuspended in 5% FCS RPMI at 1 x 106/ml and cultured in the 
coated plates coated with immobilized anti-CD3 mAb for 24 hours at 37°C, 5% CO2. 
Five million cells were cultured per well. After stimulation lymphocytes were washed, 
counted and resuspended in 5% FCS RPMI.  
 
2.3.2 Cytokine stimulation of lymphocytes 
 Freshly elutriated lymphocytes were resuspended in RPMI supplemented with 10% 
Normal Human Serum (NHS) at 1 x 106 cells/ml. Cells were stimulated with the 
addition of IL-2 (25ng/ml), IL-6 (100ng/ml) and TNFα (25ng/ml) and cultured for eight 
days at 37°C, 5% CO2. Lymphocytes were cultured in 100cm2 flasks per 15 – 25 x 
106 cells or 175cm2 flasks per 30 – 60 x 106 cells. For timecourse experiments 
lymphocytes were cultured in 25cm2 flasks for each time point or 6 well plates. At 
day 8 or at the indicated time points, cells were harvested, washed twice and 
resuspended in 5% FCS RPMI. Cells were counted and used for in further studies.  
 
2.3.3 Lymphocyte fixation 
 Where indicated, activated lymphocytes were fixed with glutaraldehyde prior to co-
culture with monocytes. This was to prevent lymphocyte cytokine production in co-
culture whilst preserving the integrity of the cell membrane. Cells were washed twice 
with PBS before being fixed for 1 minute with 1ml of ice-cold filter-sterilised 0.05% 
glutaraldehyde in PBS. Fixation was stopped by providing excess aldehyde groups 
in 1ml of ice-cold filter-sterilised 0.2M glycine RPMI for a further minute. Cells were 
washed once and resuspended in 5% FCS RPMI before incubation for 2 hours at 
37°C, 5% CO2. Fixed cells were then washed twice more with 5% FCS RPMI and 
recounted. 
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2.3.4 Monocyte co-culture with lymphocytes 
 Effector responses of activated lymphocytes were assessed in co-culture with 
monocytes. Where possible autologous monocytes from each donor were frozen 
immediately after elutriation and subsequently thawed for co-culture when required. 
Monocytes were resuspended at 1x106 cells/ml in 5% FCS RPMI and plated out at 1 
x 105/100μl in 96-well flat bottomed culture plates then allowed to rest for 30 min at 
37°C, 5% CO2. Stimulated lymphocytes (fixed or unfixed) were added at varying 
lymphocyte : monocytes ratios ranging from 0.5:1 to 7:1. In all experiments 
monocytes and lymphocytes were cultured alone to assay for background TNFα 
production. Monocytes were cultured in the presence of 10ng/ml of 
Lipopolysacchride (LPS) (Salmonella Minnesota from Calbiochem, USA) as a 
positive control for TNFα production. Cells were co-cultured at 37°C, 5% CO2 for 18 
hours. Culture supernatants were removed (180μl) and assayed for TNFα by ELISA. 
In section 3.3, PI 3-kinase inhibitor LY294002 (0.5-5μM) was added to the 
monocytes for 15 minutes prior to the addition of lymphocytes.  
 
2.3.4.1 Blockade of cell surface molecules in co-culture 
 CD4+CD45RO+ T cells were isolated from freshly elutriated PBLs by negative 
selection (section 2.2.4). Cells were cultured for eight days in the presence of IL-2, 
IL-6 and TNFα (section 2.3.2). On day 8 T cells were harvested, washed once with 
5% FCS RPMI and twice with 1% FCS in PBS prior to resuspension at 4 x 106 
cells/ml. 400µl of cell suspension was placed in a sterile tube, one for every antibody 
to be tested. Neutralising or isotype control antibodies (Table 2.5) were added to 
cells a final concentration of 5-10µg/ml, mixed and incubated for 30 minutes at room 
temperature. Cells were then washed once with 1% FCS PBS and once with 5% 
FCS RPMI before resuspension in 400µl 5% FCS RPMI. 100µl of T cells were 
removed and placed in co-culture with 100µl of pre-plated autologous monocytes (at 
1 x 106/ml), as in section 2.3.4. In these experiments monocytes were preincubated 
with 10% NHS RPMI at 2 x 106 cells/ml for 30 minutes at 37°C, 5% CO2 to block Fc 
receptor ligation by antibodies. Monocytes were washed, resuspended at 1 x 106/ml 
in 5% FCS and plated out as before. 
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2.3.5 Isolation of RA synovial membrane mononuclear cells 
 Synovial tissue was obtained from patients with RA undergoing joint replacement 
surgery at Charing Cross Hospital, London; Central Middlesex Hospital, London; or 
Bath University Hospital, Bath, UK; after receiving signed and informed patient 
consent (covered by ethics approval RREC 1752). 
 
 Synovial tissue was removed from the specimens and placed into a petri dish 
containing 10ml RPMI supplemented with 10% FCS and HEPES.  The tissue was 
dissected and gently homogenised using sterile scissors and forceps, before being 
incubated in 20ml filter-sterilised RPMI (serum free) containing 5mg/ml collagenase 
A and 0.15mg/ml Dnase type I for 1 – 1.5 hours at 37oC, 5% CO2 to digest the 
extracellular matrix.  Cells were sieved to remove debris, washed thrice and re-
suspended in 10% FCS RPMI.  All centrifugation steps were carried out at 200g. 
Collection of synovial membranes and isolation of RA synovial cells was kindly 
performed by Ms. Renee Best.  RA cells were counted, checked for viability prior to 
cell surface flow cytometry analysis and/or culture.   
 
2.3.5.1 RA synovial tissue cultures and blockade of cell surface molecules 
 RA cells were resuspended at 1 x 106 cells/ml in 5% FCS RPMI. 100µl of cell 
suspension (equivalent to 1 x 105 cells) was placed in wells of a 96 well flat-bottomed 
plate. All conditions were assayed in triplicate. Control (untreated) wells were made 
up to a final volume of 200µl with 5% FCS RPMI. Neutralising or isotype control 
antibodies were added at a final concentration of 5-10µg/ml, where the final volume 
of each well was 200µl. Cells were left for 30 minutes at room temperature before 
being placed at 37°C, 5% CO2 for 24 hours. 180µl of supernatant was harvested 
from each well and frozen at -20°C until TNFα ELISA. 
 
2.3.6 Cell viability and counting 
 Cell viability was checked using trypan blue dye which is excluded from viable cells 
but taken up by dead or dying cells. Prior to counting, cells were diluted 1:1 with 
0.4% trypan blue (Sigma Aldrich, UK) in PBS. Uptake was assessed under the light 
microscope upon counting. Cells were counted using a hemocytometer prior to, and 
following stimulation. The number of cells in the sixteen-square area of the 
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hemocytometer were counted and multiplied by 1x104 to give the number of cells per 
ml.  The cell count was further multiplied by two to account for trypan blue dilution. 
 
2.3.7 Freezing and thawing of cells 
 Cells were frozen in ice cold FCS supplemented with 10% DMSO at approximately 
5 – 20 x 106/ml in 1ml cooled sterile cryovials at -70°C. Cells stored for longer than 8 
days were moved to liquid nitrogen storage. To thaw, cryovials were rapidly warmed 
in a water bath at 37°C and cells were diluted into culture media as soon as possible 
to remove toxic DMSO. Cells were washed and counted where viability was checked 
using trypan blue. 
 
2.4 Measurement of cytokines by ELISA 
 Cytokine concentrations in cell culture supernatants were assessed by enzyme 
linked immuno-sorbent sandwich assay (ELISA). Recombinant cytokines used as 
standard for ELISA are shown in Table 2.1. The working concentrations for capture 
and detect antibodies for each cytokine ELISA are shown in Table 2.2. Each ELISA 
follows the same basic protocol. Firstly capture antibody, at the appropriate 
concentration in PBS, was immobilised onto 96-well Maxisorb™ plates (Nunc A/S 
Roskilde, DK) at 4°C overnight. Plates were then blocked with blocking buffer 
(Section 2.1.6) for 1 hour at room temperature to saturate non-specific binding sites. 
Samples were diluted as required in 0.5% BSA/PBS ELISA buffer and incubated for 
a minimum of 1.5 hours at room temperature or overnight at 4°C. Biotinylated 
detecting antibody was diluted in ELISA buffer to the appropriate concentration and 
added to the plates for 1 hour at room temperature. Each plate was then incubated 
with streptavidin-HRP (R&D Systems, USA) at 1:400 dilution in ELISA buffer for 1 
hour at room temperature. After each of the above steps, two washes of PBS/T 
(Section 2.1.6) were carried out. Plates were developed with TMB substrate system 
and the reaction subsequently stopped with H2SO4 (Section 2.1.6). Absorbance was 
read at 450nm on a Multiskan® BiochromicaticTM plate reader using Ascent™ 2.4.2 
software (Labsystems, Helsinki, FI). All steps were carried out at a total volume of 
100μl per well per step with the exception of blocking which was at 200μl. One 
modification to this standard protocol was required for IL-17 ELISA. The detection 
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antibody was diluted in 2% goat serum and 1% BSA in PBS and incubated for 2 
hours at room temperature. 
  
 TGFβ and soluble CD62L (sCD62L) were assayed using ELISA kits according to 
manufacturer’s instructions. The Quantikine® human TGFβ1 Immunoassay kit was 
purchased from R&D systems, Minneapolis, USA and the soluble CD62L kit was 
purchased from Diaclone Research, Besancon, FR. 
 
2.5 Flow Cytometry 
2.5.1 Analysis of phenotype  
 Flow cytometry in this thesis was carried out either on a LSR™ bench top cytometer 
(BD Biosciences Immunocytometry, UK) or on a FACS Canto II cytometer (BD 
Biosciences Immunocytometry, UK). Data was analysed using either Cell Quest 
Pro™ (BD Biosciences Immunocytometry, UK) or FlowJo (Tree Star, OR, USA) 
software. 
 
 The assay is based on the use of specific antibodies which are conjugated to a 
fluorochrome against an antigen of choice. Cells are passed through the laser of the 
FACS machine one by one, the fluorochrome of any antibody bound to the cell 
surface is excited and emits an optical signal of a unique wavelength. The optical 
signal is converted into an electrical signal allowing the detection of specific cell 
surface markers.  
 
 Table 2.4 lists the fluorochrome-conjugated antibodies used in this thesis and the 
volume of each antibody used per test (2 x 105 cells). PBLs or RA cells were washed 
twice in FACS Wash Buffer (FWB) and resuspended at 2 x 106 cells/ml. 100µl of cell 
suspension was incubated with the required antibody for 30 min at 4°C. Cells were 
washed twice and resuspended in 100µl of BD Cytofix/Cytoperm™ (BD Biosciences, 
UK) per test to fix the cells prior to analysis. Unless otherwise stated 10000 events 
were collected. Labelling with unconjugated antibodies (anti-CD82 or anti-CD97) was 
carried out as described above, however after 30 minutes at 4°C cells were washed 
twice with FWB and resuspended in 100µl of secondary goat anti-mouse Ig antibody 
conjugated to PE (BD Biosciences, UK) at a 1:800 dilution. Cells were incubated at 
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4°C for a further 15 minutes, followed by two FWB washes and fixation as before. 
Positive staining for a given marker was taken as that above cells only and isotype 
control levels. 
2.5.2 Fluorescence-activated cell sorting (FACS) 
 Fluorescent-activated cell sorters are specialised flow cytometers which are able to 
separate out fluorescent labelled cell populations. In a cell sorter, fluorescent cells 
become charged and are deflected by oppositely charged plates to sort cells.  
 
 Cells to be sorted were washed once with sterile 1% FCS PBS and incubated with 
required fluorescence-conjugated antibodies at 10µl per 107 cells for 30 minutes at 
4°C. Stained cells were washed and resuspended at 1 x 107 cells/ml in sterile 1% 
FCS PBS. Cell sorting was carried out on a FACS Vantage SETM sorter (BD 
Biosciences, UK) at 4oC. Sorted cells were collected in sterile tubes containing 500µl 
of neat FCS. After sorting was completed, sorted populations were pooled, washed 
with 5% FCS RPMI, and counted. Purity checks were routinely carried out and 
population were at least 85% pure. Sorting was kindly performed by Ms. Parisa 
Amjadi. 
  
2.6 Proliferation assays 
2.6.1 Carboxyfluorescein diacetate succinimidyl ester assay 
 Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a fluorescent green dye 
which binds covalently to cytoplasmic components of a cell. Upon cell division its 
concentration is sequentially halved between the mother and daughter cells.  The 
mean fluorescence intensity of CFSE can be analysed on a flow cytometer and the 
number of cell divisions undergone by cells in culture over a period of time can be 
determined by following the dilution of CFSE. In addition the proliferation profiles of 
sub-populations of cells can be followed by counterstaining with antibodies to cell 
surface markers.  
  
 Freshly elutriated lymphocytes were washed once with PBS before resuspension in 
PBS at 1x107 cells/ml, whilst vortexing, CFSE was added to a final concentration of 
2.5μM. Vortexing is essential to ensure equal uptake of CFSE by the cells. Cells 
were left at room temperature in the dark for 10 minutes before uptake was stopped 
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with the addition of an equal volume of ice cold FCS whilst vortexing. Cells were left 
for a further 10 minutes in the dark on ice. Cells were then washed with RPMI, 
followed by three washes of 10% FCS RPMI. Finally cells were resuspended in 10% 
human serum, counted and stimulated as described previously with cytokines 
(section 2.3.2). On the days indicated cells were counted and washed twice with 
FWB and either directly read on the flow cytometer or counter stained with 3μl 
fluorochrome-labelled antibodies for 30 minutes at 4°C, washed and analysed on the 
flow cytometer. Routinely 50000 events were collected per sample.  
 
2.6.2 Annexin V and PI staining 
Annexin V and PI staining allows analysis of cell death by flow cytometry. Annexin V 
binds to exposed phosphotidylserine on the outer leaf of the plasma membrane as a 
cell undergoes apoptosis. PI binds to DNA exposed in non-viable cells, both necrotic 
and apoptotic. Annexin V and PI staining was carried out prior to and at indicated 
time points during cytokine stimulation using the Apoptosis Detection kit (FITC) 
purchased from Alexis™, Lausen, CH. Cells were washed in PBS and resuspended 
in x1 of the provided binding buffer at 5 x 105 cells/ml. 195μl (approximately 1x105 
cells) was removed and 5μl of Annexin V –FITC added. Cells were incubated at 
room temperature in the dark for 10 minutes, washed and resuspended in 190μl 
binding buffer. 10μl of PI was added immediately prior to flow cytometry analysis. 
 
2.6.3 Tritiated thymidine uptake 
 The nucleoside thymidine is incorporated into the newly synthesised 
deoxyribonucleic acid (DNA) of a replicating cell.  By pulsing cells with radiolabelled 
tritiated thymidine (3[H] TdR) and measuring the amount of radiolabel incorporated 
into the cells over a set period of time, it is possible to determine the proliferation 
kinetics of the cell population. 
 
 Lymphocytes were plated in round-bottomed 96 well plates in RPMI supplemented 
with 10% NHS at the times indicated following stimulation with IL-2, IL-6 and TNFα. 
3[H] TdR (0.5μCi/well) was added and the cells incubated at 37oC, 5% CO2 for 24 
hours.  Plates were then frozen at –20oC until the end of the experiment when they 
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were thawed and harvested with an automatic plate harvester. Data is shown as the 
mean counts per minute (cpm) value of triplicate wells.  
 
2.7 Plasma membrane protein preparation 
 Cells were removed from culture and washed three times in PBS to remove serum 
proteins from culture. Cells were lysed in 10ml ice cold hypotonic lysis buffer plus 
100μl protease inhibitor cocktail for 15 min at 4°C. 40 strokes of a tight fitting Dounce 
homogeniser were applied to the lysate. The homogenate was clarified at 4000g 4°C 
for 15 minutes to remove nuclear components (p4) and generate a post-nuclear 
supernatant (PNS). PNS was further centrifuged at 20000g 4°C for 30 min to yield a 
plasma membrane rich pellet (p20). Both p4 and p20 pellets were solubilised in small 
volumes (200-300µl) of hypotonic lysis buffer supplemented with salt and Triton-
X100. Samples were stored at -20°C until SDS-PAGE or IEF/SDS-PAGE. Recovery 
of plasma membrane protein was judged by the presence of CD45 and absence of 
tubulin by western blot. Protein content was assessed by BCA assay.   
 
2.7.1 Optimal cell breakage 
 In this thesis, cellular breakage by French Press and sonication are explored. The 
Thermo spectronic French press was thoroughly washed with ultra-pure deionised 
water. Lysates were passed through the French press twice at 200psi. Sonication 
was performed with the Ultrasonic sonicator. Five bursts of 5 seconds at 90W were 
applied to lysates whilst on ice. 
 
2.7.2 Optimal centrifugal force 
 In some experiments, the PNS was centrifuged at 100000g for 1 hour at 4°C to 
generate a p100 preparation for further analysis. 
 
2.7.3 Treatment of preparations with sodium carbonate 
 In some experiments, p100 pellets were resuspended in 2ml of ice-cold sodium 
carbonate wash buffer (100mM Na2CO3, 1mM EDTA pH 11.3), vortexed and placed 
on ice for 30 minutes. Suspension was then centrifuged at 100000g for 30 minutes at 
4°C. Treated p100 pellet was resuspended in supplemented hypotonic lysis buffer as 
before. 
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2.8 Biochemical Analytical techniques 
2.8.1 BCA assay 
 Protein samples were diluted with dH2O to a total volume of 10μl or assayed neat in 
triplicate within a 96-well plate Maxisorb plate (Nunc, DK) along with a serial dilution 
of BSA as standard. The BCA solutions A and B (Pierce, USA) were mixed at a ratio 
of 50:1 and 200μl was added to each sample well. Plates were incubated at 37°C for 
30 minutes before absorbance was read at 540nm on a Multiskan® BiochromicaticTM 
plate reader using Ascent™ 2.4.2 software (Labsystems, Helsinki, FI). 
 
2.8.2 SDS-PAGE 
 Sodium Dodecyl Sulphate Polyacrylamide Electrophoresis (SDS-PAGE) is a 
technique commonly used to separate proteins based on their molecular weight 
(MW) by applying an electrical field across a polyacrylamide gel. SDS is an anionic 
detergent which binds and denatures proteins, conferring a negative charge to the 
polypeptide that is proportional to its length. As the charge-to-mass ratio is 
approximately constant among SDS-denatured polypeptides, the final separation of 
proteins is dependent almost entirely on differences in MW. Samples for SDS-PAGE 
were prepared by the addition of 5x GSB to give a 1x solution, and further denatured 
at 100°C for 10 minutes.  
  
 Twelve percent gels were used for SDS-PAGE prior to western blotting, these were 
either self-cast gels or pre-cast minigels. Gels were cast according to the recipe 
outlined in Table 2.8, between two glass plates and assembled in a BioRad Protein 
Cell II cassette (BioRad,UK) according to the manufacturer’s instructions. 
Electrophoresis was performed overnight at a constant voltage of 65 Volts. 
Alternatively, 12% Precise™ Protein Gels purchased from Pierce, USA were used. 
Electrophoresis was carried out in a XCell SureLock™ Mini-Cell system (Invitrogen, 
UK) for 45 minutes to 1 hour at 100V. An estimation of the MW of separated proteins 
was determined by comparison with protein standards (Table 2.6) of known MW, run 
in parallel with samples.  
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Table 2.8 SDS-PAGE gel composition 
Reagent 4% stacking gel 12% Resolving Buffer 
30% Acrylamide 1.33ml 12ml 
Resolving buffer - 18ml 
Stacking buffer 8.67ml - 
10% (w/v) APS 200μl 200μl 
TEMED 15μl 15μl 
  
 SDS-PAGE of samples for subsequent analysis by mass spectrometry was carried 
out using gradient gels to provide greater resolution of proteins when visualised by 
silver staining. Again both self cast and pre-cast gels were used. Gradient SDS-
PAGE gels were cast using a device to mix 4% and 18% acrylamide solutions as 
they gradually flowed between the glass plates, and a stacking gel was cast upon 
the set gradient gel (Table 2.9). Alternatively, samples were run on 4-20% 
Criterion™ Precast Gels in a Criterion™ Cell according to the manufacturer’s 
instructions (BioRad, UK).  
 
Table 2.9 Gradient SDS-PAGE gel 
Reagent 4%  18%  Stacking  
Tris 1M (pH 8.8) 11.25ml 11.25ml 1.25ml 
10% SDS 0.3ml 0.3ml 0.1ml 
Acyrlamide 4.0ml 18.15ml 1.0ml 
H2O 14.5ml - 7.65ml 
TEMED 15 μl 15 μl 15 μl 
APS 225 μl 225 μl 50 μl 
 
2.8.3 Solution phase Isoelectric Focussing (IEF) 
 Isoelectric focussing (IEF) separates proteins according to their pI value and is 
commonly used in two-dimensional (2D) separation. In this thesis solution-phase IEF 
preceded SDS-PAGE to achieve 2D separation. Figure 2.3 shows a diagrammatic 
representation of the ZOOM® IEF fractionator (Invitrogen, Paisley, UK). It consists of 
five consecutive chambers separated by ZOOM® disks of increasing pH values thus 
forming a pH gradient. These disks are tiny polyacyrlamide gels with covalently 
attached buffers of a defined pH value on a polyethylene support. 
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 Plasma membrane preparations were thawed and protein concentration was 
assessed by the BCA assay. The following was added to each sample to be 
separated by solution-phase IEF:  
• 3.24ml IEF denaturant (section 2.1.6) 
• 36μl ZOOM™ Carrier ampholytes pH 3-10 
• 36μl 2M DTT 
• trace bromophenol dye 
• Protease inhibitor (1:100) 
 
 The total volume was made up to 3.6ml with deionised H2O.  The ZOOM® IEF 
fractionator was assembled according to the manufacturer’s instructions. IEF anode 
and cathode buffers were made according to manufacturer’s instructions and section 
2.1.6. Electrode buffers (17.5ml) were loaded into their respective reservoirs. 670μl 
of prepared sample was loaded into each of the five chambers. The system is run at 
100V for 20mins, 200V for 80mins and 600V for 80mins. IEF fractions were removed 
from each chamber. Chambers were washed with 230µl of IEF denaturant for 10 
minutes at room temperature by placing the apparatus on a bench-top shaker. Wash 
from each chamber was added to the respective fraction. IEF fractions 
(approximately 900µl) were concentrated using Microcon® centrifugal filter columns 
with a 10KD cut off (Millipore, Massachusetts, USA) to a volume of 50μl. Urea and 
thiourea was removed from fractions using either protein desalting spin columns 
(Pierce, USA) or SDS-PAGE Clean-up kit (Amersham Biosciences, UK). Samples 
were then separated by SDS-PAGE on a gradient gel (section 2.8.2). 
 
Anode 
Reservoir
Cathode 
Reservoir
pH 3.0 pH 6.2 pH 7.0 pH 10.0pH 5.4pH 4.6
Anode end 
sealer
Cathode end 
sealer
+ -
Sample
Blank Blank1 2 3 4 5
 
 Figure 2.3 ZOOM® solution phase IEF fractionator 
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 2.8.4 Western Blot 
 Proteins separated by SDS-PAGE were transferred to polyvinylidene difluoride 
(PDVF) membrane, which allows them to be identified using specific antibodies 
(Table 2.3). PVDF membrane was hydrated in methanol and equilibrated in transfer 
buffer (section 2.1.6). The membrane was layered on top of the gel, immersed in 
transfer buffer and sandwiched between filter paper within a transfer cassette 
(BioRad, UK), avoiding bubble formation between the layers. Proteins were 
transferred to the membrane in cooled transfer buffer within a specialised tank at 
100V for 2 hours. The membrane was blocked with 5% milk blocking buffer (section 
2.1.6) for 1 hour at room temperature. Membrane was incubated with primary 
antibody overnight at 4°C. The membrane was thoroughly washed 3 times with 
TBS/Tween prior to incubation with an appropriate secondary HRP-conjugated 
antibody (1:2000) for 1 hour at room temperature. The membrane was developed 
with chemiluminescent substrate solution ECL (Amersham, UK) and visualised using 
Hyperfilm™ and an AGFA Cruis-60 film processor (AGFA, UK).  Blots can be re-
probed for other proteins several times by stripping the membrane of antibodies 
using acid stripping buffer (Table 2.3) followed by re-blocking in 5% milk blocking 
buffer. 
  
2.8.5 Silver stain 
Gels were stained using the classical method of Shevchenko (Shevchenko et al., 
1996) which is compatible with protein identification by mass spectrometry. The 
solutions required for silver staining can be found in Table 2.3 and ultra-pure 
deionised water was used in all solutions. The gel was fixed for 20 min and then 
washed once in 50% (v/v) methanol for 10 min and once in 500ml H2O for 1 hour. 
The fixed gel was then sensitised for 1 min and washed twice in H2O for 1 min each. 
The gel was incubated at 4°C for 30 min in cold silver nitrate solution to stain. 
Following two 1 min washes in H2O, the gel was developed until the desired image 
intensity was acquired when the process was halted with stop solution.  
 
2.8.6 Sample preparation for mass spectrometry 
Silver stained bands were excised from the gel and digested in-gel with trypsin 
according to published methods (Jeno et al., 1995; Shevchenko et al., 1996; Wilm et 
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al., 1996) and modified for use with a robotic digestion system (Investigator ProGest, 
Genomic Solutions, UK) (Wait et al., 2001). Silver was removed by washing with 
30μl, of 15 mM potassium ferricyanide / 50 mM sodium thiosulphate followed by 
three washes with 100 μl deionised water. Cysteine residues were reduced with DTT 
and derivatized by treatment with iodoacetamide. After further washing with 
ammonium hydrogen carbonate buffer the gel pieces were dehydrated with 
acetonitrile and dried at 60°C, prior to addition of modified trypsin (Promega, 
Wisconsin, USA). Digestion proceeded for 8 hours at 37°C and products were 
recovered by sequential extractions with 25 mM ammonium hydrogen carbonate, 5% 
formic acid, and acetonitrile. The pooled extracts were lyophilized, and redissolved in 
0.1% formic acid for mass spectrometry. 
2.9 Tandem Mass Spectrometry 
 Tandem electrospray mass spectra were recorded using a Q-ToF hybrid 
quadrupole/ orthogonal acceleration time of flight spectrometer interfaced to a 
Micromass CapLC capillary chromatograph (Waters, Massachusetts, USA). Samples 
were dissolved in 0.1% aqueous formic acid, and 6 µl injected onto a Pepmap C18 
column (300 µm x 0.5 cm; Dionex, Surrey, UK), and washed for 3 min with 0.1 % 
aqueous formic acid (with the stream select valve diverting the column effluent to 
waste). The flow rate was then reduced to 1 µl per min, the stream select valve was 
switched to the data acquisition position, and the peptides were eluted into the mass 
spectrometer with an acetonitrile / 0.1% formic acid gradient (5% to 70 % acetonitrile 
over 20 minutes). The capillary voltage was set to 3500 V. A survey scan over the 
m/z range 400-1300 was used to identify protonated peptides with charge states of 
2, 3 or 4, and fragmented by collision with argon. The resulting product ion spectra 
were transformed onto a singly charged m/z axis using a maximum entropy method 
(MaxEnt3, Waters, USA) and proteins were identified by correlation of uninterpreted 
spectra to entries in SwissProt/TrEMBL, using ProteinLynx Global Server (Version 
1.1, Waters) (Wait, 2005 #145). The database was created by merging the FASTA 
format files of SwissProt, TrEMBL and their associated splice variants. No taxonomic 
or protein mass and pI constraints were applied. One missed cleavage per peptide 
was allowed, and the fragment ion mass tolerance window was set to 100 ppm. 
Identifications were confirmed by searching the MS/MS spectra against the NCBI 
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non redundant protein database and SwissProt using the Mascot search algorithm 
(www.matrixscience.com). Mass spectrometry was carried out by Ms Shajna Begum 
and Dr Robin Wait. 
2.10 Statistical analysis 
 Mean, standard deviation (SD) and statistical significance were calculated using 
GraphPad Prism version 5 software. Statistical significance was assessed using 
paired t-test (Wilcoxon), student t-test, one-way ANOVA with Bonferroni correction or 
Spearman correlation analysis where appropriate. 
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3.0 Introduction 
 Understanding the underlying mechanisms that induce excessive and pathogenic 
TNFα production in rheumatoid arthritis has been the focus of many studies at the 
Kennedy Institute. The role of T cells and their physical contact with 
monocytes/macrophages within the synovium was shown to be important in TNFα 
production (Brennan et al., 2002). The polyclonal nature of synovial lymphocytes 
with an active but ‘frustrated’ memory phenotype led to the hypothesis these T cells 
may have a unique status caused by antigen-independent activation by the pro-
inflammatory cytokine microenvironment of synovial tissue, rather than via the TCR.  
 Previous studies in the laboratory demonstrated contact-dependent induction of 
TNFα and IL-10 from monocytes in co-culture with peripheral blood lymphocytes 
(PBLs) which had been activated through anti-CD3 antibody ligation (Parry et al., 
1997).  In contrast, monocytes in co-culture with PBLs that had been cultured for 8 
days in the presence of IL-2, IL-6 and TNFα, produced TNFα but not IL-10 (Sebbag 
et al., 1997). Cytokine-activated PBLs thus mimic RA synovial T cells; when fixed 
and placed in co-culture RA synovial lymphocytes also only induce TNFα production 
from peripheral blood monocytes (Brennan et al., 2002). In addition, physical 
separation of cytokine-activated PBLs from monocytes by an insert in culture 
confirmed TNFα production to be contact dependent (Sebbag et al., 1997). The 
differences observed in the cytokines induced in monocytes between anti-CD3 and 
cytokine-activated PBLs may be explained by the observed differences in signalling 
pathways activated in the monocyte.   Adenoviral transfer of Inhibitor to NFκB kinase 
α (IκBα) to M-CSF treated monocytes demonstrated that TNFα induced by cytokine-
activated PBLs was abrogated by NFκB inhibition. Whereas monocyte TNFα 
induced in co-culture with anti-CD3 activated PBLs was unaffected by NFκB 
inhibition. Monocytes treated with phosphotidylinositide 3-kinase (PI 3-kinase) 
inhibitors (wortmannin or LY294002), produced less TNFα when co-cultured with 
anti-CD3 activated PBLs but higher TNFα levels in co-culture with cytokine-activated 
PBLs, compared to untreated monocyte controls. Crucially, monocytes treated with 
the same inhibitors placed in co-culture with RA synovial lymphocytes responded in 
a similar manner to those co-cultured with cytokine-activated PBLs (Brennan et al., 
2002).  Therefore IL-2, IL-6 and TNFα stimulation of PBLs is considered a good 
model in which to study the properties of T cells in the inflamed synovium of RA.  
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 The PBL population comprises of NK and B cells in addition to T cells. Analysis of 
these populations over 8 days of cytokine stimulation revealed that the CD56+ NK 
population responded to the greatest extent, undergoing up to six rounds of division, 
when compared to the CD3+ T cells (Brennan et al., 2008). Both populations are 
able to induce monocytic TNFα when sorted and individually placed in co-culture. 
However, only LY294002-treated monocytes in co-culture with cytokine-activated T 
cells and not NK cells produce super-induced levels of TNFα, mimicking the effector 
function of synovial lymphocytes in the same assay. B cells are not found in the PBL 
population after 8 days in culture with cytokines. Therefore my studies have 
focussed on the T cell population of cytokine-activated PBLs as an effector 
population relevant in the pathogenesis of RA. 
 The aim of this chapter was to further define the T cell population which upon 
chronic cytokine-stimulation is responsible for the induction of TNFα from 
monocytes, and to characterise the phenotype, proliferation and cytokine production 
of these cells.  In order to do this, both magnetic bead and flow cytometry sorting 
techniques were used to enrich specific T cell subsets. Flow cytometry was also 
used to study the effect of IL-2, IL-6 and TNFα on the expression of activation 
markers, chemokine receptors and adhesion molecules. The kinetics of cell division 
and apoptosis was investigated using tritiated thymidine incorporation and Annexin 
V/PI staining respectively.  Further insights were gained from CFSE dilution assays 
in combination with cell surface flow cytometry. Throughout this chapter, the function 
and phenotype of cytokine-activated T cells is compared to that of RA synovial 
lymphocytes to assess their relevance as a model of T cell function in rheumatoid 
arthritis.   
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3.1 Induction of monocyte TNFα by T cells following cytokine-activation   
The relative contribution of the CD4+ and CD8+ subsets to the effector function of 
cytokine-activated T cells was investigated by magnetic bead separation. CD4 
Dynabeads™ were used to positively separate freshly elutriated PBLs according to 
CD4 expression prior to activation (section 2.2.3). Flow cytometry showed the purity 
of the separated populations to be ≥90%. The separated CD4+ and CD4- PBL 
populations, along with a third population of total (unseparated) PBLs from the same 
donor, were cultured in the presence of IL-2, IL-6 and TNFα (section 2.3.2). On day 
eight, cells were washed and placed in co-culture with autologous monocytes at 
lymphocyte: monocyte ratios of 5:1 and 7:1 for 18 hours. 
 Figure 3.1 a) is representative of four independent experiments and shows TNFα 
production from monocytes cultured in the presence of CD4+ cytokine-activated 
PBLs (236-241pg/ml) was significantly higher (P<0.001) than in the presence of total 
PBLs (48-49pg/ml) or CD4- PBLs (39-44pg/ml) at both ratios. There was no 
significant difference between the levels of TNFα induced by the total and CD4- 
cytokine-activated PBLs (P>0.05).  Table 3.1 summarises data from all four donors. 
In each donor cytokine-activated CD4+ PBLs induce the highest levels of TNFα. 
Thus the ability to induce monocytic TNFα resides in the CD4+ population of T cells 
and not the depleted CD4- population containing NK cells, NKT cells and CD8+ T 
cells.  
 
Table 3.1 Monocyte TNFα production from co-cultures with cytokine-activated 
CD4+/- PBLs (pg/ml) 
Donor Total CD4+ CD4- 
1 49 ± 7 236 ± 33 44 ± 6  
2 105 ± 23 621 ± 100 94 ± 18 
3 47 ± 33 633 ±31 25 ± 9 
4 49 ± 25 101 ± 33 28 ± 11 
 
 
 To confirm the role of CD4+ over CD8+ T cells and to exclude the possibility of an 
artefact from CD4 ligation by the anti-CD4 Dynabeads; CD8+ Dynabeads were used 
to isolate CD8+ and CD8- (CD4+, NK and NKT cells) populations from the same 
donor prior to cytokine-activation. Figure 3.1b) shows TNFα induced by CD8- 
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cytokine-activated PBLs was greater than that by CD8+ T cells at a ratio of 5:1, 
121pg/ml versus 23pg/ml respectively. This difference was statistically significant in 
a paired t-test (P<0.001).  
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Figure 3.1 Induction of monocyte TNFα by subsets of cytokine-activated PBLs.  Freshly 
elutriated PBLs were separated using CD4 (a) or CD8 (b) Dynabeads. Separated and unseparated 
(Total) populations were cultured for 8 days in the presence of IL-2, IL-6 and TNFα. On day 8 cells 
were co-cultured at the indicated lymphocyte:monocyte ratios for 18 hours. Supernatants were 
removed, assayed for TNFα by ELISA. Data shown as mean ± SD of triplicate wells and is 
representative of 4 donors in a) and of 2 donors in b). Monocytes activated with 10ng/ml LPS as a 
positive control produced 3175 ± 453pg/ml TNFα in a) and >5000pg/ml TNFα in b). One-way 
ANOVA with Bonferroni correction statistical analysis was applied in a) and a student t-test 
(Wilcoxon) in b) where *** = P<0.001. 
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3.2 Induction of monocyte TNFα by CD4+ T cell subsets following cytokine 
activation 
 Having established that cytokine-activated CD4+ T cells reproducibly induced the 
highest TNFα responses in co-culture with monocytes, the relative roles of the naϊve 
and memory CD4+ populations were investigated. These populations can be 
distinguished on the basis of CD45 isoform expression. Naϊve T cells predominately 
express the longer CD45RA isoform but after encountering antigen the shorter 
CD45RO isoform predominates. The distribution of naϊve and memory cells was 
assessed in PBL populations from 25 donors. Table 3.2 shows that approximately 
17% of total lymphocytes are CD4+CD45RA+ naϊve T cells and 20% are 
CD4+CD45RO+ memory T cells. A small percentage of CD4+ T cells were positive 
for both CD45 isoforms (6.8%).   
 
Table 3.2 Distribution of CD4+ T cells in peripheral blood lymphocytes 
Population Mean ± SD (%) Range % (min  - max ) 
CD4+ 44.1 ± 10.4 26.0 – 62.5 
CD4+CD45RA+ 16.7 ± 8.3 3.2 – 35.7 
CD4+CD45RO+ 19.7 ± 9.4 6.5 – 42.0 
CD4+CD45RA+CD45RO+ 6.8 ± 4.0 1.2 – 19.8 
 
 
 
 
 
 CD4+CD45RO+ memory T cells and CD4+CD45RA+ naϊve T cells were separated 
by flow cytometry based on CD45RA expression in a CD4+ lymphocyte gate prior to 
cytokine stimulation. On day 8, each population was co-cultured with autologous 
monocytes and the CD4+CD45RA- memory population was found to induce 
significantly higher levels of TNFα compared to the naϊve population. Shown in 
Figure 3.2, this result was reproducible in 3 independent donors and published in 
Brennan et al, 2008.  
 
Freshly elutriated peripheral blood lymphocytes were stained with fluorochrome-conjugated 
antibodies against CD4, CD45RA and CD45RO and analysed by flow cytometry on a BD 
LSR. The percentages of cells positive are shown for 25 independent PBL populations. Data 
was analysed using Cell Quest Pro software. 
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Figure 3.2 Induction of monocyte TNFα by cytokine-activated CD4+ naϊve and 
memory T cells. Freshly elutriated PBLS were sorted by flow cytometry into 
CD4+CD45RA+ (naϊve) and CD4+CD45RA- (memory) populations prior to cytokine 
stimulation. A combination of anti-CD4+ and anti-CD45RA antibodies was used. After 8 
days T cells were placed in co-culture with autologous monocytes at the indicated 
lymphocyte:monocyte ratios in triplicate. Induced TNFα after 18 hours was analysed by 
ELISA and shown is mean + SD for a representative donor. *** = P<0.001 for 
CD4+CD45RA+ versus CD4+CD45RA- at 1:1 ratio using One-way ANOVA with 
Bonferroni correction and not significant (ns) at 0.5:1 ratio. Sorting and figure by Ms P. 
Amjadi. 
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3.2.1 Enrichment of CD4+ memory T cells prior to activation enhances TNFα 
responses in co-culture with monocytes 
 The separation of cell populations by flow cytometry, although accurate, is time 
intensive and can yield low cell numbers of sorted populations. Therefore a magnetic 
bead separation protocol was established (section 2.2.4). The method uses negative 
selection to enrich for CD4+CD45RO+ cells from the total PBL population achieving 
greater than 90% purity. Figure 3.3 a) is representative of 10 donors and compares 
cytokine-activated PBLs (Total) and CD4+CD45RO+ T cells enriched from the same 
donor. Cells were fixed and placed in co-culture with monocytes at a lymphocyte: 
monocyte ratio of 3:1 and 5:1. Cytokine-activated PBLs induced significantly 
(P<0.05) less TNFα than the separated population of CD4+CD45RO+ T cells (102 
pg/ml vs. 162 pg/ml) at 3:1. At 5:1 the enriched population induced approximately 2-
fold more TNFα than the total PBL population, this difference was also significant 
(P<0.01) in one-way ANOVA with Bonferroni correction analysis.    
 TNFα levels from autologous co-cultures of 12 donors with paired total and 
CD4+CD45RO+ populations are shown in Figure 3.3 b). In 9 of the 12 donors TNFα 
levels were greater in the supernatants from CD4+CD45RO+ co-cultures. Overall 
cytokine-activated CD4+CD45RO+ T cells induced a mean of 136 pg/ml of TNFα 
and the total PBL population induced a mean of 79 pg/ml. This 1.7-fold difference 
was statistically significant in a paired t-test (p<0.05).  Levels of induced TNFα were 
donor dependent in both populations where the range was 10 – 238 and 14 – 397 for 
total and CD4+CD45RO+ populations respectively.  
3.2.2 Induction of monocyte TNFα by cytokine-activated CD4+ memory T cells 
is dose-dependent  
 The enrichment of CD4+ memory T cells by negative selection with magnetic beads 
reproducibly induced stronger effector responses when compared to the complete 
PBL population, confirming initial flow cytometry sorting data and indicating that the 
cells capable of producing the greatest effector responses reside in this population of 
cytokine-activated PBLs.   
 Figure 3.3 c) demonstrates dose-dependent induction of TNFα by fixed cytokine-
activated CD4+CD45RO+ cells. As the ratio of lymphocyte: monocyte increases from 
0.5:1 to 6:1, the production of TNFα increases from approximately 14 to 94 pg/ml, 
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confirming that TNFα production is due to the presence of the activated lymphocytes 
and not other activating factors.  
3.2.3 Effector function of CD4+ memory T cells over 8 days of cytokine-
activation 
 Previous studies showed the acquisition of effector function by cytokine-activated 
PBLs to be dependent on the length of time in culture with cytokines. Cells activated 
for 8 days were more effective than those activated for shorter periods (Sebbag et 
al., 1997). In order to investigate whether a more defined population of cells have 
similar effector acquisition kinetics, CD4+CD45RO+ T cells were enriched at day 0 
and placed immediately in co-culture or were activated for 2, 5, 6 ,7 or 8 days with 
IL-2, IL-6 and TNFα prior to co-culture. Induced TNFα levels at each time-point are 
shown in Figure 3.3 d) for a single donor. At day 5 CD4+CD45RO+ T cells are 
capable of inducing a TNFα response from monocytes in co-culture (53 ± 12 pg/ml) 
however highest response was still observed after 8 days cytokine-stimulation (205 ± 
16 pg/ml). After 9 days cell viability, as measured by trypan blue, is minimal and an 
insufficient number of cells are recovered for the co-culture assay.  
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Figure 3.3 Induction of monocyte TNFα by cytokine-activated CD4+ memory T cells. PBLs were 
enriched for CD4+CD45RO+ T cells and stimulated with IL-2, IL-6 and TNFα for 8 days prior to co-
culture with monocytes for 18 hours. a) Fixed day 8 total PBL population or CD4+CD45RO+ T cells from 
the same donor were placed in co-culture at ratios of 3:1 and 5:1 at day 8. Data is shown as mean ± SD 
TNFα of triplicate wells and is representative of 10 donors. One-way ANOVA with Bonferroni correction 
was applied where * = P<0.05 and ** = P<0.01. b) TNFα induced from autologous monocytes in co-
culture with activated total PBLs or CD4+CD45RO+ (3:1) from 12 matched donors. Mean TNFα value of 
triplicate wells shown for each donor and mean of all donors is represented by a line. Paired t test * = 
P<0.05 c) Fixed cytokine activated CD4+CD45RO+ cells were placed in co-culture with monocytes at 
increasing ratio. Mean ± SD TNFα of triplicate wells shown. Representative of 6 donors. d) 
CD4+CD45RO+ PBLs were placed in co-culture with monocytes at the indicated day. Mean ± SD TNFα 
of triplicate wells shown for each time point. Representative of 5 donors. In all experiments PBLs and 
monocytes were cultured alone as controls. Monocytes + LPS produced at least 3000pg/ml TNFα (not 
shown). 
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3.3 PI 3-kinase inhibition in monocytes super-induces TNFα in co-culture with 
cytokine-activated CD4+ memory T cells 
 Cytokine-activated PBLs are able to induce TNFα from peripheral blood monocytes 
in a similar manner to lymphocytes isolated from rheumatoid synovium: TNFα 
production is reduced upon inhibition of NFκB and super-induced upon inhibition of 
PI 3-kinase. In contrast, a co-culture with anti-CD3 activated PBLs monocyte TNFα 
production is inhibited by PI 3 kinase inhibition (Brennan et al., 2002). To investigate 
whether the effector function acquired by CD4+CD45RO+ T cells mimics that of RA 
synovial lymphocytes, cytokine-activated cells were fixed and placed in co-culture 
with untreated monocytes or monocytes pre-treated with PI 3-kinase inhibitor 
LY294002.  
 Figure 3.4 shows that at a ratio of 3:1, monocytes produced 306 ± 31 pg/ml TNFα 
but in the presence of 5µM LY294002 this was significantly increased 4-fold, to 1260 
± 177 pg/ml (P>0.001). The super-induction observed was dose-dependent. 
However, in this donor the control co-culture of cytokine-activated CD4+CD45RO+ 
and monocytes treated with a 1:400 dilution of DMSO (equivalent to the dilution of 
inhibitor required for 5µM) also caused a moderate induction of TNFα.  
 In experiments from four donors 5µM LY294002 treatment induced monocyte TNFα 
levels to between 2 and 8 times (mean = 4.8) above that of untreated monocytes, 
although this was not statistically significant in a paired test. Therefore cytokine-
activated CD4+CD45RO+ T cells are able to activate TNFα production in monocytes 
via a pathway similar to that of RA synovial lymphocytes, and hence are a good 
model to further investigate the role of T cells in the pathogenesis of RA.  
 
 
 
 
 
 
 
 
 
 
Chapter 3       Results 
123 
 
 
 
 
3:
1 M μ
0.
5
M μ1
M μ5
D
M
SO
C
D
4+
C
D
45
R
O
+
M
on
oc
yt
es
M
 L
Y
μ
M
on
oc
yt
es
 +
 5
M
on
oc
yt
es
 +
 D
M
SO
0
250
500
750
1000
1250
1500 ***
+ LY294002
Controls
TN
F 
pg
/m
l
ns
ns
ns
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Effect of PI 3-kinase inhibition on the induction of monocyte TNFα by 
cytokine-activated CD4+ memory T cells. Freshly elutriated PBLs were negatively 
separated to enrich CD4+CD45RO+ T cells and stimulated with IL-2, IL-6 and TNFα 
for 8 days. Cells were fixed with glutaldehyde/glycine and co-cultured at a ratio of 3:1 
with either untreated monocytes or monocytes pre-treated with 0.5 - 5µM LY294002 
or DMSO (1:400) as a diluent control. Cytokine-activated PBLs, untreated and treated 
monocytes were also cultured alone as negative controls. In addition monocytes 
produced >5000pg/ml TNFα when stimulated with 10ng/ml LPS (positive control). 
Data is representative of 4 donors. *** P<0.001 and ns = not significant in a one-way 
ANOVA with Bonferroni correction. 
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3.4 Cytokine-production by T cells upon activation 
 The ability of cytokine-activated T cells to secrete common T cell cytokines was 
assessed. The cumulative cytokine production of CD4+CD45RO+ T cells separated 
at day 0 and cultured in the presence of IL-2, IL-6 and TNFα  for 8 days was 
determined by ELISA and compared to that of a total cytokine-activated PBL 
population in paired donors. Results are shown as mean ± SD and range (minimum 
– maximum) for n donors in Table 3.3. 
 
Table 3.3 Cytokine production from cytokine-activated PBLs 
Cytokine 
Mean ± SD (Range) pg/ml Fold 
difference P value n Total CD4+CD45RO+
IFNγ 8675 ± 5651 (3036 – 17512) 
2297 ± 2959 
(36 – 2959) 3.8 
*** 
0.0006 10
LT 13228 ± 10773 (1813 – 26331) 
1615 ± 1316 
(84– 2872) 8.2 
n.s 
0.0527 5 
GM-CSF 2190 ± 874 (1308 – 3338) 
619 ± 408 
(213 – 1282) 3.5 
* 
0.0157 5 
TGFβ 437 ± 57 (355 – 488) 
329 ± 48 
(247 – 462) 1.3 
n.s 
0.1250 4 
IL-8 1271 ± 1191 (290 – 2794) 
1236 ± 971 
(438 – 2349) 1.0 
n.s 
0.7584 5 
IL-10 41 ± 44 (10 – 137) 
162 ± 149 
(20 – 444) 4.0 
* 
0.0325 7 
IL-17 <100 <100 - - 7 
  
 
  
  
 
 
 Cytokine-activated CD4+CD45RO+ T cells produced 3.2-fold less IFNγ, 3.5-fold 
less GM-CSF and 8.2-fold less LT; all differences except the latter were significant. 
In contrast significantly more IL-10 (P<0.05) was detected in the supernatants of 
CD4+CD45RO+ T cells. No difference in IL-8 production was found between the two 
populations of cells. There was also no significant difference in the amount of TGFβ 
Freshly elutriated PBLs were either directly placed in culture with IL-2, IL-6 and TNFα for 8 
days or enriched for CD4+CD45RO+ cells prior to stimulation. Day 8 culture supernatant was 
assayed for the indicated cytokines by ELISA. Mean ± SD pg/ml of cytokine from matched total 
and CD4+CD45RO+ PBL populations from n donors are shown. Range is shown as (min – 
max). P values from paired t test where * = P<0.05, **=P<0.01 and ***=P<0.001. 
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observed between the two populations, with the total PBL population only producing 
30% more than the CD4+ memory cells. However it is important to note that the 
culture medium contains 10% normal human serum and this equates to 
approximately 190pg/ml of TGFβ (when 4 independent preparations of media were 
assayed). IL-17 was not detected in the supernatants obtained from either cytokine-
activated population where the sensitivity of our ELISA is approximately 100pg/ml. 
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3.5 Phenotype of CD4+ memory T cells upon IL-2, IL-6 and TNF stimulation  
 This section looks at the phenotype of CD4+ memory T cells upon cytokine-
activation. Changes in the expression of common CD4+ T cell activation markers, 
adhesion molecules and chemokine receptors were assessed by flow cytometry. 
CD4+CD45RO+ T cells were separated from freshly elutriated PBLs and were 
labelled with PE-conjugated antibodies against CD25, CD69, HLA-DR, CD18, CD29, 
CD49d, CD62L, CCR7, CXCR4, CCR5, CXCR3 or Cyc-conjugated anti-CD62L; plus 
FITC-conjugated anti-CD45RO antibody. The percentage of cells expressing each 
molecule at day 8 is shown in Figure 3.5, for a representative donor, and the 
expression levels at day 0 and day 8 from at least 13 independent donors are 
summarised in Table 3.4.  
3.5.1 Expression of activation markers 
 CD25, CD69 and HLA-DR are all common markers of T cell activation and have 
been described on T cells in sites of inflammation. CD25 is a type 1 transmembrane 
protein and is the alpha chain of the IL-2 receptor complex. It is highly expressed on 
antigen and mitogen activated T cells but is also found on activated B cells and 
monocytes (Waldmann, 1994).  CD69 is a type 2 membrane protein, it contains a C-
type lectin domain and is expressed as a homodimer on activated T, B and NK cells. 
It is involved in the early activation stages of T cells, contributing to calcium influx 
and cytokine synthesis, however its ligand is unknown (Lopez-Cabrera et al., 1993).   
Unlike antigen presenting cells, T cells do not constitutively expressed class II 
human leukocyte antigen (HLA)–DR, but upregulate it on activation (Matsushima et 
al., 1993). Changes in the mean fluorescence intensity (MFI) of CD25, CD69 and 
HLA-DR on the surface on CD4+ memory cells were assessed over 8 days in culture 
with IL-2, IL-6 and TNFα.  
  Flow cytometry data indicating the percentage of cytokine-activated 
CD4+CD45RO+ cells which are positive for CD25, CD69 or HLA-DR plus CD45RO 
from a single donor is shown in Figure 3.5. By day 8  approximately 14% of cells 
were CD45RO+CD25+, 24% were CD45RO+CD69+ and 17% were CD45RO+HLA-
DR+. This data is representative of 15-17 donors where the mean percentage of 
double positive cells were approximately 22%, 24% and 21% for CD25, CD69 and 
HLA-DR respectively (Table 3.4). Mean fluorescence intensity (MFI) was determined 
as an indication of overall expression levels at day 0 and day 8. A significant 
Chapter 3       Results 
127 
 
increase in the expression of all activation markers was observed. Median CD25 
expression increased 4-fold from 19.4 to 77.7. The increase in MFI for both CD69 
and HLA-DR was at approximately 5-fold. However over 8 days the percentage of 
cells positive for CD69 increases 13-fold whereas the percentage positive for HLA-
DR only increases 3-fold.  
3.5.2 Expression of adhesion molecules 
 CD62L (L-selectin) and integrin expression by T cells enables differential trafficking 
in vivo. CD18 has been shown to be important in a variety of cell-cell interactions as 
part of LFA-1, and that VLA-4 (CD49d/CD29) has a role in T cell co-stimulation plus 
cellular migration Changes in cell surface expression of these proteins were 
investigated in our system by flow cytometry.  
 The percentage of cells expressing integrin subunits remained roughly constant as a 
result of cytokine stimulation; the majority of cells express CD18, CD29 and CD49d 
at day 0 and 8. Despite little modulation in the percentage of cells expressing integrin 
subunits, a universal increase in the number of molecules expressed was observed 
as MFI values were significantly increased (Table 3.4). CD18 is upregulated roughly 
6-fold from 77.3 to 444.0 (P<0.001), and CD49d increases almost 2-fold from 141.4 
to 271.0 (P<0.01). A modest 1.4-fold increase in the MFI of CD29 was not significant 
in a paired t-test. The mean percentage of CD45RO+CD62L+ cells almost doubled 
from 30% to 51% in 15 donors. Furthermore MFI levels significantly increased 10-
fold (P<0.001). Therefore CD62L was the most highly modulated adhesion molecule 
investigated. 
3.5.3 Expression of chemokine receptors 
  CXCR3 and CCR5 are inflammatory chemokine receptors characteristic of Th1 
cells, whereas CXCR4 and CCR7 are often defined as constitutive receptors.  These 
chemokine receptors were studied as they have been shown to be involved in 
recruitment and sequestering of T cells within the rheumatoid joint (Burman et al., 
2005). In general, expression was lower than that of the activation and adhesion 
molecules.  
 When chemokine receptor expression was investigated over a larger number of 
donors, only CXCR4 expression was significantly modified. The MFI increases 2.4-
fold (P<0.01), in line with a 1.9-fold increase in the percentage of CD45RO+CXCR4+ 
cells (Table 3.4). The proportion of CD4+CD45RO+ cells expressing CXCR3 
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remains at approximately 28%. The expression of CCR5 is low, changing only 1.2-
fold in terms of MFI and the percentage of cells positive. Levels of CCR7 were also 
low and showed a slight, but not significant, decrease after 8 days in terms of MFI. 
The percentage of positive cells approximately halved, declining from approximately 
12 % to 6%. 
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Table 3.4 Changes in phenotype of CD4+ memory T cells upon cytokine 
activation 
Phenotype 
MFI median (Range) 
Mean percent positive 
Fold 
Change 
(MFI) 
n 
Day 0 Day 8 
CD25 19.4   (4.1 - 44) 13.5% 
77.7  (17.8 – 421.6) 
22.2% 
*** 
4.0 16 
CD69 5.8  (3.3 – 42.7) 1.8% 
31.9  (4.5 – 190.8) 
23.9% 
** 
5.5 17 
HLA-DR 11.0  (4.0 – 58.5) 8.0% 
56.3  (11.2 – 237.2) 
20.9% 
*** 
5.1 15 
CD18 77.3  (16.8 – 514.8) 92.7% 
444.0  (56.9 – 2040.0) 
93.1% 
*** 
5.7 13 
CD29 74.5  (5.9 – 419) 76.7% 
104.2  (14.1 – 280.4) 
87.4% 
n.s 
1.4 17 
CD49d 141.4  (15.6 – 372.0) 77.6% 
271.0  (63.2 – 1249.0) 
79.1% 
** 
1.9 13 
CD62L 39.2  (8.0 – 446.2) 29.5% 
397.5  (7.0 – 979.4) 
50.6% 
*** 
10.1 15 
CCR7 15.1  (4.4 – 51.0) 11.7% 
10.9  (6.1 – 43.7) 
5.7% 
n.s 
0.7 16 
CXCR4 98.8  (21.9 – 494.0) 39.9% 
267.0  (133.0 – 896.1) 
74.4% 
** 
2.7 16 
CCR5 11.0  (4.2 – 22.6) 3.7% 
13.4  (6.2 – 30.1) 
4.6% 
n.s 
1.2 15 
CXCR3 50.1  (12.0 – 309.0) 29.0% 
40.9  (25.6 – 125.9) 
26.8% 
n.s 
0.8 16 
 
Freshly elutriated PBLs were enriched for CD4+CD45RO+ T cells prior to stimulation with IL-2, IL-6 
and TNFα. At day 0 and day 8 cells were labelled with either PE- conjugated antibodies to CD25, 
CD69, HLA-DR, CD18, CD29, CD49d, CCR7, CXCR4, CCR5, CXCR3 or with PE-Cy5 conjugated 
anti-CD62L. Cells were fixed and analysed by flow cytometry on a LSR II instrument and Cell Quest 
Pro software. 10000 events were collected per sample. Data is shown as median, range (min – max) 
of mean fluorescence intensity and mean percentage positive for n donors. Paired t test and fold 
change was calculated from MFI values - ** = P<0.01, *** = P<0.001, n.s = not significant.  
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Figure 3.5 The cell-surface phenotype of CD4+ memory T cells after cytokine-activation. 
Cytokine-activated CD4+CD45RO+ T cells were labelled with PE-conjugated antibodies against 
CD25, CD69,HLA-DR, CD18, CD29, CD49d, CCR7, CXCR4, CCR5, CXCR3 or Cyc-conjugated anti-
CD62L plus FITC-conjugated anti CD45RO, 30 min at 4°C. Cells were fixed and analysed on a LSR II 
flow cytometer. 10000 events were collected per sample and analysed using Cell Quest Pro software. 
The percentage of double positive cells is shown. Data shown is from the same donor and 
representative of 13-17. 
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3.6 Role of CD62L on cytokine-activated CD4+ memory T cells 
 CD62L (L-selectin) binds carbohydrate moieties on the endothelium enabling 
leukocyte migration and is subsequently cleaved from the cell surface after 
activation. Thus loss of CD62L expression is often associated with effector T cells. 
As seen in section 3.5.2, CD62L expression increases approximately 10-fold on 
CD4+CD45RO+ T cells upon cytokine activation. However when induced TNFα 
levels were compared to expression at day 8 over multiple donors, CD62L 
expression at day 8 was found to negatively correlate with induced TNFα levels 
(Brennan et al., 2008), suggesting CD62L- cells may be more potent effector cells 
than CD62L+ cells.  Alternatively, upregulation of CD62L could purely be a marker of 
activation in this system and the negative correlation observed a consequence of 
cleavage from the cell surface. To assess this, the level of soluble CD62L (sCD62L) 
in the supernatant of cytokine-activated CD4+CD45RO+ cell cultures was measured 
by ELISA over 8 days. Culture medium containing 10% normal human serum was 
assayed as a day 0 control and found to contain 200 ± 14 ng/ml sCD62L. Over 8 
days the concentration increases above background to 264 ± 32 ng/ml (Figure 3.6 
a).  
 In order to assess the relative potency of CD62L positive and negative cytokine-
activated CD4+ memory T cells, these were sorted by flow cytometry at day 8. TNFα 
production from monocytes in co-culture from both sorted and unsorted populations 
is shown in Figure 3.6 b). CD4+CD45RO+CD62L+ cytokine-activated T cells induced 
793 ± 470 pg/ml TNFα, whereas CD4+CD45RO+CD62L- cells induced 476 ± 222 
pg/ml TNFα at a ratio of 3:1. TNFα induction was not significant at this or lower ratios 
by one-way ANOVA with Bonferroni correction analysis.  This experiment has only 
been performed twice and requires at least one more replicate. 
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Figure 3.6 Role of CD62L expression on cytokine-activated CD4+ memory T cells. 
CD4+CD45RO+ T cells were activated with IL-2, IL-6 and TNFα for 8 days. a) Conditioned 
supernatants from separate cultures of the same donor were assayed at day 0, 2, 5, 6, 7 and 8 for 
sCD62L by ELISA. Representative of 3 donors. b) Cells were sorted by flow cytometry according 
to CD62L expression at day 8. Sorted and unsorted populations were placed in co-culture with 
monocytes at the indicated lymphocyte: monocyte ratios. Mean ± SD TNFα pg/ml of triplicate 
wells shown. Data is representative of 2 donors. T cell populations and monocytes were culture 
alone as negative controls. n.s = not significant in a one-way ANOVA with Bonferroni’s correction. 
FACS sorting carried out by Ms P.Amjadi and Dr C. Li. 
a) 
b) 
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3.7 CD4+ central and effector memory T cells following cytokine stimulation 
  Table 3.4 showed a 30% decrease in both the MFI of CCR7 and percentage of 
CD45RO+CCR7+ cells upon cytokine stimulation. CD4+ memory T cells can be 
divided into functional subsets according to CCR7 expression and therefore although 
neither of the above observations reached statistical significance, the relative 
function of CCR7+ central memory (TCM) and CCR7- effector memory (TEM) CD4+ T 
cells in our system was investigated. Figure 3.7 illustrates the distribution of these 
subsets in a resting CD4+ PBL population. Naϊve cells are CD45RA+CD45RO-
CCR7+ whereas the TCM cells are CD45RA-CD45RO+CCR7+ and TEM cells are 
CD45RA-CD45RO+CCR7-. 
 
 
  
 
 
 I assessed changes in the absolute numbers of CD4+CD45RO+CCR7+ (TCM) and 
CD4+CD45RO+CCR7- (TEM) cells upon cytokine-activation in 11 donors. Figure 3.8 
shows that in the majority of donors (7 out of 11) the number of TCM cells decreases 
over 8 days and TEM cell numbers increase. On average, mean (± SD), the TCM 
population decreases from 0.164 (± 0.151) cells to 0.0639 (± 0.044) million cells per 
ml; and the TEM population increases from 0.796 (± 0.161) to 0.829 (± 0.367) million 
cells per ml. 
Figure 3.7 CD4+ subsets in resting peripheral blood lymphocyte population. Freshly 
elutriated PBLs were stained with conjugated antibodies against CD4, CCR7 and either 
CD45RA or CD45RO. CD4+ lymphocytes were gated and expression of CCR7 versus 
CD45RA or CD45RO was analysed.  CD4+ subsets indicated in relevant quadrants. 
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 As the relative numbers of TCM and TEM change as a result of cytokine-activation, 
their ability to individually induce TNFα in co-culture experiments was investigated by 
cell sorting. CD4+CD45RO+ T cells were isolated from freshly elutriated PBLs by 
magnetic separation and were sorted based on CCR7 expression at either day 0 
prior to culture with cytokines, or after 8 days in culture. Each sorted and unsorted 
cytokine-activated T cell population was placed in co-culture with autologous 
monocytes and TNFα production was assayed by ELISA.  
 Figure 3.9 shows that whether sorted at day 0 or at day 8, cytokine activated TEM 
cells induced significantly higher levels of TNFα from monocytes compared to TCM 
cells (P<0.001 in one-way ANOVA with Bonferroni correction analysis). TEM cells 
sorted at day 0 induced significantly more TNFα than those sorted at day 8, 1224 ± 
196 pg/ml compared to 798 ± 147 pg/ml. Additionally, TCM cells sorted at day 0 were 
capable of inducing a monocyte TNFα response (237 ± 25 pg/ml) yet those sorted on 
day 8 were not (below ELISA detection). This trend is reflected in Table 3.5 which 
summarises data from three independent sorting experiments. Although absolute 
levels of TNFα vary between donors in each donor TEM cells induce higher levels 
than TCM, moreover cytokine-activated TEM cells sorted at day 0 induced more TNFα 
than those sorted at day 8. These data indicate that CD4+ effector memory cells are 
the most able population in the activation of monocytes by cytokine-activated T cells.  
 
Table 3.5 Monocyte TNFα production from co-cultures with CCR7+/-  cytokine-
activated CD4+ memory T cells (pg/ml) 
 
Day 0 sort Day 8 sort 
Donor Unsorted CD4+CD45RO+ TCM TEM TCM TEM 
1 1822 ± 189 237 ± 25 1223 ± 196 20 ± 1 791 ± 147 
2 55 ± 13 29 ± 15 131 ± 39 23 ± 8 63 ± 0 
3 779 ± 310 42 ± 13 641 ± 276 102 ± 56 184 ± 15 
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Figure 3.8 Changes in the number of central and effector memory CD4+ T cells 
following cytokine-activation. Freshly elutriated PBLs were enriched for 
CD4+CD45RO+ T cells prior to stimulation with IL-2, IL-6 and TNFα. At day 0 and day 8 
cells were labelled with anti-CD45RO FITC and anti-CCR7 PE antibodies for 30 minutes 
at 4°C. Cells were fixed and 10000 events were collected on a LSR II flow cytometer and 
analysed using Cell Quest Pro software. The density of central a) and effector memory b) 
cells (106/ml) shown at day 0 and 8, for 11 donors.
a) 
b) 
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Figure 3.9 Induction of monocyte TNFα by CD4+ memory subsets. Freshly 
elutriated PBLs from the same donor were sorted by flow cytometry according to 
CCR7 expression at either day 0 prior to cytokine activation or after 8 days in culture 
into TCM (CD4+CD45RO+CCR7+) or TEM (CD4+CD45RO+CCR7-) populations. 
Cytokine-activated T cells were placed in co-culture with autologous monocytes at 1:1 
(lymphocyte:monocyte) including unsorted  day 8 CD4+CD45RO+ cytokine-activated 
T cells. Cytokine-activated cells and monocytes were cultured alone as controls. Data 
shown as mean ± SD TNFα of triplicate wells as assessed by ELISA. *** = P<0.001, * 
= P<0.05 and n.s = not significant using one-way ANOVA with Bonferroni correction 
statistical test. Data is representative of 3 donors.  
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3.8 Proliferative response of CD4+ memory T cells to IL-2, IL-6 and TNFα 
activation. 
3.8.1 Proliferation and apoptosis kinetics 
 Initially, changes in the density of viable cells during culture were investigated. 
Figure 3.10 a) shows the kinetics of cell survival to be biphasic. Data from a number 
of donors shows a decrease in the number of viable cells in the first 48 hours post 
stimulation, falling to a mean of 0.685 million cells per ml. Numbers briefly recover 
back to 0.960 million cells per ml by day 4, before an approximate 20% drop at day 5 
and 6. A modest expansion of CD4+CD45RO+ cells is observed by day 7 and 8. On 
average 16% more cells were recovered after eight days than were originally 
activated. However a large range in recovery was observed, between 0.61 and 1.92 
million cells per ml, again highlighting the variability between donors in response to 
chronic cytokine stimulation. It was hypothesised that the biphasic response 
observed may be due to the relative rates of proliferative and apoptotic processes at 
different stages of culture.  
 Cellular division was measured by the incorporation of 3H-thymidine into the DNA of 
cells over the eight days. Figure 3.10 b) is representative of 2 donors and reveals a 
slow period of 3H-thymidine uptake over the first 4 days followed by rapid uptake 
from day 5 to 8. In fact, on the 5th day in culture a 3-fold increase in incorporated 
radioactivity was observed in this donor.  
 Apoptosis was assessed by flow cytometry using Annexin V and propidium iodine 
(PI).  Annexin V binds to phosphotidylserine that is exposed on the cell-surface as it 
enters into apoptosis. In the later stages of apoptosis the cellular membranes are 
compromised such that PI is able to access and bind to DNA.  
 Figure 3.10 c) shows the percentage of cells in early apoptosis (Annexin V+) or in 
late apoptosis (Annexin V+ PI+) on cytokine stimulation in one of two donors 
assayed. By day two, 19% of cells are in the early stages of apoptosis, from day 5 to 
day 8 this increases to 26%. The number of late apoptotic cells steadily increases to 
21% over 8 days, such that by day 8 they equal the number of cells entering 
apoptosis in this donor. In contrast to the proliferation kinetics observed, which 
shows a lag phase early on, cells rapidly enter apoptosis after cytokine stimulation 
which slowly increases as the culture continues. This differential kinetics is reflected 
in the biphasic changes in cell numbers seen in Figure 3.10 a).   
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3.8.2 Investigating cellular division by CFSE 
 Carboxylfluoroescein succinimidyl ester (CFSE) is a green fluorescent dye which 
when taken up by a cell undergoes an ester cleavage becoming evenly distributed 
through the cytoplasm. Upon cell division, CFSE divides equally from mother to 
daughter cell, this is concomitant with a halving in fluorescence intensity. Up to 
seven rounds of cellular division can be accurately observed using this technique. 
CFSE was used to investigate the number of cellular divisions undertaken by 
CD4+CD45RO+ T cells when stimulated with IL-2, IL-6 and TNFα.  
 Figure 3.11 is a representative profile of the cellular divisions observed at day 2 b), 
day 5 c), day 6 d), day 7 e) and day 8 f). The percentage of cells for each peak and 
division are shown. Panel a) illustrates equal loading of CD4+CD45RO+ cells at day 
1, shown by a single fluorescent peak.  There is no change in profile at day 2, but by 
day 5 the profile has broadened and approximately 7% of cells have a lower MFI. 
Over the next 24 hours, 5 peaks appear indicating that cells have undergone 5 
divisions.  By day 7, a sixth division is visible comprising of around 16% of cells 
which increases to 29% over the last 24 hours in culture.  If the non divided cells 
comprise of the M1 peak then the subsequent divisions are termed the M2-M7 
peaks. Table 3.6 shows the MFI units of each peak in the population at day 8. An 
approximate halving of MFI is seen between consecutive peaks, providing 
confirmation of true cell division and no significant leaching or loss of fluorescence 
signal.  
 
Table 3.6 Fluorescence of CFSE peaks from cytokine-activated CD4+ memory 
T cells 
Peak MFI 
M1 23149 
M2 9152 
M3 4459 
M4 2376 
M5 1200 
M6 622 
M7 187 
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b) 
c) 
Figure 3.10 Proliferation and apoptosis of CD4+ memory T cells in response to IL-2, IL-6 and 
TNFα. a) CD4+CD45RO+ T cells from 13 donors and stimulated with IL-2, IL-6 and TNFα at a cell 
density of 1 x 106 /ml. At indicated days viable cells were counted using trypan blue exclusion. Mean 
value represented by red line. b) CD4+ CD45RO+ T cells were removed from culture at the indicated 
time points cells and pulsed with tritiated thymidine for 24 hours in triplicate in a 96-well plate. 
Radioactive cultures were frozen, and subsequently thawed and harvested together. c) 
CD4+CD45RO+ T cells were stimulated with cytokines in 5 separate cultures from one donor. Prior to 
culture and at the indicated time points, cells were stained using Annexin V conjugated to FITC and PI. 
10000 events were collected on a FACS Canto II. Data shown as percentage of cells annexin V+ and 
annexin V+PI+. b) and c) are representative of 2 donors. 
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The CFSE dilution profiles of 5 donors are summarised in Table 3.7. All donors were 
found to undergo at least 5 cellular divisions and in one donor, 7 divisions were 
observed. Overall, a mean of 53% of cells did not divide and 45% of cells underwent 
at least one division. Interestingly, the lowest proportion of cells entering cell division 
was seen in donor 2 despite these cells eventually undergoing to up to 7 divisions. 
Furthermore, approximately half of the 25% of the cells that entered proliferation 
underwent a full 7 rounds of division.  In fact, in four out of five donors this trend was 
repeated despite the percentage of total dividing cells ranging from 25% to 64%.  
This suggests that a sub-population of CD4+CD45RO+ T cells which are more 
responsive to IL-2, IL-6 and TNFα may exist.  
 
Table 3.7 Proliferation of CD4+ memory T cells upon cytokine activation as 
determined by CFSE 
Donor Non divided % Divided % 
Number of 
divisions 
Final division 
% 
1 34.57 64.34 6 29.37 
2 74.82 24.45 7 13.02 
3 68.02 27.28 5 15.75 
4 41.32 55.84 5 24.94 
5 48.08 51.04 6 6.22 
 
 
 
 
CD4+CD45RO+ T cells from 5 donors were loaded with CFSE prior to cytokine-stimulation. At day 8, 
the percentage of cells that had not divided (non divided), undergone one or more divisions (divided 
%) or completed the maximum number of divisions observed for that donor (final division %) was 
assessed.  
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3.8.3 Comparison of phenotype between dividing and non dividing CD4+ 
memory T cells 
b) 
Figure 3.11 Proliferation of cytokine-activated CD4+ memory T cells: CFSE. CD4+CD45RO+ T 
cells were loaded with 2.5µM CFSE prior to stimulation with IL-2, IL-6 and TNFα. On day 1 a), day 2 
b), day 5 c), day 6 d), day 7 e) and day 8 f) cells were removed from separate cultures and CFSE 
levels were analy ed on a FACS Canto. 50000 vents were collecte  per sample and analysed 
using FlowJo software. Percentage cells for given marker shown. Data is representative of 5 
donors.   
a) 
c) 
e) 
d) 
f) 
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 One particular advantage of studying cell proliferation by CFSE dilution is the ability 
to differentiate between dividing and non dividing cells according to phenotype 
through counter-staining with antibodies conjugated to fluorochromes that fall outside 
the green emission spectrum. The phenotype of dividing and non divided populations 
was examined in our system.  
 The percentage of cells expressing activation markers, adhesion molecules or 
chemokine receptors on dividing and non dividing cells are shown for a 
representative donor in Figure 3.12. Table 3.8 compares the MFI (mean and range) 
for each molecule in divided and non divided cells against each other, and the total 
population. 
 When the MFI of CD25, CD69 and HLA-DR was compared for the divided and non 
divided populations, the divided population was found to express higher levels of 
activation markers – 4.3, 2.6 and 3.7 fold respectively. Despite this similar trend 
Figure 3.12 shows differences in the profiles for each molecule. The majority of 
CD4+CD45RO+CD25+ cells divide, however a small but distinct population (7.8%) 
remain undivided. In contrast, very few CD4+CD45RO+HLA-DR+ cytokine-activated 
cells do not divide (1.5%). Even though the divided population has a higher CD69 
MFI (Table 3.8), the most divided cells are CD69 negative. 
 Table 3.8 shows that the adhesion molecules CD18, CD29 and CD49d are more 
highly expressed on divided cells compared to non-divided cells. Figure 3.12 e) – g) 
demonstrates that approximately 60% of the CD4+CD45RO+ cytokine-activated T 
cells which have undergone proliferation and express either CD18, CD29 or CD49d. 
Data from three donors indicates that it is the non-divided cells which express the 
greatest levels of CD62L.  
 The MFI of CCR7, CXCR3 and CCR5 are similar on cells that have divided and 
those that have not. However, the expression of CXCR4 is more than 2-fold higher 
on non-divided cells compared to divided. Figure 3.12 demonstrates that CXCR4+ 
cells may undergo 2-3 divisions but the cells divide beyond this point are 
predominantly CXCR4 negative. 
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Table 3.8 Comparison of phenotype of divided and non divided cytokine-
activated CD4+ memory T cells  
 
 
Divided Nondivided Total 
n Mean 
(min – max) 
Mean
(min – max) 
Mean 
(min – max) 
CD25 7379 (5561 – 11280) 
1706 
(1168 – 3219) 
4229 
(3063 – 5068) 5 
CD69 2205 (528 – 2949) 
851 
(382 – 1764) 
1440  
(495 – 2369) 5 
HLA-DR 4525 (3804 – 5925) 
1234 
(356 – 4198) 
2919 
(1402 – 4596) 5 
CD62L 3967 (299-9829) 
5440 
(2404-7962) 
4478 
(1157-8586) 3 
CD18 10647 (6254 – 17065) 
4931 
(2682 – 7745) 
7471 
(4900 – 10757) 5 
CD29 3219  (1306 – 4752) 
1954 
(935 – 3395) 
2573 
(1197 – 3669) 5 
CD49d 14704 (8952 – 17247) 
5436 
(3459 – 7464) 
10079 
(6794 – 13200) 5 
CCR7 639 (264 – 1332) 
648 
(207 – 1272) 
569 
(83 – 1073) 5 
CXCR4 1641 (205 – 5395) 
3991 
(935 – 10844) 
3603 
(534 – 8067) 4 
CXCR3 1048 (239 – 2542) 
1076 
(254 – 2376) 
955 
(254 – 8067) 5 
CCR5 176 (95 – 293) 
287 
(105 – 605) 
211 
(109 – 383) 4 
 
 
 
 
Freshly elutriated PBLs were enriched for CD4+CD45RO+ T cells and loaded with 2.5µM CFSE prior to 
stimulation with IL-2, IL-6 and TNFα. On day 8 cells were stained with PE-conjugated antibodies against 
the indicated markers for 30 min at 4°C. Cells were analysed on a BD FACS Canto, 50000 events per 
sample. Mean fluorescence intensity (MFI) for the appropriate marker was obtained for the complete, 
non divided and divided populations using FlowJo software for n donors. 
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3.9 Relative induction of monocyte TNFα by non divided and dividing 
populations of cytokine-activated CD4+ memory T cells. 
Figure 3.12 Phenotype of proliferating CD4+ memory T cells. CD4+CD45RO+ T cells were 
loaded with 2.5µM CFSE prior to stimulation with IL-2, IL-6 and TNFα. On day 8 cells were stained 
with PE conjugated antibodies against CD25, CD69, HLA-DR, CD62L, CD18, CD29, CD49d, CCR7, 
CXCR4, CXCR3 or CCR5 for 30 min at 4°C. Cells were analysed on a BD FACS Canto. 50000 
events were collected per sample and analysed using FlowJo software. Quadrants indicate 
percentage of non-divided or divided cells expressing the appropriate marker. Data is representative 
of 5 donors.  
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  Section 3.8.3 revealed that proliferating CD4+CD45RO+ cytokine-activated T cells 
express higher levels of activation markers and integrin subunits, but lower levels of 
adhesion molecule CD62L and chemokine receptor CXCR4 in comparison to non-
divided cells. Thus the potential for differences in effector function, as well as in 
phenotype, between non divided and dividing cells was investigated.  
 CD4+CD45RO+ T cells were loaded with CFSE dye and stimulated with IL-2, IL-6 
and TNFα, as normal. On day 8, cells were separated according to CFSE intensity. 
Figure 3.13 a) shows CFSE loaded cells at day 8 and indicates the gates used for 
FACS sorting to separate the non divided and divided populations to ≥ 90% purity 
(Figure 3.13 b). Sorted populations were placed in co-culture with autologous 
monocytes at a ratio of 2:1. Unsorted, but CFSE loaded, CD4+CD45RO+ cytokine-
activated T cells were also placed in co-culture. Cells that had divided in response to 
cytokine stimulation induced significantly more TNFα compared to non divided cells 
(P<0.001). Non divided cells also induced significantly less TNFα than the complete 
CD4+CD45RO+ population (P<0.001), but there was no significant difference 
observed between the unsorted population and the divided cells. These results 
suggest that a proliferative response to cytokines is a pre-requisite to effector 
function. Table 3.9 summarises the data from four independent experiments, in each 
donor the divided population of cytokine-activated T cells induced significantly higher 
levels than the non-divided. 
 
Table 3.9 Monocyte TNFα production from co-cultures with non-divided and 
divided cytokine-activated CD4+ memory T cells 
Donor Unsorted CD4+CD45RO Non-divided Divided 
1 813 ± 54 39 ± 42 758 ± 37 
2 163 ± 90 13 ± 5 194 ± 22 
3 1192 ± 133 35 ± 9 980 ± 95 
4 395 ± 94 990 ± 319 1788 ± 416 
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3.10 Cytokine-activated CD4+ memory T cells resemble rheumatoid synovial 
lymphocytes 
Figure 3.13 Induction of monocyte TNFα by non-divided versus divided cytokine-activated 
CD4+ memory T cells. CD4+CD45RO+ T cells were loaded with 2.5µM CFSE prior to stimulation 
with IL-2, IL-6 and TNFα. Activated cells were separated according to CFSE levels. a) CFSE 
profile from which non-divided cells were sorted from those that have divided at least once b). 
Sorted populations at least 90% pure c) Non-divided and divided populations were placed in co-
culture with autologous monocytes at  ratio of 2:1 alongside unsorted CD4+CD45RO+ population 
was assayed after 18 hours by ELISA. Cytokine-activated PBLs and monocytes were cultured 
alone as controls. Data shown as mean ± SD TNFα of triplicate wells and is representative of 4 
donors. *** = P<0.001 in one-way ANOVA with Bonferroni’s correction.   
a) 
b) 
c) 
Divided Non divided 
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 In order to assess the relevance of cytokine-activated CD4+CD45RO+ T cells as a 
RA T cell model, their phenotype was compared to that of CD4+ lymphocytes from 
synovial tissues. Mononuclear cells were isolated from tissue (section 2.3.5) and the 
expression of activation markers, adhesion molecules and chemokine receptors was 
assessed for CD4+ cells in a lymphocyte gate (as judged by FSC vs SSC).  
Expression is shown as the percentage of CD4+ lymphocytes positive for both 
CD45RO and the indicated marker for one tissue in Figure 3.14. Data from multiple 
donors is summarised in Table 3.10 
 The expression of CD25 and CD69 on CD4+ synovial lymphocytes was highly donor 
dependent. On average 9% of cells were CD25+, however this ranged from almost 
no expression through to 14%. The range of CD69 expression was even greater, 
from approximately 5 - 78%. In contrast, expression of HLA-DR was consistent 
between the 3 tissues investigated (approximately 26%).  In 3 out of 4 tissues the 
majority of synovial CD4+ lymphocytes are positive for both CD45RO and the 
integrin subunits assessed (CD18, CD29 and CD49d). CD62L was absent from 
synovial lymphocytes in all bar one tissue, where approximately 16% of 
CD4+CD45RO+ cells were CD62L+. Few synovial CD4+ memory T cells were found 
to express CCR7 (approximately 4%) and the proportion of synovial CD4+ 
lymphocytes expressing CXCR4 was highly variable, ranging from 3 – 73% over 4 
tissues.  
 The proportion of cells expressing CD18, CD29, CD49d, CCR7, CXCR3 or HLA-DR 
are comparable between cytokine-activated CD4+CD45RO+ T cells and synovial 
lymphocytes. Both cell types also contained small populations of CD25+ and CCR5+ 
cells. In the synovium the percentage of cells expressing CD25 is approximately half 
that of day 8 cytokine-activated cells (9% versus 22%), and the percentage of 
CCR5+ cells is 4.6 fold higher (21% versus 5%). The level of CXCR4 and CD69 
expression by synovial lymphocytes was highly tissue dependent, but both 
molecules are also present on cytokine-activated CD4+CD45RO+ T cells. The most 
notable difference in phenotype between the RA synovial and cytokine-activated 
lymphocytes is in the expression of CD62L. Very few synovial lymphocytes stained 
positive for CD62L (5%) whereas around half of all cytokine-activated 
CD4+CD45RO+ cells express this marker. 
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Table 3.10 Expression of activation markers, adhesion molecules and 
chemokine receptors on synovial CD4+ lymphocytes 
Phenotype Mean % Range %  (min- max) n 
CD25 8.9 0.6 – 13.8 4 
CD69 53.9 4.6 – 78.3 4 
HLA-DR 25.7 20.1 – 30.3 3 
CD18 79.2 30.7 – 97.4 4 
CD29 86.1 79.6 – 94.6 3 
CD49d 75.3 26.7 – 93.7 4 
CD62L 5.3 0.04 – 15.9 4 
CCR7 3.2 0.5 – 7.9 3 
CXCR4 28.9 3.0 – 73.2 4 
CCR5 21.2 8.7 – 40.4 3 
CXCR3 31.3 0.9 – 73.8 3 
  
 
  
 
Synovial tissue was incubated with PE-conjugated antibodies against CD25, CD69, HLA-
DR, CD18, CD29, CD49d, CCR7, CXCR4, CCR5, CXCR3 or Cyc-conjugated anti-CD62L 
plus FITC-conjugated anti-CD45RO and PE/Cyc-conjugated anti-CD4 antibodies, for 30 
minutes at 4°C. Cells were fixed, 50000 events per sample were collected on an LSR II 
instrument. Analysis was carried out using Cell Quest Pro software. The percentage 
CD45RO+ X+ is shown for cells within a CD4+ lymphocyte gate from n tissues.  
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3.11 Effect of neutralising antibodies against CD18, CD49d and CD69 in the 
induction of TNFα by cytokine-activated CD4+ memory T cells   
Figure 3.14 Phenotype of synovial CD4+ lymphocytes. Freshly digested synovial tissue was 
stained with PE-conjugated antibodies against CD25, CD69, HLA-DR, CD18, CD29, CD49d, CCR7, 
CXCR4, CCR5, CXCR3 or Cyc-conjugated anti-CD62L plus FITC-conjugated anti-CD45RO and 
PE/Cyc-conjugated anti-CD4, 45 min at 4°C. Cells were fixed and analysed on a LSR II flow 
cytometer. 50000 events were collected per sample and analysed using Cell Quest software. CD4+ 
lymphocytes were analysed and the percentage CD45RO+ X+ within this gate are shown. Data 
shown s from the same tissue and r present tive of at least 3.  
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 Based on their expression on the cell surface and on published data concerning 
their role in intercellular contacts, the role of CD18, CD49d and CD69 in ligation 
events between cytokine-activated CD4+CD45RO+ T cells and monocytes was 
investigated. 
 Cytokine-activated CD4+CD45RO+ T cells were pre-incubated with neutralising 
antibodies to CD18, CD49d and CD69 (section 2.3.4.1) and placed in co-culture with 
monocytes at a ratio of 8:1. TNFα levels were measured after 18 hours by ELISA. 
Figure 3.15 shows that cytokine-activated CD4+CD45RO+ T cells in the absence of 
antibody induced 607.9pg/ml TNFα, this was significantly reduced in the presence of 
anti-CD18 and anti-CD69 antibodies to 160 pg/ml and 232 pg/ml (P<0.01). No 
inhibition was observed with blockade of CD49d. T cells incubated with a non-specfic 
IgG1 isotype control induced monocyte TNFα levels equivalent to those observed in 
the absence of antibody. Table 3.11 summarises data from 3-5 donors. 
 
Table 3.11 Inhibition of monocyte TNFα production by blocking antibodies to T 
cell-surface molecules 
Inhibition % 
 
Mean Range 
n 
CD18 60.3 39 - 74 3 
CD49d 10.8 0 - 26 5 
CD69 18.4 2 - 62 4 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine-activated CD4+CD45RO+ T cells were resuspended at 8 x 
106/ml treated with anti-CD18, CD49d or CD69 at 10µg/ml prior to co-
culture with monocytes at a ratio of 8:1. TNFα was measured by ELISA 
after 18 hours. Percentage inhibition for each antibody treatment was 
calculated relative to TNFα production from the untreated co-culture for 
each donor. Table shows mean percentage inhibition for each antibody 
in n donors. 
Chapter 3       Results 
151 
 
 
 
 
 
8:
1
C
D
18
C
D
49
d
C
D
69
C
D
4+
C
D
45
R
O
+
M
on
oc
yt
es
0
200
400
600
800
1000
Controls
+ antibody
n.s
**
**
TN
F 
pg
/m
l
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Blockade of CD18, CD49d and CD69 in cytokine-activated CD4+ memory 
T cell-monocyte co-cultures. Freshly elutriated PBLs were enriched for CD4+CD45RO+ T 
cells and stimulated with IL-2, IL-6 and TNFα for 8 days. On day 8 cells were resuspended 
at 8 x 106/ml in PBS supplemented with 1% FCS. Antibodies to CD18, CD49d and CD69 
(plus isotype control - not shown) were added at a final concentration of 10µg/ml for 30 
minutes at room temperature. Cells were washed and placed in co-culture with monocytes 
at a ratio of 8:1. Supernatants were harvested after 18 hours and assayed by ELISA. Data 
shown as mean ± SD TNFα of triplicate wells and is representative of 3 donors. Cytokine-
activated PBLs and monocytes were cultured alone as controls. Monocytes plus LPS 
produced >5000pg/ml TNFα (not shown). Significance was calculated using one-way 
ANOVA with Bonferroni correction where **=P<0.01 and n.s = not significant. 
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3.12 Effect of neutralising antibodies to CD18, CD49d and CD69 on 
spontaneous TNFα release from rheumatoid synovial tissue 
 As shown in sections 3.3 and 3.10, CD4+CD45RO+ T cells which have been 
chronically activated with a cocktail of IL-2, IL-6 and TNFα functionally and 
phenotypically resemble rheumatoid synovial lymphocytes and hence form a good 
model with which to study the activation of monocytes/macrophages by T cells in the 
diseased joint.  Having demonstrated that neutralisation of CD18 led to a significant 
inhibition of TNFα and blockade of CD69 and CD49d showed a slight but variable 
inhibitory effect; the role of CD18, CD49d and CD69 in the induction of TNFα in ex 
vivo synovial tissue cultures was investigated.  
 Synovial mononuclear cells were dissociated from a rheumatoid joint following 
replacement surgery. Cultures were treated with neutralising and isotype control 
antibodies prior to 24 hours in culture. Inhibition of spontaneous TNFα release from a 
single donor is shown in Figure 3.16. TNFα release was 299 pg/ml and was 
significantly reduced to 222 pg/ml (P<0.01), 191 pg/ml (P<0.01) and 231 pg/ml 
(P<0.05) upon neutralisation of CD18, CD49d and CD69 respectively. TNFα release 
from IgG1 control treated cultures was not significantly different from untreated 
cultures (not shown). Significance was calculated using one-way ANOVA with 
Bonferroni correction analysis. 
 Up to 4 experiments were carried out on different tissues and the data is 
summarised in Table 3.12. Only CD69 blockade consistently inhibited TNFα 
production in the 3 donors, however this was not statistically significant in every 
donor.  In 3 out of 4 donors anti-CD18 treatment inhibited TNFα release, up to 51% 
in donor 4. Addition of anti-CD49d in 2 of 4 tissues reduced TNFα release but this 
was only significant in one donor.  
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Figure 3.16 Inhibition of spontaneous TNFα release from synovial tissue. 
Synovial tissue was dissociated and digested from a rheumatoid joint. Cells were left 
untreated or treated with 5µg/ml of the appropriate antibody and cultured for 24 hours 
at 37°C. Supernatants were harvested and assayed for TNFα by ELISA. Data shown 
as mean ± SD TNFα of triplicate wells and is one of four tissues. Significance was 
calculated using one-way ANOVA with Bonferroni correction where *=P<0.05 and 
**=P<0.01. 
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Table 3.12 Inhibition of spontaneous TNFα release from synovial tissue 
Donor 
Anti-CD18 Anti-CD49d Anti-CD69 
% 
inhibition 
P 
value 
% 
inhibition 
P
value 
% 
inhibition 
P 
value 
1 0 n.s 0 n.s 17 ** 
2 22 ** 36 ** 22 * 
3 26 n.s 23 n.s 23 n.s 
4 51 ** 0 n.s - - 
Mean 24.8 14.8 20.7 
  
 
  
 
   
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synovial tissue was dissociated and digested from 4 donor tissues. Cells were pre-
incubated with 5µg/ml of anti-CD18, anti-CD49d or anti-CD69 antibody for 30 minutes at 
room temperature then cultured for 24 hours at 37°C. A non-specific IgG1 antibody was 
used as an isotype control. Supernatants were harvested and assayed for TNFα by ELISA. 
Data shown as percentage inhibition for each antibody and donor tissue. Significance was 
calculated using one-way ANOVA with Bonferroni correction where *=P<0.05 and 
**=P<0.01. 
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3.13 Discussion 
 A major role for TNFα in the pathology of rheumatoid arthritis has been widely 
accepted with the success of anti-TNFα therapies in the clinic. However the precise 
mechanisms by which drive dysregulated TNFα production within the joint remain 
unknown. The contribution of T cells through cell-contact mediated events with 
macrophages has been demonstrated at the Kennedy Institute and elsewhere 
(Brennan et al., 2002; Burger and Dayer, 2002; McInnes et al., 1997). In order to 
study the nature of this interaction an ex vivo model was established where PBLs are 
activated, independent of the TCR, with a cocktail of IL-2, IL-6 and TNFα (Sebbag et 
al., 1997). The induction of monocyte TNFα by these PBLs was shown to mimic that 
of RA synovial T cells with respect to the signalling pathways elicited. Furthermore 
analysis of the relative roles of T cells and NK cells in the total PBL population 
demonstrated that it was in fact only the cytokine-activated T cell population that 
mimicked RA T cells in effector function despite the NK population exhibiting a 
greater proliferative response in culture. The experiments presented in this chapter 
have dissected the roles of specific T cell subsets in the induction of monocyte 
TNFα. I demonstrate that the most potent effectors are cytokine-activated T cells 
generated from CD4+CD45RO+CCR7- effector memory T cells and that proliferation 
of these cells is also a prerequisite for maximal effector function.  
 
 The isolation of CD4+ T cells, and not CD8+ T cells, from human PBLs, prior to 
stimulation with IL-2, IL-6 and TNFα, enriches a population of cells with a higher 
capacity to induce TNFα from monocytes after 8 days. When flow cytometry was 
used to sort naϊve and memory CD4+ T cells populations from PBLs, prior to 
activation, the results indicated that effector function resided within the memory 
population. This was confirmed over multiple donors where negative enrichment of 
CD4+CD45RO+ cells from the complete PBL population by magnetic bead 
separation, consistently led to significantly higher TNFα responses. CD4+CD45RO+ 
T cells required 8 days in culture with cytokines for maximal induction of TNFα. In 
addition, the TNFα response induced in monocytes increased with increasing 
numbers of fixed CD4+CD45RO+ T cells in co-culture; indicating increased physical 
interactions with monocytes account for the higher levels of TNFα induced.  
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 The finding that the CD4+ memory subset of cytokine-activated T cells are the most 
capable cells at inducing monocytic TNFα is in keeping with the predominance of 
these antigen-experienced T cells in the RA joint. In order to investigate whether this 
induction of TNFα was relevant to TNFα induction by RA synovial T cells in the joint, 
I investigated the effect of PI 3-kinase inhibition in monocytes. Previously, inhibition 
of PI 3-kinase was found to super-induce TNFα production from monocytes in co-
culture with cytokine-activated PBLs and from synovial tissue cultures, but to inhibit 
TNFα from anti-CD3 activated PBLs and cytokine-activated NK cells co-cultures. 
Treatment of monocytes with LY294002 prior to co-culture with cytokine-activated 
CD4+CD45RO+ T cells resulted in a mean 5-fold super-induction of TNFα over 4 
donors; therefore, in some manner, interactions between these cells activate a 
pathway which is suppressed by the activity of PI 3-kinase, when this is inhibited the 
expression of TNFα then increases. The pathways activated within monocytes by 
cytokine-activated CD4+CD45RO+ T cells leading to TNFα synthesis appear to 
mimic those observed by RA synovial T cells and cytokine-activated CD4+CD45RO+ 
T cells thus represent valid in vitro model for RA synovial T cell function.  
 Chronic cytokine activation induced the production of Th1 cytokines; IFNγ, GM-CSF 
and LT, from CD4+CD45RO+ T cells. However, this was lower than cytokine 
production from total PBLs, indicating that enrichment of CD4+CD45RO+ cells does 
not enrich for the most prolific cytokine producing PBLs. In contrast, an increase in 
IL-10 was observed in supernatants from CD4+ memory T cells cultures compared 
to total PBL cultures. This could be due to concomitant enrichment of IL-10 secreting 
naturally occurring Treg cells with CD4+CD45RO+ isolation, or the induction of such 
cells over the 8 days. Cytokine activation of both the total and CD4+ memory T cell 
populations resulted in similar cumulative production of IL-8 and TGFβ to a similar 
level; thus IL-2, IL-6 and TNFα appears to provide a universal stimulus for IL-8 and 
TGFβ production independent of PBL subset. In the rheumatoid joint IL-8 is a potent 
chemoattractant, produced by macrophages and fibroblasts, where synthesis by the 
latter is promoted by TNFα but is constitutive from the former (Koch et al., 1991b). 
IL-8 production from anti-CD3 activated T cells can be induced by the inflammatory 
mediator prostaglandin E2, but data presented here suggests pro-inflammatory 
cytokines also have a role in IL-8 synthesis from T cells as well as from fibroblasts 
(Caristi et al., 2005). TGFβ has reported roles in the differentiation of Treg and Th17 
cells, although the latter is disputed in the human system. My data suggests 
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CD4+CD45RO+ cells activated with IL-2, IL-6 and TNFα are not able to produce IL-
17, thus excluding a role for this combination of cytokines in the maintenance of 
Th17 polarised cells. As neither IL-23 nor IL-1 are provided in our in vitro system this 
is perhaps not surprising; although preliminary data from our laboratory has shown 
that addition of IL-23 at day 5 can induce IL-17 production from cytokine-activated T 
cells. Furthermore, Th1 IFNγ producing cells have been shown to negatively regulate 
Th17 differentiation which could also account for the lack of IL-17 in culture 
supernatants.  There is however, increasing evidence for a subset of IFNγ secreting 
Th17 cells at sites of inflammation in humans (Annunziato et al., 2007). Therefore 
experiments to investigate the effect of IFNγ from cytokine-activated T cells on IL-17 
production through the addition of exogenous IL-23/IL-1 in combination with 
neutralizing IFNγ antibodies during culture are warranted; particularly with 
intracellular flow cytometry staining for IFNγ and IL-17 detection on a cell by cell 
basis, and Th17 cell surface markers such as CCR6.   
 As CD4+CD45RO+ cells were found to be precursors of a population of T cells 
capable of an effector function which is independent of TCR ligation, their phenotype 
was closely examined. I found that expression of activation markers, adhesion 
molecules and chemokines receptors on CD4+CD45RO+ T cells did not peak at day 
8 when effector function was maximal. Nevertheless, after eight days in culture with 
IL-2, IL-6 and TNFα, CD4+CD45RO+ T cells have significantly upregulated CD25, 
CD69, HLA-DR, CD18, CD49d, CD62L and CXCR4. These cells appear highly 
activated and with migratory potential, moreover, they closely resemble rheumatoid 
synovial T cells. CXCR4 was the only chemokine receptor investigated whose 
expression was significantly modulated by the cytokine cocktail. It is known to play a 
key role in T cell trafficking to, and retention within, the inflamed synovium. Cytokines 
such as TGFβ and IL-15 in synovial fluid upregulate CXCR4 expression on synovial 
T cells and enhance their response to CXCL12 (SDF-1) (Buckley et al., 2000; Nanki 
and Lipsky, 2000). Whether TGFβ synthesis by cytokine-activated T cells feeds back 
and contributes to the observed increase in CXCR4 warrants further investigation. 
Both CD49d and CD29, which constitute the α and β chains of integrin VLA-4 
respectively, are expressed on the majority of cytokine-activated and synovial 
CD4+CD45RO+ T cells. A VLA-4 ligand, VCAM-1, is selectively upregulated on RA 
synovium endothelium, fibroblasts and macrophages by TNFα and plays an 
important role in T cell trafficking to the inflamed joint (Tak et al., 1996). CD49d is 
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expressed on resting T cells and up-regulated 2-fold upon cytokine-activated T cells, 
in addition its expression positively correlated with induced monocytic TNFα over 
multiple donors (Brennan et al., 2008). However, blockade in co-culture assays or in 
synovial tissue cultures had minimal effect on TNFα production, indicating a potential 
role for VLA-4 in extravasation, as opposed to cell-cell contact events. This is 
supported by findings published by the Fox group, who observed no effect of VLA-4 
blockade on IL-6 production from synovial fibroblasts in co-culture with cytokine-
activated T cells (Tran et al., 2007b). Together, these data suggest antigen-
independent activation by pro-inflammatory cytokines not only induces cells capable 
of perpetuating disease but also upregulates molecules that facilitate the 
accumulation of these pathogenic cells at sites of inflammation. Studies in the 
laboratory are now examining the capacity of cytokine-activated CD4+CD45RO+ T 
cells to migrate in vitro, and to human RA synovial grafts on SCID mice, particularly 
with respect to the roles of CD49d, CXCR4 and CD18.  
 Despite a 10-fold increase in CD62L (L-selectin) expression on the surface of 
CD4+CD45RO+ T cells at day 8, sorting experiments showed no difference in the 
ability of CD62L positive or negative cells to induce TNFα from monocytes in co-
culture. CD62L expression is downregulated post-activation by proteolytic cleavage 
and the release of a soluble form of the protein; this was detected in culture 
supernatants of cytokine-activated CD4+CD45RO+ T cells. It is tempting to 
hypothesise that those donors which respond the greatest to cytokine stimulation 
have a lower CD62L MFI due to activation-induced loss of CD62L from the cell 
surface and therefore, the negative correlation observed is not indicative of effector 
function residing in a CD62L negative population but of activation status.  The loss of 
CD62L expression on proliferating cells upon cytokine-activation also supports this 
concept. One would therefore expect a positive correlation between soluble CD62L 
levels in culture supernatants and induced monocyte TNFα. The expression of 
CD62L is lost from the leukocyte cell surfaces after migration from the blood, as a 
result it is not unexpected that CD62L expression is low within the synovium.  
 A role for LFA-1(CD11a/CD18) in T cell activation and cognate interactions with 
monocytes and macrophages has been shown in a number of cellular systems. Here 
I show CD18 expression increases upon cytokine-activation of CD4+ memory T cells 
and neutralisation abrogates monocyte TNFα production by 60% in co-culture. This 
agrees with the effects of LFA-1 inhibition observed with phorbol-ester activated T 
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cell and/or cell lines (Isler et al., 1993; Vey et al., 1992). Another molecule previously 
implicated in T cell mediated monocyte/macrophage activation is CD69. Cytokine-
stimulation of CD4+CD45RO+ T cells induces CD69 expression such that after 8 
days almost one-quarter of cells are positive and the level of expression increases 
over 5-fold. In our system, inhibition of monocyte TNFα by neutralising anti-CD69 
antibodies varied between donors, with a mean of 20% observed in 4 donors. 
Blockade also inhibited spontaneous TNFα release from synovial tissue cultures by 
the same proportion. The latter was despite a range in CD69 expression on synovial 
T cells from 5% to 78%. My data suggests both CD18 and CD69 contribute to the 
induction of TNFα by cytokine-activated CD4+CD45RO+ T cells and in synovial 
tissue, but neither abolishes it, suggesting further factors are required for monocyte 
activation by cytokine-activated T cells.  
  
 CD4+ memory T cells are a heterogeneous population of central memory (TCM) and 
effector memory (TEM) cells. The expression of CCR7 distinguishes TCM cells, they 
have a limited capacity to produce cytokines but the potential to expand rapidly upon 
re-activation and predominate in lymphoid tissues. Whereas CCR7- TEM cells in the 
periphery have a limited proliferative capacity but rapidly produce effector cytokines. 
As expected, CD4+ memory T cells in the peripheral blood are predominantly TEM; 
only 12% of cells in 16 donors expressed CCR7. Cytokine stimulation reduced CCR7 
expression and closer analysis revealed a decrease in the absolute numbers of TCM 
cells and a increase in TEM cell numbers in the majority of donors. The significance of 
TEM cells was demonstrated by sorting the two populations prior to, and after 
activation; TEM cells induced significantly more TNFα from autologous monocytes 
compared to TCM. According to the Lanzavecchia theory, TEM cells are intermediates 
which have arrested during the differentiation to conventional helper T effector cells 
(Lanzavecchia and Sallusto, 2005), my results demonstrate that these cells 
represent a population in the peripheral blood capable of an effector function not only 
in response to antigenic re-stimulation but to cytokine stimulation independent of 
antigen specificity. Experiments have shown that TEM cells can acquire the 
characteristics of an opposing helper T cell subset to their original polarisation if re-
activated under the appropriate conditions (Messi et al., 2003). The production of 
IFNγ and maintenance of the Th1 chemokine receptor CXCR3 suggests that the 
cocktail of IL-2, IL-6 and TNFα promotes a Th1-like effector response from TEM 
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however this requires confirmation, as mentioned before, through dual staining for 
intracellular cytokines and CCR7. Interestingly, I observed no difference in the level 
of CCR7 expression between the divided and non divided populations of viable 
cytokine-activated CD4+CD45RO+ T cells. Thus in terms of proliferation TCM and TEM 
respond equally to chronic cytokine stimulation contrasting to their reported 
behaviour upon reactivation via the TCR. The observed increase in TEM cells 
therefore, may be due to the increased resistance of these cells to TNFα-induced 
apoptosis (Gupta et al., 2005).  
  
 The proliferative response of CD4+CD45RO+ T cells to chronic cytokine-activation 
can be broken down into two phases, reflecting the relative kinetics of cell division 
and cell death. Annexin V staining of cells reveals that a proportion of cells 
immediately enter apoptosis on cytokine activation, but there is a lag in the 
proliferative response as shown by a slow increase in tritium incorporation. Initially 
the number of viable CD4+CD45RO+ T cells falls, but as the culture period 
continues the number of cells dividing begins to exceed those in apoptosis. On 
average 45% of CD4+ memory T cells undergo at least one division and, depending 
on the donor, approximately half of those will undergo a further 4-6 divisions over the 
eight days. Dividing T cells are a phenotypically heterogeneous population, 
compared to non divided cells they are CD25+ CD69+ HLA-DR+ CD62L- CD18+ 
CD29+ CD49d+ and CXCR4-. When sorted based on CFSE intensity, these divided 
cells induced significantly more TNFα from monocytes in comparison to non divided 
cells. Interestingly, this implies CXCR4 may not be required for migration of the most 
pathogenic cytokine-activated T cells and we eagerly await the results of in vivo 
experiments in RA/SCID mice to clarify the role of CXCR4. At least one cellular 
division is required for the acquisition of maximal effector function by a 
CD4+CD45RO+ T cell and these cells selectively maintain a pattern of cell-surface 
expression that is distinct from those that do not proliferate.   
 
 In summary, the results presented in this chapter demonstrate that CD4+ TEM cells 
(CD4+CD45RO+CCR7-) are precursors for the most potent cytokine-activated T cell 
population. These cells differentiate into effector cells in the absence of antigen, 
expressing integrins and classical T cell activation markers which either, contribute 
to the effector function acquired (CD18 and CD69), act as a marker for effector 
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function (CD49d) and/or may contribute to cellular migration of these pathogenic T 
cells. Importantly cytokine-activated CD4+ memory T cells phenotypically and 
functionally resemble RA synovial T cells. The key molecules on the surface of these 
cells which ultimately confer the ability to induce TNFα still remain elusive but this 
chapter has defined a novel population of T cells which, independently of antigen, 
contribute to chronicity of disease and warrant further investigation. 
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4.0 Introduction 
 Our understanding of the way in which synovial T cells mediate contact-dependent 
activation of macrophages and drive dysregulated TNFα production could be greatly 
enhanced by examining the plasma membrane proteome of in vitro cytokine-
activated T cells. 
 Previous studies at the Kennedy Institute demonstrated the successful identification 
of plasma membrane proteins from murine splenocytes and T cell lines (Peirce et al., 
2004). In this chapter I have investigated whether using a similar approach of 
differential centrifugation, followed by two-dimensional separation with solution 
phase IEF and mass spectrometry could be applied to cytokine-activated primary 
human peripheral blood lymphocytes. Using a qualitative test with western blotting I 
determine a threshold of the minimum number of cells required for an enriched 
plasma membrane preparation. Initially I assessed whether plasma membrane 
protein profiles of resting cells and cytokine-activated cells from the same donor can 
be compared in two-dimensions and identified by mass spectrometry. Subsequent 
optimisation of sample preparation is also presented, and the balance between the 
quality and the quantity of protein sample obtained is illustrated throughout by 
western blotting and one-dimensional analysis. Together this chapter evaluates of 
the suitability of proteomic studies for the generation of novel candidate molecules 
within our model system. 
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4.1 Isolation of plasma membrane proteins from primary human peripheral 
blood lymphocytes 
  Membrane proteome studies in general require large amounts of sample, as 
plasma membrane proteins constitute only a small fraction (2%) of the cell’s total 
protein. Depending on the analytical method, a large number of cells may be 
required to isolate sufficient plasma membrane protein to profile (Kearney and 
Thibault, 2003). This problem is exacerbated when studying primary cells rather than 
transformed cell lines, because of lower cell numbers available and donor-donor 
variation. We obtain peripheral blood lymphocytes from elutriation of single donor 
heparinised leucophoresis residues (known as buffy coats). The number of cells 
available is therefore limited by the donor in question; one buffy coat can yield 
between 90 and 400 million PBLs, with a mean and standard deviation of 207 ± 96 
where n=25. Thus 200 x106 cytokine-activated cells were initially used to isolate 
membrane proteins, to give an indication of protein recovery from an average donor. 
Plasma membrane proteins were isolated using a procedure previously used for 
identification of plasma membrane proteins from murine cells (Peirce et al., 2004). 
Cells were lysed, homogenised and plasma membrane proteins were enriched by 
centrifugation at 20000g after a preceding clearance of nuclei and organelles by 
4000g centrifugation (section 2.7). Material from each stage of the preparation was 
retained and total protein concentration was assayed by BCA. Table 4.1 shows that 
489µg of total protein was obtained from 200 x 106 cells. 
 
Table 4.1 Protein recovery from 200 x 106 cytokine-activated PBLs 
Fraction 
Protein concentration 
µg/ml 
Volume 
µl 
Amount of protein 
µg 
p4 6200 1000 6200 
s20 1258 1500 1887 
p20 1956 250 489 
 
 The recovery of plasma membrane versus cytosolic proteins was assessed by 
western blotting. The common leukocyte phosphatase CD45 was chosen as a 
marker for plasma membrane proteins, along with CD4. Non plasma membrane 
protein contamination was indicated by the presence of glucose regulated protein 75 
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(GRP75) and tubulin as markers of the mitochrondrial and cytosolic compartments 
respectively. CD4 and CD45 were detected by western blot in the p20 membrane 
fraction (Figure 4.1 a) but was also observed in the nuclear/organelle pellet (p4) and, 
in the case of CD4, in the supernatant s20 fraction. Mitochondrial GRP75 was 
present only in the p4 nuclear/organelle fraction. The presence of tubulin is useful, 
not only as a marker of the cytosol, but is also indicative of associations of 
cytoskeletal proteins with the plasma membrane and in this way may be co-enriched. 
However tubulin was not detected within the p20 fraction. 
 200 x106 cytokine-stimulated PBLs yielded a preparation of 1.955mg/ml which 
equated to just under 0.5mg of sample that is enriched for a common lymphocyte 
plasma membrane protein, and is devoid of the contaminating proteins investigated. 
To investigate changes in the expression profile of lymphocytes on cytokine 
stimulation, it is necessary to compare resting and activated cells from the same 
donor. Although cytokine stimulation of PBLs induces proliferation, the number of 
cells available for proteomic analysis at day 8 is still limited (Chapter 3 and Brennan 
et al, 2008). When 25 independent donors were assessed for changes in the 
absolute numbers of PBLs upon cytokine-activation, the mean increase was only 1.3 
fold. Therefore if plasma membrane preparations from resting and activated cells are 
to be compared from a single donor, it is likely that 200 million cells is the upper limit 
available for analysis, and on average fewer would be available for each condition. 
Therefore the number of cells required to routinely yield a sufficient preparation in 
terms of both the quality of plasma membrane enrichment and quantity of protein 
recovered was investigated.      
 Table 4.2 summarises the protein obtained from independent experiments in which 
p20 membrane preparations were generated from varying numbers of cytokine-
activated and resting PBLs. Figures 4.1 and 4.2 show the representative western 
blots. The concentration of protein samples recovered from the same number of cells 
varied between p20 preparations. Protein recovered from 50 million resting PBLs 
ranged from 506 – 950µg/ml and from 50 million activated PBLs the range was 
greater, 194 - 2470µg/ml. Membrane preparations from 50 million cytokine-activated 
cells contained on average 2-fold more protein than 50 million resting PBLs.  
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Figure 4.1 Plasma membrane preparations from cytokine-activated PBLs. Cytokine-
activated PBLs were lysed, subjected to 40 strokes of a tight fitting Dounce homogeniser and 
spun at 4000g to generate a post-nuclear supernatant (PNS) and a nuclear/organelle pellet 
(p4). PNS spun at 20 000g to yield a plasma membrane-enriched pellet (p20). Both pellet and 
supernatant (s20) were retained for analysis. 20μg protein of each fraction was separated on 
12% SDS PAGE, transferred onto PDVF membrane and probed with anti-CD45 (1:2000) and 
anti-GRP75 (1:5000) antibodies. The membrane was stripped and re-probed with anti-CD4 
(1:2000) and anti-tubulin (1:2000). Samples obtained from 200 x 106 a); 50 x106 b) and 20 
x106 cells c).  
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Table 4.2 Minimum cell numbers required for plasma membrane protein 
enrichment. 
 
                                               
 
 
The table also indicates whether or not CD45, tubulin or GRP75 were detected by 
western blot in each preparation. Tubulin was assessed in 3 independent p20 
preparations from 50 million cytokine-activated PBLs and was found to be absent in 
only 2.  
 Figure 4.1 b) demonstrates western blot analysis of one such successful 
preparation. There is loss of CD45 in the nuclear/organelle pellet; however no 
contamination of p20 with GRP75 or tubulin was observed.  In the third membrane 
preparation, from 50 million cells, and also in those from 44 and 28 million cells 
tubulin was detected. CD45 was detected in all samples from between 28 and 200 
million cytokine-activated cells. However, in 2 independent p20 preparations from 20 
million cells neither CD45 nor tubulin was detected and GRP75 was observed from 
only for a single donor, as shown in Figure 4.1 c). Thus 50 million cytokine-activated 
cells is judged as the lower limit from which to purify membrane proteins.  
 Figure 4.2 illustrates western blot analysis of membrane preparations from 80 
million a) and 50 million resting cells b). Only the p20 fraction from 80 million cells 
Presence in p20 by western blot 
PBLs 
Cell 
number 
( x 106) 
Protein 
conc. 
(µg/ml) CD45 Tubulin GRP75 
80 1448 Yes No Yes 
50 950 Yes - No 
50 500 No No No Resting 
50 506 No No No 
200 1955 Yes No No 
100 1121 Yes No No 
50 1020 Yes No No 
50 2470 Yes - Yes 
50 1550 Yes No No 
50 194 Yes Yes - 
44 334 Yes Yes - 
28 80 Yes Yes - 
20 2910 No - Yes 
Cytokine-
activated 
20 520 No No Yes 
Fourteen separate membrane preparations were made from resting or cytokine-activated PBLs. Protein 
concentration was determined by BCA assay. Preparations were assessed by western blot for recovery 
of plasma membrane proteins as judged by the presence of CD45, tubulin and GRP75. Table shows 
protein concentration from decreasing numbers of cells and the presence (Yes) or absence (No) of 
marker proteins.  
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contained CD45 although CD4 was detectable in the 50 million cell preparation. 
Neither preparation contained any detectable tubulin in any fraction (p4, s20 or p20). 
Data from further membrane preparations are summarised in Figure 4.2 a) - b) and 
indicate that for consistent membrane preparations with resting PBLs the lower limit 
is greater than 50 million cells, since in 2 out of 3 independent p20 preparations 
CD45 was absent. 
 
 
GRP75
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Tubulin
GRP75
CD45
p4 p20
p4 p20s20
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CD4
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Figure 4.2 Plasma membrane preparations from resting PBLs. PBLs were lysed, subjected 
to 40 strokes of a tight fitting Dounce homogenizer and spun at 4000g to generate a post 
nuclear supernatant (PNS) and a nuclear/organelle pellet (p4). PNS spun at 20 000g to yield a 
plasma membrane-enriched pellet (p20). Both pellet and supernatant (s20) were retained for 
analysis. 20μg protein of each fraction was separated on 12% SDS PAGE, transferred onto 
PDVF membrane and probed with anti-CD45 (1:2000) and anti-GRP (1:5000) antibodies. The 
membrane was stripped and re-probed with anti-CD4 (1:2000) and anti-tubulin (1:2000). 
Samples obtained from a) 80 x 106 and b) 50 x106 cells.  
Chapter 4       Results 
169 
 
4.2 Enrichment and identification of plasma membrane proteins expressed 
upon cytokine stimulation of PBLs 
 100 million freshly elutriated PBLs were cultured in the presence of IL-2, IL-6 and 
TNFα for 8 days (as before). A further 128 million PBLs from the same donor were 
frozen and stored at -80°C for 8 days. On day eight, 80 million thawed and viable 
PBLs, and 100 million cytokine-stimulated PBLs were lysed, homogenised and 
enriched for membrane proteins as before. Plasma membrane protein enrichment 
was verified in the p20 preparations by western blotting, and protein concentration 
was assessed by BCA assay (summarised in Table 4.2). Both samples contained 
detectable CD45 but not tubulin. The p20 generated from 100 million cytokine-
activated PBLs also contained GRP75, indicating organelle contamination. 160μg of 
protein from each p20 preparation was fractionated by pI using a ZOOM™ solution 
phase isoelectric focusing unit (section 2.8.3). The focussed proteins were then 
separated according to mass on a 4-18% SDS gradient gel, to achieve resolution in 
two dimensions. Samples were also analysed by 1D SDS-PAGE alone.   
 From left to right, Figure 4.3 shows the one dimensional separation of resting and 
cytokine-activated p20 samples, followed by five IEF fractions of increasing pH 
alternating between resting and cytokine-activated (Tck) samples. Silver stained 
bands were excised and analysed by tandem mass spectrometry (MS/MS) after 
tryptic digestion.  
 Thirty eight and twenty five bands were excised from the 1D resting and cytokine-
activated lanes respectively. Eleven bands from the resting PBL sample were not 
identified by Mascot database search, a further 2 were due to experimentally added 
trypsin and the remaining 12 matched to 11 different proteins. The predominant sub-
cellular location of each protein identified was established using the UniProt 
knowledgebase (Swiss-Prot/TrEMBL) from the ExPASy proteomic server at 
http://www.expasy.ch/sprot/. Two proteins were found to be located in the plasma 
membrane; Ezrin (P15311 EZRI_HUMAN) is a peripheral membrane protein on the 
cytoplasmic side which is involved in linking the cytoskeleton to the plasma 
membrane and is key to the formation of microvilli and cellular projections in certain 
cell types.  Extended-synaptotagmin-1 protein (E-Syt1) (Q9BSJ8 ESYT1_HUMAN) is 
an integral membrane protein with two predicted transmembrane regions and five C2 
(calcium dependent phospholipid binding) domains. It is a member of the 
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Figure 4.3 Resolution of plasma membrane preparations in two-dimensions.  
Membrane-enriched fractions (p20) from 80 x 106 resting PBLs and 100 x 106 cytokine-
stimulated PBLs from the same donor were prepared. 160μg of total protein from each was 
subjected to separation in a ZOOM solution phase isoelectric focusing unit. The focussed 
proteins were then resolved on a 4-18% SDS gradient gel and silver stained. Protein 
bands were excised, digested and analysed by MS/MS. From left to right: molecular weight 
markers; 1D separation of p20 from resting PBLs (30μg); 1D separation of p20 from 
cytokine-stimulated PBLs (30μg); IEF focussed fractions of increasing  pI value alternating 
between resting and cytokine-stimulated PBLs. Identified plasma membrane proteins 
indicated by arrows. 
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synaptotagmin family of proteins that transduce Ca2+ signals for the release of 
neurotransmitters, but it is widely expressed and its exact function is unclear. Thirty 
four proteins were identified from 1D analysis of the cytokine-activated p20 sample, 
of which 9 are located in the plasma membrane; CD45, E-Syt1, moesin, ezrin, MHC 
Class I, MHC Class II, CD81 and  β2 microglobulin. Moesin (P26038 
MOES_HUMAN) is another peripheral membrane protein involved in connecting 
major cytoskeletal proteins to the plasma membrane via a variety of scaffold 
complexes. CD81 (P60033 CD81_HUMAN) has many reported functions; it forms 
part of the B cell receptor, is a member of the tetraspanin superfamily of proteins, is 
expressed on T cells, can act as a co-stimulatory molecule independent of CD28 in 
CD4 and CD8 T cell activation and is the cellular receptor for hepatitis C virus 
(Witherden, 2000 #135; Levy, 2005 #136). MHC Class I and II proteins plus β2 
microglobulin are all components of the antigen-presenting machinery of a cell and 
are commonly upregulated upon activation. 
 Upon two-dimensional separation, the majority of proteins migrate to IEF fractions 2-
4 (pH 4.6-7.0). The lower MW protein bands were all detected in the fifth fraction (pH 
7.0-10.0). Sixty seven different proteins were identified from 180 excised bands, of 
which 8 were plasma membrane proteins (12%): CD18, CD11a, CD41b, ezrin, 
guanine nucleotide-binding protein (BP), moesin, flotillin-1 and E-Syt1. CD41b 
(P08514 ITA2B_HUMAN) was identified within the pH 4.6 - 5.4 fraction of resting 
PBLs only. It is usually only expressed on platelets in association with β3 integrin, 
and may thus result from platelet contamination from elutriation. CD11a (P20701 
ITAL_HUMAN) and CD18 (P05107 ITB2_HUMAN) were detected in both resting and 
cytokine-activated samples, as were ezrin and guanine nucleotide-BP (P62873 
GBB1_HUMAN). Upon two-dimensional separation E-Syt1 was only detected in the 
cytokine-activated p20 sample, and not in resting cells, inconsistent with the one-
dimensional data. Bands corresponding to moesin, and to the peripheral membrane 
scaffolding protein flotillin-1 (O75955 FLOT1_HUMAN), were identified only in the 
cytokine-activated p20 preparation.  
 Figure 4.4 summarises the presumed sub-cellular locations of the identified proteins 
from one dimensional separation of resting p20 (a), cytokine-activated p20 (b) and 
two-dimensional separation by IEF of both samples combined (c). A lower 
percentage of plasma membrane proteins was detected from one-dimensional 
Chapter 4       Results 
172 
 
separation of resting compared to cytokine-activated cells, (18% and 26% 
respectively). Contaminating proteins originated from the cytoplasm, nucleus and 
mitochrondria in the resting PBL sample, and secreted and ER proteins were also 
identified in the cytokine-activated p20 preparation. Over 50% of identified proteins 
from the solution phase IEF two-dimensional separation were cytosolic 
contaminants, many of which were cytoskeletal, including actin, tubulin, talin, coronin 
and major vault protein. Fifty bands did not yield useful identifications, either 
because they were below the limit of detection, or because of the presence of 
exogenous contaminants such as keratin. Despite equal amounts of protein (30µg) 
being loaded in one-dimension (lanes 2 and 3), silver staining revealed more protein 
bands in the p20 fraction from cytokine stimulated PBLs than from resting PBLs, and 
three times as many proteins were identified by Mascot. This may be due to a global 
upregulation of protein expression after cytokine stimulation, or to inefficient recovery 
of proteins from the resting population. Section 4.4 addresses the optimisation of 
protein recovery for both populations. 
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Figure 4.4 Summary of the sub-cellular locations of proteins identified in plasma 
membrane preparations from resting and cytokine-activated PBLs. p20 plasma membrane 
samples were prepared from 80 million resting PBLs or 100 million cytokine-activated PBLs and 
analysed by 1D or 2D separation, silver staining and MS/MS. Pie charts summarise the sub-
cellular locations of identified proteins in 1D separation of resting a) and activated PBLs b) and 2D 
separation c). Percentage is displayed in each segment. 
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4.3 Confirmation of MS/MS results by flow cytometry 
 Chapter 3 (section 3.5.2) showed the expression of adhesion molecules including 
CD18 increase upon cytokine-activation of freshly elutriated PBLs. This is consistent 
with identification of CD18 and other adhesion molecules (CD11a and CD41b) by 
mass spectrometry. CD81 is an integral plasma membrane protein with four 
transmembrane domains and reported roles in T cell activation, which was observed 
in the one-dimensional separation of cytokine-activated cells. The validity of this 
identification was investigated by cell surface flow cytometry. Figure 4.5 shows 
increased in CD81 expression in 3 donors upon cytokine-activation, and the 
expression of CD81 by the majority of peripheral blood T cells at day 8.  
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 Thus proof-of-principle of a proteomic approach to studying cytokine-activation of 
PBLs is provided by the resolution of proteins from activated and resting PBLs from 
the same donor and the subsequent identification of proteins known to be present 
(e.g. CD18, CD45). This result increased my confidence in the validity of the 
unexpected proteins identified, and justified their further investigation (e.g. CD81). 
p20 preparations can be described as approximately a 5-fold enrichment for plasma 
membrane proteins given that 12% of the proteins identified in Figure 4.4 are located 
in the membrane, when and on average only 2-3% of cellular proteins are plasma 
membrane located.   
Figure 4.5 Expression of CD81 by cytokine-activated PBLs. PBLs were cultured in the 
presence of IL-2, IL-6 and TNFα for 8 days. At day 0, prior to activation, and day 8 cells were 
stained PE-conjugated anti-CD81 and FITC-conjugated anti-CD3 antibodies. a) Change in CD81 
mean fluorescence intensity (MFI) is shown for 3 donors. b) Expression of CD81 on CD3+ 
cytokine-activated T cells in a single donor. Data was analysed using Cell Quest software 
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4.4 Optimising plasma membrane sample preparation 
 As a high proportion of proteins identified were not located in the plasma 
membrane, optimisation of the preparation protocol was needed to increase 
enrichment and reduce the number of cells required. This is particularly important for 
studying the plasma membrane profile of the defined effector population of 
CD4+CD45RO+ T cells (Chapter 3).  
4.4.1 Cell breakage 
 The initial step in any sub-cellular or organelle purification is the disruption of the 
membrane and cellular breakage which can be achieved by physical methods. My 
initial studies used homogenisation of cells in suspension with a tight-fitting glass 
Dounce homogeniser, where cells are forced through a narrow space between a 
glass pestle and an outer glass tube resulting in shearing of the membrane. 
Alternative methods of physical disruption, French press and sonication, were 
compared to homogenisation, to investigate the relative quality and quantity of 
protein recovered. The French press forces cells through a small aperture under 
pressure. In experiments with PBLs two rounds of disruption at 200psi each were 
carried out. Sonication uses high frequency sound waves from a vibrating probe to 
form microscopic bubbles which implode causing shock waves which dissipate 
throughout the sample and break open cells. Sonication must be used in short bursts 
to avoid overheating the sample. In my experiments five 5 second pulses at 90W 
were applied.  
 Cytokine-activated PBLs were subjected to 15 minutes hypotonic lysis at 4°C prior 
to homogenisation (H), French press (FP) or sonication (SON). Centrifugation and 
plasma membrane preparation was then carried out as before. The protein recovery 
in solubilised p4 and p20 pellets was assessed by BCA assay, and samples were 
analysed by western blot for the presence of CD45 (plasma membrane), ATP-
synthase subunit β (mitochrondria) and tubulin (cytosol). 
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 CD45 was detected in all p20 membrane-enriched pellets, irrespective of the 
method of cellular breakage (Figure 4.6). However the intensity of the tubulin bands 
varied between methods. Sonicated p20 samples contained less tubulin than 
homogenised or French pressed p20 samples. In addition no CD45 was detected in 
the nuclear/organelle p4 pellet, whereas no CD45 is seen in p4 preparation post 
homogenisation and French press breakage. Thus qualitative western analysis 
indicates that sonication of cytokine-activated PBLs allows for the greatest 
enrichment of plasma membranes. No differences in ATP-synthase content were 
observed between each condition or between p4 and p20 pellets, suggesting 
mitochrondrial membrane contamination of p20 samples is independent of the mode 
of cell disruption. Figure 4.6 is representative of 3 independent experiments. In all 
experiments the protein concentration was assessed by BCA assay, and was 
greatest in p20 samples that were French pressed, and lowest in those that were 
Figure 4.6 Effect of different cell breakage methods on relative protein content of plasma 
membrane preparations. 50 x 106 cytokine-activated PBLs were lysed in a hypotonic buffer 
in15 minutes at 4°C and either subjected to 40 strokes of a tight fighting Dounce homogeniser 
(H), 2 x 200psi pressure in a French press (FP) or sonication with 5 x 5sec 90W pulses (SON). 
Each lysate was clarified by centrifugation (4000g 15 minutes) to generate a post-nuclear 
supernatant (PNS) and a nuclear/organelle pellet (p4). PNS was subjected to 20 000g at 30 
minutes to yield a plasma membrane-enriched pellet (p20). Total protein concentration was 
assessed by BCA assay and found to be 194µg/ml in the homogenised sample, 273µg/ml in the 
French pressed sample and 243µg/ml in the sonicated sample. 20µg of each p4 and p20 was 
separated on a 12% SDS-PAGE, transferred onto PDVF membrane and probed with anti-CD45, 
anti-tubulin and anti-ATP synthase antibodies. Figure is representative of 3 separate 
experiments.  
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homogenised, however the differences observed were not consistent between 
experiments as shown in Table 4.3. Sonication may be regarded as a compromise 
between quantity and quality of sample obtained. 
 
Table 4.3 Effect of cell breakage method on protein recovery  
Protein concentration (µg/ml) 
Experiment 
Homogenisation French Press Sonication 
1 194 273 243 
2 334 2322 1560 
3 80 359 126 
 
4.4.2 Increased centrifugal force 
 Cellular fractionation by differential centrifugation enables the separation of 
organelles depending upon their density and shape. Smaller centrifugal forces are 
required to sediment dense organelles, such as nuclei, compared to the forces 
required to sediment membranes. In the preceding experiments cell lysates were 
initially subjected to 4000g, which is sufficient to sediment nuclei, and also some 
mitochrondria, as shown by the presence of GRP75 and ATP-synthase in p4 pellets 
in figures 4.2 and 4.7. Insufficient cellular breakage could result in pelleting of intact 
cells also. Section 4.4.1 demonstrated that cell disruption by sonication reduced 
levels of CD45 in the p4 pellet, which could indicate an increase in cellular breakage, 
because fewer intact CD45+ cells remain to be pelleted. Lysates were then 
subjected to 20000g to sediment plasma membranes; however in section 4.2 I 
showed that 12% of proteins within a p20 pellet originate from the plasma 
membrane. It is possible that 20000g may be insufficient to sediment all plasma 
membrane vesicles within the lysate, resulting in incomplete protein recovery. 
Therefore cytokine-activated PBLs were lysed, sonicated and spun at 4000g. The 
post-nuclear supernatant (PNS) was then divided equally by volume, and subjected 
to either 20000g for 30 minutes (as before) or 100000g for 1 hour. Proteins pellets 
were assessed by western blot. A representative experiment is shown in Figure 4.7.   
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This experiment was carried out on the equivalent of 50 million cells per condition i.e. 
at the limit ascertained in section 4.1 for successful isolation. CD45 and tubulin were 
observed in all pellets. Table 4.4 illustrates that over three independent experiments 
there was greater protein recovery upon 100000g centrifugation, ranging from 1.7-
fold to 3.7-fold (mean of 2.8) compared to 20000g. 
 
Table 4.4 Protein recovery with 20000g or 100000g centrifugation  
Protein concentration (µg/ml) Experiment 
p20 p100 
Fold 
change 
1 159 464 2.9 
2 284 479 1.7 
3 564 2087 3.7 
 
 Plasma membrane prepared from human PBLs by centrifugation at 100000g was 
further investigated by qualitatively comparing protein recovery by western blot and 
BCA assay with varying numbers of resting or activated cells. Results are 
summarised in Table 4.4.  
 After 100000g centrifugation the quality and quantity of a membrane preparation 
varies with cell number. However overall CD45 was detected in p100 preparations 
Figure 4.7 Effect of centrifugal force on relative protein content of plasma membrane 
preparations. 100 x 106 cytokine-activated PBLs were lysed in a hypotonic buffer for 15 
minutes at 4°C and sonicated (5 x 5 sec 90W pulses). Lysate was clarified by 4000g 15 minute 
centrifugation (p4). The post nuclear supernatant was briefly vortexed, split equally by volume 
and subjected to either 20000g 30 minutes (p20) or 100000g 1 hour (p100).  Pellets were 
solubilised in Triton-X100 supplemented buffer and protein concentration was assessed by BCA 
assay: p20 = 159µg/ml protein and p100 = 464µg/ml. 10µg of p4, p20 and p100 was separated 
on a 12% SDS-PAGE, transferred onto PDVF membrane and probed with anti-CD45 and anti-
tubulin antibodies. Figure is representative of 3 experiments.  
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from fewer resting and cytokine-activated PBLs, compared to p20 preparations. With 
the exception of one experiment, all preparations from between 20 and 50 million 
resting cells contained CD45, and a successful preparation (CD45 present and no 
tubulin) was obtained from as few as 20 million resting cells. In ten out of eleven 
preparations obtained from 70 to 7.5 million cytokine-activated PBLs, CD45 was 
present.  Four of these were devoid of tubulin even with as few as 25 million cells. 
Increasing the centrifugal force applied to PBL lysates decreases the number of cells 
required for CD45 isolation, but increases co-isolation of tubulin. 
 
Table 4.5 Summary of protein recovery in p100 preparations 
PBLs Cell number  ( x 106) 
Protein conc. 
(µg/ml) 
Presence in p100 by western 
blot 
CD45 Tubulin
Resting 
50 541 Yes No 
50 155 Yes Yes 
50 400 Yes Yes 
47 82 Yes Yes 
25 177 No No 
25 66 Yes Yes 
20 224 Yes No 
12.5 25 Yes Yes 
Cytokine-
activated 
70 2712 Yes No 
50 404 Yes Yes 
50 464 Yes Yes 
39 383 Yes No 
33 2087 Yes No 
32.5 592 Yes Yes 
30 479 Yes Yes 
25 152 Yes Yes 
24 725 Yes No 
16 44 No Yes 
7.5 215 Yes Yes 
 
 
 
 
 
 
 
A range of PBL numbers were (resting or cytokine-activated) were lysed, sonicated and underwent a 
4000g 15 minute centrifugation followed by a 100000g 1 hour centrifugation to obtain membrane protein 
preparation (p100). Total protein content of each p100 fraction was determined by BCA assay and was 
assessed by western blot for the recovery of plasma membrane proteins as judged by the presence 
(Yes) or absence (No) of CD45 and tubulin. 
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4.4.3 High pH treatment of p100 pellets reduces cytosolic protein 
contamination 
 It has been reported that treatment of samples with high pH sodium carbonate 
buffer disrupts membrane vesicles, releasing cytosolic proteins contained within and 
stripping the membrane of weakly associated proteins. (Santoni et al., 2000; Wu et 
al., 2003). Thus the effect of sodium carbonate buffer treatment on the protein 
composition of a p100 pellet was investigated.  Cytokine-activated PBLs were lysed, 
sonicated, and spun at 4000g for 15 minutes at 4°C. The post-nuclear supernatant 
was divided equally by volume in two, and spun at 100000g for 1 hour at 4°C. The 
resulting pellets were either solubilised in hypotonic buffer plus Trition-X100 as 
normal or resuspended in 100mM Na2CO3 1mM EDTA buffer at pH 11.3 for 30 
minutes at 4°C, prior to 30 minutes at 100000g (section 2.7.3). The protein 
concentration of the original lysate, p4, untreated p100 pellet, s100 supernatant, 
treated p100 pellet and sodium carbonate supernatant (wash) was assessed by BCA 
assay. 20µg of protein from each sample was separated by SDS-PAGE in a pre-cast 
4-20% gel and silver stained. Individual bands were excised and analysed by 
MS/MS.  
  
 Figure 4.8 is representative of 3 independent experiments. The protein 
concentration of p100 pellet was reduced approximately 4-fold (2713 to 701µg/ml) 
upon sodium carbonate treatment. Twenty five bands were excised from treated 
p100 (p100 Na2CO3), six of which corresponded to three common leukocyte 
membrane proteins (CD18, CD11a and MHC Class I) and a seventh to the 
previously unseen (in my work) CD98 sodium independent amino acid transporter 
(P08195 4F2_HUMAN). Two unknown hypothetical proteins were also identified. Of 
the seventeen bands excised from the untreated p100 sample, only one was 
identified as a plasma membrane protein (CD11a). The majority were matched to 
ribosomal components, heat shock proteins, metabolic enzymes or cytoskeleton 
components such as vimentin, actin, profilin-1 and cofilin-1. No bands excised from 
the treated p100 sample were matched to cytoskeletal proteins. The 35KD band 
corresponding to the enzyme glyceraldehyde-3-phosphate dehydrogenase is 
indicated by a red box in Figure 4.8. Its presence can be tracked through the entire 
procedure – it is present in the original lysate and the initial 20000g and 100000g 
centrifugation steps but is also observed in the supernatant s100. Upon sodium 
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carbonate treatment glyceraldehyde-3-phosphate dehydrogenase is removed from 
the p100 pellet and only detected in the resulting supernatant (wash). In three 
independent experiments sodium carbonate treatment reduces the protein 
concentration of plasma membrane preparations by a mean of approximately 4-fold.  
The quantity and quality of protein recovery of sodium carbonate treated p100 
plasma membrane preparations was further assessed by western blot and BCA 
assay of resting and cytokine-activated PBLs in experiments with decreasing 
numbers of cells. As before, data is summarised in both tabular and bar chart form 
(Table 4.6). 
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Figure 4.8 Effect of a high pH wash on the protein content of p100 preparation. 140 x 106 
PBLs were lysed in a hypotonic buffer for 15 minutes at 4°C and sonicated (5 x 5sec 90W pulses). 
Lysate (Lys) was clarified by 15 minutes at 4000g centrifugation. The post nuclear supernatant 
was briefly vortexed, split equally by volume and subjected to 1 hour at 100000g, the resulting 
pellets were either solubilised in Triton-X100 supplemented buffer as normal (p100) or  
resuspended in 100mM Na2CO3 1mM EDTA pH 11.3 for 30 minutes at 4°C prior to 100000g 30 
minutes and solubilisation (p100 Na2CO3) . The post-100000g supernatant (s100) and post-
Na2CO3 treatment supernatant (Wash) were retained and protein concentration of all steps was 
assessed by BCA assay: lysate = 536µg/ml, p4 = 5057µg/ml, s100 = 355µg/ml, p100 = 2713µg/ml, 
p100 Na2CO3 = 701µg/ml and wash = 381µg/ml. 20µg of each sample was separated on a pre-
cast 4-20% SDS-PAGE and silver stained. Protein bands were excised, digested and analysed by 
MS/MS. Red boxes highlight bands identified as glyceraldhyde-3-phosphate dehydrogenase. Gel 
representative of 3 separate experiments.  
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Table 4.6 Summary of protein recovery in sodium carbonate treated p100 
preparations 
PBLs Cell number  ( x 106) 
Protein conc. 
(µg/ml) 
Presence in p100 Na2CO3 by 
western blot 
CD45 Tubulin
Resting 
222 304 Yes No 
204 258 Yes No 
202 178 Yes No 
185 245 Yes No 
120 158 Yes No 
116 109 Yes No 
100 129 Yes No 
100 888 Yes No 
85 349 Yes No 
80 207 Yes No 
58 108 Yes No 
50 221 Yes No 
45 234 Yes No 
20 143 Yes No 
Cytokine-
activated 
192 515 Yes No 
189 355 Yes No 
108 1780 Yes No 
107 719 Yes No 
105 1665 Yes No 
103 1052 Yes Yes 
85 315 Yes No 
70 701 Yes Yes 
57 289 Yes No 
46 176 Yes No 
45 462 Yes No 
28 166 Yes No 
25 227 Yes No 
25 275 Yes Yes 
24 242 Yes No 
15 245 Yes Yes 
 
 
 
 
 
 
  
Table shows protein recovery from 30 separate membrane preparations. A range of PBL numbers 
(resting or cytokine-activated) were lysed, sonicated and spun at 4000g for 15 minute followed by a 
100000g 1 hour centrifugation to obtain membrane protein preparation (p100) which was 
resuspended in Na2CO3 for 30 minutes at 4°C prior to a final 100000g 30 minute centrifugation (as 
described above) to obtain a treated membrane protein preparation (p100 Na2CO3). Total protein 
content of each p100 fraction was determined by BCA assay. Preparations were separated by SDS-
PAGE and western blotting was carried out to assess the recovery of plasma membrane proteins as 
judged by the presence (Yes) or absence (No) of CD45 and tubulin. 
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 The minimum number of PBLs required to generate a sample containing CD45 and 
devoid of tubulin is reduced to around 20 million resting and 25 million cytokine-
activated PBLs by the removal of intercellular proteins such tubulin and other 
cytosolic proteins through a high pH wash. 
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4.5 Analysis of plasma membrane protein expression of cytokine-activated T 
cells by mass spectrometry 
 
4.5.1 One dimensional separation 
 The previous section demonstrated that a purified membrane preparation can be 
obtained from around 25 million cells by 100000g centrifugation in conjunction with a 
high pH wash, but the total amount of protein recovered via this method is reduced 
by approximately 75%. Therefore in order to obtain sufficient protein for analysis, 
large numbers of cells are still required. In this section one-dimensional separation of 
a slightly more refined effector PBL population of cytokine-activated CD3+ cells is 
performed, to assess the success of optimised sample preparation more accurately, 
and to continue proteomic analysis without compromising cell number. 
  
 Freshly elutriated PBLs were depleted of NK cells using anti-CD56 magnetic beads 
prior to cytokine-stimulation (section 2.2.5). Plasma membrane proteins were 
enriched from resting and cytokine-activated cells obtained from individual donors. 
Western blot analyses of samples from four independent donors are shown in Figure 
4.12. In four donors CD45 was present, and tubulin was absent from all p100 
preparations from both resting and cytokine-activated T cells.  
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Figure 4.9 Plasma membrane preparations from cytokine-activated T cells. Freshly 
elutriated PBLs were depleted of CD56+ cells by magnetic beads prior to culture with IL-2, IL-6 
and TNFα for 8 days from 4 independent donors. Resting and cytokine-activated cells were 
thoroughly washed prior to lysis in a hypotonic buffer 15 minutes at 4°C and sonicated (5 x 5 sec 
90W pulses). Lysate (Lys) was clarified by 4000g 15 minute centrifugation (p4) and the 
subsequent post nuclear supernatant was spun at 100000g for 1 hour, the resulting pellet was 
resuspended in 100mM Na2CO3 1mM EDTA pH 11.3 for 30 minutes at 4°C prior to 100000g 30 
minutes and solubilised in Triton-X100 supplemented buffer as normal (p100N). Pellets and 
supernatants were assessed by BCA assay for protein concentration and 10µg was separated on 
a 12% SDS-PAGE, transferred onto PDVF membrane and probed with anti-CD45 and anti-tubulin 
antibodies. a) Plasma preparations from 100 million resting and cytokine-activated T cells (Tck); 
b) from 200 million resting and 85 Tck cells; c) from 220 resting and 100 Tck cells and d) from 
180 million resting and 100 Tck cells.
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 Cytokine-activated preparations were further assessed by one-dimensional 
separation and MS/MS. 20µg of each cytokine-activated p100 Na2CO3 sample was 
separated by electrophoresis on a 4-20% SDS PAGE gel and silver stained. Bands 
were excised and analysed by MS/MS. One-dimensional gels for each donor and the 
plasma membrane proteins identified are shown in Figure 4.13. Between 26 and 29 
bands were excised from each gel, and 25-33 different proteins were matched to the 
NCBI non-redundant database by Mascot. MHC Class I, CD18 and CD11a were 
common to all four donors. MHC Class II and CD45 were identified in 3 out of 4 gels. 
The invariant chain of antigen presentation CD74 (P04233 HG2A_HUMAN), 
transferrin receptor CD71 (P02786 TFR1_HUMAN), CD2 (P06729 CD2_HUMAN) 
and CD98 (P08195 4F2_HUMAN) and phosopholipase Cα (Q8WWY8 
LIPH_HUMAN) were all identified as plasma membrane proteins not previously 
observed in p20 one-dimensional separation of cytokine-activated PBLs. Figure 4.14 
summarises the sub-cellular locations of the identified proteins for each donor. The 
percentage of plasma membrane proteins identified ranged from 27-41% (mean= 
33.25%) and in general the proportions of proteins identified in each location 
remained was consistent between all 4 donors.  
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Figure 4.10 One-dimensional analysis of plasma membrane preparations from cytokine-activated 
T cells. CD3+ T cells were isolated from freshly elutriated peripheral blood lymphocytes by negative 
selection with CD56+ magnetic beads prior to culture with IL-2, IL-6 and TNFα. After 8 days 100 million 
a), c), d) or 85 million activated cells b) were lysed in a hypotonic buffer for 15 minutes at 4°C and 
sonicated (5 x 5sec 90W pulses). Lysate was clarified by 15 minutes at 4000g centrifugation. The post 
nuclear supernatant was subjected to 1 hour at 100000g, the resulting pellet was resuspended in 
100mM Na2CO3 1mM EDTA pH 11.3 for 30 minutes at 4°C prior to 100000g 30 minutes and solubilised 
in Triton-X100 supplemented buffer as normal. Protein recovery was assessed by BCA assay. 20μg was 
separated on a pre-cast 4-20% SDS-PAGE gel under reducing conditions and silver stained. Bands 
were excised, digested and analysed by MS/MS. Plasma membrane proteins identified are shown.  
Chapter 4       Results 
188 
 
 
33
204
33
10
41
18
35
6
32
16
36
16
27
15
3
43
12
Plasma membrane
Endoplasmic reticulum 
Mitochrondria
Cytoplasm
Nucleus
a) b)
c) d)
 
 
 
 
 
 
 
 
 
4.5.2 Two-dimensional separation 
  Previously (section 4.2) 160µg of protein from membrane fractions generated from 
resting and cytokine-activated PBLs by 20000g centrifugation were resolved by 
solution phase isoelectric focussing and SDS PAGE, enabling protein resolution and 
identification via mass spectrometry. Subsequently the preparation of plasma 
membrane fractions was optimised so that the levels of contaminating cytoplasmic 
proteins were reduced. However in line with this, the amount of protein recovered 
per million cells was also reduced. Therefore to gain sufficient protein for two-
dimensional separation, samples from different donors were pooled.  
 
Figure 4.11 Summary of the sub-cellular location of identified proteins in plasma 
membrane preparations from T cells separated by 1D. Freshly elutriated PBLs were 
depleted of CD56+ cells by magnetic beads prior to culture with IL-2, IL-6 and TNFα for 8 
days from 4 independent donors. Plasma membrane preparations from 100 million a), c), d) 
or 85 million cytokine-activated CD3+ T cells (Tck) b) were analysed by 1D separation, silver 
staining and MS/MS analysis (Figure 4.12). Pie charts summarises the sub-cellular locations 
of the identified proteins within each preparation according to the key shown. Percentage 
shown in each segment.   
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 In the first experiment (Figure 4.15 a), three sets of membrane preparations (resting 
and cytokine-activated) were pooled from donors corresponding to the westerns 
seen in Figure 4.12 a) – c) and one-dimensional separations in Figure 4.13 a) – c). 
The quantity of protein taken from each donor for the resting and the cytokine-
activated pools was matched, such that donors provided 21µg, 51µg and 47µg of 
protein to a total of 111µg for both resting and cytokine-activated plasma membrane 
preparations. A 2nd set of pools, shown in figure 4.15 b), was made up of 37µg of 
protein from the donor preparations shown in Figures 4.12 d) and 4.12 d) and 85µg 
of protein from preparations generated from 140 million resting and 50 million 
cytokine-activated CD3+ cells of a fifth donor. Proteins in each pool were separated 
in solution using the ZOOM™ isoelectric focussing unit (as before) to generate five 
fractions of proteins with different pI ranges. Each fraction was concentrated and 
urea, thiourea and CHAPS removed using a SDS-PAGE Clean-Up kit (Amersham 
Biosciences, UK) prior to resolution on a 4-20% SDS-PAGE gradient gel. The gel 
was silver stained and bands were excised for MS/MS analysis. The plasma 
membrane proteins identified are indicated by arrows in Figure 4.15. 
 
 Of the 245 protein bands excised from Figure 4.15 a), 142 (58%) were not identified 
by mass spectrometry probably because insufficient protein was present. A further 
51 bands were identified as laboratory contaminants such as casein, lactoglobulin 
and bovine serum proteins. Thirty seven different proteins were identified from the             
remaining 52 bands and their sub-cellular locations (according to UniProt 
knowledgebase) are summarised in Figure 4.16 a). Sixteeen percent of identified 
proteins are located in the cell’s plasma membrane. The majority of the remainder 
were cytoplasmic, predominantly proteosome subunits and translation elongation 
factors. A number of intracellular membrane proteins were identified including ATP 
synthase β from mitochrondria and calreticulin from the endoplasmic reticulum. One 
hundred and forty two bands were excised from the 2D separation of the 2nd pool 
shown in Figure 4.15 b). In this experiment thirty bands could not be identified by 
MS/MS, and sixty three were found to be laboratory contaminants. The sub-cellular 
locations of 24 different proteins identified from the remaining 49 bands are 
summarised in Figure 4.16 b). The four plasma membrane proteins identified, 
indicated in Figure 4.15 b), represent 23% of all those identified. Once again the 
majority of proteins are cytoplasmic.  
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Figure 4.12 Two-dimensional separation of plasma membrane preparations from T cells. p100 
Na2CO3 preparations from resting and cytokine-activated PBLs from 5 independent donors were 
pooled. a) 21µg, 51µg and 47µg of protein from resting and cytokine-activated fractions from 3 
donors were pooled to give a total of 111µg. b) 37µg and 83µg of protein from resting and cytokine-
activated fractions from 2 donors were pooled giving a total of 120µg. Each pool of samples was 
separated in a ZOOM solution phase isoelectric focusing unit. Focussed protein fractions then 
resolved on a precast 4-20% SDS gradient gel and silver stained. Bands were excised, digested and 
analysed by MS/MS. From left to right: molecular weight markers; IEF focussed fractions of 
increasing  pI value alternating between resting and cytokine-activated PBLs. Identified plasma 
membrane proteins indicated by arrows.  
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Figure 4.13 Summary of the sub-cellular location of identified proteins following 
2D separation. Freshly elutriated PBLs were depleted of CD56+ cells by magnetic 
beads prior to culture with IL-2, IL-6 and TNFα for 8 days from 5 independent donors. 
Preparations from resting and cytokine-activated PBLs from matched donors were 
combined into 2 pools for analysis by 2D separation, silver staining and MS/MS analysis 
(Figure 4.14). Pie charts summarise the sub-cellular locations of the identified proteins 
within each pool according to the key shown. Percentage shown in each segment.  
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4.6 One-dimensional separation of cytokine-activated CD4+ memory T cells 
 In section 4.5.1 it was shown that on average approximately one-third of proteins 
identified from one-dimensional separation of p100 Na2CO3 -washed pellets originate 
from the plasma membrane, and some of them were consistently identified between 
donors. As 1D separation requires less protein than two dimensional methods, 
analysis of samples obtained from limited cell populations such as CD4+CD45RO+ 
PBLs available from a single donor was attempted. Fifty six million cytokine-activated 
CD4+CD45RO+ T cells were washed and lysed in hypotonic buffer as before. The 
lysate was clarified by 4000g centrifugation and the post nuclear supernatant was 
centrifuged for 1 hour at 100000g. The resulting pellet was resuspended in sodium 
carbonate buffer pH 11.3 for 30 minutes at 4°C, prior to a 30 minute at 100000g, and 
was solubilised in Triton-X100 supplemented buffer as previously described. The 
concentration of the 210µl preparation was found to be 54µg/ml; therefore 
approximately 11µg total protein was obtained. After western blot analysis (not 
shown) 7.5µg remained for separation on a 4-20% SDS-PAGE gel and silver 
staining, as shown in Figure 4.17.  
 
 Twenty seven bands were excised and analysed by tandem mass spectrometry. 
Only one excised band could not be matched to a database entry by Mascot. Ten 
plasma membrane proteins were identified and are shown in Figure 4.17. Once 
again the LFA-1 integrin components CD11a and CD18, plus MHC Class I, CD45, 
Moesin, CD98, and E-Syt1 were observed. In addition CD5 (P06127 CD5_HUMAN) 
and CD97 (P48960 CD97_HUMAN) were also identified.  In total 27 different 
proteins were identified within the preparation and their sub-cellular locations are 
summarised in Figure 4.18. 
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Figure 4.14 One-dimensional analysis of a plasma membrane preparation from 
cytokine-activated CD4+ memory PBLs. 56 x 106 cytokine-activated CD4+CD45RO+ T 
cells were lysed in a hypotonic buffer for 15 minutes at 4°C and sonicated (5 x 5sec 90W 
pulses). Lysate was clarified by 15 minutes at 4000g centrifugation. The post nuclear 
supernatant was subjected to 1 hour at 100000g, the resulting pellet was resuspended in 
100mM Na2CO3 1mM EDTA pH 11.3 for 30 minutes at 4°C prior to 100000g 30 minutes and 
solubilised in Triton-X100 supplemented buffer as normal. Protein recovery was assessed 
by BCA assay. 7.5μg was separated on a pre-cast 4-20% gradient SDS-PAGE gel under 
reducing conditions and silver stained. Bands were excised, digested and analysed by 
MS/MS. Plasma membrane proteins identified are shown.  
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 An equal proportion of the proteins identified are located in the cytoplasm as in the 
plasma membrane, (37%). Organelle membrane proteins from mitochrondria and the 
endoplasmic reticulum including ATP synthase subunits and calreticulin were 
identified and together comprised 14% of the identified proteins. Two secreted 
proteins were identified; laminin and annexin A2, however both are closely 
associated with the external surface of plasma membranes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Summary of sub-cellular location of identified proteins in plasma membrane 
preparation from cytokine-activated CD4+CD45RO+ cells. CD4+CD45RO+ T cells were isolated 
from freshly elutriated PBLs prior to 8 day stimulation with IL-2, IL-6 and TNFα. p100 plus Na2CO3  
plasma membrane fraction was prepared from 56 million cytokine-activated cells after 8 days and 
analysed by 1D separation, silver staining and MS/MS. Pie chart summarises the sub-cellular 
location of 27 identified proteins. Percentage is displayed in each segment. 
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4.7 Summary of proteomic analysis of cytokine-activated PBLs 
 Twenty two different plasma membrane proteins have been identified from plasma 
membrane preparations from either resting or cytokine-activated PBLs. Table 4.6 
illustrates the number of identifications made for each protein from one- or two-
dimensional separations, and the cell and preparation type from which each 
identification was made. Thirteen proteins were identified only in preparations from 
cytokine-activated PBLs, compared to three from resting PBLs alone and six from 
both. No protein was identified in every experiment performed. CD11a, CD18, CD45 
and MHC Class I were observed in five or more (out of seven) 1D experiments, and 
a further four proteins, MHC Class II, Moesin, β2 microglobulin and E-Syt1, were 
observed in four independent 1D separations. Two proteins CD3δ and peptidoglycan 
recognition protein were identified in 2D separation only.    
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Table 4.7 Identified plasma membrane proteins 
Protein 
Number of 1D 
experiments  
(out of 7) 
Number of 2D 
experiments  
(out of 3) 
Resting
or 
Cytokine-
activated 
Preparation 
type Classification
β2 microglobulin 4 2 Both Both Peri EC 
CD2 1 0 Tck p100 Na2CO3 Type 1 
CD3δ 0 1 Resting p100 Na2CO3 Type 1 
CD5 1 0 Tck p100 Na2CO3 Type 1 
CD11a 5 1 Both Both Type 1 
CD18 6 1 Both Both Type 1 
CD41b 1 0 Resting p20 Type 1 
CD45 5 0 Tck p100 Na2CO3 Type 1 
CD71(Transferrin 
receptor) 3 0 Tck p100 Na2CO3 Type 2 
CD74 (Invariant 
chain) 1 0 Tck p100 Na2CO3 Type 2 
CD81 1 0 Tck p20 4TM 
CD97 1 1 Tck p100 Na2CO3 7TM 
CD98 (Amino 
acid transporter) 3 0 Tck p100 Na2CO3 Type 2 
E-Syt1 4 1 Both Both 2TM 
Ezrin 2 2 Both Both Peri IC 
Flotillin-1 0 1 Tck p20 Unknown 
Guanine 
nucleotide BP 0 2 Both Both Peri IC 
MHC Class I 6 0 Tck Both Type 1 
MHC Class II 4 2 Tck Both Type 1 
Moesin 4 1 Tck Both Peri IC 
Peptidoglycan 
recognition 
protein 
0 1 Resting p100 Na2CO3 Peri EC 
Phospholipase 
Cα 2 1 Tck p100 Na2CO3 Peri IC 
 
 
 
Table summarises seven 1D and three 2D; 1D analysis during optimisation (section 4.4.3) are not 
included in this summary. Abbreviations – EC = extracellular, IC = intracellular, Na2CO3 = sodium 
carbonate, p20 = 20000g pellet, p100 = 100000g pellet, Tck = cytokine-activated PBL, TM = 
transmembrane. 
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4.8 Discussion 
 This chapter used a ‘classical’ proteomic approach to examine the cell surface 
phenotype of primary human lymphocytes within an in vitro model of RA. Initially 
proof-of-principle was achieved with the identification of CD81, an unexpected 
candidate molecule from one-dimensional separation and the identification of known 
cell-surface markers of cytokine-activated T cells in two-dimensional separation. 
Subsequently steps were taken to improve plasma membrane protein enrichment 
during sample preparation and to reduce the number of cells required. In doing so, 
sample enrichment was improved, but the quantity of protein recovered per donor 
diminished, leading to a choice between the cell population analysed and resolution.  
 
 Two-dimensional electrophoresis by solution phase IEF and SDS PAGE of samples 
generated from murine splenocytes and hydridoma cell lines resulted in a 58% 
identification rate in the detection of plasma membrane proteins. Despite this, 
application to a primary human T cell model was not as successful since only 12% of 
identified proteins were associated with the plasma membrane. This difference is 
likely to be due to the additional purification step used in the mouse experiments. 
Cell surface biotinylation was performed prior to lysis and labelled proteins were 
recovered from the p20 samples through affinity-capture by streptavidin-agarose 
beads. This step was originally excluded from my studies because of the 10-fold 
difference in cell numbers available in the murine studies and the average number of 
lymphocytes obtained from an elutriated buffy coat (2 x 109 versus 2 x 108 
respectively). The extensive washing which is required post-affinity capture leads to 
protein losses and thus is less suitable when cell number is already limiting. In the 
event, optimisation resulted in the addition of high pH  step which, although 
successful in removing cytoskeletal proteins, reduced the quantity of protein 
recovered, such that peripheral blood T cells from a single donor could not provide 
enough protein for 2D separation so and samples from separate donors were 
pooled. 
 
 The aim of optimisation steps undertaken in this chapter was to increase the 
enrichment of plasma membrane proteins by reducing the number of contaminating 
proteins from other sub-cellular compartments and to reduce the number of cells 
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required for sample preparation, such that plasma membrane protein expression 
could be assessed from more defined PBL subsets. An improvement in sample 
preparation with minimal additional steps was desirable to reduce losses and 
contamination during sample handling. Initially I assessed the effect of different cell 
breakage methods on the quality and quantity of samples prepared. I found that 
compared to homogenisation or French press, sonication of cell lysates reduced 
CD45 losses on sample clarification (4000g, 15 minutes) probably due to the 
increased breakage and reduced sedimentation of intact cells. Lysis and breakage of 
cells results in the formation of vesicles of plasma membranes and other intracellular 
organelle membranes such as the Golgi and ER. Vesicles are not sedimented at 
4000g which removes intact organelles such as nuclei, mitochrondria and ER. 
Published protocols for plasma membrane enrichment differ  in the centrifugal force 
required to sediment vesicles, starting at 20000g. In this thesis I compared the 
plasma membrane protein preparation from cytokine-activated PBLs by 20000g or 
by 100000g. Analysis by western blotting revealed little difference in the intensity of 
CD45 observed, but a reduction in tubulin abundance in p100 samples compared to 
p20 samples. More importantly this was concomitant with an increase in protein 
concentration. Over three experiments, 3-fold more protein was recovered from 
solubilisation of p100 pellets compared to p20 pellets. Sonication and centrifugation 
at 100000g steps were subsequently used for the preparation of plasma membrane 
samples from human PBLs, as they qualitatively and quantatively improved 
enrichment. This is in agreement with a number of published protocols (Cox and 
Emili, 2006; Miguet et al., 2006). In addition the modified protocol enabled sample 
preparation from fewer cells. A ‘successful’ preparation was judged by the presence 
of CD45 and the absence of tubulin in western blotting. Using these criteria the 
improved protocol lowered the threshold for a successful preparation to 50 million 
resting PBLs. When the effect of a high pH buffer on p100 pellets was investigated 
the threshold was further reduced to 20 million resting PBLs and 25 million cytokine-
activated PBLs. High pH conditions open vesicles, releasing any contaminating 
proteins contained within and dissociating proteins loosely associated with the 
membrane. One-dimensional separation and mass spectrometry analysis comparing 
treated and untreated p100 pellets, plus their respective supernatants, showed 
effective removal of some non-plasma membrane proteins from p100 pellets. The 
loss of contaminating proteins coincided with an approximate 75% reduction in 
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protein recovered from a single donor. Although western blotting indicated that 
optimisation had led to increased enrichment of plasma membrane proteins from 
fewer cells, subsequent analysis by one-dimensional SDS-PAGE and mass 
spectrometry revealed only a modest increase in the percentage (9%) of plasma 
membrane proteins identified from cytokine-activated T cells (CD3+ or 
CD4+CD45RO+). However, with the exception of CD81, all plasma membrane 
proteins identified in one-dimensional analysis prior to optimisation (CD45, E-Syt, 
Ezrin, Moesin, MHC Class I, MHC Class II and β2 microglobulin) were also identified 
post-optimisation over 5 experiments alongside additional proteins (CD2, CD5, 
CD71, CD74, CD97, CD98 and phospholipase Cα).   
 
 A major obstacle in conventional 2D IEF/SDS-PAGE electrophoresis of plasma 
membrane proteins is their intrinsic hydrophobicity, which renders them highly 
insoluble in aqueous solutions, more prone to precipitation at their pI and inefficient 
in transferring from IPG strips to SDS gels. The use of non-ionic detergents such as 
Triton-X100 facilitates the extraction of membrane proteins from the lipid-bilayer and 
is compatible with IEF separation.   Friso et al compared a range of different 
conditions for IEF and found that a solution of 2M thiourea, 7M urea and 4% CHAPS 
(a zwitterionic detergent) provided the best resolution of high MW and hydrophobic 
proteins (Friso and Wikstrom, 1999). This, in combination with solution-phase IEF 
(Zuo and Speicher, 2000) is efficient at resolving plasma membrane proteins, and 
forms the basis of the Invitrogen ZOOM™ fractionator used in this thesis.  It is 
designed to reproducibly fractionate between 1-2mg of protein. Despite the 
enrichment gained by a high pH wash, resolution of even 100µg of protein prepared 
from primary human T cells required pooling of 2 or 3 individual donors, with the 
potential of losing information by averaging donor variation. The proteins in the 
pooled samples were resolved by solution-phase IEF and SDS-PAGE, and 
visualised by silver staining; however the majority of these were either not identified 
by MS/MS or proved to be contaminants originating from sample preparation. Failure 
in identification was usually a consequence of the low quantity of sample available. 
The source of contaminants is likely to be from the solution-phase IEF and/or 
subsequent fraction concentration procedures prior to SDS-PAGE, because 
contamination was virtually absent in 1D analyses. Nevertheless, as with one-
dimensional separation, a slight increase in the proportion of identified proteins 
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which were from the plasma membrane in both 2D separations resulted from 
optimising the preparation protocol. Due to time limitations I was unable to assess 
whether the pooling of a greater number of donors, and separation of more protein in 
solution phase IEF would have allowed identification of more resolved proteins. 
Overall identification of plasma membrane preparations from human T cells was 
more successful from 1D separation than from 2D experiments despite the lower 
resolution achieved. 
 
The sub-cellular location of identified proteins was classified according to the main 
location given in the UniProt Knowledgebase complied from Swiss-Prot and TrEMBL 
databases. However many membrane proteins have multiple cellular locations due 
to continuous protein trafficking and secretory pathways in cells. For instance in 
these experiments calnexin and calreticulin were classified as ER proteins. The 
contamination observed in sample preparations in this thesis and in the majority of 
published plasma membrane proteomic studies results from incomplete separation 
of sub-cellular membranes due to physical connections between them e.g. nuclear 
envelope and ER, Golgi and secretory vesicles and co-isolation. Foster et al 
examined this phenomenon and found that 39% of proteins identified from mouse 
livers had multiple cellular locations (Foster et al., 2006). 
 
 The original aim of this chapter was to compare proteins from resting PBLs with 
those from cytokine-activated PBLs resolved in 2D, to identify changes in plasma 
membrane expression between in two cellular states. In the three 2D experiments, 
fourteen different plasma membrane proteins were found. Four proteins were 
identified in fractions from cytokine-activated T cells only; CD97, Flotillin-1, MHC 
Class II and Moesin. In chapter 3 flow cytometry demonstrated in both populations 
the proportion of cells expressing Class II HLA-DR and the level of expression after 
cytokine-activation increased, which is consistent with the MS data.  
 
 Flotillin-1 is a marker for microdomains in the plasma membrane known as lipid 
rafts. These are regions in the lipid bilayer containing high levels of cholesterol and 
sphingolipids, which concentrate specific proteins under given conditions, whilst 
excluding others, thus generating specialised loci on the cell surface (Simons and 
Ikonen, 1997). Lipid rafts have been implicated in the stabilisation of and signal 
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transduction from the immune synapse (Gombos et al., 2006). They are defined as 
regions resistant to solubilisation by non-ionic detergents or high pH at 4°C. However 
Peirce et al demonstrated that the use of Triton-X100 detergent to solubilise p20 
pellets did not prevent isolation of the lipid raft resident protein Thy1 (CD90) (Peirce 
et al., 2004). Using the same detergents, and following a similar protocol I showed 
that lipid rafts are also not excluded from p20 preparations from human PBLs by  the 
identification of the raft specific markers flotillin-1 by MS and LAT and CD4 via 
western blotting (data not shown). However no lipid raft proteins were found by MS 
of one- and two- dimensional analysis of sodium carbonate treated p100 sample 
preparations. It is possible that residual sodium carbonate buffer may cause a rise in 
pH of the hypotonic buffer supplemented with Triton-X100 during solubilisation of 
treated p100 pellets and so prevent the isolation of lipid rafts. Western blot analysis 
of sodium carbonate treated p100 pellets for CD4, which is constitutively present in 
lipid rafts, would address this issue.  
 
 Lipid rafts are not the only microdomains which act as organisers of the membrane. 
The tetraspanin family of proteins form homo- and heterotypic interactions with other 
family members and other proteins, to promote the formation of supramolecular 
clusters. These have been shown to be biophysically and biochemically distinct from 
lipid rafts, but are also classified by their resistance to solubilisation by non-ionic 
detergents. A tetraspanin family member CD81 was identified in the1D separation of 
p20 sample preparation of cytokine-activated PBLs; thus proteins contained in these 
microdomains are also not excluded upon solubilisation of p20 pellets by hypotonic 
lysis buffer supplemented with Triton-X100. As with lipid raft marker proteins, no 
tetraspanin family members were observed in either 1D or 2D separations of sodium 
carbonate p100 preparations. CD81 has documented T cell co-stimulatory 
properties; its expression was validated on cytokine-activated PBLs in this chapter 
and is explored further on the CD4+ memory T cell population in chapter 5.  
 
 Moesin and ezrin are peripheral plasma membrane proteins located on the 
intracellular side of the membrane which act as linkers to the actin cytoskeleton. 
Actin was detected in preparations from cells prior to optimisation, but was largely 
absent from those treated with sodium carbonate, indicating efficient stripping of 
associated proteins and increased enrichment. Moesin and ezrin have been shown 
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to be important in rearrangements of the T cell cytoskeleton and in the organisation 
of membrane microdomains at the immunological synapse (Allenspach et al., 2001; 
Delon et al., 2001). Although ezrin was detected in both resting and cytokine-
activated T cells by 2D and MS, moesin was only identified in cytokine-activated T 
cell preparations. This observation while requiring validation by independent 
methods such as western blotting of whole cell lysates, suggests that moesin may be 
upregulated on cytokine-activation whereas ezrin is expressed at a constant level, 
leading to specific organisation of the lipid bilayer microdomains which promote 
intercellular interactions with monocytes and the induction of TNFα.  
 
 CD97 is a seven TM integral plasma membrane protein which is upregulated when 
T cells are activated. It has a large extracellular domain, with a number of known 
ligands, and thus represents an interesting candidate molecule in the induction of 
TNFα from monocytes. Validation of CD97 expression and its potential role is 
presented in chapter 5.  
 
 CD97 and E-Syt1 were the only multi-spanning integral membrane proteins 
identified by 2D and MS analysis. Little is known about the function of the two TM 
containing protein E-Syt1, except that is exhibits calcium dependent binding to 
phospholipids. The majority of plasma membrane proteins identified were either type 
1 single TM or peripheral proteins, which are less hydrophobic than those with more 
than one TM domain, thus even in the solution-phase there is a strong bias against 
the resolution of highly hydrophobic plasma membrane proteins. Figures 4.12 a) - c) 
and 4.14 a) demonstrate loss of integral plasma membrane proteins previously 
identified in 1D on resolution of the same preparations in 2D. Thirteen different 
plasma membrane proteins were identified in 1D, of these only three peripheral 
membrane proteins were resolved and identified in 2D; however three previously 
unidentified integral proteins were identified in 2D alone. Therefore it is necessary to 
study plasma membrane proteins using both these methods. My data supports the 
use of 1D electrophoresis to complement 2D methods for plasma membrane 
proteomics previously proposed (Zhang et al., 2005).  
 
 Other 2D electrophoretic methods use the powerful solubilising effect of ionic 
detergents on hydrophobic proteins to bypass IEF and perform orthogonal 
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separation by mass alone. Resolution is achieved through the differential use of 
detergents and/or percentage gels in both directions. Use of SDS/SDS-PAGE, 16-
BAC/SDS-PAGE or CTAB/SDS-PAGE has increased resolution of plasma 
membrane proteins in comparative studies against IEF/SDS-PAGE (Braun et al., 
2007). However in recent years technology has advanced such that gel-free 
resolution of proteins by liquid chromatography (LC) directly coupled to tandem mass 
spectrometry (MS/MS) has become the favoured method for proteomic studies 
including that of plasma membrane proteins. Moreover, it has allowed relative 
quantitation of protein expression between samples by mass spectrometry as it is 
readily compatible with a variety of tagging and isotopic labelling techniques, 
bringing proteomics on a par with genomics (Cox and Mann, 2007; Ong and Mann, 
2005). LC-MS/MS or ‘shot-gun’ proteomic approaches have profiled plasma 
membrane proteins from, amongst others; rat and mouse brains , human 
mesenchymanal stem cell lines, human embryonic stem cells and human embryonal 
carcinoma cells (Dormeyer et al., 2008; Foster et al., 2005; Nielsen et al., 2005; 
Olsen et al., 2004). Of particular interest to our in vitro model is the work by 
Dormeyer et al. They applied a similar protocol to one applied in this thesis, the only 
difference was a sucrose cushion in ultracentrifugation to isolate a membranous 
layer instead of a pellet, to enrich 50µg of protein from only 5 x 105 stem cells. They 
optimised sequential deglycosylation and proteolytic digestion prior to LC-MS/MS to 
identify over 200 plasma membrane proteins, representing approximately 50% of all 
proteins identified. On the face of it such a protocol seems highly applicable to 
studying cytokine-activation of primary human CD4+CD45RO+ T cells. Nevertheless 
studies presented in this chapter have demonstrated 1D SDS-PAGE and 2D 
IEF/SDS-PAGE is capable of generating candidate molecules previously not 
examined in cytokine-activated T cells for validation. 
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5.0 Introduction 
 Proteomic studies carried out in Chapter 4 identified CD81 and CD97 as plasma 
membrane proteins present in samples from cytokine-activated PBLs but absent 
from resting PBLs. In this chapter I describe my attempt to validate the identification 
of each molecule by western blotting and flow cytometry. In Chapter 3 cytokine-
activated CD4+CD45RO+ T cells were found to be a key effector population in the 
induction of TNFα from monocytes; thus expression of CD97 and CD81 on these 
cells upon cytokine activation and their potential role in the induction of TNFα was 
investigated.     
5.0.1 CD97 
 CD97 is a member of the epidermal growth factor – seven transmembrane (EGF-
TM7) family of class B seven-span transmembrane (7TM) receptors and is 
expressed by myeloid cells, smooth muscle cells and activated lymphocytes (Eichler 
et al., 1997; Hamann et al., 1995; Jaspars et al., 2001).  This family of proteins is 
characterised by a unique dimeric structure in which a seven transmembrane β 
subunit is non-covalently coupled to a large extracellular α subunit containing 
between 3 – 5 epidermal growth factor (EGF) domains. The heterodimer is produced 
as a result of proteolytic cleavage of a single precursor polypeptide. There are three 
isoforms of the polypeptide generated by alternative splicing of the N terminal α 
domain as shown in Figure 5.1. The largest isoform contains all 5 possible EGF 
domains EGF(1,2,3,4,5), the intermediate isoform has lost domain 4 - EGF(1,2,3,5) 
and the smallest isoform contains only domains 1, 2 and 5 known as EGF(1,2,5) 
(Gray et al., 1996).  Other members of this family of proteins include EMR1, 2, 3, 4 
and mouse F4/80. EMR2 is highly homologous to CD97; only a difference of 3 amino 
acids separates the two. In addition EMR2 has 3 comparable isoforms to CD97, but 
in contrast to CD97, EMR2 expression is myeloid restricted (Kwakkenbos et al., 
2002).  
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 The structure of CD97, with its EGF domains and G protein-coupled like 
transmembrane domain, points towards adhesive and signal tranducing properties. 
Whilst little is known about the latter, a number of ligands have been demonstrated 
for the extracellular protein. CD55, also known as Decay Accelerating Factor after its 
role in complement regulation, is the main cellular ligand for CD97 (Hamann et al., 
1996). The affinity of this interaction is generally low, and depends on the CD97 
isoform. CD97 EGF(1,2,5) isoform binds CD55 with the greatest affinity at 86µM (KD) 
but the interaction with the larger isoforms is even weaker. CD97-CD55 ligation has 
been implicated in the migration of neutrophils in bacterial infection (Leemans et al., 
2004), in the pathogenesis of multiple sclerosis (Visser et al., 2002) and in fibroblast-
macrophage interactions within the rheumatoid synovium (Hamann et al., 1999). The 
largest isoform, CD97 EGF(1,2,3,4,5), binds chrondroitin sulphate and has been 
shown to be important in interactions between CD97+ leukocytes and B cells 
(Kwakkenbos et al., 2005). Finally, the presence of an integrin binding Arg-Gly-Asp 
(RGD) binding motif on the C-terminal side of the EGF-like domain 5 further 
indicates a role in cellular migration and adhesion. Indeed CD97 has been shown to 
bind VLA-5A on endothelial cells and promote angiogenesis (Wang et al., 2005). 
Figure 5.1 CD97 isoforms. A schematic representation of the three CD97 isoforms. Each isoform 
consists of extracellular α subunit with 3-5 EGF- like domains (triangles) and a seven 
transmembrane β subunit.  
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 Resting T cells do not express CD97, but it is rapidly upregulated on PMA or 
antigenic stimulation (Eichler et al., 1994). T cells are also express CD55, and co-
stimulation of T cells via cell surface CD55 by CD97 has been demonstrated in vitro 
by the Spendlove laboratory (Capasso et al., 2006). Immobilised anti-CD55 or CD97 
Fc-fusion protein in combination with anti-CD3 and IL-2, increased proliferation and 
cytokine production by CD4+ T cells. However, this interaction appears to be 
bidirectional, as blockade of CD55 on peptide pulsed monocytes, or of CD97 on T 
cell clones, inhibited T cell proliferation and IFNγ production (Abbott et al., 2007).  
 CD97 is implicated in a number of cell-cell contact events and thus provides an 
interesting candidate molecule in the interaction of T cells and monocytes within our 
in vitro model of RA, and is worthy of further investigation presented in this chapter. 
5.0.2 CD81 
CD81 is one of 33 members of the human tetraspanin superfamily of proteins that 
form specific lateral interactions with each other, and with other associated proteins, 
forming a network within the plasma membrane known as the tetraspanin web or 
tetraspanin-enriched microdomains (TEM) (Rubinstein et al., 1996). Tetraspanins 
are proteins (up to 350 amino acids) which share a number of common structural 
features, as summarised by Figure 5.2. The four transmembrane spanning regions 
(TM1 – 4), containing conserved polar residues, flank a small extracellular loop 
(SEL) domain between TM1 - 2 and a large extracellular loop (LEL) domain between 
TM3 – 4.  All LEL domains of tetraspanins contain a conserved Cys-Cys-Gly motif 
that is integral in the formation of a constant fold of 3 helices. Intracellular domains 
link tetraspanins to signalling molecules, and the cytoskeleton; in addition a number 
of conserved cysteines found close to the inner side of the membrane provide sites 
for palmitoylation which promotes membrane association and TEM formation 
(Kitadokoro et al., 2001; Levy and Shoham, 2005).  
 CD81 is widely expressed, with the exception of red blood cells and platelets (Engel 
and Tedder, 1994) and was originally identified as the target of anti-proliferative 
antibody on human B cells; as a result it is also known as TAPA-1 (Oren et al., 
1990). CD81 forms multiple associations with different proteins within cell type 
specific TEMs. In the context of the immune system these associations result in a 
variety of roles for CD81 on leukocytes. On B cells CD81 directly associates with 
CD19 in the co-receptor complex of the BCR, which also includes complement 
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receptor CD21. CD81 lowers the threshold for B cell responses to opsonised antigen 
by organising and stabilising signalling complexes formed upon co-engagement of 
the BCR and CD21 (Fearon and Carter, 1995; Matsumoto et al., 1993). Moreover, 
CD81 is thought to act as a chaperone for CD19 during transportation to the B cell 
surface, as CD81 knockout mice have sub-optimal CD19 levels (Shoham et al., 
2003; Shoham et al., 2006; Tsitsikov et al., 1997). CD81 also acts as a co-
stimulatory molecule in T cells, since co-engagement of CD3 and CD81 increased 
proliferation, IFNγ production, and CD25 and CD69 expression, via signalling 
pathways that were independent of CD28 co-stimulation (Witherden et al., 2000). 
CD81 knockout mice reveal that CD81 expression on both T and B cells is required 
for Th2 responses (Deng et al., 2002; Maecker et al., 1998).  Upon antigen 
stimulation the protein accumulates in TEM at the synapses between T and B cells 
(also between T and dendritic cells) on both cell types (Mittelbrunn et al., 2002).  
CD81 has been found to associate with specific MHC Class II molecules (HLA-DR, -
DQ) within the TEM which are distinct from those Class II molecules found in lipid 
rafts (Angelisova et al., 1994; Kropshofer et al., 2002). It also interacts with the 
cytoplasmic domains of the CD4 and CD8 molecules (Imai et al., 1995).  
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 Integrins form a main group proteins known to partner tetraspanins. A number of 
specific interactions between different tetraspanins and integrins have been 
identified, and their importance in the strengthening of integrin – ligand adhesion has 
Figure 5.2 Tetraspanin structure. A schematic representation of the structure of 
tetraspanin superfamily proteins showing 4 transmembrane domains, conserved CCG 
motif (green), conserved polar residues (P), cysteines (C), potential palmitate (red 
lines), small extracellular loop (SEL) and large extracellular loop (LEL) domains. 
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been demonstrated. A common association of tetraspanins is with β1 integrins, for 
instance VLA-4 has been shown to form individual complexes with different 
tetraspanin molecules including CD81 (Berditchevski, 2001; Mannion et al., 1996). 
CD81 has no direct effect on affinity of VLA-4 for VCAM-1, however under shear flow 
conditions CD81 facilitates rapid multivalent integrin contacts with VCAM-1, 
promoting rolling and arrest of monocytes and B cells (Feigelson et al., 2003).  Other 
possible protein partners of CD81 within the TEM of cells include the plasma 
membrane proteins CD2, CD20, CD46, the Ewing receptors (EWI) of the 
immunoglobulin superfamily (IgSF), signalling molecules including protein kinase C 
(PKC) and phosphatidylinositol 4-kinase (PI 4-K), and other tetraspanin family 
members CD9, CD37, CD53 and CD82 (Charrin et al., 2002; Imai and Yoshie, 
1993). CD81 is unusual as it is the only human tetraspanin with a known ligand; it 
acts as a receptor for Hepatitis C Virus (HCV) binding the envelope protein E2. 
Ligation of CD81 by E2 has been shown to induce B and T cell proliferation, and to 
inhibit NK cell cytotoxicity (Crotta et al., 2002; Rosa et al., 2005; Tseng and Klimpel, 
2002; Wack et al., 2001). 
 The presence of CD81 on multiple cell surfaces is known to play a variety of roles in 
the immune response to antigen. However little is known about the modulation of this 
and other tetraspanins in a chronic inflammatory environment. This chapter 
describes the profile of CD81 and tetraspanins CD9, CD53, CD63, CD82 and CD151 
expression on CD4+ memory T cells plus their modulation upon anti-CD3 and 
cytokine activation. The expression of these molecules in synovial tissue is also 
explored. Tetraspanins were chosen for investigation based on their structural 
homology to CD81 (CD9), lymphoid expression profile (CD37, CD53), co-stimulatory 
capacity (CD9, CD53, CD82) or association with integrin or Class II molecules.  
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5.1 Confirmation of CD97 protein in plasma membrane preparations 
 The presence of CD97 in plasma membrane preparations from resting and cytokine-
activated T cells from three independent donors was investigated. Plasma 
membrane samples were prepared as described in section 4.5.3; briefly cells were 
lysed, sonicated and spun at 4000g to generate a post-nuclear supernatant that was 
centrifuged at 100000g prior to 100mM Na2CO3 1mM EDTA treatment (pH 11.3). 
Samples were generated from freshly elutriated PBLs depleted of CD56+ cells 
(section 2.2.5) prior to, and after 8 days in culture with IL-2, IL-6 and TNFα. Samples 
were assayed for protein concentration by BCA assay and for the presence of CD97 
by western blot.  
 Figure 5.3 confirms expression of CD97 on cytokine-activated T cells from three 
donors (A-C). Low level CD97 was also detected in 2 out of 3 resting plasma 
membrane preparations (donors B and C). Western blotting confirms the 
identification of CD97 in plasma membrane preparations as seen in Chapter 4.  
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Figure 5.3 Presence of CD97 on the surface of cytokine-activated T cells. Preparations 
from resting peripheral blood T cells were prepared from three independent donors. Following 8 
days stimulation with IL-2, IL-6 and TNFα matched membrane preparations were made from the 
same donors. Protein content was assessed by BCA assay and 1μg of each preparation was 
separated on a 12% mini SDS PAGE gel under non-reducing conditions. Proteins were 
transferred onto PDVF membrane and probed with anti-CD97 (1:2000) overnight at 4°C. 
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5.2 Expression of CD97 upon cytokine activation of CD4+ memory PBLs  
 The expression of CD97 on antigen stimulated T cells is well documented, and the 
upregulation of CD97 upon cytokine activation has been implicated using mass 
spectrometry (sections 4.6 and 4.7) and western blot analysis (section 5.1) in this 
thesis. Here modulation of CD97 expression upon cytokine-activation of the effector 
T cell population in our model is investigated. CD4+CD45RO+ cells were isolated 
from freshly elutriated PBLs and CD97 expression on resting cells, cytokine-
activated cells and cells after 24 hours in culture with immobilised anti-CD3, was 
assessed by flow cytometry. Histograms in Figure 5.4 (a–c) demonstrate 
fluorescence profiles for unlabelled cells (red), anti-IgG2a plus anti-Ig PE secondary  
isotype control (green), anti-Ig PE secondary antibody control (blue) and anti-CD97 
plus anti-Ig PE secondary (brown). No CD97 is observed above control levels prior 
to activation. CD97 is induced on cytokine and anti-CD3 activation, and the MFI was 
found to be 1515 and 535 units respectively. The proportion of CD97+ cells was also 
greater in cytokine-activated cells compared to anti-CD3 cells (95% and 28% 
respectively). When data from four independent donors was pooled (Figure 5.4 (d–
e)), expression of CD97 by cytokine-activated CD4+CD45RO+ T cells was 
significantly higher than on either resting or anti-CD3-stimulated CD4+CD45RO+ 
cells (one-way ANOVA with Bonferroni correction) in terms of both MFI and 
percentage positive cells. Increase in expression observed on anti-CD3 activation 
was not significant. A 15-fold increase in the mean MFI of CD97 was observed on 
cytokine-activation and again after 8 days in culture with cytokines a higher 
proportion of cells (88%) are CD97+ compared to activation by anti-CD3 (20%).    
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Figure 5.4 Expression of CD97 on resting and activated CD4+ memory T cells. CD4+CD45RO+ T 
cells were activated via immobilised anti-CD3 for 24 hours or IL-2, IL-6 and TNFα for 8 days. Resting, 
cytokine-activated (Tck) and anti-CD3 activated cells were incubated with anti-CD97 for 30 minutes 
followed by PE-conjugated anti-mouse IgG for 15 minutes at 4°C. Cells were fixed and read on a BD 
FACS Canto™. Expression on resting cells a), cytokine-activated b) and anti-CD3 activated c) is 
shown where red = unlabelled cells, green = IgG2a isotype control, blue = cells incubated with 
secondary PE antibody only and brown = anti-CD97 labelled cells. d) and e) show expression from 4 
separate donors in terms of percentage positive and mean fluorescence intensity (MFI) respectively. 
Mean values of 4 donors represented by solid line. Data analysed by FlowJo sortware. Statistical 
analysis by one way ANOVA with Bonferroni correction where ** = P<0.01 and *** = P<0.001. 
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5.3 Expression of CD97 ligand CD55 
 Binding of CD97 to its ligand CD55 has been implicated in a number of cellular 
interactions including those between T cell – monocyte involved in regulating antigen 
dependent T cells responses (Abbott et al., 2007; Capasso et al., 2006). CD55 is 
widely expressed on leukocytes, where is protects against complement-mediated 
lysis (Lublin and Atkinson, 1989). This section describes the expression of CD55 on 
both resting monocytes and T cells activated by IL-2, IL-6 and TNFα. 
5.3.1 Expression of CD55 by human peripheral monocytes  
 Freshly elutriated human peripheral monocytes were blocked with 10% human 
serum in PBS prior to incubation with anti-CD55 PE conjugated antibody for 30 
minutes at 4°C. IgG2a isotype PE-conjugated antibody was used as a control. Figure 
5.5 is representative of 3 independent donors and illustrates CD55 expression by 
100% of human peripheral blood monocytes. Mean MFI for CD55 over 3 donors was 
7818 units over 260 and 141 units for isotype and cells alone, respectively. 
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Isotype control
Anti-CD55 
 
  
 
 
 
Figure 5.5 Expression of CD55 on human peripheral blood monocytes. Freshly elutriated 
monocytes were incubated with 10% human serum in PBS for 15 minutes at room temperature, 
washed and followed by anti-CD55 for 30 minutes at 4°C. Cells were fixed and read on a BD 
FACS Canto™ and analysed on FlowJo.  Expression shown as histogram where red = unlabelled 
monocytes, green = IgG2a isotype control antibody, blue = anti-CD55 labelled monocytes. 
Representative of 3 donors. 
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5.3.2 Expression of CD55 by human CD4+ memory T cells 
 Freshly elutriated PBLs were enriched for CD4+CD45RO+ T cells by negative 
selection (Section 2.2.4).  Cells were immediately assayed for CD55 expression or 
cultured for 8 days in the presence of IL-2, IL-6 and TNFα. Resting and cytokine-
activated cells were incubated with anti-CD55 and IgG2a control (not shown) for 30 
minutes at 4°C prior to fixation and analysis by flow cytometry. Figure 5.6 
demonstrates the presence of CD55 on all resting T cells (green peak) and an 
increase in expression on cytokine-activated cells (blue peak).   
 
 
Resting cells + no antibody 
Tck cells + no antibody 
Resting cells + anti-CD55 
Tck cells + anti-CD55 
 
 
 
 
 
 Table 5.1 summarises the mean fluorescence intensity of resting and cytokine-
activated CD4+ memory T cells from 3 donors. Chronic activation by IL-2, IL-6 and 
TNFα induces a 5-fold average increase in the MFI of CD55 on CD4+CD45RO+ T 
cells. Donor 3 expressed the lowest levels of CD55 under both conditions; however 
the fold increase was the greatest in this donor.  
 
 
 
Figure 5.6 Expression of CD55 on CD4+ memory PBLs. Resting and cytokine-activated 
CD4+CD45RO+ cells were incubated with anti-CD55 for 30 minutes at 4°C. Cells were fixed and 
read on a BD FACS Canto™.  Expression shown as histogram where red = unlabelled resting 
cells, brown = unlabelled cytokine-activated (Tck) cells; green = anti-CD55 labelled resting cells 
and blue = anti-CD55 labelled Tck cells. Representative of 3 donors. 
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Table 5.1 CD55 expression (MFI) on CD4+ memory T cells 
Donor Resting Cytokine-activated Fold increase 
1 1756 7991 4.6 
2 1661 5473 3.3 
3 206 1460 7.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resting and cytokine-activated CD4+CD45RO+ cells were incubated with anti-CD55 for 30 
minutes at 4°C. Cells were fixed, read on a BD FACS Canto™ and analysed on FlowJo.  Table 
shows the mean fluorescence intensity (MFI) for each population from 3 donors. Fold increase in 
MFI between resting and activated cells also shown. 
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5.4 Effect of CD97 neutralisation on the induction of TNFα by cytokine-
activated CD4+ memory T cells  
 Having established that CD97 is highly expressed by cytokine-activated 
CD4+CD45RO+ T cells, and that its ligand, CD55, is expressed by human peripheral 
monocytes, a role for this ligation pair in the induction of TNFα was investigated by 
the use of antibodies to neutralise T cell CD97 expression in co-culture. 
 Cytokine-activated CD4+CD45RO+ T cells were pre-incubated with neutralising 
antibody to CD97 at 5 or 10µg/ml, washed and co-cultured with monocytes at a 
lymphocyte : monocyte ratio of 8:1 (section 2.3.4.1). TNFα production after 18 hours 
was measured by ELISA.  Figure 5.7 a) is representative of 5 donors. In the absence 
of antibody 104pg/ml of TNFα was induced from the 8:1 co-culture, this was reduced 
to 75pg/ml and 74pg/ml in the presence of 10 µg/ml and 5µg/ml respectively. The 
latter was statistically significant (* = P<0.05) in one-way ANOVA with Bonferroni 
correction. Data from 5 independent experiments are shown in Figure 5.7 b), where 
TNFα production in the absence of antibody has been normalised to 100%, the effect 
of anti-CD97 and isotype control (IgG2a) antibodies are shown as relative values. The 
mean relative TNFα production in the presence of anti-CD97 was 79%, equating to 
21% inhibition. Inhibition ranged from 10% - 35%, however the effect of isotype 
control ranged from 23% inhibition to 80% induction where the mean was 15% 
induction of TNFα. 
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Figure 5.7 Effect of blocking CD97 on cytokine-activated CD4+ memory T cells on 
monocyte TNFα production. PBLs were enriched for CD4+CD45RO+ T cells, cultured with 
IL-2, IL-6 and TNFα for 8 days. On day 8 cells were resuspended at 4 x 106/ml in PBS 
supplemented with 1% FCS. Anti-CD97 antibody or IgG2a isotype control were added to cells 
at a final concentration of 5 or 10µg/ml for 30 minutes at room temperature. Cells were 
washed and placed in co-culture with monocytes at 8:1 for 18 hours. Data shown as mean ± 
SD TNFα of triplicate wells. a) Representative donor where n.s = not significant and * = 
P<0.05 in one-way ANOVA statistical analysis with Bonferroni correction (8:1 vs. isotype 
control (n.s) not shown). Cytokine-activated PBLs and monocytes were cultured alone, and 
monocytes produced >5000pg/ml TNFα when stimulated with 10ng/ml LPS (positive control). 
b) Relative production from 5 donors where TNFα in the absence of 5µg/ml of antibody was 
normalised to 100%.  
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5.5 Expression of CD97 and its ligand CD55 in rheumatoid tissue 
 The distribution of CD97 and CD55 in human synovial tissue was investigated by 
flow cytometry. Tissue was digested from the joint as described in section 2.3.5. In 
order to overcome the inherent auto-fluorescence of synovial tissue, cells were 
stained with antibody as normal but data was collected twice – once with voltage and 
compensation settings suitable for the lymphocyte population and once on settings 
optimal for the non-lymphocytic population of macrophages, fibroblasts etc. 
Populations were distinguished on the basis of forward versus side-scatter and 
10000 events were recorded in each one. The lymphocyte population was 
counterstained with CD3. 
 Table 5.2 summarises data obtained from at least 6 different donor tissues for the 
lymphocytic population, and cytometry plots for a single donor are shown in Figure 
5.8 (a–b). Pooled data from 7 donors revealed that, on average, 27% of synovial 
lymphocytes express CD97, and that the majority of these are T cells (CD3+). In 
contrast approximately half of all lymphocytes are CD55+ but a mean of only 18% 
are also CD3+. The expression of both molecules was highly variable between 
tissues. For instance the number of CD55+ lymphocytes ranged from 22% - 66%.  
 
Table 5.2 Expression of CD97 and its ligand CD55 on synovial tissue 
lymphocytes 
% positive % positive CD3+  
Mean ± Std Range Mean ± Std Range 
n 
CD97 27 ± 12 12 – 47 22 ± 9 10 - 31 7 
CD55 46 ± 17 22 - 66 18 ± 11 2 – 30 6 
 
 
 
 
Fresh synovial tissue was stained with either anti-CD97 for 30 minutes followed by secondary PE-
conjugated anti-mouse IgG for 15 minutes or with PE-conjugated anti-CD55 for 30 minutes at 
4°C. Cells were fixed, read on a BD FACS Canto™ and analysed by FlowJo. 10000 events were 
collected from the lymphocyte gate of each tissue. Data is shown as mean and range (min-max) 
for percentage positive and percentage positive for both CD3 and CD97/CD55 from n donors. 
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Figure 5.8 Expression of CD97 and its ligand CD55 in synovial tissue. Fresh synovial 
tissue was stained with either anti-CD97 for 30 minutes followed by secondary PE-
conjugated anti-mouse IgG for 15 minutes or with PE-conjugated anti-CD55 for 30 
minutes in combination with either anti-CD3-FITC, anti-CD14-FITC or CD45-FITC. 
Matched isotype antibodies were used as controls. All staining was carried out at 4°C. 
Cells were fixed, read on a BD FACS Canto™ and analysed by FlowJo. 10000 events 
were collected from either the lymphocyte population a) - b) or from the 
macrophage/fibroblastic population c) - f) as judged by forward vs side scatter. Figure 
representative of 3-7 donors. 
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 CD97 and CD55 expression in the non-lymphocytic population is summarised in 
Table 5.3. 17% of cells were CD97+ from 6 donors however, since the standard 
deviation is almost the same value, and the range of expression is 3 – 45%, this is 
once again highly donor dependent. Figure 5.8 c) - e) shows counterstaining of the 
non-lymphocytic population for a single tissue. Low expression of CD97 is observed 
in this donor, but the CD97+ cells are CD14+ and CD45+ indicating these cells 
belong to the monocyte/macrophage lineage. Fifty eight percent of non-lymphocytic 
cells were CD55+. Figure 5.8 d) and f) illustrates that these cells are also 
predominantly, but not exclusively negative for CD14 and CD45. In three tissues 
where counterstaining was performed, a mean of 57% of cells were CD55+, 13% 
were CD14+CD55+ and 17% were CD45+CD55+. This approximates to 70% of 
CD55+ cells being within the CD45 negative fibroblast lineage. 
 
Table 5.3 Expression of CD97 and its ligand CD55 on non-lymphocytic 
synovial cells 
% positive  
Mean ± Std Range 
n 
CD97 17 ± 16 3 – 45 6 
CD55 58 ± 16 36 - 79 5 
 
 
 
 
 
 
 
 
 
 
 
 
Fresh post-operative synovial tissue was stained with anti-CD97 plus 
secondary or anti-CD55 PE-conjugated antibody for 30 minutes at 4°C. Cells 
were fixed, read on a FACS Canto and analysed by FlowJo. 10000 events 
were collected from the macrophage/fibroblast gate of each tissue. Data is 
shown as mean and range (min-max) percentage positive from n donors. 
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5.6 Effect of neutralising CD97 on spontaneous TNFα release by rheumatoid 
synovial tissue 
 Having shown that CD97 is upregulated by chronic cytokine activation of CD4+ 
memory T cells, is expressed by a fraction of synovial T cells, and that neutralisation 
of CD97 in the co-culture model caused about a 20% inhibition in TNFα, the role of 
CD97 in the induction of TNFα in ex vivo synovial tissue cultures was investigated. 
Synovial mononuclear cells were dissociated from a rheumatoid joint following 
replacement surgery (section 2.3.5). Cultures were pre-incubated with neutralising 
antibody and isotype control, and then cultured for 24 hours. Spontaneous TNFα 
release was assessed by ELISA. Four different tissues produced between 279 – 
943pg/ml of TNFα (Table 5.4). In two tissues TNFα production was significantly 
inhibited when cultures were treated with anti-CD97 antibody (P<0.01 in one-way 
ANOVA with Bonferroni comparison). TNFα release was normalised to 100% and 
relative TNFα release upon anti-CD97 and isotype treatment is shown in Figure 5.9. 
The effect of CD97 neutralisation ranged from 58% to 106% relative to production in 
the absence of antibody; equating to 42% inhibition and to a 7% induction of TNFα 
release respectively. Mean inhibition of 21% was observed compared to 6% with 
isotype control.   
 
Table 5.4 Effect of anti-CD97 on spontaneous TNFα release from RA synovial 
tissue 
Spontaneous TNFα production (pg/ml) Mean ± SD Donor 
Untreated + anti-CD97 + Isotype 
Untreated vs. 
Anti-CD97 
1 459 ± 24 383 ± 24 441 ± 70 ns 
2 299 ± 26 205 ± 11 252 ± 21 ** 
3 943 ± 77 548 ± 46  938 ± 99 ** 
4 479 ± 69 511 ± 9 431 ± 47 ns 
 
 
 
 
 
Synovial tissue from rheumatoid joint was dissociated and cultured. Cells were left untreated or 
treated with 10µg/ml of anti-CD97 or IgG2a isotype control antibody and cultured for 24 hours at 
37°C. Supernatants were assayed for TNFα by ELISA. Table shows spontaneous TNFα release from 
untreated and treated cultures from 4 donors. One-way ANOVA with Bonferroni correction analysis 
compared each condition with each other. Results for untreated vs. anti-CD97 treatment shown 
where ** = P<0.01 and ns = not significant.  
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Figure 5.9 Effect of anti-CD97 on spontaneous TNFα release from synovial tissue. 
Synovial tissue from rheumatoid joint was dissociated and cultured. Cells were left untreated or 
were treated with 10µg/ml of anti-CD97 or IgG2a isotype control antibody and cultured for 24 
hours at 37°C. Supernatants were assayed for TNFα by ELISA.  Results are shown as a 
relative spontaneous TNFα release to untreated cells (100%) for four independent donors. Line 
indicates the mean response for each condition.  
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5.7 Confirmation of CD81 in plasma membrane preparations 
 CD81 was identified by 1D separation and MS/MS analysis of plasma membrane 
preparations from cytokine-activated T cells, and its expression was confirmed by 
flow cytometry (sections 4.3 and 4.4). Its presence in optimised plasma membrane 
preparations from resting and cytokine-activated T cells in three independent donors 
by western blot analysis is described in this section. Cells were lysed, sonicated and 
spun at 4000g to generate a post nuclear supernatant that was centrifuged at 
100000g  prior to 100mM Na2CO3 1mM EDTA treatment (pH 11.3) (section 4.5.3). 
Samples were generated from freshly elutriated PBLs depleted of CD56+ cells 
(section 2.2.5) prior to, or after 8 days in culture with IL-2, IL-6 and TNFα. Samples 
were assayed for protein concentration by BCA assay, and for the presence of CD81 
by western blot under non-reducing conditions. 
 Figure 5.10 shows that CD81 was present in 1µg of resting and cytokine-activated 
(Tck) plasma membrane preparations, indicating that TEM components are not 
excluded from my preparations. The signal from each sample is variable indicating 
no consistent increase or decrease in CD81 expression.  
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Figure 5.10 Presence of CD81 on the surface of cytokine-activated T cells. Membrane 
preparations from resting peripheral blood T cells were prepared from three independent 
donors. Following 8 days stimulation with IL-2, IL-6 and TNFα matched membrane 
preparations were made from cytokine-activated cells (Tck) of the same donors. Protein 
content was assessed by BCA assay and 1μg of each preparation was separated on a 12% 
mini SDS PAGE gel under non-reducing conditions. Proteins were transferred onto PDVF 
membrane and probed with anti-CD81 (1:2000) overnight at 4°C.  
25kD 
15kD 
Chapter 5       Results 
224 
 
5.8 Expression of CD81 and other tetraspanin superfamily members on CD4+ 
memory PBLs 
 In section 4.4 upregulation of CD81 was observed by flow cytometry after cytokine-
activation of a complete PBL population; however analysis by western blot (section 
5.7) revealed variation in expression levels from donor to donor in resting and 
activated CD3+ PBLs.  Chapter 3 demonstrated that the ability of cytokine-activated 
PBLs to induce TNFα production from monocytes in co-culture is greatest within the 
CD4+CD45RO+ population. Thus the expression of CD81 was assessed in this 
effector population of cells after cytokine-activation and compared to activation by 
immobilised anti-CD3. In addition expression of 6 other members of the tetraspanin 
family (CD9, CD37, CD53, CD63, CD82 and CD151) are also investigated. 
 Resting and activated CD4+ memory T cells all express CD81. Figure 5.11 a) 
demonstrates that there is a significant (P<0.05) increase in the mean fluorescence 
intensity of CD81 on cytokine-activation of resting CD4+CD45RO+ T cells. In seven 
matched donors, expression increased 2 fold from a mean of 1387 units to 2731 
units. The level of CD81 expression by cytokine-activated T cells was also 
significantly higher (P<0.05) than that of anti-CD3 activated T cells (5 matched 
donors). In contrast, Figure 5.11 b) shows that the percentage of cells positive for 
CD81 after 8 days in culture with IL-2, IL-6 and TNFα decreases from 82 ± 17% to 
64 ± 27%, though this change is not significant. Activation via the TCR with 
immobilised anti-CD3 led to no significant change in mean MFI levels and the 
percentage of positive cells declined after 24 hours.    
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 Figure 3.12 illustrates the changes in MFI of CD9, CD37, CD53, CD63, CD82 and 
CD151 after either cytokine stimulation or anti-CD3 activation of CD4+CD45RO+ T 
cells. For each protein the mean level of expression is highest on those cells 
activated with IL-2, IL-6 and TNFα for 8 days; however the extent is different from 
molecule to molecule. The MFI of CD53 increases almost 4-fold on cytokine-
activation (P<0.001) from a mean of 326 to 1254 units. Expression is also 
significantly higher (P<0.05) on these cells when compared to anti-CD3 activated 
cells (Figure 3.12 c)). In 7 independent donors resting CD4+CD45RO+ T cells were 
expressing CD63 (a mean of 232 units), cytokine stimulation induces a 3-fold and 
Figure 5.11 Expression of CD81 on CD4+ memory T cells. PBLs were enriched for 
CD4+CD45RO+ T cells and activated via immobilised anti-CD3 for 24 hours or with IL-2, IL-6 and 
TNFα for 8 days. Resting, cytokine-activated (Tck) and anti-CD3 activated cells were incubated 
with anti-CD81 for 30 minutes at 4°C. Cells were fixed, read on a BD FACS Canto™ and analysed 
on FlowJo software. Expression is shown as mean fluorescence intensity (MFI) a) and percentage 
positive b) of viable cells. Mean values of donors represented by solid line.
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significant (P<0.01) increase to 683 units whereas activation via immobilised anti-
CD3 antibodies in 5 donors induces a 2-fold increase that was not significant (Figure 
5.12d)). The range of CD82 expression in 4 donors is highly variable, ranging from  
75 - 5913 for resting cells, 1486 -  13999 in cytokine-activated cells and 97 - 10818 
in anti-CD3 activated cells (Figure 5.12 e)). The mean level of CD151 expression by 
CD4+CD45RO+ T cells increased approximately 2-fold after both cytokine and anti-
CD3 activation (Figure 5.12 f)). CD9 expression on CD4+CD45RO+ T cells was not 
altered alot, with only a 15% increase in the mean MFI in the 7 donors, (Figure 5.12 
a)). CD9 on resting cells ranged from 539 – 2499 units and was greater than that of 
either activated cell type. No change in CD9 level was observed after anti-CD3 
activation.  
 Figure 3.13 indicates the percentage of cells positive for each tetraspanin under 
resting, cytokine-activated and anti-CD3 activated conditions. Positive indicates that 
levels were greater than cells alone and isotype controls. Panel b) shows that CD37 
is not expressed by CD4+ memory T cells under the conditions tested, consistent 
with the low MFI in Figure 5.12 b). Activation of CD4+ memory cells by cytokines or 
anti-CD3 in 7 donors reduced the percentage of CD9 positive cells to 38% and 27% 
respectively. Figure 5.13 a) shows that donors fall into two groups under resting 
conditions: low CD9 expressers (mean of 9% where n=3) and high expressers 
(mean of 82% where n=4). The only significant change in the proportion of 
tetraspanin positive cells was observed for CD53 expression. The majority of resting 
CD4+CD45RO+ T cells do not express CD53 (mean 2%). After 8 days in culture with 
cytokines, an average of 20% are CD53+, this increase is significant (P<0.01) in a 
one-way ANOVA with Bonferroni correction. An increase to 8% CD63+ after anti-
CD3 activation was not significant. Analysis indicates that CD4+CD45RO+ T cells do 
not express CD63 or CD151, but by day 8 of cytokine-activation a mean of 9% and 
7% of cells are positive. As observed with CD9, donors appear to fall into low or high 
CD82 expressing groups under resting conditions (Figure 5.13 e)). After cytokine 
stimulation all donors were positive for CD82 (mean 90%).  
Chapter 5       Results 
227 
 
 
Resting Tck Anti-CD3
0
500
1000
1500
2000
2500
3000
3500
C
D
9 
M
FI
Resting Tck Anti-CD3
0
200
400
600
800
1000
C
D
37
 M
FI
Resting Tck Anti-CD3
0
500
1000
1500
2000 *** *
C
D
53
 M
FI
Resting Tck Anti-CD3
0
500
1000
1500 **
C
D
63
 M
FI
Resting Tck Anti-CD3
0
3000
6000
9000
12000
15000
C
D
82
 M
FI
Resting Tck Anti-CD3
0
500
1000
1500
C
D
15
1 
M
FI
c)
a)
e) f)
d)
b)
 
 
 
 
Figure 5.12 Expression of tetraspanins (MFI): Cytokine versus anti-CD3 activated CD4+ 
memory T cells. Freshly elutriated PBLs were enriched for CD4+CD45RO+ T cells and activated 
via immobilised anti-CD3 for 24 hours or with IL-2, IL-6 and TNFα for 8 days. Resting, cytokine-
activated (Tck) and anti-CD3 activated cells were incubated with anti-tetraspanin PE conjugated 
antibodies for 30 minutes at 4°C or with anti-CD82 e) for 30 minutes followed by a secondary PE-
conjugated anti-mouse IgG for 15 minutes. Cells were fixed, read on a BD FACS Canto™ and 
analysed on FlowJo. MFI of tetraspanins on viable cells shown for each condition for 3-7 matched 
donors where the solid line represents mean MFI value. Statistical analysis by one way ANOVA 
with Bonferroni’s correction where * = P<0.05, ** = P<0.01 and *** = P<0.001.    
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Figure 5.13 Expression of tetraspanins (%): Cytokine versus anti-CD3 activated CD4+ memory 
T cells. PBLs were enriched for CD4+CD45RO+ T cells and activated via immobilised anti-CD3 for 24 
hours or with IL-2, IL-6 and TNFα for 8 days. Resting, cytokine-activated (Tck) and anti-CD3 activated 
cells were incubated with anti-tetraspanin PE conjugated antibodies for 30 minutes at 4°C or with anti-
CD82 e) for 30 minutes followed by a secondary PE-conjugated anti-mouse IgG for 15 minutes, 
washed, fixed, read on a BD FACS Canto™. Percentage of viable cells positive for tetraspanin under 
each condition for 3-7 matched donors is shown where solid line represents mean MFI value. 
Statistical analysis by one way ANOVA with Bonferroni’s correction where ** = P<0.01. 
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5.9 Relationship between tetraspanin superfamily expression and effector 
function of cytokine-activated CD4+ memory T cells. 
 Profiling of the tetraspanin superfamily on the surface of CD4+CD45RO+ T cells 
described in section 5.8 showed that changes in expression levels differed between 
family members, and that the proportion of positive cells after 8 days ranged from 0 
to 90% for CD37 and CD82 respectively. As in Chapter 3, correlation analysis was 
performed to assess whether expression levels of any of these molecules were 
related to the effector function of CD4+CD45RO+ T cells after cytokine-activation. 
CD37 was not expressed by cytokine-activated CD4+CD45RO+ T cells, so 
correlation analysis was not performed. Table 5.5 summarises non-parametric 
Spearman correlation analysis from n donors, where matched MFI and TNFα 
induction data (at 5:1 lymphocyte: monocyte) was available. No tetraspanin proteins 
were significantly correlated with TNFα production.  
 
Table 5.5 Correlation of tetraspanin expression and effector function of CD4+ 
memory T cells 
 Correlation (r) P value n 
CD9 0.2000 0.7139 ns 6 
CD53 0.02857 1.000 ns 6 
CD63 0.2571 0.6583 ns 6 
CD81 0.08571 0.9194  ns 6 
CD82 0.2000 0.9167 ns 4 
CD151 0.3143 0.5639 ns 6 
  
 Freshly elutriated PBLs were separated to enrich for CD4+CD45RO+ T cells prior to stimulation 
with IL-2, IL-6 and TNFα. Expression (MFI) of indicated tetraspanins on day 8 were correlated 
with induced TNFα production in 5:1 co-cultures of n donors using non-parametric (Spearman) 
analysis. Data shown as correlation value (r) and significance (P value) to four significant figures 
where ns = not significant. 
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5.10 Expression of tetraspanin molecules within synovial tissue  
 The expression of CD9, CD53, CD63, CD81, CD82 and CD151 by lymphocytic and 
non-lymphocytic populations in human synovial tissue was investigated by flow 
cytometry. As in section 5.5, data for the lymphocyte and non-lymphocyte 
populations were collected separately using settings suitable for each. The 
lymphocyte population was counterstained with CD3. 
 Table 5.6 summarises data all the donors (n=3-7) and Figure 5.14 shows 
expression from a representative example. Within the synovial lymphocyte, 
population CD82 is the most highly expressed tetraspanin with a mean of 39% of 
lymphocytes positive, and 26% double positive for CD3 and CD82. However 
expression is highly donor dependent with a range of 18 – 61%. CD53 and CD151 
expression was also highly variable, and one donor did not express either in the 
lymphocyte population, but in another 17% and 25% of lymphocytes were positive 
respectively. In 4 donors, a mean of 18% of lymphocytes were CD63+. Expression of 
all tetraspanin proteins investigated, expression was not fully accounted for by CD3+ 
T cells alone. In particular, the majority of CD9+, CD63+ and CD81+ lymphocytes 
are CD3- as illustrated in Figure 5.14 a), c) and d). These cells are likely to be B or 
NK cells, but CD19 and CD56 counterstaining will confirm this. 
 
Table 5.6 Expression of tetraspanin molecules on synovial tissue lymphocytes 
 % Positive % positive and CD3+  n 
Mean ± Std Range Mean 
CD9 25 ± 9 16 - 33 11 3 
CD53 9 ± 7 0 - 17 6 4 
CD63 18 ± 10 8 - 27 4 4 
CD81 15 ± 9 6 – 29 6 7 
CD82 39 ± 17 18 – 61 26 5 
CD151 8 ± 11 0 - 25 3 4 
  
 
 
Fresh post-operative synovial tissue was stained with anti-tetraspanin PE-conjugated 
antibody for 30 minutes at 4°C. Cells were fixed, read by BD FACS Canto™ and analysed 
by FlowJo. 10000 events were collected from the lymphocyte gate of each tissue. Data is 
shown as mean and range (min-max) percentage positive for tetraspanin and percentage 
positive for both CD3 and tetraspanin from n donors
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 Table 5.7 demonstrates the percentage of non-lymphocytic cells within the digested 
synovial tissue which express each tetraspanin. On average, over half of the cells 
present CD63, and around one third express CD81, CD82 or CD151. CD53 was the 
least frequently expressed (mean 10% in 4 donors) and CD9 was expressed by 
between 17% and 39% of cells, depending on the donor. 
 
Table 5.7 Expression of tetraspanin molecules on non-lymphocytic synovial 
cells 
 % Positive 
n 
Mean ± Std Range 
CD9 28 ± 15 17 – 39 3 
CD53 10 ± 5 3 - 24 4 
CD63 54 ± 26 15 – 73 4 
CD81 30 ± 8 17 - 41 7 
CD82 36 ± 19 16 - 70 6 
CD151 38 ± 32 8 - 84 4 
  
 
 
 
 
 
 
 
 
 
 
 
Fresh post-operative synovial tissue was stained with anti-tetraspanin PE-conjugated 
antibody for 30 minutes at 4°C. Cells were fixed, read by FACS Canto™. 10000 
events were collected from the lymphocyte gate of each tissue. Data is shown as 
mean and range (min-max) percentage positive for tetraspanin from n donors. 
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Figure 5.14 Expression of tetraspanins on synovial tissue lymphocytes. Fresh synovial tissue 
was stained with either PE-conjugated anti-CD9, anti-CD53, anti-CD63, anti-CD81 or anti-CD151 
for 30 minutes in combination with either anti-CD3-FITC a)-e) or with anti-CD82 for 30 minutes 
followed by a secondary PE-conjugated anti-mouse IgG for 15 minutes and anti-CD3-FITC for a 
further 30 minutes. Matched isotype antibodies were used as controls. All staining was carried out 
at 4°C. Cells were fixed, read on a BD FACS Canto™ and analysed on FlowJo. 10000 events 
were collected from the lymphocyte population. Figure representative of 3-7 donors. 
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5.10 Discussion  
 This chapter describes the use of western blotting and flow cytometry to confirm the 
expression of two candidate molecules CD97 and CD81, previously identified by 
mass spectrometry, on cytokine-activated T cells. In addition the expression of 
ligands and related proteins in our in vitro model and disease tissue is described.  
5.10.1 CD97 and CD55 
 Western blot analysis confirmed the presence of CD97 in plasma membrane 
preparations from cytokine-activated T cells, but also showed low levels in resting 
cells from two out of three donors. Flow cytometry revealed a lack of CD97 on a 
more defined CD4+ memory T cell population in a resting state, confirming previous 
observations. This agrees with the literature where CD97 expression is only 
observed upon activation of human T cells (Jaspars et al., 2001). My data 
demonstrates that the mode of activation affects the extent to which CD97 is 
upregulated. Antigen-independent activation by cytokines led to significantly higher 
levels of CD97 compared to ligation with anti-CD3 mimicking TCR dependent 
activation. I have shown that chronic-activation of CD4+ memory T cells by cytokines 
for 8 days in fact results in CD97 expression by all cells in culture. In order to 
investigate whether the presence of CD97 contributes to the effector function of 
these cells in inducing TNFα from monocytes, the protein was neutralised on the 
surface of activated T cells with antibody prior to co-culture. Blockade of CD97 led to 
a 20% inhibition of TNFα production from monocytes, indicating CD97 may make a 
small contribution to ligation events resulting in TNFα induction.  
 CD97 has been shown to interact with a number of molecules including the 
glycosaminoglycan, chrondroitin sulphate (CS) (Kwakkenbos et al., 2005) and 
specific integrins (Wang et al., 2005); but its main cellular ligand is CD55 (Hamann et 
al., 1996). CD55 or DAF protects cells against complement-mediated lysis by 
dissociating C3 convertase, preventing C3a anaphylatoxin production and C3b 
deposition, thus halting formation of the membrane attack complex (MAC) (Medof et 
al., 1984). It is a single polypeptide chain of four N-terminal extracellular short 
consensus repeat (SCR) domains in an extended formation linked via a spacer 
domain at the C-terminus to a glycosylphosphatidylinositol (GPI) anchor in the 
plasma membrane (Lukacik et al., 2004). By modelling structural data from the 
homologous protein EMR2 and NMR chemical shift data upon CD55 ligation, the 
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binding interface of CD97-CD55 has been mapped to EGF domains 1 and 2 of CD97 
and the SCR1 domain of CD55. Binding of CD97 and of C3 convertase (SCR 2-3) 
occur on opposing faces of CD55, allowing for independent complement regulation 
and CD97 ligation (Abbott et al., 2007; Lukacik et al., 2004). CD55 is widely 
expressed on cells to protect them from complement. Data presented here reaffirms 
previous studies demonstrating CD55 expression on the surface of human peripheral 
monocytes. The importance of a CD97-CD55 interaction has been demonstrated for 
the T cell response to antigen-presentation by monocytes, where neutralisation of 
CD97 on the T cell or CD55 on activated monocytes inhibited IFNγ production and 
proliferation of T cell clones (Abbott et al., 2007). Data presented here suggests a 
role for the same ligation event in an antigen-independent model. However 
experiments such as blockade of CD55 on monocytes in co-culture and knockdown 
of CD55 with siRNA are required to confirm CD55 as the monocyte ligation partner 
of CD97 in our system.  
 Apart from protecting resting T cells from complement, CD55 also acts as a co-
stimulatory molecule, as cross-linking of CD55 with either submitogenic 
concentrations of phorbol ester or anti-CD3 increases proliferation and IL-2 
production. The GPI anchor of CD55 is associated with the lymphocyte-specific 
protein tyrosine kinase (lck) within lipid rafts on the T cell surface. When CD55 is 
cross-linked phosphorylation of lck, CD3-ζ chain and ZAP70 occurs, enabling TCR 
signal transduction upon activation (Shenoy-Scaria et al., 1992; Tosello et al., 1998). 
Furthermore co-stimulation can be elicited by specific binding of CD97 to CD55, 
inducing proliferation and cytokine production, particularly of IL-10, from CD4+ T 
cells (Capasso et al., 2006). The CD97 – CD55 interaction is emerging as an 
important event in T cell responses.  As well as an increase in CD97, data presented 
here demonstrates that the expression of CD55 on CD4+ memory T cells also 
increases under antigen-independent conditions. It is interesting to speculate 
whether this would be reflected in an increase in subsequent T cell responses to 
anti-CD55/CD3 cross-linking or antigen. In addition, upregulation of both CD97 and 
CD55 in our system could result in T cell-T cell interactions promoting the 
proliferation and cytokine-production that is observed in culture (described in 
Chapter 3). CD97 is constitutively expressed by myeloid cells including monocytes 
(Jaspars et al., 2001) and upregulation of CD55 on T cells means there is also the 
potential for the inverse interaction between this pair of proteins on monocytes and T 
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cells. Upregulation of CD55 on myeloid cells in inflammatory conditions is well 
documented (Abbott et al., 2007; Li et al., 2001), my data proposes that it not 
restricted to these cells, but also occurs on T cells and may increase the avidity of 
interactions with CD97 on other cell surfaces. The mechanism of signal transduction 
by CD97 remains unclear in the work of Abbott et al on T cells, as is the ability of 
CD55 to transmit a signal within monocytes that could induce TNFα production. 
CD55 signal transduction in T cells relies upon its location in lipid rafts and its 
association with intracellular signalling molecules; whether similar associations occur 
in monocytes is unclear. A dissection of CD97-CD55 interactions in our co-culture 
assay by neutralising each protein on each cell-type with antibodies, beyond that 
presented in this chapter, is required to clarify to what extent CD97-CD55 binding 
plays a role in TNFα induction from monocytes.  
 Neither PMA activated T cells, nor synovial lymphocytes show preferential 
expression for any of the CD97 isoforms (Eichler, 2000), however any differences in 
isoform expression by cytokine-activated CD4+ memory T cells would provide clues 
to the ligand partners and its role in these cells. For instance, the small EGF(1,2,5) 
isoform has the highest affinity for CD55 whereas the largest EGF (1,2,3,4,5) isoform 
has greater affinity for CS which has been shown to be important in the T-B cell 
interactions and interactions of between cells in synovial tissue (Kwakkenbos et al., 
2005).  
 A previous study of the expression of CD97 and CD55 in RA synovial biopsies 
found fibroblasts expressed high levels of CD55, which is consistent with the results 
described here where CD45 negative synoviocytes are the highest expressers of 
CD55 in synovial tissue cultures (Hamann et al., 1999). CD97 expression is localised 
to intimal lining layer macrophages and the majority of sublining macrophages, but is 
absent from fibroblasts. Thus the variability of CD97 expression within the non-
lymphocyte population described in this thesis could correlate to the relative 
percentages of macrophages and fibroblasts, this will be verified further by 
counterstaining of the non-lymphocytic population. Hamann et al propose a role for 
the CD97-CD55 interaction between macrophages and fibroblasts in the 
maintenance of the intimal layer’s microarchitecture, and perpetuation of 
inflammation. Furthermore, analysis of homologue EMR2 in RA revealed expression 
on macrophages and dendritic cells, and its interaction with CS within the sublining 
layer (Kop et al., 2005). Neutralisation of CD97 in our synovial tissue cultures led to 
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a modest reduction in spontaneous TNFα release; however, whether this reflects 
disruption of CD97 - CD55 or CD97 - chrondroitin sulphate interactions, and between 
which cells types, requires further investigation. For instance a role for CD97 in T cell 
– macrophage interactions in RA synovium is suggested by the expression of CD97 
on synovial tissues T cells, by the dramatic upregulation of CD97 in our in vitro 
model and the comparable inhibition of TNFα production observed in co-culture 
assays and synovial tissue cultures. Addition of neutralising antibodies to CD55 or 
chrondroitinase treatment of synovial tissue cultures will address the relative 
importance of CD97 ligands for pro-inflammatory cytokine-production within the 
whole tissue. These experiments also need to be carried out on the adherent non-
lymphocytic population and  isolated synovial lymphocytes in culture with PB 
monocytes to further define cell types between which functional CD97 ligations 
occur. 
5.10.2 Tetraspanins  
 In Chapter 4 of this thesis flow cytometry demonstrated an increase in the intensity 
of CD81 expression in the complete human PBL population on cytokine-activation, 
and endorsed the proteomic approach. T, B and NK cell subsets present in the 
elutriated PBL population are all known to express CD81. B cells do not survive eight 
days of culture with our cytokine cocktail; in contrast NK cells dominate the response 
to cytokines (Brennan et al., 2008). Differences in the role of CD81 in activation of T 
and NK cells have been observed; thus to confirm the observations of Chapter 4 and 
the relevance to our model, changes in CD81 expression on T cells alone were 
assessed (Crotta et al., 2006; Crotta et al., 2002; Tseng and Klimpel, 2002). Results 
presented in this chapter not only confirmed the presence of CD81 in plasma 
membrane-enriched samples generated from both resting and cytokine-activated 
human peripheral blood T cells but also demonstrate upregulation on the CD4+ 
memory subset, further validating the proteomic approach and its application to our 
model. 
 The emergence of the tetraspanin superfamily came from their discovery and 
cloning as leukocyte antigens, and has led to investigations into their role in various 
aspects of the immune system beyond the other physiological roles implicated by 
their wide spread expression. CD9, CD63, CD81 and CD151 are expressed in a 
broad range of tissues and only CD37 and CD53 are restricted to leukocytes 
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(Tarrant et al., 2003). Preferential expression of individual tetraspanins on specific 
leukocyte subsets is well documented, particularly in mice, humans and their derived 
cell lines (Horejsi and Vlcek, 1991; Levy and Shoham, 2005).  Analysis of human 
PBL populations showed T cell CD53 and CD82 levels to be low when compared to 
other cells. CD63 and CD151 were completely absent from the T cells, whereas 
CD81 expression was greatest. CD9 expression although highest on monocytes, 
generally is the lowest expressing tetraspanin on PBLs (Tohami et al., 2004). Data 
presented here demonstrates that on the CD4+ memory subset of resting human 
peripheral blood T cells there is also minimal expression of CD53, CD63, CD151 and 
high levels of CD81.  In contrast to the reported low levels of CD82 and CD9 on the 
whole T cell population, my results indicate that the expression of both these 
molecules is highly donor dependent, where CD4+ memory T cells of individual 
donors are either positive for each tetraspanin or express minimal levels. Whether 
this reflects interdonor differences that are contextual to current and past immune 
responses or genetic variation is unknown. CD37 expression by T cells has been 
shown to be important in regulation of TCR signalling (van Spriel et al., 2004) 
however in these studies CD37 was not detected on CD4+ memory T cells under 
resting or activated conditions.  
 Chronic cytokine stimulation by the IL-2, IL-6 and TNFα cocktail modulates the 
expression of individual tetraspanin molecules. Significant changes in the intensity of 
CD81, CD53 and CD63 were observed upon cytokine-activation of CD4+ memory 
cells. All three molecules when ligated have been shown induce co-stimulatory 
signals for T cell activation.  Ligation of CD53 induces a variety of signalling events 
such as the activation of protein kinase C (PKC) and c-jun-dependent N-terminal 
kinase (JNK) dependent pathways, and an increase in CD45 tyrosine phosphatase 
activity and lck activation (Lagaudriere-Gesbert et al., 1997; Lazo, 2007; Yunta et al., 
2002; Zhang et al., 2001). CD53 alone signals via JNK but shares lck and PKC 
activating properties with CD63 and CD81 respectively. Thus the tetraspanin 
molecules which show the greatest modulation on cytokine-activation of CD4+ 
memory cells are those also capable of enhancing recall responses to antigen. 
Indeed this significant increase in CD81, CD53, and to a lesser extent CD63 may be 
unique to antigen-independent activation of these cells as expression is greater than 
that obtained by activation via the TCR using anti-CD3 cross-linking. Evidence from 
the literature leads to the hypothesis that CD53 expression by a proportion of 
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cytokine-activated cells could confer survival signals. A microarray study showed 
increased expression of CD53 on cells resistant to hydrogen peroxide treatment, 
ultra-violet light, gamma-irradiation and apoptosis (Voehringer et al., 2000). Ligation 
of CD53 with monoclonal antibodies reduces caspase activation and increases the  
survival protein Bax via a PI 3-kinase – AKT dependent pathway (Yunta and Lazo, 
2003). Furthermore, CD53, CD81 and CD82 have been shown to co-precipitate with 
a crucial enzyme in the control of cellular redox potential, γ-glutamyl transpeptidase 
(GGT) (Nichols et al., 1998). Thus expression of these molecules by cytokine-
activated CD4+ memory cells may promote additional survival factors and protect 
against oxidative stress. A recent paper demonstrated an increase in CD53 
expression on PBLs from RA patients in comparison to healthy individuals. They also 
observed decreased levels of surface-thiols on these cells suggesting CD53 
upregulation is associated with an increase in GGT as a homeostatic response to 
dysregulated redox potential in RA, and contributes to reduce apoptosis associated 
with this disease (Pedersen-Lane et al., 2007). In this chapter, analysis of synovial 
tissue indeed demonstrated low level CD53 expression on comparable proportions 
of lymphocytes and myeloid cells/fibroblasts; whether this contributes to 
dysregulation of redox in the diseased joint will require further investigation.   
 In contrast to the increased intensity of CD81 expression on cytokine-activation, 
expression was comparable between resting and cells activated via anti-CD3 and 
the percentage of CD81+ cells declines irrespective of mode of activation. One 
possible explanation is that some cells are primed to increase cell surface 
expression either by de novo synthesis and/or increased trafficking from intracellular 
compartments whereas others either do not respond or actively downregulate 
expression. A similar decrease in proportion of positive cells was observed with 
donors that initially expressed CD9 on the majority of resting CD4+ memory T cells. 
A strong association of CD81 and CD9 has been shown in a number of cell lines; 
thus it is tempting to speculate that downregulation of either protein from the cell 
surface may influence the other. There is evidence from studies of other family 
members that tetraspanins can be lost from the cell surface by endocytosis or 
proteolytic cleavage (Berditchevski and Odintsova, 2007; Mollinedo et al., 1998). 
Those donors with few CD9 expressing resting cells were found to increase the 
proportion of CD9+ cells in response to cytokine. The degree of increase or 
decrease in CD9+ cells also varied between donors, such that there is a broad range 
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in final proportions of CD4+ memory cells expressing CD9; but the range in absolute 
CD9 levels between donors was tighter suggesting a maximum capacity for CD9 
expression in response to cytokines. As previously mentioned, CD82 expression on 
resting CD4+ memory cells was also found to be split into low and high expressing 
donors. In contrast to CD9, after cytokine-stimulation CD82 expression increased to 
the point that CD82 was present on all cells from all donors. Modulation of CD82 by 
cytokines is not unprecedented, since IL-1β, IL-4, IL-6, IL-13, IFNγ and TNFα all 
increased CD82 in the monocytic U937 cell line (Lebel-Binay et al., 1995).  
 MFI levels of assayed tetraspanins after 8 days of cytokine stimulation did not 
correlate with TNFα induction in a Spearman correlation analysis, indicating that 
levels of tetraspanin expression do not influence effector function of cytokine-
activated T cells; however a much larger sample number is required to confirm this. 
As it is the interactions of these molecules with proteins partners that determine their 
specific functions and understanding the components of TEMs on individual cell-
types under particular conditions is essential for deciphering the function of individual 
tetraspanins. Cytokine-activated CD4+ memory cells express, to varying degrees, 
CD82, CD81, CD9, CD53 and CD63. All five tetraspanins have been shown to 
associate with VLA-3, VLA-4 and VLA-6, on various cell types and with the 
fibronectin receptor (VLA-5A) with the exception of CD53 (Berditchevski, 2001; 
Feigelson et al., 2003; Mannion et al., 1996).  A direct interaction of tetraspanin and 
integrin was shown to occur between the LEL of CD151 and α chain of VLA-5A. This 
and other interactions of CD151 with integrins are vital for the adhesion of many cell 
types to the extracellular matrix (Nishiuchi et al., 2005; Yamada et al., 2008). The 
observed change in intensity of CD151 on cytokine or anti-CD3 activation was two-
fold, but very few activated cells actually expressed CD151.  The association of LFA-
1 with CD81 and CD63 has been demonstrated, but as with all tetraspanin protein 
associations, these are dependent on cell type (Levy et al., 1998). Since I have 
shown that VLA-4 and LFA-1 are expressed on cytokine-activated CD4+CD45RO+ T 
cells, it is tempting to hypothesise their association with one or more of these 
tetraspanins on the cell surface. Immunoprecipitation and chemical cross-linking 
studies would reveal associations of each of these molecules with other proteins 
such as the integrins and each other within the plasma membrane. 
 A broad range of cellular functions of the individual tetraspanins have been 
implicated from the diverse effects of different monoclonal antibodies. For instance in 
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the case of CD81, cross-linking induces anti-proliferative effects in B cells, while T 
cells are insensitive to the same antibodies. Some antibodies induce homotypic 
adhesion resulting in aggregation and changes in cell morphology that are 
dependent on specific integrin interactions and actin-cytoskeletal rearrangements 
(Crotta et al., 2006; Todd et al., 1996). In contrast to anti-proliferative effects, 
monoclonal antibodies (and HCV-E2 ligation) have also revealed the co-stimulatory 
capacity of CD81 in T and B cells. Inhibiting the function of CD81 by antibody 
blockade is a less appropriate approach because the binding partners of the 
tetraspanins are not classical ligands of receptors but specific laterally associated 
proteins. Antibody binding could alter interactions within TEMs or even co-ligate Fc 
receptors, as has been reported with CD9 and CD82 (Moseley, 2005), potentially 
generating conflicting results and artefacts as the microdomain is artificially modified.  
 Studies using knockout animals clarified the role of CD81 in T and B cell co-
stimulation in vivo. Thus knockdown approaches may provide more dissectible 
observations. Cytokine-activation of CD81-depleted T cells and subsequent effects 
on the induction of TNFα from monocytes along with knowledge of the individual 
components of the TEM would provide insights into the role of CD81 on the surface 
of these cells. 
 This chapter presents a profile of tetraspanin expression in synovial tissue. 
Expression was greatest in the non-lymphocytic population of synovial cells; in 
particular CD63 expression was the most highly expressed molecule. In general few 
synovial lymphocytes express tetraspanin family members and in the case of CD9, 
CD63, CD81 and CD151 these are mainly CD3- cells (probably B and/or NK cells). 
However a large number of synovial T cells do express CD82, up to 61% in one 
donor. CD63 and CD151 are expressed at low, but comparable levels, on synovial 
and cytokine-activated CD4+CD45RO+ T cells however these are the only 
tetraspanins which show a similar level of distribution between the two. A greater 
proportion of cytokine-activated CD4+CD45RO+ T cells are CD9+, CD53+, CD81+ 
or CD82+ than synovial T cells. However in terms of relative expression cytokine-
activated T cells do mimic RA synovial T cells as both may be described as CD82 > 
CD81 > CD53 and CD9 > CD63 and CD151. 
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6.0 Concluding Discussion 
 A deeper understanding of the mechanisms that drive chronic TNFα production in 
RA is required to advance therapeutic opportunities beyond TNFα blockade. As the 
number of known cytokines expands, and their respective roles in the pro-
inflammatory hierarchy are clarified additional targets for therapeutic intervention 
which act independent of TNFα may emerge. Recently, with the identification of 
regulatory T cells and IL-17 producing T helper cells and the success of a CTLA4 
fusion protein in the clinic, the pathogenic role of CD4+ T cells has returned to the 
foreground in RA research. The rationale behind the studies presented in this thesis 
derives from the active but hyporesponsive nature of synovial T cells, and a lack of 
TCR restriction in the synovium. This led to the hypothesis of bystander activation of 
T cells by the pro-inflammatory environment rather than by autoantigen. Such 
antigen-independent activation of T cells permits contact-dependent activation of 
macrophages, and acts as a major driving force for dysregulated pro-inflammatory 
cytokine production in RA.  
 In this thesis I describe a subset of human peripheral blood lymphocytes which 
differentiate into effector T cells that phenotypically and functionally mimic RA 
synovial T cells when stimulated in vitro with IL-2, IL-6 and TNFα. Cytokine-activated 
CD4+ memory T cells reproducibly induced higher levels of TNFα from monocytes in 
comparison to other lymphocytes. These cells proliferate and express pro-
inflammatory cytokines, activation and adhesion molecules in response to IL-2, IL-6 
and TNFα stimulation. The most potent cytokine-activated cells are generated from 
CD4+ effector memory T cell (TEM) precursors, and are those which undergo at least 
one cell division over eight days. Functional analysis revealed that neither CD62L 
nor CD49d directly contributed to the induction of monocytic TNFα but levels of both 
molecules could mark successful acquisition of effector function. In contrast, CD69 
and CD18 contributed in part to the contact-dependent activation of monocytes. 
Thus understanding the precise mechanism of TNFα induction requires the 
identification of additional participating molecules. 
 The approach I pursued was to profile cell surface expressed proteins using 
cytokine-activated T cells as a model system. In chapter 4 I showed that plasma-
membrane protein-enriched samples can be generated from as few as 20 million 
primary human T cells, and that fractionation of these samples by one-dimensional 
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SDS PAGE was more successful in identifying plasma membrane proteins than 
separation in two dimensions using solution phase IEF. Two candidate molecules 
were identified by mass spectrometry after one-dimensional analysis. CD81 was 
detected in a sample from a complete population of cytokine-activated PBLs 
whereas CD97 was extracted from  CD4+CD45RO+ T cells obtained using an 
optimised protocol which enabled plasma membrane protein enrichment from a 
limited source of cells. Solution phase IEF followed by SDS-PAGE provided greater 
protein resolution but a poorer identification rate by MS. The amount of protein 
recovered from human peripheral blood lymphocytes (resting or activated), even 
when pooled from more than one donor, is at the lower limit of detection using 
solution phase IEF and the additional steps required to concentrate the generated 
fractions prior to SDS-PAGE separation result in further sample loss and the 
introduction of contaminants. However, CD97 was also identified from an IEF / SDS 
PAGE separation of cytokine-activated T cells pooled from 2 donors. Plasma 
membrane protein analysis of primary human T cells is a trade off between the 
number of cells analysed and the resolution acquired. The most successful work flow 
employed an optimised preparation of plasma membrane proteins from a small 
population of the most relevant effector cells which was sufficient only for low 
resolution separation prior to MS. Pierce et al demonstrated a comparable rate of 
plasma membrane protein identification to ‘shotgun’ approaches but with ten times 
as many cells than are available in our system. Recent advances in MS technology 
have improved sensitivity and could compensate for the sample limitation in our 
model, so it is likely that in the future a ‘shotgun’ MS approach to proteomic analysis 
of cytokine-activated T cells would identify more candidate molecules than one-
dimensional electrophoresis. Despite the limitations of our current instruments, I 
have shown that a proteomic approach identified two molecules of interest and 
relevance to contact-dependent activation of monocytes by cytokine-activated T cells 
and RA. 
 Chapter 5 validated the presence of CD81, CD97 and other functionally related 
proteins on CD4+CD45RO+ T cells and in RA tissue. Further experiments are 
required to clarify the relevance of these molecules to the effector function of 
cytokine-activation of T cells and within RA (Sections 5.10, 6.1 and 6.2).  
 Changes in the phenotype of T cells after cytokine-activation can be examined 
through analysis of plasma membrane protein expression or by transcriptomics using 
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microarrays. A preliminary microarray study carried out in our laboratory identified 
mRNA for 25 plasma membrane-associated proteins that were upregulated at least 
2-fold on day 6 cytokine-activated CD4+CD45RO+ T cells compared to day 1 or  day 
3 cytokine-activated cells or to anti-CD3 treated cells. However, investigation of 
seven of these candidates revealed that only one was significantly upregulated at the 
protein level in day 8 cytokine-activated T cells compared to both resting and anti-
CD3 activated T cells from multiple donors. In addition, only CD74 (the MHC 
invariant chain) was common between the gene data set and the twenty two plasma 
membrane proteins identified in this thesis. Together this suggests that a proteomic 
approach may be more relevant to our system but further microarray experiments 
are warranted particularly as sample mRNA can be amplified for analysis thus 
overcoming the sample limitations encountered in analysing protein expression.  
6.1 Future work  
6.1.1 Role of CD97 in RA 
  A role for CD97 and its ligand CD55 in T cell-monocyte interactions is beginning to 
emerge, ligation of either molecule by the other promotes T cell activation via the 
TCR (Abbott et al., 2007; Capasso et al., 2006). Data presented in this thesis 
demonstrated significantly higher CD97 expression on CD4+ memory T cells 
activated independently of the TCR by cytokine stimulation, compared to resting 
cells and those activated via anti-CD3 cross-linking. Neutralisation of CD97 on 
cytokine-activated CD4+CD45RO+ T cells with a commercially available antibody 
abrogated TNFα production from monocytes in co-culture suggesting that inhibition 
is due to blockade of the interaction of CD97 and monocyte CD55. As discussed in 
section 5.10, experiments to neutralise or knockdown CD55 expression in 
monocytes are required to verify this. The epitope to which the commercially 
available anti-CD97 antibody is directed is unknown, but only an antibody directed 
towards the EGF domains 1 or 2 of CD97 would block CD97-CD55 interactions. 
Abbott et al demonstrated that only a monoclonal (CLB 97/1) directed against CD97 
EGF domain 1, and not one against the stalk region (CLB 97/3), inhibited T cell 
proliferation. Use of CLB 97/1 to neutralise CD97 on cytokine-activated 
CD4+CD45RO+ T cells is highly desirable to assess whether the level of TNFα 
inhibition observed in this thesis is real.       
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 As discussed in Chapter 5, previous reports indicate that CD97 expression in 
synovial tissue is restricted to macrophages (Hamann et al., 1999); however my data 
demonstrate that a comparable proportion of synovial lymphocytes also express 
CD97, supporting a potential role for this molecule on T cells. In the CIA model, 
treatment with neutralising antibodies to CD97 significantly reduced arthritis (Kop et 
al., 2006). The reduction in cellular infiltrate observed was mainly attributable to 
reduced numbers of neutrophil in treated mice, and no significant changes were 
observed in the abundance of macrophages or T cells, or to cytokine or antibody 
production. However, they did not examine changes in TNFα or IL-17 levels in the 
treated mice, and ex vivo stimulation of splenocytes from treated mice show a two-
fold increase in IFNγ production, which could be indicative of a protective effect of 
Th1 cells over Th17. A CD97 null mouse has been created by Deltagen Inc. on the 
C57BL/6 background, and shows a normal phenotype (www.informatic.jax.org MGI 
ID number 1347095). Recent data has demonstrated that CIA can be induced in 
mice on a C57BL/6 background (Inglis et al., 2008). Therefore understanding of the 
function of CD97 in arthritis would be greatly enhanced by studying CIA in the CD97 
null mouse.  
6.1.2 Tetraspanin microdomains 
 A preliminary investigation into the expression of individual tetraspanin molecules by 
primary human T cells demonstrated differential modulation on cytokine-activation. 
Significant upregulation of CD63, CD53 and CD81 expression was observed; but 
cytokine-activated CD4+CD45RO+ T cells also expressed CD9 and CD82. The 
relative expression profile of synovial T cells also mimicked that of cytokine-activated 
T cells. All cell types (except erythrocytes) are known to express members of the 
tetraspanin superfamily, yet each member exhibits a different tissue distribution. In 
this thesis, I have shown a difference in tetraspanin expression between the synovial 
lymphocyte and non-lymphocytic populations, but more detailed multi-colour flow 
cytometry is required to determine cell-type specific expression in this inflamed 
tissue.  
 Tetraspanins act as organisers of multi-molecular complexes on the cell surface, 
forming primary associations with other membrane proteins, and targeting these 
proteins to tetraspanin-enriched microdomains (TEM) through the formation of 
secondary interactions with other tetraspanins. Thus knowledge not only of individual 
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tetraspanin expression, but of their specific interaction partners is essential to the 
understanding the roles of TEM on particular cells. A study of colon cancer lines 
revealed differences in the proteins associated with CD9 between lines derived from 
a primary tumour and those derived from metastases; thus an understanding of TEM 
can reveal information on disease pathology (Le Naour et al., 2006). If the  surface 
TEM composition of human CD4+CD45RO+ T cells changes on cytokine-stimulation 
it could facilitate contact-dependent activation of monocytes, so the associations of 
integrins and tetraspanins would be of particular interest. Due to their high level of 
expression, co-stimulatory-like properties and reported localisation to immunological 
synapses (Mittelbrunn et al., 2002), CD81 and CD82 would be good starting points 
for analysis of TEM on cytokine-activated T cells. Such studies could involve 
immunoprecipitation (IP) of the target tetraspanin from cell lysates under mild 
detergent conditions (e.g. Brij-97) to preserve the TEM, followed by elution with a 
stronger detergent such as Triton-X100 to dissociate the microdomain, and analysis 
by western blotting and/or ‘shot gun’ MS. As with global plasma membrane 
proteomics, the application of these techniques to primary human cells could be 
hampered by low cell numbers and require pooling of lysates from different donors 
prior to IP.  
6.1.3 Cytokine-activated CD4+CD45RO+ T cells 
 Contact-dependent production of monocyte TNFα by cytokine-activated PBLs and 
RA synovial T cells was demonstrated through the physical separation of fixed 
lymphocytes from monocytes in co-culture and the resultant inhibition of TNFα  
production (Brennan et al., 2002; Sebbag et al., 1997). Contact-dependency was 
also demonstrated in autologous co-culture assays in which cytokine-activated PBLs 
were not chemically fixed, and separation with a porous insert reduced TNFα 
production by approximately 70% (unpublished data from the laboratory circa 2004). 
In this thesis I have presented data demonstrating TNFα induction by both fixed and 
non-fixed cytokine-activated CD4+CD45RO+ T cells, as indicated. Although TNFα 
production from monocytes cultured with chemically fixed T cells implies 
independence from soluble factors and monocyte activation via physical interaction 
with T cells, contact-dependency needs to be formally demonstrated for the 
CD4+CD45RO+ T cell subset. 
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 Cytokine-activated CD4+CD45RO+ T cells were found to secrete the pro-
inflammatory cytokines IFNγ, LT and GM-CSF as well as anti-inflammatory cytokines 
TGFβ and IL-10. Detection of the latter suggests that Treg cells may be expanded in 
the culture with IL-2, IL-6 and TNFα. In addition, the variation in monocyte TNFα 
induced by cytokine-activated CD4+CD45RO+ T cells from different donors could be 
attributed to Treg cells modulating the acquisition of an effector phenotype by 
CD4+CD45RO+ T cells over 8 days and/or the induction of TNFα by monocytes in 
co-culture. Further support for this hypothesis is the increase in the proportion of 
CD25-expressing cells and the greater CD25 levels observed in the dividing versus 
the non-dividing population. Studies now underway in the laboratory indicate that IL-
10 detected in cytokine-activated CD4+CD45RO+ T cell cultures is not derived from 
a Treg population, and, although the numbers of CD25+foxp3+ cells increase in 
culture, they are unable to modify cytokine-activated CD4+CD45RO+ T cell 
proliferation or effector function. Furthermore, despite acquiring a similar phenotype 
to non-regulatory cells, cytokine-activated CD25+foxp3+ appear to be unable to 
induce TNFα from monocytes in co-culture. The nature of this anergy exhibited by 
cytokine-activated Treg is particularly interesting, as it implies that, like resting T 
cells, these cells lack the cell surface molecules required for activation of monocytes 
in an antigen–independent system. 
 Another avenue of further study that has been opened up by work presented in this 
thesis is confirmation of the migratory potential of CD4+CD45RO+ T cells after 
activation with cytokines since they express high levels of CXCR4, VLA-4, LFA-1 
and CD62L. Experiments in vivo with human synovial tissues explants engrafted 
onto SCID mice will investigate the pathogenicity of these cells and their capacity to 
home to diseased tissue. 
 The expression of ‘classical’ co-stimulatory molecules by cytokine-activated T cells 
has not been addressed in this thesis.  Analysis of expression levels of molecules 
such as CD28, CTLA-4, ICOS, CD40L and OX40 cytokine-activatedCD4+CD45RO+ 
T cells   is warranted, particularly in the light of data presented in this thesis showing 
upregulation of cell surface molecules with co-stimulatory-like properties, including 
CD97, CD55 and the tetraspanins CD53, CD63, CD81 and CD82.  
CD28 is constitutively expressed by the majority of CD4+ T cells, but loss of 
expression has been associated with expanded autoreactive clonotypes in the PB of 
RA patients (Schmidt et al., 1996). Amyes et al have also reported the existence of 
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novel CCR7- CD28- subsets of antigen-experienced CD4+ T cells in the PB of 
healthy individuals. They show that a small sub-population of CD28- cells exists 
within the TEM cell population  and that a separate lineage of memory, yet CD45RA+ 
CCR7- T cells, which also can be subdivided into CD28+ or CD28- cells also exist 
(Amyes et al., 2005). Whether there is modulation in the numbers of CD28- T cells or 
a gain of CD45RA expression after cytokine-stimulation of CD4+CD45RO+CCR7- T 
cells, and if so, whether this is reflected in effector function is worthy of investigation.   
6.2 Conclusion 
 This thesis has demonstrated that CD4+ effector memory T cells represent a 
precursor population in peripheral blood which can be re-activated independently of 
antigen by chronic cytokine-stimulation, thereby acquiring a phenotype capable of 
perpetuating inflammatory processes through the activation of monocytes. Thus 
infiltration of circulating TEM cells into an inflamed joint environment, and the 
generation of pathological T cells there, is a potentially dominant mechanism driving 
disease. CD4+CD45RO+ T cells activated in vitro express the necessary machinery 
to traffic to and/or be retained within inflammatory sites, although the exact migratory 
capacity of these cells in vivo is currently being determined. CD18, CD69 and CD97 
have been shown to contribute to the contact-dependent induction of monocyte 
TNFα. The counter ligands for CD69 and CD97 and subsequent signal transduction 
pathways activated have yet to be determined, but CD18 is likely to act as a ‘tether’ 
for cell-cell interactions. Tetraspanin molecules may also have a vital role in specific 
organisation of proteins on the cell surface that play direct or indirect roles in the 
effector function observed by cytokine-activated T cells.
       
249 
 
 
 
 
 
 
 
 
Chapter 7 
References
Chapter 7      References  
250 
 
Abbott, R.J., Spendlove, I., Roversi, P., Fitzgibbon, H., Knott, V., Teriete, P., 
McDonnell, J.M., Handford, P.A., and Lea, S.M. (2007). Structural and functional 
characterization of a novel T cell receptor co-regulatory protein complex, CD97-
CD55. J Biol Chem 282, 22023-22032. 
Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A., and Sallusto, F. (2007). 
Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the 
differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8, 942-
949. 
Adessi, C., Miege, C., Albrieux, C., and Rabilloud, T. (1997). Two-dimensional 
electrophoresis of membrane proteins: a current challenge for immobilized pH 
gradients. Electrophoresis 18, 127-135. 
Agarwal, S.K., and Brenner, M.B. (2006). Role of adhesion molecules in synovial 
inflammation. Curr Opin Rheumatol 18, 268-276. 
Allan, S.E., Passerini, L., Bacchetta, R., Crellin, N., Dai, M., Orban, P.C., Ziegler, 
S.F., Roncarolo, M.G., and Levings, M.K. (2005). The role of 2 FOXP3 isoforms in 
the generation of human CD4+ Tregs. J Clin Invest 115, 3276-3284. 
Allenspach, E.J., Cullinan, P., Tong, J., Tang, Q., Tesciuba, A.G., Cannon, J.L., 
Takahashi, S.M., Morgan, R., Burkhardt, J.K., and Sperling, A.I. (2001). ERM-
dependent movement of CD43 defines a novel protein complex distal to the 
immunological synapse. Immunity 15, 739-750. 
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, 
F., Poli, V., and Ciliberto, G. (1998). Interleukin 6 is required for the development of 
collagen-induced arthritis. J Exp Med 187, 461-468. 
Alvaro-Gracia, J.M., Zvaifler, N.J., Brown, C.B., Kaushansky, K., and Firestein, G.S. 
(1991). Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells 
involved in granulocyte-macrophage colony-stimulating factor production and gene 
expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis 
factor-alpha. J Immunol 146, 3365-3371. 
Amat, M., Benjamim, C.F., Williams, L.M., Prats, N., Terricabras, E., Beleta, J., 
Kunkel, S.L., and Godessart, N. (2006). Pharmacological blockade of CCR1 
ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol 
149, 666-675. 
Amyes, E., McMichael, A.J., and Callan, M.F. (2005). Human CD4+ T cells are 
predominantly distributed among six phenotypically and functionally distinct subsets. 
J Immunol 175, 5765-5773. 
Andersson, A.K., Feldmann, M., and Brennan, F.M. (2008). Neutralizing IL-21 and 
IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J 
Immunol 68, 103-111. 
Angelisova, P., Hilgert, I., and Horejsi, V. (1994). Association of four antigens of the 
tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II 
glycoproteins. Immunogenetics 39, 249-256. 
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., 
Parente, E., Fili, L., Ferri, S., Frosali, F., et al. (2007). Phenotypic and functional 
features of human Th17 cells. J Exp Med 204, 1849-1861. 
Arai, K., Yamamura, S., Seki, S., Hanyu, T., Takahashi, H.E., and Abo, T. (1998). 
Increase of CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid 
arthritis (RA) patients: implication for an anti-inflammatory role. Clin Exp Immunol 
111, 345-352. 
Avice, M.N., Demeure, C.E., Delespesse, G., Rubio, M., Armant, M., and Sarfati, M. 
(1998). IL-15 promotes IL-12 production by human monocytes via T cell-dependent 
Chapter 7      References  
251 
 
contact and may contribute to IL-12-mediated IFN-gamma secretion by CD4+ T cells 
in the absence of TCR ligation. J Immunol 161, 3408-3415. 
Avouac, J., Gossec, L., and Dougados, M. (2006). Diagnostic and predictive value of 
anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic 
literature review. Ann Rheum Dis 65, 845-851. 
Bachmann, M.F., McKall-Faienza, K., Schmits, R., Bouchard, D., Beach, J., Speiser, 
D.E., Mak, T.W., and Ohashi, P.S. (1997). Distinct roles for LFA-1 and CD28 during 
activation of naive T cells: adhesion versus costimulation. Immunity 7, 549-557. 
Banda, N.K., Vondracek, A., Kraus, D., Dinarello, C.A., Kim, S.H., Bendele, A., 
Senaldi, G., and Arend, W.P. (2003). Mechanisms of inhibition of collagen-induced 
arthritis by murine IL-18 binding protein. J Immunol 170, 2100-2105. 
Banerjee, S., Wei, B.Y., Hillman, K., Luthra, H.S., and David, C.S. (1988). 
Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor 
antibody. J Immunol 141, 1150-1154. 
Bankhurst, A.D., Husby, G., and Williams, R.C., Jr. (1976). Predominance of T cells 
in the lymphocytic infiltrates of synovial tissues in rheumatoid arthritis. Arthritis 
Rheum 19, 555-562. 
Barrat, F.J., Cua, D.J., Boonstra, A., Richards, D.F., Crain, C., Savelkoul, H.F., de 
Waal-Malefyt, R., Coffman, R.L., Hawrylowicz, C.M., and O'Garra, A. (2002). In vitro 
generation of interleukin 10-producing regulatory CD4(+) T cells is induced by 
immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing 
cytokines. J Exp Med 195, 603-616. 
Beech, J.T., Andreakos, E., Ciesielski, C.J., Green, P., Foxwell, B.M., and Brennan, 
F.M. (2006). T-cell contact-dependent regulation of CC and CXC chemokine 
production in monocytes through differential involvement of NFkappaB: implications 
for rheumatoid arthritis. Arthritis Res Ther 8, R168. 
Benito, M.J., Murphy, E., Murphy, E.P., van den Berg, W.B., FitzGerald, O., and 
Bresnihan, B. (2004). Increased synovial tissue NF-kappa B1 expression at sites 
adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 50, 
1781-1787. 
Berditchevski, F. (2001). Complexes of tetraspanins with integrins: more than meets 
the eye. J Cell Sci 114, 4143-4151. 
Berditchevski, F., and Odintsova, E. (2007). Tetraspanins as regulators of protein 
trafficking. Traffic 8, 89-96. 
Berg, L., Ronnelid, J., Klareskog, L., and Bucht, A. (2000). Down-regulation of the T 
cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell 
responsiveness. Clin Exp Immunol 120, 174-182. 
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., and 
Kuchroo, V.K. (2006). Reciprocal developmental pathways for the generation of 
pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238. 
Blackham, A., and Griffiths, R.J. (1991). The effect of FK506 and cyclosporin A on 
antigen-induced arthritis. Clin Exp Immunol 86, 224-228. 
Boissier, M.C., Chiocchia, G., Bessis, N., Hajnal, J., Garotta, G., Nicoletti, F., and 
Fournier, C. (1995). Biphasic effect of interferon-gamma in murine collagen-induced 
arthritis. Eur J Immunol 25, 1184-1190. 
Boot, E.P., Koning, G.A., Storm, G., Wagenaar-Hilbers, J.P., van Eden, W., Everse, 
L.A., and Wauben, M.H. (2005). CD134 as target for specific drug delivery to auto-
aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res Ther 7, R604-615. 
Bradfield, P.F., Amft, N., Vernon-Wilson, E., Exley, A.E., Parsonage, G., Rainger, 
G.E., Nash, G.B., Thomas, A.M., Simmons, D.L., Salmon, M., and Buckley, C.D. 
Chapter 7      References  
252 
 
(2003). Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal 
cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ 
and CD8+ T cell migration within synovial tissue. Arthritis Rheum 48, 2472-2482. 
Braun, A., Takemura, S., Vallejo, A.N., Goronzy, J.J., and Weyand, C.M. (2004). 
Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. 
Arthritis Rheum 50, 2140-2150. 
Braun, R.J., Kinkl, N., Beer, M., and Ueffing, M. (2007). Two-dimensional 
electrophoresis of membrane proteins. Anal Bioanal Chem 389, 1033-1045. 
Brennan, F.M., Allard, S., Londei, M., Savill, C., Boylston, A., Carrel, S., Maini, R.N., 
and Feldmann, M. (1988). Heterogeneity of T cell receptor idiotypes in rheumatoid 
arthritis. Clin Exp Immunol 73, 417-423. 
Brennan, F.M., Chantry, D., Jackson, A., Maini, R., and Feldmann, M. (1989a). 
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in 
rheumatoid arthritis. Lancet 2, 244-247. 
Brennan, F.M., Chantry, D., Jackson, A.M., Maini, R.N., and Feldmann, M. (1989b). 
Cytokine production in culture by cells isolated from the synovial membrane. J 
Autoimmun 2 Suppl, 177-186. 
Brennan, F.M., Gibbons, D.L., Mitchell, T., Cope, A.P., Maini, R.N., and Feldmann, 
M. (1992). Enhanced expression of tumor necrosis factor receptor mRNA and 
protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J 
Immunol 22, 1907-1912. 
Brennan, F.M., Hayes, A.L., Ciesielski, C.J., Green, P., Foxwell, B.M., and 
Feldmann, M. (2002). Evidence that rheumatoid arthritis synovial T cells are similar 
to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and 
nuclear factor kappaB pathways in tumor necrosis factor alpha production in 
rheumatoid arthritis. Arthritis Rheum 46, 31-41. 
Brennan, F.M., Smith, N.M., Owen, S., Li, C., Amjadi, P., Green, P., Andersson, A., 
Palfreeman, A.C., Hillyer, P., Foey, A., et al. (2008). Resting CD4+ effector memory 
T cells are precursors of bystander-activated effectors: a surrogate model of 
rheumatoid arthritis synovial T-cell function. Arthritis Res Ther 10, R36. 
Brentano, F., Ospelt, C., Stanczyk, J., Gay, R.E., Gay, S., and Kyburz, D. (2008). 
Abundant expression of the IL-23 subunit p19, but low levels of bioactive IL-23 in the 
rheumatoid synovium. Ann Rheum Dis. 
Bresnihan, B. (2002). Anakinra as a new therapeutic option in rheumatoid arthritis: 
clinical results and perspectives. Clin Exp Rheumatol 20, S32-34. 
Bruhl, H., Cihak, J., Schneider, M.A., Plachy, J., Rupp, T., Wenzel, I., Shakarami, M., 
Milz, S., Ellwart, J.W., Stangassinger, M., et al. (2004). Dual role of CCR2 during 
initiation and progression of collagen-induced arthritis: evidence for regulatory 
activity of CCR2+ T cells. J Immunol 172, 890-898. 
Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko, S.A., 
Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell, F. (2001). Disruption of a 
new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative 
disorder of the scurfy mouse. Nat Genet 27, 68-73. 
Buch, M.H., Bingham, S.J., Seto, Y., McGonagle, D., Bejarano, V., White, J., and 
Emery, P. (2004). Lack of response to anakinra in rheumatoid arthritis following 
failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50, 725-728. 
Buchan, G., Barrett, K., Fujita, T., Taniguchi, T., Maini, R., and Feldmann, M. 
(1988a). Detection of activated T cell products in the rheumatoid joint using cDNA 
probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol 71, 
295-301. 
Chapter 7      References  
253 
 
Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R.N., and Feldmann, M. 
(1988b). Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid 
arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 73, 449-455. 
Buckley, C.D., Amft, N., Bradfield, P.F., Pilling, D., Ross, E., Arenzana-Seisdedos, 
F., Amara, A., Curnow, S.J., Lord, J.M., Scheel-Toellner, D., and Salmon, M. (2000). 
Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T 
cells contributes to their accumulation within the rheumatoid synovium. J Immunol 
165, 3423-3429. 
Bullard, D.C., Mobley, J.M., Justen, J.M., Sly, L.M., Chosay, J.G., Dunn, C.J., 
Lindsey, J.R., Beaudet, A.L., and Staite, N.D. (1999). Acceleration and increased 
severity of collagen-induced arthritis in P-selectin mutant mice. J Immunol 163, 
2844-2849. 
Burger, D., and Dayer, J.M. (2002). The role of human T-lymphocyte-monocyte 
contact in inflammation and tissue destruction. Arthritis Res 4 Suppl 3, S169-176. 
Burger, D., Molnarfi, N., Gruaz, L., and Dayer, J.M. (2004). Differential induction of 
IL-1beta and TNF by CD40 ligand or cellular contact with stimulated T cells depends 
on the maturation stage of human monocytes. J Immunol 173, 1292-1297. 
Burger, D., Rezzonico, R., Li, J.M., Modoux, C., Pierce, R.A., Welgus, H.G., and 
Dayer, J.M. (1998). Imbalance between interstitial collagenase and tissue inhibitor of 
metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with 
stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis 
Rheum 41, 1748-1759. 
Burkhardt, H., Huffmeier, U., Spriewald, B., Bohm, B., Rau, R., Kallert, S., Engstrom, 
A., Holmdahl, R., and Reis, A. (2006). Association between protein tyrosine 
phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope 
and humoral autoimmunity to an immunodominant epitope of cartilage-specific type 
II collagen in early rheumatoid arthritis. Arthritis Rheum 54, 82-89. 
Burman, A., Haworth, O., Hardie, D.L., Amft, E.N., Siewert, C., Jackson, D.G., 
Salmon, M., and Buckley, C.D. (2005). A chemokine-dependent stromal induction 
mechanism for aberrant lymphocyte accumulation and compromised lymphatic 
return in rheumatoid arthritis. J Immunol 174, 1693-1700. 
Butler, D.M., Maini, R.N., Feldmann, M., and Brennan, F.M. (1995). Modulation of 
proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. 
Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor 
antagonist. Eur Cytokine Netw 6, 225-230. 
Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G., and Catalano, M. 
(1996). Dose-range and dose-frequency study of recombinant human interleukin-1 
receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study 
Group. Arthritis Rheum 39, 1092-1101. 
Cao, D., van Vollenhoven, R., Klareskog, L., Trollmo, C., and Malmstrom, V. (2004). 
CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with 
chronic rheumatic disease. Arthritis Res Ther 6, R335-346. 
Capasso, M., Durrant, L.G., Stacey, M., Gordon, S., Ramage, J., and Spendlove, I. 
(2006). Costimulation via CD55 on human CD4+ T cells mediated by CD97. J 
Immunol 177, 1070-1077. 
Caristi, S., Piraino, G., Cucinotta, M., Valenti, A., Loddo, S., and Teti, D. (2005). 
Prostaglandin E2 induces interleukin-8 gene transcription by activating C/EBP 
homologous protein in human T lymphocytes. J Biol Chem 280, 14433-14442. 
Chapter 7      References  
254 
 
Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., and Williamson, B. 
(1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl 
Acad Sci U S A 72, 3666-3670. 
Chabaud, M., Durand, J.M., Buchs, N., Fossiez, F., Page, G., Frappart, L., and 
Miossec, P. (1999). Human interleukin-17: A T cell-derived proinflammatory cytokine 
produced by the rheumatoid synovium. Arthritis Rheum 42, 963-970. 
Chabaud, M., and Miossec, P. (2001). The combination of tumor necrosis factor 
alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for 
controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis 
Rheum 44, 1293-1303. 
Chabaud, M., Page, G., and Miossec, P. (2001). Enhancing effect of IL-1, IL-17, and 
TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid 
arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 167, 6015-
6020. 
Chan, E.S., and Cronstein, B.N. (2002). Molecular action of methotrexate in 
inflammatory diseases. Arthritis Res 4, 266-273. 
Charrin, S., Manie, S., Oualid, M., Billard, M., Boucheix, C., and Rubinstein, E. 
(2002). Differential stability of tetraspanin/tetraspanin interactions: role of 
palmitoylation. FEBS Lett 516, 139-144. 
Chen, Z., Tato, C.M., Muul, L., Laurence, A., and O'Shea, J.J. (2007). Distinct 
regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 56, 
2936-2946. 
Chiocchia, G., Boissier, M.C., and Fournier, C. (1991). Therapy against murine 
collagen-induced arthritis with T cell receptor V beta-specific antibodies. Eur J 
Immunol 21, 2899-2905. 
Chizzolini, C., Chicheportiche, R., Burger, D., and Dayer, J.M. (1997). Human Th1 
cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor 
antagonist production upon cell/cell contact with monocytes. Eur J Immunol 27, 171-
177. 
Cho, M.L., Jung, Y.O., Moon, Y.M., Min, S.Y., Yoon, C.H., Lee, S.H., Park, S.H., 
Cho, C.S., Jue, D.M., and Kim, H.Y. (2006). Interleukin-18 induces the production of 
vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts 
via AP-1-dependent pathways. Immunol Lett 103, 159-166. 
Choy, E.H., Panayi, G.S., Emery, P., Madden, S., Breedveld, F.C., Kraan, M.C., 
Kalden, J.R., Rascu, A., Brown, J.C., Rapson, N., and Johnston, J.M. (2002). 
Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized 
monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. 
Rheumatology (Oxford) 41, 1142-1148. 
Chu, C.Q., Field, M., Feldmann, M., and Maini, R.N. (1991). Localization of tumor 
necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in 
patients with rheumatoid arthritis. Arthritis Rheum 34, 1125-1132. 
Cohen, S.B., Dore, R.K., Lane, N.E., Ory, P.A., Peterfy, C.G., Sharp, J.T., van der 
Heijde, D., Zhou, L., Tsuji, W., and Newmark, R. (2008). Denosumab treatment 
effects on structural damage, bone mineral density, and bone turnover in rheumatoid 
arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, 
phase II clinical trial. Arthritis Rheum 58, 1299-1309. 
Cope, A.P., Aderka, D., Doherty, M., Engelmann, H., Gibbons, D., Jones, A.C., 
Brennan, F.M., Maini, R.N., Wallach, D., and Feldmann, M. (1992). Increased levels 
of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients 
with rheumatic diseases. Arthritis Rheum 35, 1160-1169. 
Chapter 7      References  
255 
 
Cope, A.P., Londei, M., Chu, N.R., Cohen, S.B., Elliott, M.J., Brennan, F.M., Maini, 
R.N., and Feldmann, M. (1994). Chronic exposure to tumor necrosis factor (TNF) in 
vitro impairs the activation of T cells through the T cell receptor/CD3 complex; 
reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin 
Invest 94, 749-760. 
Corr, M., and Crain, B. (2002). The role of FcgammaR signaling in the K/B x N 
serum transfer model of arthritis. J Immunol 169, 6604-6609. 
Cox, B., and Emili, A. (2006). Tissue subcellular fractionation and protein extraction 
for use in mass-spectrometry-based proteomics. Nat Protoc 1, 1872-1878. 
Cox, J., and Mann, M. (2007). Is proteomics the new genomics? Cell 130, 395-398. 
Crotta, S., Ronconi, V., Ulivieri, C., Baldari, C.T., Valiante, N.M., Abrignani, S., and 
Wack, A. (2006). Cytoskeleton rearrangement induced by tetraspanin engagement 
modulates the activation of T and NK cells. Eur J Immunol 36, 919-929. 
Crotta, S., Stilla, A., Wack, A., D'Andrea, A., Nuti, S., D'Oro, U., Mosca, M., Filliponi, 
F., Brunetto, R.M., Bonino, F., et al. (2002). Inhibition of natural killer cells through 
engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 
195, 35-41. 
Davila, E., Kang, Y.M., Park, Y.W., Sawai, H., He, X., Pryshchep, S., Goronzy, J.J., 
and Weyand, C.M. (2005). Cell-based immunotherapy with suppressor CD8+ T cells 
in rheumatoid arthritis. J Immunol 174, 7292-7301. 
Davis, L.S., Cush, J.J., Schulze-Koops, H., and Lipsky, P.E. (2001). Rheumatoid 
synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing 
T-helper-2 effector cells. Arthritis Res 3, 54-64. 
Dayer, J.M., and Burger, D. (2004). Cell-cell interactions and tissue damage in 
rheumatoid arthritis. Autoimmun Rev 3 Suppl 1, S14-16. 
Delon, J., Kaibuchi, K., and Germain, R.N. (2001). Exclusion of CD43 from the 
immunological synapse is mediated by phosphorylation-regulated relocation of the 
cytoskeletal adaptor moesin. Immunity 15, 691-701. 
Demirci, G., and Li, X.C. (2008). Novel roles of OX40 in the allograft response. Curr 
Opin Organ Transplant 13, 26-30. 
Deng, J., Dekruyff, R.H., Freeman, G.J., Umetsu, D.T., and Levy, S. (2002). Critical 
role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol 
14, 513-523. 
Dormeyer, W., van Hoof, D., Braam, S.R., Heck, A.J., Mummery, C.L., and 
Krijgsveld, J. (2008). Plasma membrane proteomics of human embryonic stem cells 
and human embryonal carcinoma cells. J Proteome Res 7, 2936-2951. 
Dubois, S., Mariner, J., Waldmann, T.A., and Tagaya, Y. (2002). IL-15Ralpha 
recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537-547. 
Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A., and Noelle, R.J. 
(1993). Prevention of collagen-induced arthritis with an antibody to gp39, the ligand 
for CD40. Science 261, 1328-1330. 
Dustin, M.L. (2008). T-cell activation through immunological synapses and kinapses. 
Immunol Rev 221, 77-89. 
Edwards, J.C., and Cambridge, G. (2006). B-cell targeting in rheumatoid arthritis and 
other autoimmune diseases. Nat Rev Immunol 6, 394-403. 
Ehinger, M., Vestberg, M., Johansson, A.C., Johannesson, M., Svensson, A., and 
Holmdahl, R. (2001). Influence of CD4 or CD8 deficiency on collagen-induced 
arthritis. Immunology 103, 291-300. 
Chapter 7      References  
256 
 
Ehrenstein, M.R., Evans, J.G., Singh, A., Moore, S., Warnes, G., Isenberg, D.A., and 
Mauri, C. (2004). Compromised function of regulatory T cells in rheumatoid arthritis 
and reversal by anti-TNFalpha therapy. J Exp Med 200, 277-285. 
Eichler, W. (2000). CD97 isoform expression in leukocytes. J Leukoc Biol 68, 561-
567. 
Eichler, W., Aust, G., and Hamann, D. (1994). Characterization of an early 
activation-dependent antigen on lymphocytes defined by the monoclonal antibody 
BL-Ac(F2). Scand J Immunol 39, 111-115. 
Eichler, W., Hamann, J., and Aust, G. (1997). Expression characteristics of the 
human CD97 antigen. Tissue Antigens 50, 429-438. 
Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, 
B., Breedveld, F.C., Macfarlane, J.D., Bijl, H., and et al. (1994a). Randomised 
double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor 
alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110. 
Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, H., and 
Woody, J.N. (1994b). Repeated therapy with monoclonal antibody to tumour 
necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-
1127. 
Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., 
Brennan, F.M., Walker, J., Bijl, H., Ghrayeb, J., and et al. (1993). Treatment of 
rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor 
alpha. Arthritis Rheum 36, 1681-1690. 
Engel, P., and Tedder, T.F. (1994). New CD from the B cell section of the Fifth 
International Workshop on Human Leukocyte Differentiation Antigens. Leuk 
Lymphoma 13 Suppl 1, 61-64. 
Fazou, C., Yang, H., McMichael, A.J., and Callan, M.F. (2001). Epitope specificity of 
clonally expanded populations of CD8+ T cells found within the joints of patients with 
inflammatory arthritis. Arthritis Rheum 44, 2038-2045. 
Fearon, D.T., and Carter, R.H. (1995). The CD19/CR2/TAPA-1 complex of B 
lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 13, 127-149. 
Feigelson, S.W., Grabovsky, V., Shamri, R., Levy, S., and Alon, R. (2003). The 
CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening 
to vascular cell adhesion molecule 1 (VCAM-1) under shear flow. J Biol Chem 278, 
51203-51212. 
Feldmann, M. (2002). Development of anti-TNF therapy for rheumatoid arthritis. Nat 
Rev Immunol 2, 364-371. 
Feldmann, M., Brennan, F.M., and Maini, R.N. (1996). Role of cytokines in 
rheumatoid arthritis. Annu Rev Immunol 14, 397-440. 
Foey, A.D., Feldmann, M., and Brennan, F.M. (2001). CD40 ligation induces 
macrophage IL-10 and TNF-alpha production: differential use of the PI3K and p42/44 
MAPK-pathways. Cytokine 16, 131-142. 
Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, 
J.J., Garrone, P., Garcia, E., Saeland, S., et al. (1996). T cell interleukin-17 induces 
stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 
183, 2593-2603. 
Foster, L.J., de Hoog, C.L., Zhang, Y., Xie, X., Mootha, V.K., and Mann, M. (2006). A 
mammalian organelle map by protein correlation profiling. Cell 125, 187-199. 
Foster, L.J., Zeemann, P.A., Li, C., Mann, M., Jensen, O.N., and Kassem, M. (2005). 
Differential expression profiling of membrane proteins by quantitative proteomics in a 
Chapter 7      References  
257 
 
human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 
23, 1367-1377. 
Franklin, E.C., Holman, H.R., Muller-Eberhard, H.J., and Kunkel, H.G. (1957). An 
unusual protein component of high molecular weight in the serum of certain patients 
with rheumatoid arthritis. J Exp Med 105, 425-438. 
Friso, G., and Wikstrom, L. (1999). Analysis of proteins from membrane-enriched 
cerebellar preparations by two-dimensional gel electrophoresis and mass 
spectrometry. Electrophoresis 20, 917-927. 
Garred, P., Madsen, H.O., Petersen, J., Marquart, H., Hansen, T.M., Freiesleben 
Sorensen, S., Volck, B., Svejgaard, A., and Andersen, V. (1998). CC chemokine 
receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 25, 1462-1465. 
Gavin, M.A., Torgerson, T.R., Houston, E., DeRoos, P., Ho, W.Y., Stray-Pedersen, 
A., Ocheltree, E.L., Greenberg, P.D., Ochs, H.D., and Rudensky, A.Y. (2006). 
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression 
without regulatory T cell development. Proc Natl Acad Sci U S A 103, 6659-6664. 
Genovese, M.C., Becker, J.C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., 
Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005). Abatacept for 
rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 
353, 1114-1123. 
Genovese, M.C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., and 
Bekker, P. (2004). Combination therapy with etanercept and anakinra in the 
treatment of patients with rheumatoid arthritis who have been treated unsuccessfully 
with methotrexate. Arthritis Rheum 50, 1412-1419. 
Gerards, A.H., Landewe, R.B., Prins, A.P., Bruyn, G.A., Goei The, H.S., Laan, R.F., 
and Dijkmans, B.A. (2003). Cyclosporin A monotherapy versus cyclosporin A and 
methotrexate combination therapy in patients with early rheumatoid arthritis: a 
double blind randomised placebo controlled trial. Ann Rheum Dis 62, 291-296. 
Germann, T., Szeliga, J., Hess, H., Storkel, S., Podlaski, F.J., Gately, M.K., Schmitt, 
E., and Rude, E. (1995). Administration of interleukin 12 in combination with type II 
collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci U S A 92, 4823-
4827. 
Gombos, I., Kiss, E., Detre, C., Laszlo, G., and Matko, J. (2006). Cholesterol and 
sphingolipids as lipid organizers of the immune cells' plasma membrane: their impact 
on the functions of MHC molecules, effector T-lymphocytes and T-cell death. 
Immunol Lett 104, 59-69. 
Gorg, A., Weiss, W., and Dunn, M.J. (2004). Current two-dimensional 
electrophoresis technology for proteomics. Proteomics 4, 3665-3685. 
Gracie, J.A., Forsey, R.J., Chan, W.L., Gilmour, A., Leung, B.P., Greer, M.R., 
Kennedy, K., Carter, R., Wei, X.Q., Xu, D., et al. (1999). A proinflammatory role for 
IL-18 in rheumatoid arthritis. J Clin Invest 104, 1393-1401. 
Grant, E.P., Picarella, D., Burwell, T., Delaney, T., Croci, A., Avitahl, N., Humbles, 
A.A., Gutierrez-Ramos, J.C., Briskin, M., Gerard, C., and Coyle, A.J. (2002). 
Essential role for the C5a receptor in regulating the effector phase of synovial 
infiltration and joint destruction in experimental arthritis. J Exp Med 196, 1461-1471. 
Gravestein, L.A., and Borst, J. (1998). Tumor necrosis factor receptor family 
members in the immune system. Semin Immunol 10, 423-434. 
Gray, J.X., Haino, M., Roth, M.J., Maguire, J.E., Jensen, P.N., Yarme, A., Stetler-
Stevenson, M.A., Siebenlist, U., and Kelly, K. (1996). CD97 is a processed, seven-
transmembrane, heterodimeric receptor associated with inflammation. J Immunol 
157, 5438-5447. 
Chapter 7      References  
258 
 
Groh, V., Bruhl, A., El-Gabalawy, H., Nelson, J.L., and Spies, T. (2003). Stimulation 
of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in 
rheumatoid arthritis. Proc Natl Acad Sci U S A 100, 9452-9457. 
Guerne, P.A., Zuraw, B.L., Vaughan, J.H., Carson, D.A., and Lotz, M. (1989). 
Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic 
manifestations of arthritis. J Clin Invest 83, 585-592. 
Gupta, S., Bi, R., and Gollapudi, S. (2005). Central memory and effector memory 
subsets of human CD4(+) and CD8(+) T cells display differential sensitivity to TNF-
{alpha}-induced apoptosis. Ann N Y Acad Sci 1050, 108-114. 
Hamann, J., Eichler, W., Hamann, D., Kerstens, H.M., Poddighe, P.J., Hoovers, 
J.M., Hartmann, E., Strauss, M., and van Lier, R.A. (1995). Expression cloning and 
chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span 
transmembrane molecule of the secretion receptor superfamily with an unusual 
extracellular domain. J Immunol 155, 1942-1950. 
Hamann, J., Vogel, B., van Schijndel, G.M., and van Lier, R.A. (1996). The seven-
span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 
184, 1185-1189. 
Hamann, J., Wishaupt, J.O., van Lier, R.A., Smeets, T.J., Breedveld, F.C., and Tak, 
P.P. (1999). Expression of the activation antigen CD97 and its ligand CD55 in 
rheumatoid synovial tissue. Arthritis Rheum 42, 650-658. 
Harada, S., Yamamura, M., Okamoto, H., Morita, Y., Kawashima, M., Aita, T., and 
Makino, H. (1999). Production of interleukin-7 and interleukin-15 by fibroblast-like 
synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 42, 1508-1516. 
Harigai, M., Hara, M., Kawamoto, M., Kawaguchi, Y., Sugiura, T., Tanaka, M., 
Nakagawa, M., Ichida, H., Takagi, K., Higami-Ohsako, S., et al. (2004). Amplification 
of the synovial inflammatory response through activation of mitogen-activated protein 
kinases and nuclear factor kappaB using ligation of CD40 on CD14+ synovial cells 
from patients with rheumatoid arthritis. Arthritis Rheum 50, 2167-2177. 
Haringman, J.J., Kraan, M.C., Smeets, T.J., Zwinderman, K.H., and Tak, P.P. 
(2003). Chemokine blockade and chronic inflammatory disease: proof of concept in 
patients with rheumatoid arthritis. Ann Rheum Dis 62, 715-721. 
Haringman, J.J., Smeets, T.J., Reinders-Blankert, P., and Tak, P.P. (2006). 
Chemokine and chemokine receptor expression in paired peripheral blood 
mononuclear cells and synovial tissue of patients with rheumatoid arthritis, 
osteoarthritis, and reactive arthritis. Ann Rheum Dis 65, 294-300. 
Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, 
K.M., and Weaver, C.T. (2005). Interleukin 17-producing CD4+ effector T cells 
develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 
6, 1123-1132. 
Hata, H., Sakaguchi, N., Yoshitomi, H., Iwakura, Y., Sekikawa, K., Azuma, Y., Kanai, 
C., Moriizumi, E., Nomura, T., Nakamura, T., and Sakaguchi, S. (2004). Distinct 
contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous 
autoimmune arthritis in mice. J Clin Invest 114, 582-588. 
Haworth, C., Brennan, F.M., Chantry, D., Turner, M., Maini, R.N., and Feldmann, M. 
(1991). Expression of granulocyte-macrophage colony-stimulating factor in 
rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21, 
2575-2579. 
Hayashida, K., Shimaoka, Y., Ochi, T., and Lipsky, P.E. (2000). Rheumatoid arthritis 
synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells 
in a CD49/CD29-CD106-dependent mechanism. J Immunol 164, 1110-1116. 
Chapter 7      References  
259 
 
Hemler, M.E., Glass, D., Coblyn, J.S., and Jacobson, J.G. (1986). Very late 
activation antigens on rheumatoid synovial fluid T lymphocytes. Association with 
stages of T cell activation. J Clin Invest 78, 696-702. 
Hersmann, G.H., Kriegsmann, J., Simon, J., Huttich, C., and Brauer, R. (1998). 
Expression of cell adhesion molecules and cytokines in murine antigen-induced 
arthritis. Cell Adhes Commun 6, 69-82. 
Hingorani, R., Monteiro, J., Furie, R., Chartash, E., Navarrete, C., Pergolizzi, R., and 
Gregersen, P.K. (1996). Oligoclonality of V beta 3 TCR chains in the CD8+ T cell 
population of rheumatoid arthritis patients. J Immunol 156, 852-858. 
Hirota, K., Hashimoto, M., Yoshitomi, H., Tanaka, S., Nomura, T., Yamaguchi, T., 
Iwakura, Y., Sakaguchi, N., and Sakaguchi, S. (2007). T cell self-reactivity forms a 
cytokine milieu for spontaneous development of IL-17+ Th cells that cause 
autoimmune arthritis. J Exp Med 204, 41-47. 
Hopkins, A.L., and Groom, C.R. (2002). The druggable genome. Nat Rev Drug 
Discov 1, 727-730. 
Hopkins, S.J., and Meager, A. (1988). Cytokines in synovial fluid: II. The presence of 
tumour necrosis factor and interferon. Clin Exp Immunol 73, 88-92. 
Horai, R., Nakajima, A., Habiro, K., Kotani, M., Nakae, S., Matsuki, T., Nambu, A., 
Saijo, S., Kotaki, H., Sudo, K., et al. (2004). TNF-alpha is crucial for the development 
of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 114, 
1603-1611. 
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, 
M., and Iwakura, Y. (2000). Development of chronic inflammatory arthropathy 
resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J 
Exp Med 191, 313-320. 
Horejsi, V., and Vlcek, C. (1991). Novel structurally distinct family of leucocyte 
surface glycoproteins including CD9, CD37, CD53 and CD63. FEBS Lett 288, 1-4. 
Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of regulatory T cell 
development by the transcription factor Foxp3. Science 299, 1057-1061. 
Horwood, N.J., Elliott, J., Martin, T.J., and Gillespie, M.T. (1998). Osteotropic agents 
regulate the expression of osteoclast differentiation factor and osteoprotegerin in 
osteoblastic stromal cells. Endocrinology 139, 4743-4746. 
Houssiau, F.A., Devogelaer, J.P., Van Damme, J., de Deuxchaisnes, C.N., and Van 
Snick, J. (1988). Interleukin-6 in synovial fluid and serum of patients with rheumatoid 
arthritis and other inflammatory arthritides. Arthritis Rheum 31, 784-788. 
Hsu, Y.H., Li, H.H., Hsieh, M.Y., Liu, M.F., Huang, K.Y., Chin, L.S., Chen, P.C., 
Cheng, H.H., and Chang, M.S. (2006). Function of interleukin-20 as a 
proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 
54, 2722-2733. 
Husby, G., and Williams, R.C., Jr. (1988). Synovial localization of tumor necrosis 
factor in patients with rheumatoid arthritis. J Autoimmun 1, 363-371. 
Ikeuchi, H., Kuroiwa, T., Hiramatsu, N., Kaneko, Y., Hiromura, K., Ueki, K., and 
Nojima, Y. (2005). Expression of interleukin-22 in rheumatoid arthritis: potential role 
as a proinflammatory cytokine. Arthritis Rheum 52, 1037-1046. 
Imai, T., Kakizaki, M., Nishimura, M., and Yoshie, O. (1995). Molecular analyses of 
the association of CD4 with two members of the transmembrane 4 superfamily, 
CD81 and CD82. J Immunol 155, 1229-1239. 
Imai, T., and Yoshie, O. (1993). C33 antigen and M38 antigen recognized by 
monoclonal antibodies inhibitory to syncytium formation by human T cell leukemia 
Chapter 7      References  
260 
 
virus type 1 are both members of the transmembrane 4 superfamily and associate 
with each other and with CD4 or CD8 in T cells. J Immunol 151, 6470-6481. 
Inglis, J.J., Simelyte, E., McCann, F.E., Criado, G., and Williams, R.O. (2008). 
Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 3, 612-618. 
Isler, P., Vey, E., Zhang, J.H., and Dayer, J.M. (1993). Cell surface glycoproteins 
expressed on activated human T cells induce production of interleukin-1 beta by 
monocytic cells: a possible role of CD69. Eur Cytokine Netw 4, 15-23. 
Isomaki, P., Panesar, M., Annenkov, A., Clark, J.M., Foxwell, B.M., Chernajovsky, 
Y., and Cope, A.P. (2001). Prolonged exposure of T cells to TNF down-regulates 
TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol 
166, 5495-5507. 
Iwai, H., Kozono, Y., Hirose, S., Akiba, H., Yagita, H., Okumura, K., Kohsaka, H., 
Miyasaka, N., and Azuma, M. (2002). Amelioration of collagen-induced arthritis by 
blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol 
169, 4332-4339. 
Jang, E., Kim, H.R., Cho, S.H., Paik, D.J., Kim, J.M., Lee, S.K., and Youn, J. (2006). 
Prevention of spontaneous arthritis by inhibiting homeostatic expansion of 
autoreactive CD4+ T cells in the K/BxN mouse model. Arthritis Rheum 54, 492-498. 
Jaspars, L.H., Vos, W., Aust, G., Van Lier, R.A., and Hamann, J. (2001). Tissue 
distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens 57, 325-331. 
Jeno, P., Mini, T., Moes, S., Hintermann, E., and Horst, M. (1995). Internal 
sequences from proteins digested in polyacrylamide gels. Anal Biochem 224, 75-82. 
John, S., Smith, S., Morrison, J.F., Symmons, D., Worthington, J., Silman, A., and 
Barton, A. (2003). Genetic variation in CCR5 does not predict clinical outcome in 
inflammatory arthritis. Arthritis Rheum 48, 3615-3616. 
Joosten, L.A., Helsen, M.M., van de Loo, F.A., and van den Berg, W.B. (2008). 
Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 
mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. 
Arthritis Rheum 58, S110-122. 
Joosten, L.A., Lubberts, E., Helsen, M.M., and van den Berg, W.B. (1997). Dual role 
of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol 159, 
4094-4102. 
Jungel, A., Distler, J.H., Kurowska-Stolarska, M., Seemayer, C.A., Seibl, R., Forster, 
A., Michel, B.A., Gay, R.E., Emmrich, F., Gay, S., and Distler, O. (2004). Expression 
of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial 
macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50, 1468-1476. 
Kanapin, A., Batalov, S., Davis, M.J., Gough, J., Grimmond, S., Kawaji, H., Magrane, 
M., Matsuda, H., Schonbach, C., Teasdale, R.D., and Yuan, Z. (2003). Mouse 
proteome analysis. Genome Res 13, 1335-1344. 
Kang, Y.M., Zhang, X., Wagner, U.G., Yang, H., Beckenbaugh, R.D., Kurtin, P.J., 
Goronzy, J.J., and Weyand, C.M. (2002). CD8 T cells are required for the formation 
of ectopic germinal centers in rheumatoid synovitis. J Exp Med 195, 1325-1336. 
Katschke, K.J., Jr., Rottman, J.B., Ruth, J.H., Qin, S., Wu, L., LaRosa, G., Ponath, 
P., Park, C.C., Pope, R.M., and Koch, A.E. (2001). Differential expression of 
chemokine receptors on peripheral blood, synovial fluid, and synovial tissue 
monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 44, 1022-1032. 
Katsikis, P.D., Chu, C.Q., Brennan, F.M., Maini, R.N., and Feldmann, M. (1994). 
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179, 1517-
1527. 
Chapter 7      References  
261 
 
Kay, J., Matteson, E.L., Dasgupta, B., Nash, P., Durez, P., Hall, S., Hsia, E.C., Han, 
J., Wagner, C., Xu, Z., et al. (2008). Golimumab in patients with active rheumatoid 
arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-
controlled, dose-ranging study. Arthritis Rheum 58, 964-975. 
Kearney, P., and Thibault, P. (2003). Bioinformatics meets proteomics--bridging the 
gap between mass spectrometry data analysis and cell biology. J Bioinform Comput 
Biol 1, 183-200. 
Keystone, E.C. (2003). Abandoned therapies and unpublished trials in rheumatoid 
arthritis. Curr Opin Rheumatol 15, 253-258. 
Kim, J.M., and Rudensky, A. (2006). The role of the transcription factor Foxp3 in the 
development of regulatory T cells. Immunol Rev 212, 86-98. 
Kim, W., Min, S., Cho, M., Youn, J., Min, J., Lee, S., Park, S., Cho, C., and Kim, H. 
(2000). The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis 
(RA). Clin Exp Immunol 119, 175-181. 
Kinloch, A., Tatzer, V., Wait, R., Peston, D., Lundberg, K., Donatien, P., Moyes, D., 
Taylor, P.C., and Venables, P.J. (2005). Identification of citrullinated alpha-enolase 
as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7, R1421-1429. 
Kirkham, B.W., Lassere, M.N., Edmonds, J.P., Juhasz, K.M., Bird, P.A., Lee, C.S., 
Shnier, R., and Portek, I.J. (2006). Synovial membrane cytokine expression is 
predictive of joint damage progression in rheumatoid arthritis: a two-year prospective 
study (the DAMAGE study cohort). Arthritis Rheum 54, 1122-1131. 
Kitadokoro, K., Bordo, D., Galli, G., Petracca, R., Falugi, F., Abrignani, S., Grandi, 
G., and Bolognesi, M. (2001). CD81 extracellular domain 3D structure: insight into 
the tetraspanin superfamily structural motifs. EMBO J 20, 12-18. 
Klareskog, L., Padyukov, L., and Alfredsson, L. (2007). Smoking as a trigger for 
inflammatory rheumatic diseases. Curr Opin Rheumatol 19, 49-54. 
Klimiuk, P.A., Sierakowski, S., Domyslawska, I., Fiedorczyk, M., and Chwiecko, J. 
(2004). Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-
selectin) and vascular endothelial growth factor levels in serum of rheumatoid 
arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol 
Ther Exp (Warsz) 52, 36-42. 
Kobayashi, K., Suda, T., Nan-Ya, K., Sakaguchi, N., Sakaguchi, S., and Miki, I. 
(2006). Cytokine production profile of splenocytes derived from zymosan A-treated 
SKG mice developing arthritis. Inflamm Res 55, 335-341. 
Koch, A.E. (2005). Chemokines and their receptors in rheumatoid arthritis: future 
targets? Arthritis Rheum 52, 710-721. 
Koch, A.E., Burrows, J.C., Haines, G.K., Carlos, T.M., Harlan, J.M., and Leibovich, 
S.J. (1991a). Immunolocalization of endothelial and leukocyte adhesion molecules in 
human rheumatoid and osteoarthritic synovial tissues. Lab Invest 64, 313-320. 
Koch, A.E., Kunkel, S.L., Burrows, J.C., Evanoff, H.L., Haines, G.K., Pope, R.M., and 
Strieter, R.M. (1991b). Synovial tissue macrophage as a source of the chemotactic 
cytokine IL-8. J Immunol 147, 2187-2195. 
Koch, A.E., Robinson, P.G., Radosevich, J.A., and Pope, R.M. (1990). Distribution of 
CD45RA and CD45RO T-lymphocyte subsets in rheumatoid arthritis synovial tissue. 
J Clin Immunol 10, 192-199. 
Koenders, M.I., Lubberts, E., van de Loo, F.A., Oppers-Walgreen, B., van den 
Bersselaar, L., Helsen, M.M., Kolls, J.K., Di Padova, F.E., Joosten, L.A., and van 
den Berg, W.B. (2006). Interleukin-17 acts independently of TNF-alpha under 
arthritic conditions. J Immunol 176, 6262-6269. 
Chapter 7      References  
262 
 
Koetz, K., Bryl, E., Spickschen, K., O'Fallon, W.M., Goronzy, J.J., and Weyand, C.M. 
(2000). T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U 
S A 97, 9203-9208. 
Komai-Koma, M., Xu, D., Li, Y., McKenzie, A.N., McInnes, I.B., and Liew, F.Y. 
(2007). IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37, 2779-
2786. 
Kong, Y.Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, 
J., Elliott, R., McCabe, S., et al. (1999). Activated T cells regulate bone loss and joint 
destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309. 
Kop, E.N., Adriaansen, J., Smeets, T.J., Vervoordeldonk, M.J., van Lier, R.A., 
Hamann, J., and Tak, P.P. (2006). CD97 neutralisation increases resistance to 
collagen-induced arthritis in mice. Arthritis Res Ther 8, R155. 
Kop, E.N., Kwakkenbos, M.J., Teske, G.J., Kraan, M.C., Smeets, T.J., Stacey, M., 
Lin, H.H., Tak, P.P., and Hamann, J. (2005). Identification of the epidermal growth 
factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial 
tissue. Arthritis Rheum 52, 442-450. 
Kotake, S., Nanke, Y., Mogi, M., Kawamoto, M., Furuya, T., Yago, T., Kobashigawa, 
T., Togari, A., and Kamatani, N. (2005). IFN-gamma-producing human T cells 
directly induce osteoclastogenesis from human monocytes via the expression of 
RANKL. Eur J Immunol 35, 3353-3363. 
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, 
S., Inoue, K., Kamatani, N., Gillespie, M.T., et al. (1999). IL-17 in synovial fluids from 
patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin 
Invest 103, 1345-1352. 
Kouskoff, V., Korganow, A.S., Duchatelle, V., Degott, C., Benoist, C., and Mathis, D. 
(1996). Organ-specific disease provoked by systemic autoimmunity. Cell 87, 811-
822. 
Kropshofer, H., Spindeldreher, S., Rohn, T.A., Platania, N., Grygar, C., Daniel, N., 
Wolpl, A., Langen, H., Horejsi, V., and Vogt, A.B. (2002). Tetraspan microdomains 
distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat Immunol 3, 
61-68. 
Krzesicki, R.F., Fleming, W.E., Winterrowd, G.E., Hatfield, C.A., Sanders, M.E., and 
Chin, J.E. (1991). T lymphocyte adhesion to human synovial fibroblasts. Role of 
cytokines and the interaction between intercellular adhesion molecule 1 and 
CD11a/CD18. Arthritis Rheum 34, 1245-1253. 
Kuhn, K.A., Kulik, L., Tomooka, B., Braschler, K.J., Arend, W.P., Robinson, W.H., 
and Holers, V.M. (2006). Antibodies against citrullinated proteins enhance tissue 
injury in experimental autoimmune arthritis. J Clin Invest 116, 961-973. 
Kwakkenbos, M.J., Chang, G.W., Lin, H.H., Pouwels, W., de Jong, E.C., van Lier, 
R.A., Gordon, S., and Hamann, J. (2002). The human EGF-TM7 family member 
EMR2 is a heterodimeric receptor expressed on myeloid cells. J Leukoc Biol 71, 
854-862. 
Kwakkenbos, M.J., Pouwels, W., Matmati, M., Stacey, M., Lin, H.H., Gordon, S., van 
Lier, R.A., and Hamann, J. (2005). Expression of the largest CD97 and EMR2 
isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B 
cells. J Leukoc Biol 77, 112-119. 
Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, 
R., Colombero, A., Elliott, G., Scully, S., et al. (1998). Osteoprotegerin ligand is a 
cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176. 
Chapter 7      References  
263 
 
Lacraz, S., Isler, P., Vey, E., Welgus, H.G., and Dayer, J.M. (1994). Direct contact 
between T lymphocytes and monocytes is a major pathway for induction of 
metalloproteinase expression. J Biol Chem 269, 22027-22033. 
Laffon, A., Garcia-Vicuna, R., Humbria, A., Postigo, A.A., Corbi, A.L., de Landazuri, 
M.O., and Sanchez-Madrid, F. (1991). Upregulated expression and function of VLA-4 
fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 
88, 546-552. 
Lagaudriere-Gesbert, C., Le Naour, F., Lebel-Binay, S., Billard, M., Lemichez, E., 
Boquet, P., Boucheix, C., Conjeaud, H., and Rubinstein, E. (1997). Functional 
analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role 
in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF 
activity. Cell Immunol 182, 105-112. 
Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, 
J.D., McClanahan, T., Kastelein, R.A., and Cua, D.J. (2005). IL-23 drives a 
pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 
233-240. 
Lanzavecchia, A., and Sallusto, F. (2002). Progressive differentiation and selection 
of the fittest in the immune response. Nat Rev Immunol 2, 982-987. 
Lanzavecchia, A., and Sallusto, F. (2005). Understanding the generation and 
function of memory T cell subsets. Curr Opin Immunol 17, 326-332. 
Lawson, C.A., Brown, A.K., Bejarano, V., Douglas, S.H., Burgoyne, C.H., 
Greenstein, A.S., Boylston, A.W., Emery, P., Ponchel, F., and Isaacs, J.D. (2006). 
Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high 
regulatory T cell population in peripheral blood. Rheumatology (Oxford) 45, 1210-
1217. 
Lazo, P.A. (2007). Functional implications of tetraspanin proteins in cancer biology. 
Cancer Sci 98, 1666-1677. 
Le Naour, F., Andre, M., Greco, C., Billard, M., Sordat, B., Emile, J.F., Lanza, F., 
Boucheix, C., and Rubinstein, E. (2006). Profiling of the tetraspanin web of human 
colon cancer cells. Mol Cell Proteomics 5, 845-857. 
Lebel-Binay, S., Lagaudriere, C., Fradelizi, D., and Conjeaud, H. (1995). CD82, 
tetra-span-transmembrane protein, is a regulated transducing molecule on U937 
monocytic cell line. J Leukoc Biol 57, 956-963. 
Lee, D.M., Kiener, H.P., Agarwal, S.K., Noss, E.H., Watts, G.F., Chisaka, O., 
Takeichi, M., and Brenner, M.B. (2007a). Cadherin-11 in synovial lining formation 
and pathology in arthritis. Science 315, 1006-1010. 
Lee, H.S., Remmers, E.F., Le, J.M., Kastner, D.L., Bae, S.C., and Gregersen, P.K. 
(2007b). Association of STAT4 with rheumatoid arthritis in the Korean population. 
Mol Med 13, 455-460. 
Lee, H.Y., Jeon, H.S., Song, E.K., Han, M.K., Park, S.I., Lee, S.I., Yun, H.J., Kim, 
J.R., Kim, J.S., Lee, Y.C., et al. (2006). CD40 ligation of rheumatoid synovial 
fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-
dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 
54, 1747-1758. 
Leemans, J.C., te Velde, A.A., Florquin, S., Bennink, R.J., de Bruin, K., van Lier, 
R.A., van der Poll, T., and Hamann, J. (2004). The epidermal growth factor-seven 
transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and 
host defense. J Immunol 172, 1125-1131. 
Levy, S., and Shoham, T. (2005). The tetraspanin web modulates immune-signalling 
complexes. Nat Rev Immunol 5, 136-148. 
Chapter 7      References  
264 
 
Levy, S., Todd, S.C., and Maecker, H.T. (1998). CD81 (TAPA-1): a molecule 
involved in signal transduction and cell adhesion in the immune system. Annu Rev 
Immunol 16, 89-109. 
Li, J., Shen, W., Kong, K., and Liu, Z. (2006). Interleukin-21 induces T-cell activation 
and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 64, 
515-522. 
Li, J.M., Isler, P., Dayer, J.M., and Burger, D. (1995). Contact-dependent stimulation 
of monocytic cells and neutrophils by stimulated human T-cell clones. Immunology 
84, 571-576. 
Li, L., Spendlove, I., Morgan, J., and Durrant, L.G. (2001). CD55 is over-expressed 
in the tumour environment. Br J Cancer 84, 80-86. 
Liang, Y., Nakamura, S., Cui, L., Johkura, K., Ogiwara, N., and Sasaki, K. (2004). 
Three-dimensional expression of adhesion molecules on the superficial synovial 
intima of LPS-induced arthritis of the mouse knee analyzed by immuno-SEM. J 
Electron Microsc (Tokyo) 53, 93-97. 
Lin, W., Haribhai, D., Relland, L.M., Truong, N., Carlson, M.R., Williams, C.B., and 
Chatila, T.A. (2007). Regulatory T cell development in the absence of functional 
Foxp3. Nat Immunol 8, 359-368. 
Linos, A., Worthington, J.W., O'Fallon, W.M., and Kurland, L.T. (1980). The 
epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, 
prevalence, and mortality. Am J Epidemiol 111, 87-98. 
Littler, A.J., Buckley, C.D., Wordsworth, P., Collins, I., Martinson, J., and Simmons, 
D.L. (1997). A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, 
VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J 
Rheumatol 36, 164-169. 
Liu, W., Putnam, A.L., Xu-Yu, Z., Szot, G.L., Lee, M.R., Zhu, S., Gottlieb, P.A., 
Kapranov, P., Gingeras, T.R., Fazekas de St Groth, B., et al. (2006). CD127 
expression inversely correlates with FoxP3 and suppressive function of human CD4+ 
T reg cells. J Exp Med 203, 1701-1711. 
Londei, M., Savill, C.M., Verhoef, A., Brennan, F., Leech, Z.A., Duance, V., Maini, 
R.N., and Feldmann, M. (1989). Persistence of collagen type II-specific T-cell clones 
in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U 
S A 86, 636-640. 
Lopez-Cabrera, M., Santis, A.G., Fernandez-Ruiz, E., Blacher, R., Esch, F., 
Sanchez-Mateos, P., and Sanchez-Madrid, F. (1993). Molecular cloning, expression, 
and chromosomal localization of the human earliest lymphocyte activation antigen 
AIM/CD69, a new member of the C-type animal lectin superfamily of signal-
transmitting receptors. J Exp Med 178, 537-547. 
Lubberts, E., Koenders, M.I., and van den Berg, W.B. (2005). The role of T-cell 
interleukin-17 in conducting destructive arthritis: lessons from animal models. 
Arthritis Res Ther 7, 29-37. 
Lublin, D.M., and Atkinson, J.P. (1989). Decay-accelerating factor: biochemistry, 
molecular biology, and function. Annu Rev Immunol 7, 35-58. 
Lukacik, P., Roversi, P., White, J., Esser, D., Smith, G.P., Billington, J., Williams, 
P.A., Rudd, P.M., Wormald, M.R., Harvey, D.J., et al. (2004). Complement regulation 
at the molecular level: the structure of decay-accelerating factor. Proc Natl Acad Sci 
U S A 101, 1279-1284. 
Lundy, S.K., Sarkar, S., Tesmer, L.A., and Fox, D.A. (2007). Cells of the synovium in 
rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 9, 202. 
Chapter 7      References  
265 
 
Maccioni, M., Zeder-Lutz, G., Huang, H., Ebel, C., Gerber, P., Hergueux, J., Marchal, 
P., Duchatelle, V., Degott, C., van Regenmortel, M., et al. (2002). Arthritogenic 
monoclonal antibodies from K/BxN mice. J Exp Med 195, 1071-1077. 
MacDonald, K.P., Nishioka, Y., Lipsky, P.E., and Thomas, R. (1997). Functional 
CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 100, 2404-
2414. 
Maecker, H.T., Do, M.S., and Levy, S. (1998). CD81 on B cells promotes interleukin 
4 secretion and antibody production during T helper type 2 immune responses. Proc 
Natl Acad Sci U S A 95, 2458-2462. 
Maier, L.M., Anderson, D.E., De Jager, P.L., Wicker, L.S., and Hafler, D.A. (2007). 
Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc Natl Acad Sci U 
S A 104, 18607-18612. 
Maini, R., St Clair, E.W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, 
J., Emery, P., Harriman, G., Feldmann, M., and Lipsky, P. (1999). Infliximab 
(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in 
rheumatoid arthritis patients receiving concomitant methotrexate: a randomised 
phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939. 
Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., 
Antoni, C., Leeb, B., Elliott, M.J., Woody, J.N., et al. (1998). Therapeutic efficacy of 
multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal 
antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. 
Arthritis Rheum 41, 1552-1563. 
Maldonado, A., Mueller, Y.M., Thomas, P., Bojczuk, P., O'Connors, C., and Katsikis, 
P.D. (2003). Decreased effector memory CD45RA+ CD62L- CD8+ T cells and 
increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of 
rheumatoid arthritis patients. Arthritis Res Ther 5, R91-96. 
Malfait, A.M., Butler, D.M., Presky, D.H., Maini, R.N., Brennan, F.M., and Feldmann, 
M. (1998). Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) 
markedly attenuates the severity of the arthritis. Clin Exp Immunol 111, 377-383. 
Mangan, P.R., Harrington, L.E., O'Quinn, D.B., Helms, W.S., Bullard, D.C., Elson, 
C.O., Hatton, R.D., Wahl, S.M., Schoeb, T.R., and Weaver, C.T. (2006). 
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 
441, 231-234. 
Mannion, B.A., Berditchevski, F., Kraeft, S.K., Chen, L.B., and Hemler, M.E. (1996). 
Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 
specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol 157, 
2039-2047. 
Manzo, A., Paoletti, S., Carulli, M., Blades, M.C., Barone, F., Yanni, G., Fitzgerald, 
O., Bresnihan, B., Caporali, R., Montecucco, C., et al. (2005). Systematic 
microanatomical analysis of CXCL13 and CCL21 in situ production and progressive 
lymphoid organization in rheumatoid synovitis. Eur J Immunol 35, 1347-1359. 
Matsui, T., Akahoshi, T., Namai, R., Hashimoto, A., Kurihara, Y., Rana, M., 
Nishimura, A., Endo, H., Kitasato, H., Kawai, S., et al. (2001). Selective recruitment 
of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid 
arthritis. Clin Exp Immunol 125, 155-161. 
Matsumoto, A.K., Martin, D.R., Carter, R.H., Klickstein, L.B., Ahearn, J.M., and 
Fearon, D.T. (1993). Functional dissection of the CD21/CD19/TAPA-1/Leu-13 
complex of B lymphocytes. J Exp Med 178, 1407-1417. 
Matsumoto, I., Staub, A., Benoist, C., and Mathis, D. (1999). Arthritis provoked by 
linked T and B cell recognition of a glycolytic enzyme. Science 286, 1732-1735. 
Chapter 7      References  
266 
 
Matsushima, G.K., Itoh-Lindstrom, Y., and Ting, J.P. (1993). Activation of the HLA-
DRA gene in primary human T lymphocytes: novel usage of TATA and the X and Y 
promoter elements. Mol Cell Biol 13, 5132. 
McGeachy, M.J., and Cua, D.J. (2008). Th17 cell differentiation: the long and 
winding road. Immunity 28, 445-453. 
McInnes, I.B., al-Mughales, J., Field, M., Leung, B.P., Huang, F.P., Dixon, R., 
Sturrock, R.D., Wilkinson, P.C., and Liew, F.Y. (1996). The role of interleukin-15 in 
T-cell migration and activation in rheumatoid arthritis. Nat Med 2, 175-182. 
McInnes, I.B., Leung, B.P., Sturrock, R.D., Field, M., and Liew, F.Y. (1997). 
Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha 
production in rheumatoid arthritis. Nat Med 3, 189-195. 
McInnes, I.B., and Schett, G. (2007). Cytokines in the pathogenesis of rheumatoid 
arthritis. Nat Rev Immunol 7, 429-442. 
Medof, M.E., Kinoshita, T., and Nussenzweig, V. (1984). Inhibition of complement 
activation on the surface of cells after incorporation of decay-accelerating factor 
(DAF) into their membranes. J Exp Med 160, 1558-1578. 
Messi, M., Giacchetto, I., Nagata, K., Lanzavecchia, A., Natoli, G., and Sallusto, F. 
(2003). Memory and flexibility of cytokine gene expression as separable properties of 
human T(H)1 and T(H)2 lymphocytes. Nat Immunol 4, 78-86. 
Miguet, L., Pacaud, K., Felden, C., Hugel, B., Martinez, M.C., Freyssinet, J.M., 
Herbrecht, R., Potier, N., van Dorsselaer, A., and Mauvieux, L. (2006). Proteomic 
analysis of malignant lymphocyte membrane microparticles using double ionization 
coverage optimization. Proteomics 6, 153-171. 
Mihara, M., Moriya, Y., Kishimoto, T., and Ohsugi, Y. (1995). Interleukin-6 (IL-6) 
induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 
receptor. Br J Rheumatol 34, 321-325. 
Mikecz, K., Brennan, F.R., Kim, J.H., and Glant, T.T. (1995). Anti-CD44 treatment 
abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1, 
558-563. 
Miller, M.J., Hejazi, A.S., Wei, S.H., Cahalan, M.D., and Parker, I. (2004). T cell 
repertoire scanning is promoted by dynamic dendritic cell behavior and random T 
cell motility in the lymph node. Proc Natl Acad Sci U S A 101, 998-1003. 
Miltenburg, A.M., van Laar, J.M., de Kuiper, R., Daha, M.R., and Breedveld, F.C. 
(1992). T cells cloned from human rheumatoid synovial membrane functionally 
represent the Th1 subset. Scand J Immunol 35, 603-610. 
Min, D.J., Cho, M.L., Lee, S.H., Min, S.Y., Kim, W.U., Min, J.K., Park, S.H., Cho, 
C.S., and Kim, H.Y. (2004). Augmented production of chemokines by the interaction 
of type II collagen-reactive T cells with rheumatoid synovial fibroblasts. Arthritis 
Rheum 50, 1146-1155. 
Miranda-Carus, M.E., Balsa, A., Benito-Miguel, M., Perez de Ayala, C., and Martin-
Mola, E. (2004). IL-15 and the initiation of cell contact-dependent synovial fibroblast-
T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 
173, 1463-1476. 
Miranda-Carus, M.E., Benito-Miguel, M., Balsa, A., Cobo-Ibanez, T., Perez de Ayala, 
C., Pascual-Salcedo, D., and Martin-Mola, E. (2006). Peripheral blood T 
lymphocytes from patients with early rheumatoid arthritis express RANKL and 
interleukin-15 on the cell surface and promote osteoclastogenesis in autologous 
monocytes. Arthritis Rheum 54, 1151-1164. 
Chapter 7      References  
267 
 
Mittelbrunn, M., Yanez-Mo, M., Sancho, D., Ursa, A., and Sanchez-Madrid, F. 
(2002). Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone 
of the immune synapse in both T lymphocytes and APC. J Immunol 169, 6691-6695. 
Mollinedo, F., Martin-Martin, B., Gajate, C., and Lazo, P.A. (1998). Physiological 
activation of human neutrophils down-regulates CD53 cell surface antigen. J Leukoc 
Biol 63, 699-706. 
Morales-Ducret, J., Wayner, E., Elices, M.J., Alvaro-Gracia, J.M., Zvaifler, N.J., and 
Firestein, G.S. (1992). Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular 
cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. 
J Immunol 149, 1424-1431. 
Morel, J.C., Park, C.C., Zhu, K., Kumar, P., Ruth, J.H., and Koch, A.E. (2002). Signal 
transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-
18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 277, 34679-
34691. 
Morgan, M.E., Flierman, R., van Duivenvoorde, L.M., Witteveen, H.J., van Ewijk, W., 
van Laar, J.M., de Vries, R.R., and Toes, R.E. (2005). Effective treatment of 
collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis 
Rheum 52, 2212-2221. 
Morgan, M.E., Sutmuller, R.P., Witteveen, H.J., van Duivenvoorde, L.M., Zanelli, E., 
Melief, C.J., Snijders, A., Offringa, R., de Vries, R.R., and Toes, R.E. (2003). CD25+ 
cell depletion hastens the onset of severe disease in collagen-induced arthritis. 
Arthritis Rheum 48, 1452-1460. 
Morita, Y., Yamamura, M., Kawashima, M., Harada, S., Tsuji, K., Shibuya, K., 
Maruyama, K., and Makino, H. (1998). Flow cytometric single-cell analysis of 
cytokine production by CD4+ T cells in synovial tissue and peripheral blood from 
patients with rheumatoid arthritis. Arthritis Rheum 41, 1669-1676. 
Moseley, G.W. (2005). Tetraspanin-Fc receptor interactions. Platelets 16, 3-12. 
Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, W., McClanahan, T., 
Kastelein, R.A., Sedgwick, J.D., and Cua, D.J. (2003). Divergent pro- and 
antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp 
Med 198, 1951-1957. 
Nadkarni, S., Mauri, C., and Ehrenstein, M.R. (2007). Anti-TNF-alpha therapy 
induces a distinct regulatory T cell population in patients with rheumatoid arthritis via 
TGF-beta. J Exp Med 204, 33-39. 
Nakae, S., Nambu, A., Sudo, K., and Iwakura, Y. (2003a). Suppression of immune 
induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171, 6173-
6177. 
Nakae, S., Saijo, S., Horai, R., Sudo, K., Mori, S., and Iwakura, Y. (2003b). IL-17 
production from activated T cells is required for the spontaneous development of 
destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci 
U S A 100, 5986-5990. 
Nakatsuka, K., Tanaka, Y., Hubscher, S., Abe, M., Wake, A., Saito, K., Morimoto, I., 
and Eto, S. (1997). Rheumatoid synovial fibroblasts are stimulated by the cellular 
adhesion to T cells through lymphocyte function associated antigen-1/intercellular 
adhesion molecule-1. J Rheumatol 24, 458-464. 
Namekawa, T., Snyder, M.R., Yen, J.H., Goehring, B.E., Leibson, P.J., Weyand, 
C.M., and Goronzy, J.J. (2000). Killer cell activating receptors function as 
costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid 
arthritis. J Immunol 165, 1138-1145. 
Chapter 7      References  
268 
 
Nandakumar, K.S., Backlund, J., Vestberg, M., and Holmdahl, R. (2004). Collagen 
type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the 
arthritis progression is enhanced by CII-reactive T cells. Arthritis Res Ther 6, R544-
550. 
Nanki, T., and Lipsky, P.E. (2000). Cutting edge: stromal cell-derived factor-1 is a 
costimulator for CD4+ T cell activation. J Immunol 164, 5010-5014. 
Nanki, T., Nagasaka, K., Hayashida, K., Saita, Y., and Miyasaka, N. (2001). 
Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from 
patients with rheumatoid arthritis. J Immunol 167, 5381-5385. 
Naylor, K., Li, G., Vallejo, A.N., Lee, W.W., Koetz, K., Bryl, E., Witkowski, J., 
Fulbright, J., Weyand, C.M., and Goronzy, J.J. (2005). The influence of age on T cell 
generation and TCR diversity. J Immunol 174, 7446-7452. 
Nepom, G.T., Byers, P., Seyfried, C., Healey, L.A., Wilske, K.R., Stage, D., and 
Nepom, B.S. (1989). HLA genes associated with rheumatoid arthritis. Identification of 
susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 32, 15-21. 
Netea, M.G., Radstake, T., Joosten, L.A., van der Meer, J.W., Barrera, P., and 
Kullberg, B.J. (2003). Salmonella septicemia in rheumatoid arthritis patients 
receiving anti-tumor necrosis factor therapy: association with decreased interferon-
gamma production and Toll-like receptor 4 expression. Arthritis Rheum 48, 1853-
1857. 
Nichols, T.C., Guthridge, J.M., Karp, D.R., Molina, H., Fletcher, D.R., and Holers, 
V.M. (1998). Gamma-glutamyl transpeptidase, an ecto-enzyme regulator of 
intracellular redox potential, is a component of TM4 signal transduction complexes. 
Eur J Immunol 28, 4123-4129. 
Niedbala, W., Wei, X.Q., Cai, B., Hueber, A.J., Leung, B.P., McInnes, I.B., and Liew, 
F.Y. (2007). IL-35 is a novel cytokine with therapeutic effects against collagen-
induced arthritis through the expansion of regulatory T cells and suppression of Th17 
cells. Eur J Immunol 37, 3021-3029. 
Nielsen, P.A., Olsen, J.V., Podtelejnikov, A.V., Andersen, J.R., Mann, M., and 
Wisniewski, J.R. (2005). Proteomic mapping of brain plasma membrane proteins. 
Mol Cell Proteomics 4, 402-408. 
Nishiuchi, R., Sanzen, N., Nada, S., Sumida, Y., Wada, Y., Okada, M., Takagi, J., 
Hasegawa, H., and Sekiguchi, K. (2005). Potentiation of the ligand-binding activity of 
integrin alpha3beta1 via association with tetraspanin CD151. Proc Natl Acad Sci U S 
A 102, 1939-1944. 
Nurieva, R., Yang, X.O., Martinez, G., Zhang, Y., Panopoulos, A.D., Ma, L., Schluns, 
K., Tian, Q., Watowich, S.S., Jetten, A.M., and Dong, C. (2007). Essential autocrine 
regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480-483. 
Ogata, T., Yamakawa, M., Imai, Y., and Takahashi, T. (1996). Follicular dendritic 
cells adhere to fibronectin and laminin fibers via their respective receptors. Blood 88, 
2995-3003. 
Okamoto, T., Saito, S., Yamanaka, H., Tomatsu, T., Kamatani, N., Ogiuchi, H., 
Uchiyama, T., and Yagi, J. (2003). Expression and function of the co-stimulator 
H4/ICOS on activated T cells of patients with rheumatoid arthritis. J Rheumatol 30, 
1157-1163. 
Olsen, J.V., Andersen, J.R., Nielsen, P.A., Nielsen, M.L., Figeys, D., Mann, M., and 
Wisniewski, J.R. (2004). HysTag--a novel proteomic quantification tool applied to 
differential display analysis of membrane proteins from distinct areas of mouse brain. 
Mol Cell Proteomics 3, 82-92. 
Chapter 7      References  
269 
 
Ong, S.E., and Mann, M. (2005). Mass spectrometry-based proteomics turns 
quantitative. Nat Chem Biol 1, 252-262. 
Oppenheimer-Marks, N., Brezinschek, R.I., Mohamadzadeh, M., Vita, R., and 
Lipsky, P.E. (1998). Interleukin 15 is produced by endothelial cells and increases the 
transendothelial migration of T cells In vitro and in the SCID mouse-human 
rheumatoid arthritis model In vivo. J Clin Invest 101, 1261-1272. 
Oren, R., Takahashi, S., Doss, C., Levy, R., and Levy, S. (1990). TAPA-1, the target 
of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol 
Cell Biol 10, 4007-4015. 
Orozco, G., Alizadeh, B.Z., Delgado-Vega, A.M., Gonzalez-Gay, M.A., Balsa, A., 
Pascual-Salcedo, D., Fernandez-Gutierrez, B., Gonzalez-Escribano, M.F., 
Petersson, I.F., van Riel, P.L., et al. (2008). Association of STAT4 with rheumatoid 
arthritis: a replication study in three European populations. Arthritis Rheum 58, 1974-
1980. 
Padyukov, L., Silva, C., Stolt, P., Alfredsson, L., and Klareskog, L. (2004). A gene-
environment interaction between smoking and shared epitope genes in HLA-DR 
provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 50, 3085-
3092. 
Paleolog, E.M., Hunt, M., Elliott, M.J., Feldmann, M., Maini, R.N., and Woody, J.N. 
(1996). Deactivation of vascular endothelium by monoclonal anti-tumor necrosis 
factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 39, 1082-1091. 
Parry, S.L., Sebbag, M., Feldmann, M., and Brennan, F.M. (1997). Contact with T 
cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J 
Immunol 158, 3673-3681. 
Pasquali, C., Fialka, I., and Huber, L.A. (1999). Subcellular fractionation, 
electromigration analysis and mapping of organelles. J Chromatogr B Biomed Sci 
Appl 722, 89-102. 
Patel, D.D., Zachariah, J.P., and Whichard, L.P. (2001). CXCR3 and CCR5 ligands 
in rheumatoid arthritis synovium. Clin Immunol 98, 39-45. 
Pawlik, A., Ostanek, L., Brzosko, I., Brzosko, M., Masiuk, M., Machalinski, B., and 
Gawronska-Szklarz, B. (2003). The expansion of CD4+CD28- T cells in patients with 
rheumatoid arthritis. Arthritis Res Ther 5, R210-213. 
Pedersen-Lane, J.H., Zurier, R.B., and Lawrence, D.A. (2007). Analysis of the thiol 
status of peripheral blood leukocytes in rheumatoid arthritis patients. J Leukoc Biol 
81, 934-941. 
Peirce, M.J., Wait, R., Begum, S., Saklatvala, J., and Cope, A.P. (2004). Expression 
profiling of lymphocyte plasma membrane proteins. Mol Cell Proteomics 3, 56-65. 
Petrovic-Rackov, L., and Pejnovic, N. (2006). Clinical significance of IL-18, IL-15, IL-
12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 25, 448-
452. 
Petrow, P.K., Thoss, K., Katenkamp, D., and Brauer, R. (1996). Adoptive transfer of 
susceptibility to antigen-induced arthritis into severe combined immunodeficient 
(SCID) mice: role of CD4+ and CD8+ T cells. Immunol Invest 25, 341-353. 
Pierer, M., Kaltenhauser, S., Arnold, S., Wahle, M., Baerwald, C., Hantzschel, H., 
and Wagner, U. (2006). Association of PTPN22 1858 single-nucleotide 
polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the 
risk allele in male compared to female patients. Arthritis Res Ther 8, R75. 
Pitzalis, C., Kingsley, G., Lanchbury, J.S., Murphy, J., and Panayi, G.S. (1987a). 
Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial 
Chapter 7      References  
270 
 
fluid T lymphocyte subsets in rheumatoid arthritis: evidence for "frustrated" 
activation. J Rheumatol 14, 662-666. 
Pitzalis, C., Kingsley, G., Murphy, J., and Panayi, G. (1987b). Abnormal distribution 
of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the 
rheumatoid joint. Clin Immunol Immunopathol 45, 252-258. 
Pohlers, D., Nissler, K., Frey, O., Simon, J., Petrow, P.K., Kinne, R.W., and Brauer, 
R. (2004). Anti-CD4 monoclonal antibody treatment in acute and early chronic 
antigen-induced arthritis: influence on T helper cell activation. Clin Exp Immunol 135, 
409-415. 
Ponchel, F., Morgan, A.W., Bingham, S.J., Quinn, M., Buch, M., Verburg, R.J., 
Henwood, J., Douglas, S.H., Masurel, A., Conaghan, P., et al. (2002). Dysregulated 
lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. 
Blood 100, 4550-4556. 
Postigo, A.A., Garcia-Vicuna, R., Diaz-Gonzalez, F., Arroyo, A.G., De Landazuri, 
M.O., Chi-Rosso, G., Lobb, R.R., Laffon, A., and Sanchez-Madrid, F. (1992). 
Increased binding of synovial T lymphocytes from rheumatoid arthritis to endothelial-
leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 
(VCAM-1). J Clin Invest 89, 1445-1452. 
Potocnik, A.J., Kinne, R., Menninger, H., Zacher, J., Emmrich, F., and Kroczek, R.A. 
(1990). Expression of activation antigens on T cells in rheumatoid arthritis patients. 
Scand J Immunol 31, 213-224. 
Quattrocchi, E., Dallman, M.J., and Feldmann, M. (2000). Adenovirus-mediated gene 
transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune 
arthritis. Arthritis Rheum 43, 1688-1697. 
Ranges, G.E., Sriram, S., and Cooper, S.M. (1985). Prevention of type II collagen-
induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 162, 1105-1110. 
Rantapaa-Dahlqvist, S., de Jong, B.A., Berglin, E., Hallmans, G., Wadell, G., 
Stenlund, H., Sundin, U., and van Venrooij, W.J. (2003). Antibodies against cyclic 
citrullinated peptide and IgA rheumatoid factor predict the development of 
rheumatoid arthritis. Arthritis Rheum 48, 2741-2749. 
Raza, K., Falciani, F., Curnow, S.J., Ross, E.J., Lee, C.Y., Akbar, A.N., Lord, J.M., 
Gordon, C., Buckley, C.D., and Salmon, M. (2005). Early rheumatoid arthritis is 
characterized by a distinct and transient synovial fluid cytokine profile of T cell and 
stromal cell origin. Arthritis Res Ther 7, R784-795. 
Remmers, E.F., Plenge, R.M., Lee, A.T., Graham, R.R., Hom, G., Behrens, T.W., de 
Bakker, P.I., Le, J.M., Lee, H.S., Batliwalla, F., et al. (2007). STAT4 and the risk of 
rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357, 977-986. 
Res, P.C., Schaar, C.G., Breedveld, F.C., van Eden, W., van Embden, J.D., Cohen, 
I.R., and de Vries, R.R. (1988). Synovial fluid T cell reactivity against 65 kD heat 
shock protein of mycobacteria in early chronic arthritis. Lancet 2, 478-480. 
Ribbens, C., Dayer, J.M., and Chizzolini, C. (2000). CD40-CD40 ligand (CD154) 
engagement is required but may not be sufficient for human T helper 1 cell induction 
of interleukin-2- or interleukin-15-driven, contact-dependent, interleukin-1beta 
production by monocytes. Immunology 99, 279-286. 
Rivino, L., Messi, M., Jarrossay, D., Lanzavecchia, A., Sallusto, F., and Geginat, J. 
(2004). Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and 
nonpolarized cells among human CD4+ central memory T cells. J Exp Med 200, 
725-735. 
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., 
Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997). Role of IL-6 and 
Chapter 7      References  
271 
 
its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 
6, 315-325. 
Rooney, T., Murphy, E., Benito, M., Roux-Lombard, P., FitzGerald, O., Dayer, J.M., 
and Bresnihan, B. (2004). Synovial tissue interleukin-18 expression and the 
response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 63, 
1393-1398. 
Roosnek, E., and Lanzavecchia, A. (1991). Efficient and selective presentation of 
antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 173, 487-489. 
Rosa, D., Saletti, G., De Gregorio, E., Zorat, F., Comar, C., D'Oro, U., Nuti, S., 
Houghton, M., Barnaba, V., Pozzato, G., and Abrignani, S. (2005). Activation of 
naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-
associated B lymphocyte disorders. Proc Natl Acad Sci U S A 102, 18544-18549. 
Rossol, M., Meusch, U., Pierer, M., Kaltenhauser, S., Hantzschel, H., Hauschildt, S., 
and Wagner, U. (2007). Interaction between transmembrane TNF and TNFR1/2 
mediates the activation of monocytes by contact with T cells. J Immunol 179, 4239-
4248. 
Rubinstein, E., Le Naour, F., Lagaudriere-Gesbert, C., Billard, M., Conjeaud, H., and 
Boucheix, C. (1996). CD9, CD63, CD81, and CD82 are components of a surface 
tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 26, 
2657-2665. 
Ruprecht, C.R., Gattorno, M., Ferlito, F., Gregorio, A., Martini, A., Lanzavecchia, A., 
and Sallusto, F. (2005). Coexpression of CD25 and CD27 identifies FoxP3+ 
regulatory T cells in inflamed synovia. J Exp Med 201, 1793-1803. 
Ruth, J.H., Amin, M.A., Woods, J.M., He, X., Samuel, S., Yi, N., Haas, C.S., Koch, 
A.E., and Bullard, D.C. (2005). Accelerated development of arthritis in mice lacking 
endothelial selectins. Arthritis Res Ther 7, R959-970. 
Sacre, S.M., Drexler, S.K., Andreakos, E., Feldmann, M., Brennan, F.M., and 
Foxwell, B.M. (2007). Could toll-like receptors provide a missing link in chronic 
inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid 
tissue. Ann Rheum Dis 66 Suppl 3, iii81-86. 
Sakaguchi, N., Takahashi, T., Hata, H., Nomura, T., Tagami, T., Yamazaki, S., 
Sakihama, T., Matsutani, T., Negishi, I., Nakatsuru, S., and Sakaguchi, S. (2003). 
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes 
autoimmune arthritis in mice. Nature 426, 454-460. 
Saklatvala, J. (1986). Tumour necrosis factor alpha stimulates resorption and inhibits 
synthesis of proteoglycan in cartilage. Nature 322, 547-549. 
Saklatvala, J., Sarsfield, S.J., and Townsend, Y. (1985). Pig interleukin 1. 
Purification of two immunologically different leukocyte proteins that cause cartilage 
resorption, lymphocyte activation, and fever. J Exp Med 162, 1208-1222. 
Sakurai, N., Kuroiwa, T., Ikeuchi, H., Hiramatsu, N., Maeshima, A., Kaneko, Y., 
Hiromura, K., and Nojima, Y. (2008). Expression of IL-19 and its receptors in RA: 
potential role for synovial hyperplasia formation. Rheumatology (Oxford) 47, 815-
820. 
Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. (1999). Two 
subsets of memory T lymphocytes with distinct homing potentials and effector 
functions. Nature 401, 708-712. 
Salmon, M., Scheel-Toellner, D., Huissoon, A.P., Pilling, D., Shamsadeen, N., Hyde, 
H., D'Angeac, A.D., Bacon, P.A., Emery, P., and Akbar, A.N. (1997). Inhibition of T 
cell apoptosis in the rheumatoid synovium. J Clin Invest 99, 439-446. 
Chapter 7      References  
272 
 
Santoni, V., Molloy, M., and Rabilloud, T. (2000). Membrane proteins and 
proteomics: un amour impossible? Electrophoresis 21, 1054-1070. 
Sawa, S., Kamimura, D., Jin, G.H., Morikawa, H., Kamon, H., Nishihara, M., 
Ishihara, K., Murakami, M., and Hirano, T. (2006). Autoimmune arthritis associated 
with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent 
homeostatic proliferation of CD4+ T cells. J Exp Med 203, 1459-1470. 
Schellekens, G.A., de Jong, B.A., van den Hoogen, F.H., van de Putte, L.B., and van 
Venrooij, W.J. (1998). Citrulline is an essential constituent of antigenic determinants 
recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101, 273-
281. 
Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., 
Saldate, C., Li, T., Aranda, R., Becker, J.C., et al. (2008). Efficacy and safety of 
abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, 
double-blind, placebo-controlled study in patients with rheumatoid arthritis and an 
inadequate response to methotrexate. Ann Rheum Dis 67, 1096-1103. 
Schmidt, D., Goronzy, J.J., and Weyand, C.M. (1996). CD4+ CD7- CD28- T cells are 
expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin 
Invest 97, 2027-2037. 
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., 
Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005). IL-33, an interleukin-1-like 
cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper 
type 2-associated cytokines. Immunity 23, 479-490. 
Sebbag, M., Parry, S.L., Brennan, F.M., and Feldmann, M. (1997). Cytokine 
stimulation of T lymphocytes regulates their capacity to induce monocyte production 
of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to 
pathophysiology of rheumatoid arthritis. Eur J Immunol 27, 624-632. 
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., 
Solomon, M., Selby, W., Alexander, S.I., Nanan, R., et al. (2006). Expression of 
interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and 
activated T cells. J Exp Med 203, 1693-1700. 
Sekine, C., Yagita, H., Miyasaka, N., and Okumura, K. (1998). Expression and 
function of CD40 in rheumatoid arthritis synovium. J Rheumatol 25, 1048-1053. 
Shenoy-Scaria, A.M., Kwong, J., Fujita, T., Olszowy, M.W., Shaw, A.S., and Lublin, 
D.M. (1992). Signal transduction through decay-accelerating factor. Interaction of 
glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 
1. J Immunol 149, 3535-3541. 
Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996). Mass spectrometric 
sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68, 850-858. 
Shih, F.F., Mandik-Nayak, L., Wipke, B.T., and Allen, P.M. (2004). Massive thymic 
deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T 
regulatory cells. J Exp Med 199, 323-335. 
Shoham, T., Rajapaksa, R., Boucheix, C., Rubinstein, E., Poe, J.C., Tedder, T.F., 
and Levy, S. (2003). The tetraspanin CD81 regulates the expression of CD19 during 
B cell development in a postendoplasmic reticulum compartment. J Immunol 171, 
4062-4072. 
Shoham, T., Rajapaksa, R., Kuo, C.C., Haimovich, J., and Levy, S. (2006). Building 
of the tetraspanin web: distinct structural domains of CD81 function in different 
cellular compartments. Mol Cell Biol 26, 1373-1385. 
Simons, K., and Ikonen, E. (1997). Functional rafts in cell membranes. Nature 387, 
569-572. 
Chapter 7      References  
273 
 
Singh, S.P., Zhang, H.H., Foley, J.F., Hedrick, M.N., and Farber, J.M. (2008). 
Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. 
J Immunol 180, 214-221. 
Smith, M.D., Barg, E., Weedon, H., Papengelis, V., Smeets, T., Tak, P.P., Kraan, M., 
Coleman, M., and Ahern, M.J. (2003). Microarchitecture and protective mechanisms 
in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum 
Dis 62, 303-307. 
Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., 
Alecock, E., Woodworth, T., and Alten, R. (2008). Effect of interleukin-6 receptor 
inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a 
double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997. 
Springer, T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte 
emigration: the multistep paradigm. Cell 76, 301-314. 
St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, 
P., Keystone, E., Schiff, M., Kalden, J.R., Wang, B., et al. (2004). Combination of 
infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, 
controlled trial. Arthritis Rheum 50, 3432-3443. 
Stastny, P. (1976). Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 
57, 1148-1157. 
Sutton, B., Corper, A., Bonagura, V., and Taussig, M. (2000). The structure and 
origin of rheumatoid factors. Immunol Today 21, 177-183. 
Szekanecz, Z., and Koch, A.E. (2007). Macrophages and their products in 
rheumatoid arthritis. Curr Opin Rheumatol 19, 289-295. 
Tada, Y., Nagasawa, K., Ho, A., Morito, F., Ushiyama, O., Suzuki, N., Ohta, H., and 
Mak, T.W. (1999). CD28-deficient mice are highly resistant to collagen-induced 
arthritis. J Immunol 162, 203-208. 
Tak, P.P., Bacchi, M., and Bertolino, M. (2006). Pharmacokinetics of IL-18 binding 
protein in healthy volunteers and subjects with rheumatoid arthritis or plaque 
psoriasis. Eur J Drug Metab Pharmacokinet 31, 109-116. 
Tak, P.P., Taylor, P.C., Breedveld, F.C., Smeets, T.J., Daha, M.R., Kluin, P.M., 
Meinders, A.E., and Maini, R.N. (1996). Decrease in cellularity and expression of 
adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody 
treatment in patients with rheumatoid arthritis. Arthritis Rheum 39, 1077-1081. 
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, 
A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000). T-cell-mediated regulation of 
osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 
408, 600-605. 
Takemura, S., Braun, A., Crowson, C., Kurtin, P.J., Cofield, R.H., O'Fallon, W.M., 
Goronzy, J.J., and Weyand, C.M. (2001). Lymphoid neogenesis in rheumatoid 
synovitis. J Immunol 167, 1072-1080. 
Tanaka, M., Harigai, M., Kawaguchi, Y., Ohta, S., Sugiura, T., Takagi, K., Ohsako-
Higami, S., Fukasawa, C., Hara, M., and Kamatani, N. (2001). Mature form of 
interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to 
interferon-gamma production by synovial T cells. J Rheumatol 28, 1779-1787. 
Tarrant, J.M., Robb, L., van Spriel, A.B., and Wright, M.D. (2003). Tetraspanins: 
molecular organisers of the leukocyte surface. Trends Immunol 24, 610-617. 
Taylor, P.C., Peters, A.M., Paleolog, E., Chapman, P.T., Elliott, M.J., McCloskey, R., 
Feldmann, M., and Maini, R.N. (2000). Reduction of chemokine levels and leukocyte 
traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid 
arthritis. Arthritis Rheum 43, 38-47. 
Chapter 7      References  
274 
 
Taylor, P.C., Plater-Zyberk, C., and Maini, R.N. (1995). The role of the B cells in the 
adoptive transfer of collagen-induced arthritis from DBA/1 (H-2q) to SCID (H-2d) 
mice. Eur J Immunol 25, 763-769. 
Thornton, A.M., and Shevach, E.M. (2000). Suppressor effector function of 
CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164, 183-
190. 
Todd, S.C., Lipps, S.G., Crisa, L., Salomon, D.R., and Tsoukas, C.D. (1996). CD81 
expressed on human thymocytes mediates integrin activation and interleukin 2-
dependent proliferation. J Exp Med 184, 2055-2060. 
Tohami, T., Drucker, L., Radnay, J., Shapira, H., and Lishner, M. (2004). Expression 
of tetraspanins in peripheral blood leukocytes: a comparison between normal and 
infectious conditions. Tissue Antigens 64, 235-242. 
Tosello, A.C., Mary, F., Amiot, M., Bernard, A., and Mary, D. (1998). Activation of T 
cells via CD55: recruitment of early components of the CD3-TCR pathway is 
required for IL-2 secretion. J Inflamm 48, 13-27. 
Tran, C.N., Davis, M.J., Tesmer, L.A., Endres, J.L., Motyl, C.D., Smuda, C., Somers, 
E.C., Chung, K.C., Urquhart, A.G., Lundy, S.K., et al. (2007a). Presentation of 
arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. 
Arthritis Rheum 56, 1497-1506. 
Tran, C.N., Lundy, S.K., White, P.T., Endres, J.L., Motyl, C.D., Gupta, R., Wilke, 
C.M., Shelden, E.A., Chung, K.C., Urquhart, A.G., and Fox, D.A. (2007b). Molecular 
interactions between T cells and fibroblast-like synoviocytes: role of membrane 
tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 171, 1588-
1598. 
Tran, C.N., Thacker, S.G., Louie, D.M., Oliver, J., White, P.T., Endres, J.L., 
Urquhart, A.G., Chung, K.C., and Fox, D.A. (2008). Interactions of T cells with 
fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3. J 
Immunol 180, 2989-2998. 
Tsai, C., Diaz, L.A., Jr., Singer, N.G., Li, L.L., Kirsch, A.H., Mitra, R., Nickoloff, B.J., 
Crofford, L.J., and Fox, D.A. (1996). Responsiveness of human T lymphocytes to 
bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. 
Arthritis Rheum 39, 125-136. 
Tseng, C.T., and Klimpel, G.R. (2002). Binding of the hepatitis C virus envelope 
protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195, 43-49. 
Tsitsikov, E.N., Gutierrez-Ramos, J.C., and Geha, R.S. (1997). Impaired CD19 
expression and signaling, enhanced antibody response to type II T independent 
antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci U S A 
94, 10844-10849. 
Tsoulfa, G., Rook, G.A., Bahr, G.M., Sattar, M.A., Behbehani, K., Young, D.B., 
Mehlert, A., Van-Embden, J.D., Hay, F.C., Isenberg, D.A., and et al. (1989). Elevated 
IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic 
of patients with rheumatoid arthritis. Scand J Immunol 30, 519-527. 
Ueki, Y., Eguchi, K., Shimada, H., Nakashima, M., Ida, H., Miyake, S., Nagataki, S., 
and Tominaga, Y. (1994). Increase in adhesion molecules on CD4+ cells and CD4+ 
cell subsets in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 21, 
1003-1010. 
Unutmaz, D., Pileri, P., and Abrignani, S. (1994). Antigen-independent activation of 
naive and memory resting T cells by a cytokine combination. J Exp Med 180, 1159-
1164. 
Chapter 7      References  
275 
 
Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E.M., and 
Lipsky, P.E. (2006). TNF downmodulates the function of human CD4+CD25hi T-
regulatory cells. Blood 108, 253-261. 
van Amelsfort, J.M., Jacobs, K.M., Bijlsma, J.W., Lafeber, F.P., and Taams, L.S. 
(2004). CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the 
presence, phenotype, and function between peripheral blood and synovial fluid. 
Arthritis Rheum 50, 2775-2785. 
van Amelsfort, J.M., van Roon, J.A., Noordegraaf, M., Jacobs, K.M., Bijlsma, J.W., 
Lafeber, F.P., and Taams, L.S. (2007). Proinflammatory mediator-induced reversal 
of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. 
Arthritis Rheum 56, 732-742. 
van Beelen, A.J., Zelinkova, Z., Taanman-Kueter, E.W., Muller, F.J., Hommes, D.W., 
Zaat, S.A., Kapsenberg, M.L., and de Jong, E.C. (2007). Stimulation of the 
intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-
17 production in human memory T cells. Immunity 27, 660-669. 
Van Boxel, J.A., and Paget, S.A. (1975). Predominantly T-cell infiltrate in rheumatoid 
synovial membranes. N Engl J Med 293, 517-520. 
van der Helm-van Mil, A.H., Verpoort, K.N., Breedveld, F.C., Huizinga, T.W., Toes, 
R.E., and de Vries, R.R. (2006). The HLA-DRB1 shared epitope alleles are primarily 
a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent 
risk factor for development of rheumatoid arthritis. Arthritis Rheum 54, 1117-1121. 
van Dinther-Janssen, A.C., Kraal, G., van Soesbergen, R.M., Scheper, R.J., and 
Meijer, C.J. (1994). Immunohistological and functional analysis of adhesion molecule 
expression in the rheumatoid synovial lining layer. Implications for synovial lining cell 
destruction. J Rheumatol 21, 1998-2004. 
Van Eden, W., and Waksman, B.H. (2003). Immune regulation in adjuvant-induced 
arthritis: possible implications for innovative therapeutic strategies in arthritis. 
Arthritis Rheum 48, 1788-1796. 
van Mierlo, G.J., Scherer, H.U., Hameetman, M., Morgan, M.E., Flierman, R., 
Huizinga, T.W., and Toes, R.E. (2008). Cutting edge: TNFR-shedding by 
CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J 
Immunol 180, 2747-2751. 
van Oene, M., Wintle, R.F., Liu, X., Yazdanpanah, M., Gu, X., Newman, B., Kwan, 
A., Johnson, B., Owen, J., Greer, W., et al. (2005). Association of the lymphoid 
tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's 
disease, in Canadian populations. Arthritis Rheum 52, 1993-1998. 
van Roon, J.A., Verweij, M.C., Wijk, M.W., Jacobs, K.M., Bijlsma, J.W., and Lafeber, 
F.P. (2005). Increased intraarticular interleukin-7 in rheumatoid arthritis patients 
stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. 
Arthritis Rheum 52, 1700-1710. 
van Spriel, A.B., Puls, K.L., Sofi, M., Pouniotis, D., Hochrein, H., Orinska, Z., 
Knobeloch, K.P., Plebanski, M., and Wright, M.D. (2004). A regulatory role for CD37 
in T cell proliferation. J Immunol 172, 2953-2961. 
van Zeben, D., Hazes, J.M., Zwinderman, A.H., Cats, A., van der Voort, E.A., and 
Breedveld, F.C. (1992). Clinical significance of rheumatoid factors in early 
rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 51, 1029-1035. 
Vang, T., Congia, M., Macis, M.D., Musumeci, L., Orru, V., Zavattari, P., Nika, K., 
Tautz, L., Tasken, K., Cucca, F., et al. (2005). Autoimmune-associated lymphoid 
tyrosine phosphatase is a gain-of-function variant. Nat Genet 37, 1317-1319. 
Chapter 7      References  
276 
 
Veale, D.J., Maple, C., Kirk, G., McLaren, M., and Belch, J.J. (1998). Soluble cell 
adhesion molecules--P-selectin and ICAM-1, and disease activity in patients 
receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 27, 296-
299. 
Veldhoen, M., Hocking, R.J., Flavell, R.A., and Stockinger, B. (2006). Signals 
mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, 
but chronic inflammation is needed to sustain disease. Nat Immunol 7, 1151-1156. 
Vermeire, K., Heremans, H., Vandeputte, M., Huang, S., Billiau, A., and Matthys, P. 
(1997). Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. 
J Immunol 158, 5507-5513. 
Vey, E., Burger, D., and Dayer, J.M. (1996). Expression and cleavage of tumor 
necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell 
lines upon direct contact with stimulated T cells. Eur J Immunol 26, 2404-2409. 
Vey, E., Dayer, J.M., and Burger, D. (1997). Direct contact with stimulated T cells 
induces the expression of IL-1beta and IL-1 receptor antagonist in human 
monocytes. Involvement of serine/threonine phosphatases in differential regulation. 
Cytokine 9, 480-487. 
Vey, E., Zhang, J.H., and Dayer, J.M. (1992). IFN-gamma and 1,25(OH)2D3 induce 
on THP-1 cells distinct patterns of cell surface antigen expression, cytokine 
production, and responsiveness to contact with activated T cells. J Immunol 149, 
2040-2046. 
Visser, L., de Vos, A.F., Hamann, J., Melief, M.J., van Meurs, M., van Lier, R.A., 
Laman, J.D., and Hintzen, R.Q. (2002). Expression of the EGF-TM7 receptor CD97 
and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol 132, 156-163. 
Voehringer, D.W., Hirschberg, D.L., Xiao, J., Lu, Q., Roederer, M., Lock, C.B., 
Herzenberg, L.A., and Steinman, L. (2000). Gene microarray identification of redox 
and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc 
Natl Acad Sci U S A 97, 2680-2685. 
Volin, M.V., Shah, M.R., Tokuhira, M., Haines, G.K., Woods, J.M., and Koch, A.E. 
(1998). RANTES expression and contribution to monocyte chemotaxis in arthritis. 
Clin Immunol Immunopathol 89, 44-53. 
Waase, I., Kayser, C., Carlson, P.J., Goronzy, J.J., and Weyand, C.M. (1996). 
Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their 
unaffected siblings. Arthritis Rheum 39, 904-913. 
Wack, A., Soldaini, E., Tseng, C., Nuti, S., Klimpel, G., and Abrignani, S. (2001). 
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-
stimulatory signal for human T cells. Eur J Immunol 31, 166-175. 
Wagner, U.G., Koetz, K., Weyand, C.M., and Goronzy, J.J. (1998). Perturbation of 
the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 95, 14447-
14452. 
Wahid, S., Blades, M.C., De Lord, D., Brown, I., Blake, G., Yanni, G., Haskard, D.O., 
Panayi, G.S., and Pitzalis, C. (2000). Tumour necrosis factor-alpha (TNF-alpha) 
enhances lymphocyte migration into rheumatoid synovial tissue transplanted into 
severe combined immunodeficient (SCID) mice. Clin Exp Immunol 122, 133-142. 
Wait, R., Gianazza, E., Eberini, I., Sironi, L., Dunn, M.J., Gemeiner, M., and Miller, I. 
(2001). Proteins of rat serum, urine, and cerebrospinal fluid: VI. Further protein 
identifications and interstrain comparison. Electrophoresis 22, 3043-3052. 
Waldmann, T.A. (1994). Lymphokine receptors: a target for immunotherapy of 
lymphomas. Ann Oncol 5 Suppl 1, 13-17. 
Chapter 7      References  
277 
 
Wallin, E., and von Heijne, G. (1998). Genome-wide analysis of integral membrane 
proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci 7, 1029-
1038. 
Walter, U.M., and Issekutz, A.C. (1997). The role of E- and P-selectin in neutrophil 
and monocyte migration in adjuvant-induced arthritis in the rat. Eur J Immunol 27, 
1498-1505. 
Wang, A.Z., Wang, J.C., Fisher, G.W., and Diamond, H.S. (1997). Interleukin-1beta-
stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is 
inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. 
Arthritis Rheum 40, 1298-1307. 
Wang, C.R., and Liu, M.F. (2003). Regulation of CCR5 expression and MIP-1alpha 
production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 
132, 371-378. 
Wang, T., Ward, Y., Tian, L., Lake, R., Guedez, L., Stetler-Stevenson, W.G., and 
Kelly, K. (2005). CD97, an adhesion receptor on inflammatory cells, stimulates 
angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 
105, 2836-2844. 
Webb, L.M., Walmsley, M.J., and Feldmann, M. (1996). Prevention and amelioration 
of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: 
requirement for both B7-1 and B7-2. Eur J Immunol 26, 2320-2328. 
Westhovens, R., Verwilghen, J., and Dequeker, J. (1997). Total lymphoid irradiation 
in rheumatoid arthritis. A ten-year followup. Arthritis Rheum 40, 426-429. 
Wilkins, M.R., Gasteiger, E., Sanchez, J.C., Bairoch, A., and Hochstrasser, D.F. 
(1998). Two-dimensional gel electrophoresis for proteome projects: the effects of 
protein hydrophobicity and copy number. Electrophoresis 19, 1501-1505. 
Wilkins, M.R., Sanchez, J.C., Gooley, A.A., Appel, R.D., Humphery-Smith, I., 
Hochstrasser, D.F., and Williams, K.L. (1996). Progress with proteome projects: why 
all proteins expressed by a genome should be identified and how to do it. Biotechnol 
Genet Eng Rev 13, 19-50. 
Williams, L.M., Ricchetti, G., Sarma, U., Smallie, T., and Foxwell, B.M. (2004). 
Interleukin-10 suppression of myeloid cell activation--a continuing puzzle. 
Immunology 113, 281-292. 
Williams, R.O., Feldmann, M., and Maini, R.N. (1992). Anti-tumor necrosis factor 
ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U 
S A 89, 9784-9788. 
Wilm, M., Shevchenko, A., Houthaeve, T., Breit, S., Schweigerer, L., Fotsis, T., and 
Mann, M. (1996). Femtomole sequencing of proteins from polyacrylamide gels by 
nano-electrospray mass spectrometry. Nature 379, 466-469. 
Wilson, N.J., Boniface, K., Chan, J.R., McKenzie, B.S., Blumenschein, W.M., 
Mattson, J.D., Basham, B., Smith, K., Chen, T., Morel, F., et al. (2007). 
Development, cytokine profile and function of human interleukin 17-producing helper 
T cells. Nat Immunol 8, 950-957. 
Witherden, D.A., Boismenu, R., and Havran, W.L. (2000). CD81 and CD28 
costimulate T cells through distinct pathways. J Immunol 165, 1902-1909. 
Wooley, P.H., Luthra, H.S., Lafuse, W.P., Huse, A., Stuart, J.M., and David, C.S. 
(1985). Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using 
monoclonal and polyclonal anti-Ia antisera. J Immunol 134, 2366-2374. 
Wooley, P.H., Luthra, H.S., Stuart, J.M., and David, C.S. (1981). Type II collagen-
induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and 
antibody correlates. J Exp Med 154, 688-700. 
Chapter 7      References  
278 
 
Wu, C.C., MacCoss, M.J., Howell, K.E., and Yates, J.R., 3rd (2003). A method for 
the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 21, 
532-538. 
Xiao, X., Kroemer, A., Gao, W., Ishii, N., Demirci, G., and Li, X.C. (2008). 
OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by 
expanding memory T cells in vivo. J Immunol 181, 3193-3201. 
Xu, D., Jiang, H.R., Kewin, P., Li, Y., Mu, R., Fraser, A.R., Pitman, N., Kurowska-
Stolarska, M., McKenzie, A.N., McInnes, I.B., and Liew, F.Y. (2008). IL-33 
exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U 
S A 105, 10913-10918. 
Xu, Y., and Song, G. (2004). The role of CD40-CD154 interaction in cell 
immunoregulation. J Biomed Sci 11, 426-438. 
Yagi, H., Nomura, T., Nakamura, K., Yamazaki, S., Kitawaki, T., Hori, S., Maeda, M., 
Onodera, M., Uchiyama, T., Fujii, S., and Sakaguchi, S. (2004). Crucial role of 
FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. 
Int Immunol 16, 1643-1656. 
Yamada, M., Sumida, Y., Fujibayashi, A., Fukaguchi, K., Sanzen, N., Nishiuchi, R., 
and Sekiguchi, K. (2008). The tetraspanin CD151 regulates cell morphology and 
intracellular signaling on laminin-511. FEBS J 275, 3335-3351. 
Yanaba, K., Bouaziz, J.D., Matsushita, T., Magro, C.M., St Clair, E.W., and Tedder, 
T.F. (2008). B-lymphocyte contributions to human autoimmune disease. Immunol 
Rev 223, 284-299. 
Yi, H., Zhen, Y., Jiang, L., Zheng, J., and Zhao, Y. (2006). The phenotypic 
characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol 
Immunol 3, 189-195. 
Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., 
Sudo, T., and Shultz, L.D. (1990). The murine mutation osteopetrosis is in the coding 
region of the macrophage colony stimulating factor gene. Nature 345, 442-444. 
Yoshino, S., Cleland, L.G., and Mayrhofer, G. (1991). Treatment of collagen-induced 
arthritis in rats with a monoclonal antibody against the alpha/beta T cell antigen 
receptor. Arthritis Rheum 34, 1039-1047. 
Yoshino, S., and Yoshino, J. (1992). Suppression of chronic antigen-induced arthritis 
in rats by a monoclonal antibody against the T cell receptor alpha beta. Cell Immunol 
144, 382-391. 
Young, D.A., Hegen, M., Ma, H.L., Whitters, M.J., Albert, L.M., Lowe, L., Senices, 
M., Wu, P.W., Sibley, B., Leathurby, Y., et al. (2007). Blockade of the interleukin-
21/interleukin-21 receptor pathway ameliorates disease in animal models of 
rheumatoid arthritis. Arthritis Rheum 56, 1152-1163. 
Yu, M.J., Pisitkun, T., Wang, G., Shen, R.F., and Knepper, M.A. (2006). LC-MS/MS 
analysis of apical and basolateral plasma membranes of rat renal collecting duct 
cells. Mol Cell Proteomics 5, 2131-2145. 
Yunta, M., and Lazo, P.A. (2003). Apoptosis protection and survival signal by the 
CD53 tetraspanin antigen. Oncogene 22, 1219-1224. 
Yunta, M., Oliva, J.L., Barcia, R., Horejsi, V., Angelisova, P., and Lazo, P.A. (2002). 
Transient activation of the c-Jun N-terminal kinase (JNK) activity by ligation of the 
tetraspan CD53 antigen in different cell types. Eur J Biochem 269, 1012-1021. 
Zhang, L., Xie, J., Wang, X., Liu, X., Tang, X., Cao, R., Hu, W., Nie, S., Fan, C., and 
Liang, S. (2005). Proteomic analysis of mouse liver plasma membrane: use of 
differential extraction to enrich hydrophobic membrane proteins. Proteomics 5, 4510-
4524. 
Chapter 7      References  
279 
 
Zhang, X.A., Bontrager, A.L., and Hemler, M.E. (2001). Transmembrane-4 
superfamily proteins associate with activated protein kinase C (PKC) and link PKC to 
specific beta(1) integrins. J Biol Chem 276, 25005-25013. 
Zhao, W., Zhang, L., Kobari, Y., Misaki, Y., and Yamamoto, K. (2004). Analysis of 
accumulating clonotypes of T cell in joints of a spontaneous murine model of 
rheumatoid arthritis. Cell Mol Immunol 1, 300-303. 
Zheng, S.G., Gray, J.D., Ohtsuka, K., Yamagiwa, S., and Horwitz, D.A. (2002). 
Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- 
precursors. J Immunol 169, 4183-4189. 
Zheng, Y., Manzotti, C.N., Burke, F., Dussably, L., Qureshi, O., Walker, L.S., and 
Sansom, D.M. (2008). Acquisition of suppressive function by activated human CD4+ 
CD25- T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol 
181, 1683-1691. 
Zuo, X., and Speicher, D.W. (2000). A method for global analysis of complex 
proteomes using sample prefractionation by solution isoelectrofocusing prior to two-
dimensional electrophoresis. Anal Biochem 284, 266-278. 
 
       
280 
 
 
 
 
 
 
 
 
Chapter 8 
Appendix 
Open Access
Available online http://arthritis-research.com/content/10/2/R36
Page 1 of 13
(page number not for citation purposes)
Vol 10 No 2Research article
Resting CD4+ effector memory T cells are precursors of 
bystander-activated effectors: a surrogate model of rheumatoid 
arthritis synovial T-cell function
Fionula M Brennan1, Nicola MG Smith1, Sally Owen1, Ching Li1, Parisa Amjadi1, Patricia Green1, 
Anna Andersson1, Andrew C Palfreeman1, Philippa Hillyer1, Andrew Foey2, Jonathan T Beech1 and 
Marc Feldmann1
1Kennedy Institute of Rheumatology Division, Imperial College Faculty of Medicine, Aspenlea Road, London, W6 8LH, UK
2School of Biological Sciences, University of Plymouth, Drake Circus, Plymouth, PL4 8AA, UK
Corresponding author: Fionula M Brennan, f.brennan@imperial.ac.uk
Received: 2 Nov 2007 Revisions requested: 12 Dec 2007 Revisions received: 4 Mar 2008 Accepted: 19 Mar 2008 Published: 19 Mar 2008
Arthritis Research & Therapy 2008, 10:R36 (doi:10.1186/ar2390)
This article is online at: http://arthritis-research.com/content/10/2/R36
© 2008 Brennan et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.  
Abstract
Background Previously we described a system whereby human
peripheral blood T cells stimulated for 8 days in a cytokine
cocktail acquired effector function for contact-dependent
induction of proinflammatory cytokines from monocytes. We
termed these cells cytokine-activated (Tck) cells and found that
the signalling pathways elicited in the responding monocytes
were identical whether they were placed in contact with Tck
cells or with T cells isolated from rheumatoid arthritis (RA)
synovial tissue.
Methods Here, using magnetic beads and fluorescence-
activated cell sorting, we extensively phenotype the Tck effector
cells and conclude that effector function resides within the
CD4+CD45RO+, CCR7-, CD49dhigh population, and that these
cells are derived from the effector memory CD4+ T cells in
resting blood.
Results After stimulation in culture, these cells produce a wide
range of T-cell cytokines, undergo proliferation and differentiate
to acquire an extensively activated phenotype resembling RA
synovial T cells. Blocking antibodies against CD69, CD18, or
CD49d resulted in a reduction of tumour necrosis factor-α
production from monocytes stimulated with CD4+CD45RO+
Tck cells in the co-culture assay. Moreover, blockade of these
ligands also resulted in inhibition of spontaneous tumour
necrosis factor-α production in RA synovial mononuclear cell
cultures.
Conclusion Taken together, these data strengthen our
understanding of T-cell effector function, highlight the multiple
involvement of different cell surface ligands in cell-cell contact
and, provide novel insights into the pathogenesis of
inflammatory RA disease.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
brought about by the activities of cells and inflammatory
cytokines in the inflamed synovial membrane (for review [1]).
Cells found in diseased synovium are predominantly blood
derived, with large numbers of activated T cells and macro-
phages, fewer plasma cells and dendritic cells, together with
expanded numbers of resident fibroblasts and endothelial
cells [2]. Of the inflammatory cytokines, tumour necrosis factor
(TNF)-α [3] was demonstrated by us to be of pivotal impor-
tance in regulating the cytokine cascade in this tissue [2].
These and other studies led to the hypothesis that TNF-α was
a therapeutic candidate in RA [4], and the demonstration that
TNF-α blockade in murine arthritis ameliorated disease [5] led
to the testing of anti-TNF biologicals in humans [6-10]. Anti-
TNF biologicals are now licensed for use in RA and well over
CCR = CC chemokine receptor; CFSE = carboxyfluoroscein succinimidyl ester; CXCR = CXC chemokine receptor; ELISA = enzyme-linked immu-
nosorbent assay; HLA = human leucocyte antigen; IFN = interferon; IL = interleukin; MFI = mean fluorescence intensity; MNC = mononuclear cell; 
NK = natural killer; RA = rheumatoid arthritis; Tck cell = cytokine-activated T cell; TNF = tumour necrosis factor; Ttcr cell = T-cell receptor stimulated 
T cell; VCAM = vascular cell adhesion molecule; VLA = very late antigen.
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one million people worldwide have been treated with them.
Patients with other chronic inflammatory diseases have also
been treated with these drugs (for review [11]). Despite the
success of these anti-TNF biologicals, which protect joints
from destruction [12], they are not a cure, and blockade of
TNF-α has the potential to compromise the immune response
(for review [13]).
In contrast to the clearly defined role of macrophage-derived
cytokines in the pathogenesis of RA, the relevance and contri-
bution of the T cells is not clear and has been challenged [14].
In particular, the expectation that the increased T cells in the
synovium are a result of clonal expansion to a given antigen
has not been established. An human leucocyte antigen (HLA)-
restricted T-cell response to antigen is suggested, because
more than 80% of Caucasian RA sufferers have a shared
epitope conserved across the HLA-DR1 and HLA-DR4 haplo-
types (0101, 0401, 0404 and 1402) [15]. However, no overall
consensus has been reached on the potential autoantigens
involved. T-cell responses to collagen type II, heat shock pro-
teins and microbial antigens have been reported in a small pro-
portion of RA patients (for review [16]) and, more recently,
autoantibodies to deiminated citrullinated peptides have been
described, suggesting that they may be important autoanti-
gens in this disease. This aside, the concordance for disease
in identical twins is still less than 15%, suggesting that other
factors are of major importance.
More recently, we explored the mechanism(s) underlying
chronic production of TNF-α in RA synovium and found that
the spontaneous TNF-α production from macrophages is
dependent upon direct interaction with T cells found in this tis-
sue [17]. Several publications, principally from the Dayer
group, describe the ability of activated T cells to induce inflam-
matory mediator production from monocytes in a contact-
dependent manner [18-21]. T cells found in the synovial joint
tissue of RA patients are predominantly memory CD4+ cells
[22], with unusual characteristics in that they are small, non-
cycling and nonapoptosing, but have features of activation
[23]. We hypothesized that these T cells are stimulated in the
joint not as a consequence of antigen exposure but through
bystander cytokine-driven activation. To test our hypothesis,
we developed a surrogate model for RA T cells by stimulating
resting normal human peripheral blood lymphocytes with a
cocktail of cytokines (IL-2, IL-6 and TNF-α) for 8 days, as was
previously reported [24]. When fixed (to exclude mediators
released by the T cells) and placed in co-culture with mono-
cytes, proinflammatory cytokines and chemokines were pro-
duced in a cell contact-dependent manner [25,26].
Comparison of cytokine-activated T (Tck) cells with conven-
tional T-cell receptor stimulated T (Ttcr) cells activated by
immobilized anti-CD3 antibodies revealed the latter to be more
activated and stimulate monocytes to produce both IL-10 and
TNF-α [27]. In contrast, Tck cells induced only TNF-α and not
IL-10.
We postulated therefore that Tck cells are important in the
perpetuation of rheumatoid disease [25] because they induce
an unbalanced, proinflammatory cytokine response from
monocytes, and could thus form part of a vicious cycle. Fur-
thermore, we demonstrated that Tck cells mimicked RA T cells
in their effector function, because identical signalling path-
ways activated within the monocyte lead to TNF-α production
[17]. The monocyte phosphoinositide 3-kinase pathway and
the transcription factor NFκB were utilised in a similar manner
for induction of TNFα but was different from those induced by
the Ttcr cells [17]. More recently [26], we demonstrated that
contact-dependent induction of seven different chemokines in
monocytes was also identical between Tck and RA T cells in
the utilization of nuclear factor-κB in the monocyte signalling
pathway but different to that by co-culture with Ttcr cells.
In this paper we investigate the phenotype of the day 8 Tck
effector cells and, by using cell sorting methodologies, we
determine the phenotype of Tck cells and their precursors in
resting blood. Our results demonstrate that the most potent
Tck effectors are from a starting population of
CD4+CD45RO+ memory T cells. Furthermore, in culture these
cells divide, become activated and express increased levels of
activation, adhesion and integrin molecules. Comparison with
T cells extracted from the RA joint indicate that day 8 Tck cells
resemble RA T cells not only in their contact-dependent effec-
tor function but also in their active phenotype, with selective
upregulation of adhesion/integrin molecules (including very
late antigen [VLA]-4) that facilitate the extravasation of T cells
into inflamed tissues, including RA synovium.
Materials and methods
Reagents
IL-6 was kindly gifted by Novartis (Vienna, Austria), IL-2 from
the US National Institutes of Health, IL-10 from Schering
Plough (Kenilworth, NJ, USA), TNF-α from Boehringer Ingel-
heim (Biberach, Germany) and IFN-γ from Bender (Wien, Aus-
tria). Lipopolysaccharide (Salmonella typhimurium) was
purchased from Sigma (Gillingham, UK) and carboxyfluoros-
cein succinimidyl ester (CFSE) from Molecular Probes (Lei-
den, The Netherlands). Flow cytometry antibodies were
purchased from BD Pharmingen (Erembodegem, Belgium).
Blocking antibodies against CD18 (clone TS1/18) and
CD11a (clone HI111) were from BioLegend (Cambridge, UK),
anti-CD69 (clone TP1.55.3) was from Beckman Coulter (High
Wycombe, Buckinghamshire, UK) and anti-CD49d (clone TA-
2) was from Endogen (Rockford, Illinois, USA). Isotype control
antibody (mouse IgG1) was purchased from BD Pharmingen.
Cells cultured in RPMI/glutamine (PAA Laboratories,
Pasching, Germany) were supplemented with 10% normal AB
human serum (Sigma Aldrich, Dorset, UK) or 5% foetal calf
serum (Biowest, Nuaillé, France), as appropriate. All reagents
had under 0.1 units/ml of endotoxin, by LAL (limulus amebo-
cyte lysate) assay (BioWhittaker, Walkersville, MD, USA).
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Isolation of lymphocyte subpopulations by magnetic 
beads
Buffy coats were purchased from the North London Blood
Transfusion Service (Colindale, UK) and peripheral blood
mononuclear cells isolated by Lymphoprep™ (Cedarlane Lab-
oratories Ltd, Ontario, Canada) centrifugation followed by elu-
triation, as described previously [17]. Lymphocyte subsets
were isolated using CD4 or CD8 isolation kits (Dynal, Invitro-
gen, Paisley, UK), in accordance with the manufacturer's
instructions. CD45RO+ cells were isolated negatively using
memory CD4+ T-cell isolation kit from Miltenyi Biotec (Guild-
ford, Surrey, UK), in accordance with the manufacturer's
instructions.
Isolation of T cell sub-populations by cell sorting 
(fluorescence-activated cell sorting)
A cocktail of anti-CD4 with either anti-CD45RA or anti-
CD45RO antibodies was used to sort negatively for memory
or naïve populations, respectively. A cocktail of anti-CD4, anti-
CD45RA and anti-CCR7 (anti-CC chemokine receptor 7)
antibodies was used to sort the CD4+ central (CD45RA-
CCR7-) and effector memory (CD45RA-CCR7+) populations
on day 0. For the day 8 sort, CCR7 antibody was used to sort
positively the central and effector memory cells from the
CD4+CD45RO+ Tck population that was previously isolated
at day 0 using the memory CD4+ T-cell isolation kit from
Miltenyi Biotec, as described above. The resulting cell purity
was routinely assessed at more than 95%. Cells were sorted
on a FACSVantage SE (BD Biosciences, Cambridge, UK).
Tck generation and monocyte co-culture
Tck cells were generated from resting blood with IL-2, IL-6 and
TNF-α, as previously described [17]. Supernatants were har-
vested and T-cell-derived cytokine (IFN-γ, granulocyte macro-
phage colony-stimulating factor, lymphotoxin-α and IL-10)
levels were measured using sandwich ELISA (BD Pharmin-
gen). Tck cells were co-cultured with human peripheral blood
monocytes for 18 hours, as previously described [17], and
TNF-α levels in supernatants were assayed by sandwich
ELISA (Pharmingen, San Diego, CA).
Isolation of RA synovial membrane mononuclear cells 
and phenotypic analysis
Mononuclear cells were obtained from RA synovial tissue, as
previously described [17]. Tissues were from joint replace-
ment surgery specimens provided by the Orthopedic/Plastic
Surgery Department, Charing Cross Hospital, London, UK
(covered by ethics approval RREC 1752), after receiving
signed and informed patient consent and anonymization.
Peripheral blood lymphocytes or RA synovial mononuclear
cells were incubated with fluorochrome-labelled antibodies
and analyzed on a Becton-Dickinson LSR I flow cytometer (BD
Biosciences). A total of 5,000 synovial lymphocytes were col-
lected and results were analyzed using CellQuest Pro soft-
ware (BD Biosciences).
CFSE assay of cell proliferation
Lymphocytes were resuspended in phosphate-buffered saline
with 2.5 to 5 μmol/l CFSE at room temperature for 10 minutes
and washed extensively before culture. At day 8, cells were
counterstained with antibodies to cell surface markers. In all,
50,000 events were routinely collected by flow cytometry.
Blockade of CD18, CD69, CD49d and CD11a on Tck cells 
and RA synovial mononuclear cells
Day 8 Tck cells were fixed in 1% paraformaldehyde at 4°C
before incubation with 1.25 μg per million cells of blocking
antibody against CD18, CD69, CD49d, or CD11a. Isotype
control antibody was also included. After 30 minutes, Tck cells
were washed to remove excess antibodies and co-cultured
with fresh monocytes at a ratio of 8:1 in the presence of puri-
fied human IgG (5 μg/ml). Supernatants were collected after
18 hours and TNF-α was assayed by ELISA. RA synovial
mononuclear cells (MNCs) were incubated in triplicate for 24
hours at 0.5 × 106/ml in the presence or absence of 5 μg/ml
of blocking antibody against CD18, CD69, CD49d, or isotype
control. Supernatants were collected for TNF-α analysis by
ELISA.
Statistical analysis
Results were analysed using Prism 4 software (GraphPad
Software Inc., San Diego, CA, USA) and statistical differences
between groups were analyzed using Wilcoxon rank test, Stu-
dent's t-test, or one-way analysis of variance with Bonferroni
post hoc corrections as appropriate. Correlation association
between groups of data was analysed using nonparametric
(Spearman) correlation analysis.
Results
Phenotype of day eight Tck cells following cytokine 
stimulation
Figure 1a illustrates the CFSE dilution of Tck cells at day 8
counterstained for CD3 (Figure 1b), CD4 (Figure 1c), CD8
(Figure 1d) and CD56 (Figure 1e). At day 8 approximately
40% of cells were undivided (peak M1), whereas 60% of cells
(peaks M2 to M7) underwent up to six rounds of cell division
(Figure 1a). The CD3+CD4+ and CD3+CD8+ cells were
mostly found within the undivided population (M1; Figure
1b,c,d), whereas most CD56+ natural killer (NK) cells (Figure
1e) underwent several rounds of cell division. Pooling data
from seven different donors indicated that overall there was a
small increase in cell number from 1 million/ml at day 0 to 1.43
million/ml at day 8, accounted for predominantly by increases
in CD3-CD56+ NK cells from 0.07 to 0.25 million/ml (about
3.5-fold) and CD3+CD8+ T cells from 0.29 to 0.64 million/ml
(2-fold). CD3+CD4+ T cells numbers were increased less,
from 0.51 to 0.67 million/ml. CD19+ B cells did not survive the
8-day culture (data not shown).
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Tck effector function resides within the CD4+ T-cell 
subset
Figure 2a demonstrates that effector function (induction of
monocyte TNF-α in a dose-dependent manner from 500 to
800 pg/ml by day 8 Tcks) resided in cells derived at day 0 from
the CD4+ (P < 0.001) but not the CD4- population (which
included NK cells, CD8+ cells and NK T cells). Less TNF-α
(<100 pg/ml) was induced with day 8 Tck cells derived from
a starting population of CD4- cells (CD8+, NK T and NK cells).
To exclude the possibility that ligation of CD4 by the anti-CD4
magnetic beads affected the result, Figure 2b shows that the
CD8+ cells enriched at day 0 (which included CD8+ T cells
and NK T cells) did not induce an effector response at day 8
(<50 pg/ml). In contrast, the CD8- enriched cells (which were
predominantly CD4+ along with CD56+ NK cells) induced a
potent Tck effector response (P < 0.001) in a dose-dependent
manner at day 8 (75 to 875 pg/ml).
CD4+CD45RO+ (memory) Tck cells induce greater 
monocyte TNF-α
CD4+CD45RO+ (memory) T cells and CD4+CD45RA+ (naïve)
T cells [28], enriched at day 0 (Figure 3a), were sorted by flow
cytometry from the same donor based on CD45RA expression
and expanded for 8 days. Figure 3b demonstrates that the
memory T cells when cultured at a ratio of 1:1 with monocytes
induced significantly higher levels (P < 0.001) of TNF-α (6.7-
fold more) than did the naïve T cells at the comparable ratio.
This result was confirmed in five independent experiments.
The most potent inducers of monocyte TNF-α production
within the CD4+ memory population was found to reside within
the effector memory population (CD4+CD45RO+CCR7-), irre-
spective of whether the cells were sorted before ex vivo
cytokine expansion or afterward (Figure 3c). Sixfold more TNF-
α was produced by the effector memory cells (CCR7-) sepa-
rated at day 0 (P < 0.001) compared with central memory
cells (CCR7+) and about 13-fold more TNF-α produced by
effector memory cells separated at day 8 (P < 0.001) com-
pared with central memory cells. This result was confirmed in
three independent experiments.
Figure 1
Proliferation pattern of cytokine-stimulated lymphocytes. (a) Resting peripheral blood lymphocytes (PBLs) undergo cell divisions when they are stim-
ulated with cytokines over 8 days. Freshly elutriated lymphocytes were labeled with 5 μmol/l carboxyfluoroscein succinimidyl ester (CFSE) and stim-
ulated with IL-2, IL-6 and tumour necrosis factor-α for 8 days. The number of cell divisions was analysed on day 8 using CellQuest software. Markers 
(M1 to M7) indicate sequential cell divisions. (b-e) Proliferation of subpopulations of PBLs stimulated with cytokines. CFSE-labelled PBLs were 
counterstained with antibodies to CD3 (panel b), CD4 (panel c), CD8 (panel d) and CD56 (panel e). On day 8 the number of cell divisions for each 
subpopulation of PBLs was acquired and analyzed using CellQuest software. Results for all figures are shown from one donor representative of 
seven different experiments.
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Figure 2
The effector function of cytokine-stimulated lymphocytes resides within the CD4+ popula
the CD4+ population. (a) Effector function of the CD4+ cytokine-acti-
vated T (Tck) cell population compared with that of the CD4- Tck popu-
lation. Lymphocytes were positively separated using CD4+ magnetic 
beads (Dynal) before stimulation for 8 days with IL-2, IL-6 and tumour 
necrosis factor (TNF)-α. On day 8 lymphocytes were co-cultured with 
autologous monocytes (at the indicated ratios) for 18 hours before 
supernatants were removed and assayed for TNF-α by ELISA. Super-
natants from cultures of monocytes and T cells alone as negative con-
trols contained under 50 pg/ml. This experiment is representative of 
seven different donors. ***P < 0.001 comparing CD4+ versus CD4- at a 
ratio of 3:1, or comparing CD4+ versus CD4- at a ratio of 5:1 using one-
way analysis of variance (ANOVA) with Bonferroni's multiple compari-
son. Because of limited CD4- cell numbers, a comparison at a ratio of 
7:1 of could not be performed in this experiment. (b) Effector function 
of CD8+ Tck population compared with that of CD8- Tck population. 
Lymphocytes were positively separated using CD8+ magnetic beads 
(Dynal) before stimulation for 8 days with IL-2, IL-6 and TNF-α. On day 
8 lymphocytes were co-cultured with autologous monocytes (at the 
indicated ratios) for 18 hours before the supernatants were removed 
and assayed for TNF-α by ELISA. Supernatants from cultures of mono-
cytes and T cells alone as negative controls contained under 50 pg/ml. 
This experiment is representative of seven different donors. ***P < 
0.001 comparing CD8+ versus CD8- at a ratio of 5:1, or comparing 
CD8+ at versus CD8- at a ratio of 7:1 using one-way ANOVA with Bon-
ferroni's multiple comparison.
Figure 3
Memory T cells exhibit greater effector function than naïve T cells. (a) 
Fluorescence-activated cell sorting analysis of CD4+ subpopulations. 
Resting CD4+ lymphocytes in normal peripheral blood contains 
CD45RA+CCR7+ (naïve) lymphocytes (left panel) together with 
CD45RO+CCR7+ central memory (TCM; right panel) and 
CD45RO+CCR7- effector memory populations (TEM; right panel). (b) 
Effector function resides mainly within the CD4+CD45RO+ population. 
Lymphocytes were sorted into naïve (CD4+CD45RA+) and memory 
(CD4+CD45RO+) populations at time zero, before stimulation for 8 
days with IL-2, IL-6 and tumour necrosis factor (TNF)-α. Lymphocytes 
were then co-cultured with monocytes at a ratio of 0.5:1 and 1:1 for 18 
hours and the supernatants assayed in triplicate for TNF-α production 
by ELISA. ***P < 0.001 comparing CD4+CD45RA+ versus 
CD4+CD45RO+ populations using one-way analysis of variance 
(ANOVA) with Bonferroni's multiple comparison. (c) Effector function 
resides predominates within CD4+ effector memory population. 
CD45RO+ cells were further sorted by flow cytometry into CCR7+ and 
CCR7- populations at day 0 (and stimulated for 8 days with cytokines) 
or at day 8 (after cytokine expansion) and then co-cultured with mono-
cytes at a ratio of 1:1 for 18 hours, and the supernatants assayed in 
triplicate for TNF-α production by ELISA. ***P < 0.001 comparing 
CD4+CD45RO+CCR7- versus CD4+CD45RO+CCR7+ after sorting at 
day 0 sort or at day 8 using one-way ANOVA with Bonferroni's multiple 
comparison. In panels b and c monocytes and T cells cultured alone as 
negative controls produced under 20 pg/ml TNF-α. Results are shown 
from one donor representative of five different experiments (panel b) 
and three different experiments (panel c). CCR, CC chemokine 
receptor.
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Phenotype of day eight CD4+CD45RO+ Tck cells after 
cytokine stimulation
Table 1 summarizes the pooled median mean fluorescence
intensity (MFI) values and percentage of cells positive for cell
surface molecules at days 0 and 8 on the CD4+CD45RO+
cells from independent experiments. T-cell activation markers
(CD25, CD69 and HLA-DR) were significantly increased at
day 8, with median MFI increases of greater than sevenfold for
CD25 (P < 0.0001), eightfold for CD69 (P < 0.0001) and
threefold for HLA-DR (P = 0.0052), respectively. CD25+ cells
increased from 9% at day 0 to 18% at day 8, indicating expan-
sion of some cells in culture. Day 8 Tck cells also exhibited a
significant increase in CD69 expression (Table 1), with 27%
of the cells positive for CD69 at day 8. HLA-DR was also
increased but to a lesser extent, from 9% at day 0 to 15% at
day 8.
Table 1
Expression of activation markers, adhesion molecules and chemokine receptors in CD4+CD45RO+ Tck cells
Cell phenotype Median MFI (range)/percentage positive (%) index Changea P n
Day 0 Day 8
CD25 8.0 (2–49)/9% 61 (6–884)/18% 7.5 <0.0001 40
CD69 5.0 (2–43)/1.1% 41 (5–552)/26.7% 8 <0.0001 41
HLA-DR 19 (4–130)/9% 60 (11–238)/15% 3 0.0052 15
CD62L 22 (8–255)/17% 339 (7–1,040)/58% 15 <0.0001 31
CD18 107 (9–1,026)/97.5% 319 (53–2,040)/98.5% 3 0.0085 21
CD29 85 (6–668)/81% 152 (14–582)/97% 2 0.0132 35
CD49d 180 (5–634)/73.3% 465 (13–1,461)/82.3% 2.6 <0.0001 42
CCR7 12 (4–57)/7.4% 13 (3–138)/8.6% 1 NS 42
CXCR4 52 (18–494)/29% 270 (124–896)/86.4% 5 <0.0001 21
CXCR3 32.3 (9–309)/34.3% 40.4 (17–129)/34.0% 1 NS 21
CCR5 8.3 (4–28)/2% 10.7 (4–262)/6% 1 NS 21
Statistically significant differences in mean fluorescence intensity (MFI) between day 0 and day 8 values from different experiments were 
calculated using Wilcoxon rank test. aChange index is calculated with reference to Day 0. CCR, CC chemokine receptor; CXCR, CXC chemokine 
receptor; HLA, human leucocyte antigen; NS, not significant; Tck, cytokine-activated T.
Table 2
Relationship between day 8 Tck phenotype (MFI) and effector function (TNF-α production from co-cultured monocytes)
Cell phenotype n r (correlation) P
CD25 40 -0.2558 NS
CD69 41 0.00053 NS
HLA-DR 15 0.4094 NS
CD62L 31 -0.4652 0.00084
CD18 21 0.1442 NS
CD29 35 0.2167 NS
CD49d 42 0.3314 0.032
CCR7 42 -0.1711 NS
CXCR4 21 -0.13 NS
CXCR3 21 0.02341 NS
CCR5 21 -0.3948 NS
Day 8 expression of cell surface markers (mean fluorescence intensity [MFI]) was correlated with effector function (tumour necrosis factor [TNF]-α production from monocytes in cytokine-activated T [Tck] cell:monocyte co-culture) using nonparametric (Spearman) correlation analysis. 
Results are expressed as correlation values (r) and level of significance.
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Adhesion marker expression was more variable. Firstly, L-
selectin (CD62L), a potential marker of central memory cells
was upregulated (15-fold) in the day 8 Tck cells (P < 0.0001).
An expansion in the central memory population is not likely
because CCR7+ expression (a more robust marker of central
memory cells) remained low in the day 8 CD4+CD45RO+ Tck
cells (Table 1). Interestingly, CD62L expression peaked at day
6, followed by a significant decrease in expression at day 8
(data not shown). This coincided with detection of soluble
CD62L in the culture supernatants (>150 ng/ml by day 6),
indicating shedding of CD62L (data not shown). Using non-
parametric (Spearman) correlation analysis (Table 2), it was
observed that CD62L expression at day 8 negatively corre-
lated (r = -0.4652; P = 0.00084) with TNF-α production in the
co-culture system (n = 31).
The proportions of cells positive for the adhesion markers
CD18, CD29 and CD49d did not increase substantially in cul-
ture, because more than 70% of the resting cells were already
positive for these markers at day 0. However, the median MFI
expression did increase for each molecule, with threefold
(CD18; P < 0.0085), twofold (CD29; P = 0.0132) and three-
fold (CD49d; P < 0.0001) increases at day 8. Interestingly,
using nonparametric (Spearman) correlation analysis (Table
2), it was observed that VLA-4 (CD49d) expression at day 8
positively correlated (r = 0.3314; P < 0.032) with TNF-α pro-
duction in the co-culture system (n = 42). It is unlikely that this
ligand is binding vascular cell adhesion molecule (VCAM)-1
(its counter ligand) on monocytes because this molecule is not
found on peripheral blood monocytes. However, this may indi-
cate that the most activated cells have the potent effector
function in the co-culture assay and that CD49d is a surrogate
marker for this activity.
Chemokine receptor expression was variable and lower than
that of the adhesion molecules. Only CXC chemokine recep-
tor (CXCR)4 increased significantly (fivefold; P < 0.0001)
over the 8-day culture period, with 86% cells positive at day 8
compared with 29% at day 0. Increases in CXCR3 and CCR5
expression were also observed but did not reach statistical
significance. Levels of CCR7 marker for naïve (CD45RA+) and
central memory (CD45RO+) cells were low (3%) and
remained unchanged over the 8-day period.
Phenotype of proliferated CD4+CD45RO+ Tck cells 
following cytokine stimulation
Figure 4a illustrates the CFSE dilution of CD4+CD45RO+ Tck
cells at day 8 (representative of four different donors) counter-
stained for CD25 (Figure 4b), CD69 (Figure 4c), CD18 (Fig-
ure 4d) and CD49d (Figure 4e). Over four independent
donors, an average of 55% of cells were undivided (M1)
whereas 45% of cells (peaks M2 to M7) underwent up to six
rounds of cell divisions. The MFI of both activation markers and
adhesion molecules were found to be higher in the divided
population. The MFI of CD25 (Figure 4b) was 3,219 in the
divided as compared with 2,126 in undivided cells; the MFI of
CD69 (Figure 4c) was 1,881 compared with 788; the MFI of
CD18 (Figure 4d) was 7,312 compared with 2,693; and
CD49d expression (Figure 4e) was 10,121 compared with
5,102.
Day 8 CD4+CD45RO+ Tck cells phenotypically resemble 
RA synovial T cells
Figure 5 illustrates the phenotype from a representative exper-
iment using peripheral blood CD4+CD45RO+ lymphocytes at
day 0 (left) and after 8 days of culture with cytokines (middle)
compared with CD4+ T cells within RA synovial membrane tis-
sue (right). CD25 expression was present in a small proportion
(9%) of resting lymphocytes, which was increased (18%) on
Figure 4
Proliferation pattern and phenotype of day 8 CD4+CD45RO+ Tck cells after cytoki e s imul tion
after cytokine stimulation. Freshly isolated CD4+CD45RO+ cells were 
labeled with 2.5 μmol/l carboxyfluoroscein succinimidyl ester and stim-
ulated with IL-2, IL-6 and tumour necrosis factor (TNF)-α for 8 days. (a) 
The number of cell divisions was analyzed on day 8 using FlowJo 7.2.2 
software (Tree Star, Inc., Oregon, USA). Cells were counterstained 
with antibodies against (b) CD25, (c) CD69, (d) CD18 and (e) 
CD49d, with mean fluorescent intensity (MFI) of these markers 
assessed in the undivided (M1) peak versus the divided (M2 to M7) 
fractions. Results are shown in the gates. Figure representative of four 
independent experiments. Tck cell, cytokine-activated T cell.
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day 8 Tck cells. A small proportion of RA synovial T cells in this
sample were also CD25+ but not to the same extent as day 8
Tck cells. The activation markers CD69 and HLA-DR were
clearly elevated on day 8 Tck cells and were similarly elevated
on RA synovial T cells. CD62L was absent from resting T cells
but increased on the day 8 Tck cells. However, RA synovial T
cells were negative for this selectin. Adhesion molecules
CD18, CD29 and CD49d were present on resting T cells but
further upregulated in day 8 Tck cells, with similar expression
to that seen on RA synovial T cells. The chemokine receptor
CCR7, a 'marker' of naïve and central memory T cells, was
expressed on the day 0 resting T cells. Its expression was
absent on the RA synovial T cells and day 8 Tck cells. The
chemokine receptors CXCR4, CXCR3 and CCR5 were all
increased on day 8 Tck cells to varying extents, but in the RA
synovial tissue examined here only CXCR3 was found to be
upregulated on the RA synovial T cells. However, on the other
RA synovial specimens examined (data not shown) both
CXCR4 and CCR5 expression was abundant, which is con-
sistent with numerous published reports (for review [29]).
Day 8 CD4+CD45RO+ Tck effector function is blocked 
with neutralizing antibodies to CD69, CD18 and CD49d
Having demonstrated that day 8 CD4+CD45RO+ Tck cells
exhibit a differentiated phenotype, we next determined
whether blocking these surface molecules with neutralizing
antibodies would result in inhibition of the effector response.
Thus, in a series of experiments CD4+CD45RO+ Tck cells
were pre-incubated with neutralizing antibodies to CD69,
CD18, CD49d, CD11a, or isotype control antibodies (as
described in Materials and methods, above), and TNF-α
production from monocytes was assessed in the co-culture
assay. In three independent experiments (Figure 6a), blockade
of CD69 resulted in an overall inhibition of 37% (P < 0.05),
with TNF-α levels reduced from 479.6 ± 310.3 pg/ml to 227.7
± 79.6 pg/ml. Blockade of CD18 resulted in an overall inhibi-
tion of 50% (P < 0.01) with TNF-α levels reduced from 479.6
± 310.3 pg/ml to 183.8 ± 48.5 pg/ml. Blockade of CD49d
resulted in 70% inhibition of TNF-α production from 69 ± 24
pg/ml to 10 ± 5 pg/ml (P = 0.04) in one experiment, although
in a further three experiments no inhibition was observed (data
not shown). Blockade of CD11a had no effect (data not
shown).
Spontaneous production of TNF-α and IL-6 is blocked in 
RA synovial MNC cultures with neutralizing antibodies 
to CD69, CD18, or CD49d
Having demonstrated that day 8 CD4+CD45RO+ Tck cells
phenotypically resemble RA synovial T cells, we next explored
whether ligation events involving CD69, CD18, or VLA-4
(CD49d) were instrumental in inducing/maintaining
proinflammatory cytokine production in RA synovial MNC ex
vivo cultures. Thus, in a series of experiments on different RA
donors, synovial MNC cells were incubated in triplicate in the
presence or absence of neutralizing antibodies to CD69,
CD18, CD49d, or an isotype control. Table 3 illustrates the
percentage inhibition of spontaneous TNF-α production from
Figure 5
Day 8 CD4+CD45RO+ Tck cells phenotypically resemble rheumatoid synovial T cells
synovial T cells. Freshly elutriated peripheral blood lymphocytes (PBLs) 
from healthy donors were stained with antibodies against CD4 and 
CD45RO in combination with antibodies against CD25, CD69, HLA-
DR, CD62L, CD18, CD29, CD49d, CCR7, CXCR4, CXCR3, or 
CCR5 at time 0 (left panels) and day 8 (middle panels) after culture 
with IL-2, IL-6 and tumour necrosis factor (TNF)-α (as detailed in Mate-
rials and methods). Rheumatoid synovial cells were also stained with 
the same panel of antibodies as PBLs. In all, 1 × 104 PBLs and 5 × 103 
synovial T cells were collected and the expression of different cell mark-
ers on the CD4+ gated lymphocyte population versus CD45RO+ 
expression was analyzed on the CellQuest Pro software. CCR, CC 
chemokine receptor; CXCR, CXC chemokine receptor; HLA, human 
leucocyte antigen.
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four different RA synovial MNC cultures compared with cells
only control (similar levels were obtained with isotype antibody
control). Blockade of CD69 had a modest (approximately
21%) inhibitory effect upon TNF-α production in all RA syno-
vial cultures, although in one of these donors this change was
not significant (Table 3). Blockade of CD18 resulted in TNF-α
inhibition in three out of the four donor RA cultures, with as
much as 50% inhibition observed in donor 4. Blockade of
CD49d resulted in inhibition of TNF-α in only two out of the
four RA donor cultures. In RA donor two (Figure 6b), blockade
of CD69, CD18, or CD49d all resulted in significant inhibition
TNF-α production (data illustrated as mean TNF-α production
[pg/ml] from triplicate cultures).
Cytokine production by CD4+CD45RO+ Tck cells in 
culture
Supernatants from the day 8 culture CD4+CD45RO+ Tck cells
were screened for T-cell cytokines and significant amounts of
lymphotoxin-α (median 358 pg/ml), IFN-γ (median 534 pg/ml)
and GM-CSF (median 2,095 pg/ml) were found, with lesser
amounts of IL-10 (median 30 pg/ml; Table 4). IL-17 was not
detected in the Tck culture supernatants at day 8 but was
induced if at day 5 the Tck cell cultures were treated with 2 ng/
ml recombinant IL-23 (data not shown).
Discussion
Although TNF-α is now acknowledged to be important in the
pathology of RA [11], the mechanisms that lead to its dysreg-
ulated production remain unknown but are of importance to
the development of improved therapies. Several pieces of evi-
dence from our group and others have emerged to indicate
that macrophage-derived TNF-α in inflamed synovial tissue is
T cell and contact dependent [17,21,30-32]. In order to study
this mechanism in more detail, we developed a human surro-
gate model system based on cytokine activation of peripheral
blood lymphocytes, and found that after 8 days these cytokine-
activated T cells (but not those activated by crosslinked anti-
CD3) mimicked the effector function of rheumatoid T cells
[17,25]. Importantly, the differences between Tck cells and
those derived from antigen activation provided an opportunity
for selective inhibition of pathogenic T cells. In this report we
characterize the generation of day 8 Tck cells in terms of the
induced lymphocyte proliferation, cell surface phenotype and
cytokine production. Furthermore, by a series of cell sorting
experiments, we not only identify the phenotype of the most
potent effector cell at day 8 but also, based upon this knowl-
edge, uncover the precursor phenotype of Tck cells within nor-
mal resting peripheral blood lymphocyte population. This may
have implications for our understanding of the generation of
pathogenic T cells in the highly proinflammatory environment
of the rheumatoid synovium.
Analysis of the lymphocytes expanded from human peripheral
blood with the cytokine cocktail in our day 8 Tck cultures
revealed a significant expansion in CD3-CD56+ cells (NK
population), with a lower overall change in the number of
CD3+CD56- T cells over the 8 days, despite cell division within
the CD8+ population. The lack of change in total cell number
at day 8 is apparently due to apoptosis in approximately 30%
of the CD3+ cells (data not shown), most likely because of
Figure 6
CD69, CD18 and CD49d blockade resulted in reduced TNF-α in Tck co-cultures and rheumatoid synovium culture
co-cultures and rheumatoid synovium culture. (a) CD4+CD45RO+ cells 
were fixed after 8 days of cytokine stimulation with 1% paraformalde-
hyde and then co-incubated with blocking antibodies against CD18 
and CD69, as described in Materials and methods. Cytokine-activated 
T (Tck) cells were co-cultured with fresh monocytes at a ratio of 8:1. 
Supernatants were harvested after 18 hours and TNF-a production 
measured by ELISA. This figure represents three experiments con-
ducted in different donors. (b) Rheumatoid arthritis (RA) synovial cell 
mononuclear cells from RA donor 2 (see Table 3) were cultured in trip-
licate in the presence of antibodies against CD69, CD18, or CD49d 
for 24 hours, as described in Materials and methods. Supernatants 
were harvested and spontaneous TNF-α production was measured 
using ELISA. **P < 0.01 and *P < 0.05, as assessed by one-way analy-
sis of variance with post hoc Bonferroni correction.
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depletion of growth factors in these cultures, particularly when
expanded together with the rapidly proliferating NK cells.
Indeed, if the human peripheral blood lymphocytes were
expanded with IL-15 alone (previously to generate effective
Tcks cells [25]), the expansion of NK cells at day 8 was even
more marked. Furthermore, if the NK cells were separated at
day 8 from the CD3+ T cells, they also exhibited contact
effector function on monocytes but in a phosphoinositide 3-
kinase dependent manner (unpublished data), similar to that
induced by anti-CD3 antibody stimulated peripheral blood
lymphocytes [17,26,33]. Only the CD3+ cells within the day 8
Tck cells (and not the CD3-CD56+) exhibited effector function
identical to that of RA synovial T cells, and thus we focused
our attention on these cells.
Closer analysis and enrichment of the CD3+ subset phenotype
(at either day 0 or day 8) revealed that the most efficient
effector cell resided within the CD3+CD4+CD45RO+ memory
subset, and more specifically within the effector memory pop-
ulation (CCR7-). The day 8 Tck cells resembled RA synovial T
cells, particularly in terms of the increased expression of sev-
eral adhesion molecules including VLA-4. The latter is of par-
ticular interest because, based on its overall expression at day
8, it was the only ligand to correlate positively with the ability
to induce monocyte production of TNF-α (Table 2). Synovial T
cells express high levels of both the alpha (CD49d) and beta
(CD29) chains of VLA-4 and exhibit ex vivo an enhanced abil-
ity to bind to fibronectin fragments (a VLA-4 ligand) [34]. Fur-
thermore, an alternate VLA-4 ligand, namely VCAM-1, is
expressed selectively on RA endothelium and macrophages in
the lining layer of the synovium, and is inhibited following anti-
TNF-α therapy in the clinic [35]. It has been hypothesized that
VLA-4 facilitates extravasation of lymphocytes across
endothelium (via VCAM-1) and their retention in the joint tissue
(via fibronectin binding and/or VCAM-1). To investigate this
further, we intend to explore the ability of VLA-4high Tck cells to
extravasate endothelium in ex vivo cultures. Furthermore (and
potentially of greater interest), we will determine the ability of
CD4+CD45RO+VLA-4high Tck cells to traffic to synovial grafts
in the RA/severe combined immunodeficient mouse model,
together with their potential to upregulate cytokines locally in
this tissue.
The fact that the resting CD4+CD45RO+ T cells from normal
blood are unable to induce TNF-α from monocytes indicates
that this effector function is acquired either due to de novo
gene transcription and/or conformational change of a surface
molecule during the differentiation process. Several cell sur-
face molecules, including integrins and adhesion molecules,
have previously been shown to be of importance in contact-
dependent effector function, including CD69 [19], lymphocyte
function-associated antigen-1 (CD11a and CD18) and others
[18,36]. We confirmed that blockade of CD18 and CD69 on
Tck cells reduced monocyte TNF-α production in the co-cul-
Table 3
Modulatory effect on spontaneous TNF-α production following blockade of cell surface ligands in RA MNC cultures
RA donor Anti-CD69 Anti-CD18 Anti-CD49d
Inhibition (%) P Inhibition (%) P Inhibition (%) P
1 17 <0.01 0 NS 0 NS
2 23 <0.05 22 <0.01 36 <0.01
3 22 NS 26 NS 23 NS
4 ND NS 51 <0.01 0 NS
Rheumatoid arthritis (RA) synovial mononuclear cell (MNC) cells were cultured in triplicate with anti-CD69, anti-CD18, or anti-CD49d antibodies 
at a final concentration of 5 μg/ml for 24 hours at 37°C, as described in Materials and methods. Spontaneous tumour necrosis factor (TNF)-α 
production was measured in the supernatants by ELISA and results expressed as percentage inhibition relative to the control wells (cells only). 
Significance (P value) was calculated using one-way analysis of variance with post hoc Bonferroni correction.
Table 4
Cytokine levels found in day 8 CD4+CD45RO+ Tck cell culture supernatants
Cytokine n Median levels (pg/ml) Range (pg/ml)
Lymphotoxin-α 25 358 (38–7,306)
IFN-γ 32 534 (8–21,280)
GM-CSF 21 2,095 (603–8,043)
IL-10 36 30 (0–310)
Supernatants from day 8 cytokine-activated T (Tck) cell cultures were harvested and cytokines detected by ELISA, as described in Materials and 
methods. GM-CSF, granulocyte monocyte colony-stimulating factor.
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ture system, which is in agreement with previous studies
[19,21,36]; also, in one single experiment blockade of CD49d
(VLA-4) also reduced monocyte TNF-α production. More
importantly, the role of these cell surface ligands was verified
in the present study using the ex vivo RA synovial MNC culture
system, reinforcing the relevance of Tck cells as surrogates for
RA synovial T cells, and highlighting the potential role of these
ligands in contributing to chronicity in RA. However, it is note-
worthy that none of these ligation events were dominant in
either system, and several different ligation events are poten-
tially 'involved' in these contact-mediated events in inflamma-
tory tissue, as was previously described [19].
VLA-4 also probably plays a role in trafficking of T cells to the
synovial microenvironment (as discussed above). Interestingly,
the chemokine receptor CXCR4 previously identified on RA
synovial T cells [37] was also increased on day 8 Tck cells.
CXCR4 plays a key role in trafficking T cells to inflamed syn-
ovium in response to ligands including stromal cell-derived
factor-1 [37,38]. Therefore, antigen-independent activation by
proinflammatory cytokines could not only induce cells capable
of perpetuating disease by cellular contact with monocytes
but also facilitate the accumulation of these pathogenic cells
at the site of disease. We are currently exploring the role of
VLA-4 (as discussed above), together with CXCR4 and stro-
mal cell-derived factor-1, in migration of these Tck cells in vivo
in the RA/SCID mouse model.
Although the series of cell sorting experiments indicated that
enriching for CD4+CD45RO+ T cells increased the Tck effec-
tor potency, variation between different experiments with dif-
ferent donors was very evident. One possible explanation is
that regulatory T cells (or factors) are present in the cultures
and suppress Tck effector function, either by modulating the
generation of effector Tck cells and/or by modulating the abil-
ity of the monocytes to produce TNF-α after contact activation
[39]. Consistent with this hypothesis was our observation that
the proportion of CD4+CD25+ cells increased in the Tck cul-
tures (Table 1) and were found within the dividing population
of CD4+CD45RO+ cells (Figure 4a). We have preliminary data
showing that CD25+Foxp3+CD127- regulatory T cells are
present in these Tck cultures and that they expand over the 8-
day culture period at a faster rate than the Tck effector cells.
Therefore, although the phenotype of the divided
CD4+CD45RO+ cells (Figure 4a) expressed more surface
activation and adhesion molecules, including CD49d (Figure
4e), they may not necessarily be more potent effectors than
the nondivided CD4+CD45RO+ cells because
CD25+Foxp3+CD127- regulatory T cells are also present
within these populations. We are currently determining in a
separate and extensive study the modulatory effect of these
CD25+Foxp3+CD127- regulatory T cells upon the expansion
of Tck cells, the acquisition of effector function and the direct
effect on the monocytes in the co-culture model. In the RA syn-
ovial tissue we examined in this report (Figure 5), the propor-
tion of CD4+CD25+ cells was relatively low compared with
that in other published reports. However, there is inconsist-
ency in the published reports, with several describing an
increase in the proportion of CD25+Foxp3+CD127- regulatory
T cells in the synovial fluid [40,41] and others describing a
reduction in synovium compared with synovial fluid [42].
Conclusion
The present study extends our previous observations on
cytokine-activated T cells (Tck cells) and their potential in
contributing to chronicity in inflammation. We found that
CD4+CD45RO+CCR7- effector memory T cells differentiate
to an effector population upon cytokine stimulation in vitro,
which mimics RA synovial T cells both in effector function and
cell surface phenotype. By defining the phenotype of effector
Tck cells, we have focused studies to gain further insight into
the exact nature of contact-dependent activation of macro-
phages in RA. The cell surface molecules CD69, CD18 and
CD49d were shown to plays roles in these contact-mediated
events. The pathogenic potential of Tck cells is currently being
explored further in the RA/severe combined immunodeficient
model, which will also allow us to explore the modulatory
effects of blocking candidate cell surface proteins on migra-
tory cells and determine their effect on the pathogenesis of
disease.
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